id,title
0,Heterologous prime-boost strategies for COVID-19 vaccines
1,Draft landscape and tracker of COVID-19 candidate vaccines. World Health Organization
2,"COVID-19: vaccine brands can be mixed in ""extremely rare occasions,"" says Public Health England"
3,Heterologous prime-boost HIV-1 vaccination regimens in pre-clinical and clinical trials
4,Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
5,Could mixing COVID vaccines bolster immune response?
6,WHO. Interim statement on heterologous priming for COVID-19 vaccines
7,"Safety and immunogenicity of heterologous and homologous 2-dose regimens of adenovirus serotype 26-and modified vaccinia Ankara-vectored Ebola vaccines: a randomized, controlled phase 1 study"
8,Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal
9,"Heterologous prime-boost immunisation in Ebola vaccine development, testing and licensure"
10,A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques
11,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia"
12,Heterologous prime-boost vaccination
13,"COVID-19: fever, chills, and aches more common when AstraZeneca and Pfizer vaccines are mixed, early data show"
14,Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
15,What we know about the COVID-19 immune response: the latest on COVID-19 immunity & the current global situation (Coronavirus Update 34
16,Innate immune sensing of coronavirus and viral evasion strategies
17,Antibodies and vaccines target RBD of SARS-CoV-2
18,Antibody responses in COVID-19: a review
19,SARS-CoV-2 antibody response in persons with past natural infection
20,Antibody-dependent enhancement and COVID-19: moving toward acquittal
21,Molecular basis of COVID-19 relationships in different species: a one health perspective
22,Interpreting diagnostic tests for SARS-CoV-2
23,Profile of specific antibodies to SARS-CoV-2: the first report
24,CDC. Interim guidelines for COVID-19 antibody testing
25,Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients
26,Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19
27,SARS-CoV-2 specific memory B cells frequency in recovered patient remains stable while antibodies decay over time
28,Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4+ T cell help
29,"A single-blind, randomised, phase II UK multi-Centre study to determine reactogenicity and immunogenicity of heterologous prime/boost COVID-19 vaccine schedules -stage 2"
30,Mix-and-match COVID vaccines trigger potent immune response
31,Next-generation vaccine platforms for COVID-19
32,Immunization guidelines. Dubai Health Authority Department of Public Health & safety
33,Development of a novel platform of virus-like particle (VLP)-based vaccine against COVID-19 by exposing epitopes: an immunoinformatics approach
34,"COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines"
35,DNA vaccines against COVID-19: perspectives and challenges
36,The different types of COVID-19 vaccines
37,Commonly used adjuvant human vaccines: advantages and side effects
38,Comparative safety of vaccine adjuvants: a summary of current evidence and future needs
39,"Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations"
40,&#x007E;:text=COVID%2D19%20vaccines%20are%20sa fe
41,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
42,Optimism and caution for an inactivated COVID-19 vaccine
43,"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a primeboost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial"
44,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial"
45,Comparing the COVID-19 vaccines: how are they different
46,Heterologous ChA-dOx1 nCoV-19/BNT162b2 prime-boost vaccination induces strong humoral responses among health care workers
47,"reactogenicity, and immunogenicity of homologous and heterologous primeboost immunisation with ChAdOx1-nCoV19 and BNT162b2: a prospective cohort study"
48,Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients
49,Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity
50,Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination. N Eng
51,Heterologous ChAdOx1-S/BNT162b2 vaccination: neutralizing antibody response to SARS-CoV-2
52,"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial"
53,Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
54,An immunogenicity report for the comparison between heterologous and homologous prime-boost schedules with ChAdOx1-S and BNT162b2 vaccines
55,mRNA vaccines enhance neutralizing immunity against SARS-CoV-2 variants in convalescent and ChAdOx1-primed subjects
56,Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination
57,SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
58,"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial"
59,Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria)
60,Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
61,Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic
62,Vaccine effectiveness when combining the ChAdOx1 vaccine as the first dose with an mRNA COVID-19 vaccine as the second dose
63,Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination
64,Neutralization of VOCs including Delta one year post COVID-19 or vaccine
65,The anti-SARS-CoV-2 immunoglobulin G levels and neutralising capacities against alpha and delta virus variants of concern achieved after initial immunisation with vector vaccine followed by mRNA vaccine boost are comparable to those after double immunisation with mRNA vaccines
66,"Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada"
67,Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2
68,Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin
69,Heterologous SARS-CoV-2 booster vaccinations -preliminary report
70,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults
71,Heterologous prime-boost immunization with CoronaVac and Convidecia
72,SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen
73,Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorVvaccinated individuals compared with homologous BNT162b2 vaccination: results of a pilot prospective cohort study from Lebanon
74,Induction of robust neutralizing antibodies against the COVID-19 Delta variant with ChAdOx1 nCoV-19 or BNT162b2 as a booster following a primary vaccination series with CoronaVac
75,Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients
76,Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming
77,Nephrotic syndrome and acute kidney injury following CoronaVac anti-SARS-CoV-2 vaccine
78,COVID-19: breaking down a global health crisis
79,Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA
80,COVID-19 vaccines: the status and perspectives in delivery points of view
81,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
82,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
83,"Sinovac's COVID-19 shot is 83% effective, not 91%, Turkey says"
84,Minimal change disease following influenza vaccination and acute renal failure: just a coincidence?
85,Minimal change nephrotic syndrome in a 65-year-old patient following influenza vaccination
86,"Minimal change nephrotic syndrome, lymphadenopathy and hyperimmunoglobulinemia after immunization with a pneumococcal vaccine"
87,Minimal change disease following the Pfizer-BioNTech COVID-19 vaccine
88,Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine
89,Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine
90,Influenza virus vaccination in children with nephrotic syndrome: insignificant risk of relapse
91,"Histological appearance of second renal biopsy. (A) Normal histological appearance of glomeruli (haematoxylen & eosin, Â200). (B) Interstitial inflammation composed predominantly of lymphocytes"
92,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer
93,Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2)/COVID-19 Detection
94,Effectiveness of Mrna COVID-19 Vaccines Against SARS-Cov-2 Infection in a Cohort of Healthcare Personnel
95,"Mitigating Covid-19 in the Face of Emerging Virus Variants, Breakthrough Infections and Vaccine Hesitancy"
96,Mrna-Based COVID-19 Vaccine Boosters Induce Neutralizing Immunity Against SARS-Cov-2 Omicron Variant
97,Risk Factors for Severe COVID-19 Outcomes Among Persons Aged ≥18 Years Who Completed a Primary COVID-19 Vaccination Series -465 Health Care Facilities
98,Covid-19 Vaccine Effectiveness in New York State
99,"Immunogenicity and Safety of a Third Dose of Coronavac, and Immune Persistence of a Two-Dose Schedule, in Healthy Adults: Interim Results From Two Single-Centre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Clinical Trials"
100,"Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, BBIBP-Corv, in People Younger Than 18 Years: A Randomised, Double-Blind, Controlled, Phase 1/2 Trial"
101,Safety and Efficacy of the BNT162b2 Mrna Covid-19 Vaccine Through 6 Months
102,Dynamic Igg Seropositivity After Rollout of Coronavac and BNT162b2 COVID-19 Vaccines in Chile: A Sentinel Surveillance Study
103,Effectiveness of the Coronavac Vaccine in Older Adults During a Gamma Variant Associated Epidemic of Covid-19 in Brazil: Test Negative Case-Control Study
104,"Efficacy and Safety of an Inactivated Whole-Virion SARS-Cov-2 Vaccine (Coronavac): Interim Results of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial in Turkey"
105,COVID-19 in Cancer and Non-Cancer Patients
106,Routine COVID-19 Testing may Not be Necessary for Most Cancer Patients
107,Multicenter Study of Antibody Seroprevalence Against COVID-19 in Patients Presenting to Iranian Cancer Centers After One Year of the COVID-19 Pandemic
108,The COVID-19 Outbreak and Oncology Centers in Iran
109,"COVID-19 Vaccination and Cancer, the Need for More Data"
110,Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-Cov-2 in Patients Undergoing Treatment for Cancer
111,Efficacy and Safety of BNT162b2 Vaccination in Patients With Solid Cancer Receiving Anticancer Therapy -A Single Centre Prospective Study
112,The Impact of Diagnostic Changes on the Rise in Thyroid Cancer Incidence: A Population-Based Study in Selected High-Resource Countries
113,Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
114,"Safety and Immunogenicity of the Vi-DT Typhoid Conjugate Vaccine in Healthy Volunteers in Nepal: An Observer-Blind, Active-Controlled, Randomised, non-Inferiority, Phase 3 Trial"
115,"Safety and Immunogenicity of a Recombinant Tandem-Repeat Dimeric RBD-Based Protein Subunit Vaccine (ZF2001) Against COVID-19 in Adults: Two Randomised, Double-Blind, Placebo-Controlled, Phase 1 and 2 Trials"
116,"Safety and Immunogenicity of an Inactivated SARS-Cov-2 Vaccine, BBIBP-Corv: A Randomised, Double-Blind, Placebo-Controlled, Phase 1/2 Trial"
117,Immunogenicity and Safety of the Inactivated SARS-Cov-2 Vaccine (BBIBP-Corv) in Patients With Malignancy
118,A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-Cov-2 Vaccine (BBIBP-Corv) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome?
119,Sex Differences and COVID-19
120,Sex Differences in Vaccine-Induced Humoral Immunity
121,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers
122,WHO Coronavirus (COVID-19) Dashboard With Vaccination Data
123,Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review
124,"Covid-19: Unvaccinated face 11 times risk of death from delta variant, CDC data show"
125,"Features, Evaluation, and Treatment of Coronavirus (COVID-19)"
126,"Four months into the COVID-19 pandemic, Sweden's prized herd immunity is nowhere in sight"
127,"Coronavirus disease (COVID-19): Herd immunity, lockdowns and COVID-19. Quest answers"
128,"Covid-19: Herd immunity is ""unethical and unachievable, "" say experts after report of 5% seroprevalence in Spain"
129,Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic EClinicalMedicine
130,COVID-19 vaccine tracker and landscape
131,Global prevalence and drivers of dental students' COVID-19 vaccine hesitancy
132,Predictors of willingness to receive COVID-19 vaccine: cross-sectional study of Palestinian dental students
133,COVID-19 vaccine in pregnant and lactating women: a review of existing evidence and practice guidelines
134,COVID-19 Vaccine acceptance of pregnant and lactating women (PLW) in Czechia: an analytical cross-sectional study
135,Hesitant or not? A global survey of potential acceptance of a COVID-19 vaccine
136,Prevalence and drivers of COVID-19 vaccine hesitancy among Czech University Students: national cross-sectional study
137,Low COVID-19 vaccine acceptance is correlated with conspiracy beliefs among university students in Jordan
138,Iads-Score. Universal predictors of dental students' attitudes towards COVID-19 vaccination: machine learning-based approach
139,Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study
140,"Effects and perceptions following COVID-19 vaccination in Jordan: a randomised, cross-sectional study implementing machine learning for predicting severity of side effects"
141,Effects reported by Jordanian healthcare workers who received COVID-19 vaccines
142,Evaluation of side effects associated with COVID-19 vaccines in Saudi Arabia
143,"Adrees AO, Side. effects and perceptions following Sinopharm COVID-19 vaccination"
144,Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic
145,Effects of mRNA-based and viral vector-based COVID-19 vaccines among German healthcare workers
146,Effects of mRNA-based COVID-19 vaccine: nationwide phase iv study among healthcare workers in Slovakia
147,Effects of mRNA-based COVID-19 vaccines among young adults
148,Years Old): an independent post-marketing study
149,Self-reported adverse events of COVID-19 vaccines in Polish healthcare workers and medical students. Cross-sectional study and pooled analysis of CoVaST project results in central Europe
150,Prevalence and risk factors of CoronaVac side effects: an independent crosssectional study among healthcare workers in Turkey
151,"COVID-19 vaccine access in Africa: global distribution, vaccine platforms, and challenges ahead"
152,Algeria's preparedness for Omicron variant and for the fourth wave of COVID-19
153,Algeria's response to COVID-19: an ongoing journey
154,"Covid-19: Algeria receives US donation of 604,800 doses of J&J vaccine"
155,Coronavirus Pandemic (COVID-19)
156,The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies
157,Questionnaire sur les effets secondaires des vaccins anti-COVID-19 chez le staff médical en Algérie −19 . Google Forms
158,Epi Info TM for Windows
159,COVID-19 Vaccines Safety Tracking (CoVaST): protocol of a multi-center prospective cohort study for active surveillance of COVID-19 vaccines' side effects
160,World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects
161,Available online at
162,Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study
163,Unfolding the mild to moderate shortterm side effects of four COVID-19 vaccines used in Bahrain: a cross-sectional study
164,Which type of the promising COVID-19 vaccines produces minimal adverse effects? A retrospective crosssectional study
165,Qualitative assessment of early adverse effects of Pfizer-BioNTech and Sinopharm COVID-19 vaccines by telephone interviews
166,SARS-CoV-2 Post vaccinated adverse effects and efficacy in the Egyptian population
167,Side effects after COVID-19 vaccinations among residents of Poland
168,Abdel-Moneim AS. BNT162b2 and ChAdOx1 SARS-CoV-2 post-vaccination side-effects among Saudi vaccinees
169,Adverse events following immunization associated with the first and second doses of the ChAdOx1 nCoV-19 vaccine among healthcare workers in Korea
170,Adverse effects of the COVID-19 vaccine reported by lecturers and staff of Kabul University of medical sciences
171,COVID-19 vaccine: side effects after the first dose of the Oxford AstraZeneca vaccine among health professionals in low-income country: Ethiopia
172,Reported adverse effects and attitudes among Arab populations following COVID-19 vaccination: a large-scale multinational study implementing machine learning tools in predicting post-vaccination adverse effects based on predisposing factors
173,Side effects and immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran
174,"Differences and disparities in seasonal influenza vaccine, acceptance, adverse reactions, and coverage by age, sex, gender, and race"
175,Short-term reactogenicity and gender effect of anthrax vaccine: analysis of a 1967-1972 study and review of the 1955-2005 medical literature
176,Sex and Gender Differences in the Outcomes of Vaccination over the Life Course
177,The gender impact assessment among healthcare workers in the SARS-CoV-2 vaccination-an analysis of serological response and side effects
178,Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study
179,Safety of ChAdOx1 nCoV-19 vaccine: independent evidence from two EU States
180,"Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city"
181,Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest
182,Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac 1 (CoronaVac) followed by AstraZeneca (Vaxzevria) 2 3 Running Title: Heterologous prime-boost with CoronaVac-AZD1222
183,Vaccines for 9
184,COVID-19: Where do we stand in 2021?
185,"Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (CKPM), the National Research Foundation of Korea (NRF) grant funded through the Korea government"
186,Clinical features of patients infected with 2019 novel coronavirus in Wuhan
187,Clinical Characteristics of Coronavirus Disease 2019 in China
188,Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate
189,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
190,Immune Correlates of Protection by mRNA-1273
191,A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
192,Extremely potent human monoclonal antibodies from COVID-19 convalescent patients
193,Dimeric Fcγ Receptor Enzyme-Linked Immunosorbent Assay To Study HIV-Specific Antibodies: A New Look into Breadth of Fcγ Receptor Antibodies Induced by the RV144 Vaccine Trial
194,Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles
195,Alter G. (2021) Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
196,Correlates of protection against SARS-CoV-2 in rhesus macaques
197,SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees
198,CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity
199,Differential contributions of central and effector memory T cells to recall responses
200,Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
201,"2021) Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
202,Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. Lancet Microbe. Epub ahead of print
203,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia
204,An interactive web-based dashboard to track COVID-19 in real time
205,WHO coronavirus (COVID-19) dashboard. 2021
206,Clinical Characteristics of Coronavirus Disease
207,response bottleneck of COVID-19 vaccine candidates
208,Novel prime-boost vaccine strategies against HIV-1. Expert review of vaccines
209,Over 1.8 bln doses of COVID-19 vaccines administered in China
210,VACCINES CANDIDATES BY TRIAL PHASE. 2021
211,WHO International Standard for anti-SARS-CoV-2 immunoglobulin
212,Intensified antibody response elicited by boost suggests immune memory in individuals administered two doses of SARS-CoV-2 inactivated vaccine
213,Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. The Lancet Microbe
214,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study. The Lancet Microbe
215,Effectiveness of CoronaVac among healthcare All rights reserved. No reuse allowed without permission. perpetuity
216,"doi: medRxiv preprint workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study"
217,"Immunogenicity and safety ofa third dose, and immune persistence of CoronaVac vaccine in healthy adultsaged 18-59 years: interim results from a double-blind, randomized,placebo-controlled phase 2 clinical trial. medRxiv"
218,Prime-boost vaccine strategy against viral infections: Mechanisms and benefits
219,The prime-boost strategy: exciting prospects for improved vaccination
220,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality
221,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
222,"Safety, reactogenicity, and immunogenicity of All rights reserved. No reuse allowed without permission. perpetuity"
223,"preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted"
224,Heterologous ChAdOx1 nCoV-19 and mRNA-1273
225,The New England journal of medicine
226,"BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. 2021. received. *A seropositivity of neutralizing antibody against SARS-CoV-2 before receiving a boost vaccination"
227,or GMFI (95% CI). n= the number of participants included the intervention modified intention-to-treat cohort. The P values are the results of comparison between the two treatment groups
228,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region"
229,"Guillain-Barre syndrome, influenza, and influenza vaccination: 405 the epidemiologic evidence"
230,A collaborative approach to investigating the risk of 407 thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark
231,"Vaccine hesitancy, vaccine refusal and the anti-vaccine 410 movement: influence, impact and implications"
232,Efficacy and Safety of the mRNA
233,CoV-2 Vaccine
234,Safety and efficacy of the ChAdOx1 nCoV-19 415 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised
235,"First-dose ChAdOx1 and BNT162b2 COVID-19 418 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland"
236,Bell's palsy following vaccination with mRNA 421 (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-422 control study
237,Case of Guillain-Barré syndrome following COVID-19 424 vaccine
238,Barré Syndrome following ChAdOx1
239,S/nCoV-19 Vaccine
240,"Guillain-Barré syndrome following the first dose of 428 SARS-CoV-2 vaccine: A temporal occurrence, not a causal association"
241,Exacerbating Guillain-Barré Syndrome Eight Days after Vector-Based
242,Cutaneous reactions reported after Moderna 432 and Pfizer COVID-19 vaccination: A registry-based study of 414 cases
243,Immune-Mediated Disease Flares or New-Onset 437 Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination
244,Prevention of Dabigatran-Related Gastrointestinal 440
245,Bleeding With Gastroprotective Agents: A Population-Based Study
246,Kawasaki disease and 13-valent pneumococcal conjugate 557 vaccination among young children: A self-controlled risk interval and cohort study with null results
247,The clinical and laboratory manifestations profile 560 of antiphospholipid syndrome among Saudi Arabia population: Examining the applicability of 561 Sapporo criteria
248,Population-based incidence and prevalence of systemic 563 lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program
249,Risk of Systemic Lupus Erythematosus in Patients With Anti-566 phospholipid Syndrome: A Population-Based Study
250,The epidemiology of infectious 568 gastroenteritis related reactive arthritis in U.S. military personnel: a case-control study
251,Reactive Arthritis A006. 29 October
252,Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines
253,Non-alcoholic fatty liver disease among patients with sleep 575 disorders: a Nationwide study of Taiwan
254,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine
255,Waning Immune Humoral Response to BNT162b2
256,Covid-19 Vaccine over 6 Months
257,Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
258,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
259,Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
260,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients
261,SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 31 10
262,Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV
263,/BNT162b2 vaccination
264,A nationwide cohort study
265,Heterologous SARS-CoV-2 Booster Vaccinations -Preliminary Report
266,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial"
267,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, singleblind, randomised controlled trial"
268,World Health Organization. WHO recommendation of Sinovac COVID-19 vaccine (Vero Cell
269,"Efficacy and safety of an inactivated wholevirion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
270,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
271,"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study"
272,Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong
273,seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study
274,Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19
275,"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule"
276,Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study
277,WHO. Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization 4-7
278,Indonesia: Coronavirus Pandemic Country Profile
279,"Pandemic inequity in a megacity: a multilevel analysis of individual, community and health care vulnerability risks for COVID-19 mortality in Jakarta"
280,27 WHO. EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION. Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody
281,Moderna announces preliminary booster data and updates strategy to address Omikron variant. News release on DSecember 12th
282,Booster-Data-and-Updates-Strategy-to-Address-Omicron-Variant-2021
283,Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
284,Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection
285,Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
286,COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
287,Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity 1 and persistence of anti-SARS-CoV-2 S antibodies 2 3 Short title: Serological Study of CoronaVac vaccine and heterologous boosters. 4 5
288,Effectiveness of 551 an Inactivated SARS-CoV-2 Vaccine in Chile
289,"Dynamics of 553 antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. and Salvador, Natalia and Franco"
290,Randomized 597 Immunogenicity and Safety Study of Heterologous Versus Homologous COVID-19 Booster 598 Vaccination in Previous Recipients of Two Doses Of Coronavac COVID-19 Vaccine
291,3@A:* =4*58>?>8A:* >4*538?@@A:* 9@*534?;6A:* 3-412-! @@*5@8?=9A:* ;3*54@?@=A:* 9@*5=4?>9A:* 46*5=8?>6A:*
292,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32"
293,an Inactivated SARS-CoV-2 Vaccine
294,Effectiveness of COVID-19 vaccines against the B.1.617.2 variant
295,Heterologous Prime-Boost Vaccination
296,"Safety and immunogenicity of an rAd26 and rAd5 vector-based 587 heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-588 randomised phase 1/2 studies from Russia"
297,Arvind Subramanian write: Why we need to count 590 the Covid dead
298,Covid-19: Indonesia becomes Asia's new pandemic epicentre as delta variant 593 spreads
299,"Epidemiological and clinical characteristics of 99 cases of 2019 novel 595 coronavirus pneumonia in Wuhan, China: a descriptive study"
300,SARS-CoV-2 variants of concern exhibit reduced sensitivity to 598 live-virus neutralization in sera from CoronaVac vaccinees and naturally infected 599 COVID-19 patients
301,Immune response elicited from heterologous SARS-CoV-2 602 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria). medRxiv 603
302,"Production, titration, neutralisation and storage of SARS-CoV-2 605 lentiviral pseudotypes (preprint)"
303,All rights reserved. No reuse allowed without permission. perpetuity
304,Boosting with heterologous vaccines effectively improves protective 612 immune responses of the inactivated SARS-CoV-2 vaccine
305,Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization
306,Reduced serum neutralization capacity against SARS-CoV-2 variants 621 in a multiplex ACE2 RBD competition assay
307,Neutralizing antibody levels are highly predictive of immune 624 protection from symptomatic SARS-CoV-2 infection
308,Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. 627 medRxiv
309,Immunogenicity of heterologous prime/booster-inactivated and 629 adenoviral-vectored COVID-19 vaccine: real-world data
310,Evidence for antibody as a protective correlate for COVID-19 632 vaccines
311,Overview of SARS-CoV-2 infection in adults living with HIV
312,Vaccine effectiveness when combining the ChAdOx1 vaccine as 636 the first dose with an mRNA COVID-19 vaccine as the second dose
313,"Safety and immunogenicity of a candidate Middle East 639 respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-640 label, non-randomised, uncontrolled, phase 1 trial. The Lancet Infectious Diseases"
314,"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine 643 administered in a prime-boost regimen in young and old adults (COV002): a single-644 blind, randomised, controlled, phase 2/3 trial"
315,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine 646 against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised 647 controlled trial"
316,Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda
317,"SARS-CoV-2 variants, spike mutations and immune escape"
318,Will SARS-CoV-2 variants of concern affect the promise of vaccines?
319,SARS-CoV-2 Variants and Vaccines
320,COVID-19 Weekly Epidemiological Update Global overview
321,Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile
322,Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
323,The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity
324,Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
325,"Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant"
326,Antigenic minimalism of SARS-CoV-2 is
327,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
328,Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
329,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
330,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
331,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
332,Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant
333,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio
334,World Health Organization. Considerations for evaluation of Covid-19 vaccines
335,Considerations in boosting COVID-19 vaccine immune responses
336,Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar
337,Waning immunity after the BNT162b2 vaccine in Israel
338,"Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. medRxiv 2021"
339,Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine
340,Ministry of Health Malaysia. Open data on Malaysia's National COVID-19 Immunisation Programme
341,Open Data on COVID-19 in Malaysia
342,SARS-CoV-2 Mutations and Variants of Interest
343,Association between mRNA vaccination and COVID-19 hospitalization and disease severity
344,Clinical characteristics and risk factors for severe COVID-19 infections in Malaysia: A nationwide observational study
345,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind"
346,Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil
347,Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273
348,Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic
349,Infection in Adults: A Randomized Clinical Trial
350,All rights reserved. No reuse allowed without permission
351,"preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted"
352,COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials
353,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
354,"Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized"
355,"doi: medRxiv preprint 10. Pietsch, B. Hundreds of Thais inoculated with Sinovac are infected as cases spike in Southeast Asia. The Washington Post"
356,SARS-CoV-2 RNA shedding in recovered COVID-19 cases and the presence of antibodies against SARS-CoV-2 in recovered COVID-19 cases and close contacts
357,Summary of Product Characteristic CoronaVac
358,COVID-19 Vaccine AstraZeneca package leaflet
359,Effectiveness of an Inactivated SARS-CoV-2
360,"A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2. medRxiv"
361,Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients
362,Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine
363,IgA dominates the early neutralizing antibody response to SARS-CoV-2
364,Highlyspecific memory B cells generation after the 2nd dose of BNT162b2 vaccine compensate for the decline of serum antibodies and absence of mucosal IgA
365,Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. medRxiv
366,Enhanced SARS-CoV-2 neutralization by dimeric IgA
367,Immune responses to inactivated and vector-based vaccines in individuals previously infected with SARS-CoV-2
368,Twelve-month specific IgG response to SARS-CoV-2 receptor-binding 467 domain among COVID-19 convalescent plasma donors in Wuhan
369,Cellular immunity in COVID-19 convalescents with PCR-470 confirmed infection but with undetectable SARS-CoV-2-specific IgG
370,Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months 473 following primary infection
371,Longitudinal analysis shows durable and broad immune memory after 475
372,SARS-CoV-2 infection with persisting antibody responses and memory B and T cells
373,Immunological memory to SARS-CoV-2 assessed for up to 8 months 478 after infection
374,"Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection 480 in a Population in Lombardy, Italy"
375,SARS-CoV-2 vaccines in development
376,Antibody responses after a single dose of SARS-CoV-2 mRNA vaccine
377,Antibody responses to the BNT162b2 mRNA vaccine in individuals 485 previously infected with SARS-CoV-2
378,Effect of previous SARS-CoV-2 infection on humoral and T-cell 487 responses to single-dose BNT162b2 vaccine
379,To appear in: Vaccine
380,COVID-19 vaccines: acting on the evidence
381,"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial"
382,Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
383,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
384,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
385,Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial
386,"A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia"
387,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial"
388,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
389,Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
390,Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
391,"Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine"
392,The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan
393,Does poor glycaemic control affect the immunogenicity of the COVID-19 vaccination in patients with type 2 diabetes: The CAVEAT study
394,Changes of Regulatory T Cells and of Proinflammatory and Immunosuppressive Cytokines in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
395,Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis
396,Immune system and COVID-19 by sex differences and age
397,"Obesity, chronic disease, age, and in-hospital mortality in patients with covid-19: analysis of ISARIC clinical characterisation protocol UK cohort"
398,Comparison of three sample size calculation methods for non-inferiority vaccine trials with multiple continuous co-primary endpoints
399,International Society of Hypertension global hypertension practice guidelines
400,Sample size determination in health studies: A practical manual. Geneva: World Health Organization
401,Inflammation and hypertension: new understandings and potential therapeutic targets
402,Inflammation in hypertension
403,GISAID's Role in Pandemic Response
404,Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2
405,Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination
406,Comparison of SARS-CoV-2 Antibody Response by Age Among Recipients of the BNT162b2 vs the mRNA-1273 Vaccine
407,"SARS-CoV-2, COVID-19 and the Ageing Immune System"
408,Immunosenescence and human vaccine immune responses
409,"Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine"
410,Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities
411,Age and Smoking Predict Antibody Titres at 3 Months after the Second Dose of the BNT162b2 COVID-19 Vaccine
412,Cell Immunometabolism and Redox Signaling in Hypertension
413,The Redox-Metabolic Couple of T Lymphocytes: Potential Consequences for Hypertension
414,Adaptive immune disorders in hypertension and heart failure: focusing on T-cell subset activation and clinical implications
415,Inflammation and Arterial Hypertension-Pathophysiological Links and Clinical Aspects
416,"Inflammation, Immunity, and Oxidative Stress in Hypertension-Partners in Crime?"
417,Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination
418,Implications of Inflammatory States on Dysfunctional Immune Responses in Aging and Obesity
419,Effectiveness of the WHO-authorized Covid-19 Vaccines: a Rapid Review of Global Reports till
420,ChAdOx1 Overall infection N/A 64%
421,BNT162b2 Overall infection N/A N/A 7 86% (78%-91%) 180766/ 51092 SCC BNT162b2 Overall infection N/A N/A 7 71%
422,SARS-CoV-2 variants: levels of neutralisation required for protective immunity. medRxiv
423,Antibody titres decline 3-month post-vaccination with BNT162b2
424,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
425,Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. medRxiv
426,Evidence for antibody as a protective correlate for COVID-19 vaccines
427,Correlates of Vaccine-Induced Protection against SARS-CoV-2
428,Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
429,Durable Humoral and Cellular Immune Responses 8
430,Months after Ad26.COV2.S Vaccination
431,Studies on the level of neutralizing antibodies produced by inactivated COVID-19 vaccines in the real world
432,"Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial"
433,Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting
434,Development of an inactivated vaccine candidate for SARS-CoV-2
435,DNA vaccine protection against SARS-CoV-2 in rhesus macaques
436,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults
437,"Overview of EU/EEA country recommendations on COVID-19 vaccination with Vaxzevria, and a scoping review of evidence to guide decision-making. 2021. Stockholm: European Centre for Disease Prevention and Control"
438,Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
439,"Serendipitous COVID-19 Vaccine-Mix in Uttar Pradesh, India: Safety and Immunogenicity Assessment of a Heterologous Regime"
440,Thailand sticks with Sinovac vaccine after cases of 'stroke-like' side effects. Reuters
441,"Immunization stress-related response: a manual for program managers and health professionals to prevent, identify and respond to stress-related responses following immunization. Geneva: World Health Organization"
442,Immunogenicity of heterologous prime/booster-inactivated and adenoviral-vectored COVID-19 vaccine: real-world data
443,"Thailand to mix Sinovac, AstraZeneca vaccine doses"
444,"Recommendation for an emergency use listing of COVID-19 vaccine (Vero cell), inactivated submitted by Sinovac. Geneva: World Health Organization"
445,European Medicines Agency. 2021. COVID-19 Vaccine AstraZeneca. AMSTERDAM: European Medicine Agency
446,"A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia. Vaccine"
447,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a doubleblind, randomised, placebo-controlled, phase 3 trial in Turkey"
448,Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
449,"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study"
450,Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein and its consequences
451,Longterm Specific IgG Response to SARS-CoV-2 Nucleocapsid Protein in Recovered COVID-19 Patients
452,Human IgG and IgA responses to COVID-19 mRNA vaccines
453,COVID-19 vaccination and IgG and IgA antibody dynamics in healthcare workers
454,Evolution of Antibody Immunity to SARS-CoV-2. bioRxiv
455,Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile
456,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial"
457,Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total Test in Recently Vaccinated Individuals
458,Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
459,Memory T cell responses targeting the SARS coronavirus persist up to 11 years postinfection. Vaccine
460,Limited and Short-Lasting Virus Neutralizing Titers Induced by Inactivated SARS-CoV-2 Vaccine. Emerg Infect Dis
461,Thailand cites positive results from Sinovac-AstraZeneca vaccine formula. Reuters
462,"preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in"
463,Waning of SARS-CoV-2 Antibody levels response to inactivated cellular vaccine over 6 months among healthcare workers
464,COVID-19) Dashboard with vaccination data
465,Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil
466,Infection and death in healthcare workers due to COVID-19: a systematic review
467,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variantassociated epidemic of COVID-19 in Brazil: a test-negative casecontrol study
468,Covid-19 breakthrough infections in vaccinated health care workers
469,Efcacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV Study
470,Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
471,Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test
472,"Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern Alpha, Delta, Beta) in Thai Healthcare Workers"
473,COVID-19 vaccine development pipeline gears up
474,Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis
475,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
476,"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac -PROFISCOV: A structured summary of a study protocol for a randomised controlled trial"
477,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
478,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence"
479,Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
480,WHO SAGE values framework for the allocation and prioritization of COVID-19
481,Safety and immunogenicity of ChAdOx1
482,"nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial"
483,Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study
484,Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
485,CoronaVac induces lower neutralising activity against variants of concern than natural infection
486,Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination
487,"COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron"
488,World Health Organization. WHO Coronavirus (COVID-19) Dashboard
489,Correlation of SARS-CoV-2-breakthrough 155 infections to time-from-vaccine
490,Covid-19 breakthrough infections in vaccinated 157 health care workers
491,Omicron variant showed lower neutralizing sensitivity than 159 other SARS-CoV-2 variants to immune sera elicited by vaccines after boost
492,Safety and 162 immunogenicity of heterologous and homologous inactivated and adenoviral
493,COVID-19 vaccines in healthy adults
494,Immunogenicity of a third 165 dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in 166 healthy adults
495,Reduced neutralization of SARS-CoV-2 B.1.1.7 168 variant by convalescent and vaccine sera
496,Correlates of protection against symptomatic and 170 asymptomatic SARS-CoV-2 infection
497,Antibody response and variant cross-172 neutralization after SARS-CoV-2 breakthrough infection
498,mRNA vaccination boosts cross-variant 175 neutralizing antibodies elicited by SARS-CoV-2 infection
499,Increased risk of SARS-CoV-2 178
500,reinfection associated with emergence of the Omicron variant in South Africa. medRxiv
501,SARS-CoV-2 B. 1.1. 529 variant (Omicron
502,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis
503,World Health Organization. WHO coronavirus disease (COVID-19) dashboard
504,Efficacy and Safety of the mRNA-1273
505,SARS-CoV-2 Vaccine
506,COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection
507,Prevalence of anti-platelet factor4/polyanionic antibodies after COVID-19 vaccination with ChAdOx1 nCoV-19 and CoronaVac in Thais
508,Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
509,Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
510,Pathologic Antibodies to Platelet Factor 4 after
511,Vaccination
512,An observational study to identify the prevalence of thrombocytopenia and anti-PF4/polyanion antibodies in Norwegian health care workers after COVID-19 vaccination
513,"Safety, Immunogenicity, and Efficacy of COVID-19 Vaccine in Children and Adolescents: A Systematic Review"
514,CDC. Vaccines: The Basics
515,Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases
516,Inference of COVID-19 epidemiological distributions from Brazilian hospital data
517,Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data
518,World Health Organization W. WHO SAGE Roadmap For Prioritizing Uses Of
519,Vaccines In The Context Of Limited Supply
520,Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus
521,101205. the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality. EClinicalMedicine
522,World Health Organization W. Evaluation of COVID-19 vaccine effectiveness
523,Cohort study design for estimating the effectiveness of seasonal influenza vaccines in real time based on register data: The Finnish example
524,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet"
525,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet
526,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study"
527,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. The Lancet"
528,Effectiveness of CoronaVac among healthcare workers in the setting of high SARS
529,"Gamma variant transmission in Manaus, Brazil: A test-negative case-control study"
530,BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
531,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
532,Efficacy Estimates for Various COVID-19 Vaccines: What we Know from the Literature and Reports
533,"Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study Summary Background"
534,World Health Organization. Tracking SARS-CoV-2 variants
535,Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
536,"Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance"
537,Tianjin Municipal Health Commission. Vaccination of COVID-19 in Tianjin
538,World Health Organization. Laboratory testing strategy recommendations for COVID-19: interim guidance
539,World Health Organization. Living guidance for clinical management of COVID-19: living guidance
540,SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo
541,The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters
542,Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis
543,Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study
544,AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific TH1 response with a diverse TCR repertoire
545,Decoupling of omicron variant infections and severe COVID-19
546,Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? The Lancet Respiratory medicine 2021
547,Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
548,Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates
549,"Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada"
550,Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study
551,COVID infection severity in children under 5 years old before and after Omicron emergence in the US
552,"Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections"
553,Alkaline
554,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness
555,A Novel Coronavirus from Patients with Pneumonia in China
556,COVID-19 vaccines and decreased transmission of SARS-CoV-2
557,Prevention of host-to-host transmission by SARS-CoV-2 vaccines
558,COVID-vaccine booster shot shows promise in Israeli study
559,Reconstruction of the full transmission dynamics of COVID-19 in Wuhan
560,Special report: The simulations driving the worlds response to COVID-19
561,Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons
562,In vivo kinetics of SARS-CoV-2 infection and its relationship with a persons infectiousness
563,"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. The Lancet Infectious Diseases"
564,mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
565,Homeostatic proliferation of B cells
566,Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies
567,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
568,Remdesivir for the Treatment of Covid-19 -Final Report
569,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
570,COVID-19 and the Path to Immunity
571,Cross-reactive memory T cells and herd immunity to SARS-CoV-2
572,"Optimising Vaccine Dose in Inoculation against SARS-CoV-2, a Multi-Factor Optimisation Modelling Study to Maximise Vaccine Safety and Efficacy. Vaccines (Basel) 9"
573,Mechanisms of SARS-CoV-2 Transmission and Pathogenesis
574,Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals
575,Estimating infectiousness throughout SARS-CoV-2 infection course
576,Social contacts and mixing patterns relevant to the spread of infectious diseases
577,Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants
578,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants
579,Risking further COVID-19 waves despite vaccination. The Lancet Infectious Diseases
580,Relaxing restrictions at the pace of vaccination increases freedom and guards against further covid-19 waves
581,Controlling the pandemic during the SARS-CoV-2 vaccination rollout: a modeling study
582,Immunological characteristics govern the transition of COVID-19 to endemicity
583,Concerns about sars-cov-2 evolution should not hold back efforts to expand vaccination
584,Low case numbers enable long-term stable pandemic control without lockdowns. medRxiv
585,The challenges of containing SARS-CoV-2 via test-trace-and-isolate
586,Sars-cov-2 incidence and vaccine escape
587,The variant gambit: COVID's next move
588,Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein. medRxiv
589,Gisaid: Global initiative on sharing all influenza data -from vision to reality
590,Alarming COVID variants show vital role of genomic surveillance
591,The genomic landscape of sars-cov-2: Surveillance of variants of concern
592,How cooperative engagement programs strengthen sequencing capabilities for biosurveillance and outbreak response
593,Limited resources of genome sequencing in developing countries: challenges and solutions
594,Socioeconomic status determines covid-19 incidence and related mortality in santiago
595,Estimating the effect of social inequalities on the mitigation of covid-19 across communities in santiago de chile
596,All things equal? heterogeneity in policy effectiveness against covid-19 spread in chile
597,On the heterogeneous spread of covid-19 in chile
598,A multi-group SEIRA model for the spread of COVID-19 among heterogeneous populations
599,Geographical distribution of genetic variants and lineages of sars-cov-2 in chile
600,Covid-19: Chile joins top five countries in world vaccination league
601,The story behind chile's rapid rollout of covid-19 vaccination
602,Coronavirus pandemic (covid-19)
603,The effect of covid-19 on the economy: Evidence from an early adopter of localized lockdowns
604,"Nyna Llanovarced-Kawles, and Álvaro Olivera-Nappa. Statistically-based methodology for revealing real contagion trends and correcting delay-induced errors in the assessment of COVID-19 pandemic"
605,National strategy for test-trace-and-isolate (COVID-19
606,"Vacunas contra sars-cov-2 utilizadas en chile mantienen altos niveles de efectividad para evitar hospitalización, ingreso a uci y muerte"
607,Effectiveness of an inactivated sars-cov-2 vaccine in chile
608,Mutation in a sars-cov-2 haplotype from sub-antarctic chile reveals new insights into the spike's dynamics
609,Infectivity and immune escape of the new sars-cov-2 variant of interest lambda. medRxiv
610,The emergence of sars-cov-2 variant lambda (c. 37) in south america. medRxiv
611,Emergencia de variante delta-b. 1.617. 2. su impacto potencial en la evolución de la pandemia por sars-cov-2
612,Comunicado de sochinf sobre variante delta en chile
613,"Viral deep sequencing needs an adaptive approach: IRMA, the iterative refinement meta-assembler"
614,MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform
615,Subject_term: Classification and taxonomy;Phylogenetics;Phylogeny;SARS-CoV-2;Viral evolution Subject_term_id: classification-and-taxonomy
616,Estimating Individual and Household Reproduction Numbers in an Emerging Epidemic
617,Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe
618,"Yarin Gal, and Jan Kulveit"
619,Inferring change points in the spread of COVID-19 reveals the effectiveness of interventions
620,Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
621,Bayesian phylodynamic inference with complex models
622,BEAST 2.5: An advanced software platform for Bayesian evolutionary analysis
623,Systemic effects of missense mutations on SARS-CoV-2 spike glycoprotein stability and receptor-binding affinity
624,Characterizing SARS-CoV-2 mutations in the United States
625,"Soodeh Hooshmandi, Behrooz Ataei, and Shaghayegh Haghjooy Javanmard. Novel and emerging mutations of SARS-CoV-2: Biomedical implications"
626,Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England
627,"Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study"
628,Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity
629,First identification of SARS-CoV-2 Lambda (C.37) variant in Southern Brazil. medRxiv
630,"COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence"
631,Virology Subject_term_id: sars-cov-2;virology
632,Different mutations in SARS-CoV-2 associate with severe and mild outcome
633,Increased transmissibility and global spread of sars-cov-2 variants of concern as at
634,Ongoing global and regional adaptive evolution of SARS-CoV-2
635,Subject_term: Protein analysis;SARS-CoV-2;Vaccines;Viral evolution
636,Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda. medRxiv
637,An interactive web-based dashboard to track covid-19 in real time
638,"Journal Pre-proofs Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Be- ta) in Thai Healthcare Workers Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV- 2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers"
639,Vaccine Breakthrough Infections with SARS-CoV-2 Variants
640,WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination
641,"39) Body mass index: kg/m 2 (median, IQR)"
642,*Statistical significance (p-value < 0.05) comparing between ChAdOx1 and CoronaVac group
643,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days
644,COVID-19 Vaccine: Where Are We Now and Where Should We Go?
645,Neutralizing Antibody Levels Are Highly Predictive of Immune Protection From Symptomatic SARS-CoV-2 Infection
646,Development of an Inactivated Vaccine Candidate for SARS-CoV-2
647,Looking Beyond COVID-19 Vaccine Phase 3 Trials
648,Progress and Prospects on Vaccine Development Against SARS-CoV-2. Vaccines (2020)
649,Systems Vaccinology of the BNT162b2 mRNA Vaccine in Humans
650,Human Neutralizing Antibodies Against SARS-CoV-2 Require Intact Fc Effector Functions for Optimal Therapeutic Protection
651,Critical Role of Neutralizing Antibody for SARS-CoV-2 Reinfection and Transmission
652,A Longitudinal Study of SARS-CoV-2-Infected Patients Reveals a High Correlation Between Neutralizing Antibodies and COVID-19 Severity
653,Licence: CC BY-NC-SA 3.0 IGO.). Available at
654,Neutralizing Antibodies Titers and Side Effects in Response to BNT162b2 Vaccine in Healthcare Workers With and Without Prior SARS-CoV-2 Infection
655,"Antibodies Against Receptor Binding Domain of SARS-CoV-2 Spike Protein Induced by BNT162b2 Vaccine: Results From a Pragmatic, Real-Life Study"
656,Dynamics of SARS-CoV-2 Neutralising Antibody Responses and Duration of Immunity: A Longitudinal Study
657,Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
658,Incidence of SARS-CoV-2 Infection in Health Care Workers From Northern Italy Based on Antibody Status: Immune Protection From Secondary Infection-A Retrospective Observational Case-Controlled Study
659,Isolation of Potent SARS-CoV-2 Neutralizing Antibodies and Protection From Disease in a Small Animal Model
660,Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques
661,Regeneron Reports Positive Interim Data With REGEN-COVTM Antibody Cocktail Used as Passive Vaccine to Prevent COVID-19
662,Long-Term Protection at 20-31 Years After Primary Vaccination With Plasma-Derived Hepatitis B Vaccine in a Chinese Rural Community
663,Duration of Immunity Against Pertussis After Natural Infection or Vaccination
664,Effectiveness of Influenza Vaccination on Influenza-Associated Hospitalisations Over Time Among Children in Hong Kong: A Test-Negative Case-Control Study
665,Evolution of Antibody Immunity to SARS-CoV-2
666,Evolution of Immune Res1ponses to SARS-CoV-2 in Mild-Moderate COVID-19
667,Immunological Memory to SARS-CoV-2 Assessed for Up to 8 Months After Infection
668,mRNA Vaccines Induce Durable Immune Memory to SARS-CoV-2 and Variants of Concern
669,WHO Approval of Chinese CoronaVac COVID Vaccine Will be Crucial to Curbing Pandemic
670,IgA Dominates the Early Neutralizing Antibody Response to SARS-CoV-2
671,IgA Antibodies and IgA Deficiency in SARS-CoV-2 Infection
672,Enhanced SARS-CoV-2 Neutralization by Dimeric IgA
673,Clinical outcomes in hospitalized vaccine-breakthrough COVID-19 cases compared with contemporary unvaccinated hospitalized adults
674,et als for the COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
675,-Chile´s Ministry of Health daily official report
676,Chile´s Ministry of Health. Effectiveness of the SARS-CoV-2 vaccine program
677,2%) COVID-19 admissions in adults with incomplete vaccination and/or <14 days of last dose at COVID-19 diagnosis; these patients were not eligible for the study CCU: Critical Care Unit
678,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines
679,"Excess deaths associated with COVID-19, by age and race and ethnicity: United States"
680,Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine: United States
681,International consensus (ICON): allergic reactions to vaccines
682,"COVID-19 vaccine anaphylaxis: IgE, complement or what else? A reply to -COVID-19 vaccine anaphylaxis -PEG or not?"
683,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, doubleblind, placebo-controlled, phase 1/2 clinical trial"
684,Centers for Disease Control and Prevent. Interim clinical considerations for use of COVID-19 vaccines currently approved and authorized in the United States
685,CDC_ AA_refVal=https%3A%2F%2F Accessed
686,Allergic reactions to CO-VID-19 vaccinations-unveiling the secret(s)
687,"EAACI statement on the diagnosis, management and prevention of severe allergic reactions to CO-VID-19 vaccines"
688,"The international EAACI/GA2LEN/EuroGuiDerm/ APAAACI guideline for the definition, classification, diagnosis, and management of urticaria"
689,Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: results of the PURIST Study
690,Chronic urticaria and autoimmunity: associations found in a large population study
691,Multiple drug hypersensivity: insight into the underlying mechanism and correlation with autoimmune diseases
692,Autoreactivity is highly prevalent in patients with multiple intolerances to NSAIDs
693,Intolerance to nonsteroidal anti-inflammatory drugs might precede by years the onset of chronic urticaria
694,Coagulation cascade and fibrinolysis in patients with multipledrug allergy syndrome
695,Vasovagal episode or anaphylaxis
696,Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine -United States
697,Vaccine allergy: evidence to consider for COVID-19 vaccines
698,World allergy organization anaphylaxis guidance 2020
699,"Anaphylaxis: clinical patterns, mediator release, and severity"
700,Scadding GK. Allergic rhinitis
701,Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines
702,Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care: asthma and rhinitis
703,Global strategy for asthma management and prevention (update 2021)
704,Adverse reactions to COVID-19 vaccines: a practical approach
705,Allergy to COVID-19 vaccines: a current update
706,Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines
707,Polyethylene glycol-induced systemic allergic reactions (Anaphylaxis)
708,Polyethylene glycol may be the major allergen in depot medroxyprogesterone acetate
709,Anaphylaxis to PEGylated liposomal echocardiogram contrast in a patient with IgE-mediated macrogol allergy
710,Aluminum and vaccines: current state of knowledge
711,Allergic and cutaneous reactions following inactivated SARS-CoV-2 vaccine (CoronaVac®) in healthcare workers
712,Cutaneous reactions following CoronaVac COVID-19 vaccination: a case series of six healthcare workers from a single centre
713,Petechial skin rash associated with CoronaVac vaccination: first cutaneous side effect report before phase 3 results
714,CoronaVac COVID-19 vaccineinduced anaphylaxis: clinical characteristics and revaccination outcomes
715,Successful SARS-CoV-2 vaccine allergy risk-management: the experience of a large Italian University hospital
716,Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine
717,Safety of CO-VID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome
718,mRNA CO-VID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis
719,Clinical characteristics and risk profile of patients with elevated baseline serum tryptase
720,Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration
721,Risk of allergic reaction in patients with atopic disease and recent coronavirus disease 2019 vaccination
722,The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients
723,Quick COVID-19 healers sustain anti-SARS-CoV-2 antibody production
724,Administration of a second dose of the Moderna CO-VID-19 vaccine after an immediate hypersensitivity reaction with the first dose: two case reports
725,Immediate-type systemic hypersensitivity reactions after the inactivated Sars-Cov-2 vaccine in healthcare workers
726,The Journal of Headache and Pain
727,The International Classification of Headache Disorders
728,Biphasic neurovascular changes in prolonged migraine aura in familial hemiplegic migraine type 2
729,Hemiplegic migraine aura begins with cerebral hypoperfusion: imaging in the acute phase
730,Pathophysiology of Migraine: A Disorder of Sensory Processing
731,Diagnostic and therapeutic aspects of hemiplegic migraine
732,Migraine headache is present in the aura phase: a prospective study
733,A population-based study of familial hemiplegic migraine suggests revised diagnostic criteria
734,Sporadic hemiplegic migraine with permanent neurological deficits
735,Enhanced subcortical spreading depression in familial hemiplegic migraine type 1 mutant mice
736,Spreading depression and the clinical correlates of migraine
737,Reduced threshold for cortical spreading depression in female mice
738,Menstrual migraine: a distinct disorder needing greater recognition
739,"A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial"
740,Induction of production of nitric oxide in microglial cells by insoluble form of aluminium
741,Aluminum treatment induces nitric oxide synthase in the rat brain
742,Glyceryl trinitrate triggers premonitory symptoms in migraineurs
743,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
744,WHO. WHO coronavirus disease (COVID-19) dashboard. 2020
745,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"
746,Association between age and clinical characteristics and outcomes of COVID-19
747,COVID-19 and older adults: what we know
748,"SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes"
749,Study of the immune response in the elderly: is it necessary to develop a vaccine against Neisseria meningitidis for the aged?
750,"Nutrition, diet and immunosenescence"
751,Draft landscape of COVID-19 candidate vaccines
752,Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults
753,Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates
754,"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial"
755,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial"
756,Durability of responses after SARS-CoV-2 mRNA-1273 vaccination
757,Our progress in developing a potential COVID-19 vaccine
758,AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
759,Sputnik V: general information
760,"Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults"
761,Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials
762,Guidelines for grading standards of adverse events in clinical trials of preventive vaccines
763,Estimates of influenza vaccine effectiveness in primary care in Scotland vary with clinical or laboratory endpoint and method-experience across the 2010/11 season
764,Pancreatitis after human papillomavirus vaccination: a matter of molecular mimicry
765,Severe necrotizing pancreatitis following combined hepatitis A and B vaccination
766,An effective COVID-19 vaccine needs to engage T cells
767,An mRNA vaccine against SARS-CoV-2-preliminary report
768,A new accelerated vaccination schedule for rapid protection against hepatitis A and B
769,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial
770,World Health Organization. WHO coronavirus (COVID-19) dashboard 2021
771,Repurposed antiviral drugs for COVID-19 -interim WHO Solidarity Trial results
772,COVID-19 vaccine efficacy and effectivenessthe elephant (not) in the room
773,Adaptive immunity to SARS-CoV-2 and COVID-19
774,Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients
775,How the world is (not) handling surplus doses and expiring vaccines
776,Immunogenicity and safety of reduced-dose intradermal vs intramuscular influenza vaccines: a systematic review and meta-analysis
777,"Vaccination into the dermal compartment: techniques, challenges, and prospects. Vaccines (Basel) 2020"
778,Intradermal COVID-19 vaccination could solve supply problems
779,Delivery systems for intradermal vaccination
780,WHO international standard for anti-SARS-CoV-2 immunoglobulin
781,Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay
782,A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction
783,CD8+ T cells as a source of IFN-gamma production in human cutaneous leishmaniasis
784,"Th1 cytokines, true functional signatures for protective immunity against TB?"
785,"Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone(R)) administered by intradermal and intramuscular route in healthy adults"
786,"Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents"
787,Detection of neutralizing antibodies against SARS-CoV-2 by using a commercial surrogate virus neutralization ELISA: can it substitute the classical neutralization test?
788,Surrogate test performance for SARS-CoV-2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): how useful could they be?
789,Adenovirus vector-based vaccine for infectious diseases
790,A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters
791,"Intradermal delivery of adenoviral type-35 vectors leads to high efficiency transduction of mature, CD8+ T cellstimulating skin-emigrated dendritic cells"
792,Antigen presentation and adaptive immune responses in skin
793,Antigen-presenting cells in the skin
794,A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity
795,Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice. Sci Rep
796,Adenovirus receptors
797,Adenovirus receptors and their implications in gene delivery
798,Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization
799,World Health Organization. Rabies vaccines: WHO position paper
800,"Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy"
801,Intradermal ChAdOx1 vaccine following two CoronaVac shots: a case report. Vaccines (Basel)
802,Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
803,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2
804,WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic [Internet]. Nature. Nature
805,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
806,Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study
807,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine. Front Immunol
808,5% de la población objetivo ha recibido la primera o única dosis de la vacuna contra SARS-CoV-2 -Ministerio de Salud -Gobierno de Chile
809,Protection duration after vaccination or infection -Swiss National COVID-19
810,Science Task Force
811,Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
812,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine. Front Immunol
813,World medical association. World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects
814,2403 Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody
815,despite high seroprevalence
816,BNT162b2 vaccine booster dose protection: A nationwide study from Israel. medRxiv
817,Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly
818,Available from: All rights reserved. No reuse allowed without permission
819,"A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled"
820,Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells
821,BNT162b2 vaccination induces durable SARS-CoV-2 specific T cells with a stem cell memory phenotype
822,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine
823,Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination
824,"Confronting the Delta variant of SARS-CoV-2, Summer"
825,Coronavirus Pandemic (COVID-19). Our World in Data
826,COVID-19 (SARS-CoV-2) variants. GOV.UK; 2021
827,Effectiveness of covid-19 vaccines against the B.1.617.2 (Delta) variant
828,Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
829,Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
830,COVID-19 vaccines for moderately to severely immunocompromised people. Cdc.gov; 2021
831,Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals. U.S. Food and Drug Administration
832,A country-by-country guide to coronavirus vaccine booster plans. POLITICO; 2021
833,Turkey's national immunization program
834,Indonesia begins to give third COVID-19 shots to 1.5 million health workers. Jakarta Post
835,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers
836,Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers
837,Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience
838,A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine
839,"Clinical evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative IgG and IgM assays among infected, recovered, and vaccinated groups"
840,Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis
841,Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study
842,Quantitative SARS-CoV-2 antispike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status
843,Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses
844,Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)
845,Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors
846,Third dose of the BNT162b2 vaccine in heart transplant recipients: immunogenicity and clinical experience
847,Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis
848,Reactogenicity of a third BNT162b2 mRNA COVID-19 vaccine among immunocompromised individuals and seniors-a nationwide survey
849,Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
850,Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
851,Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose
852,Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary
853,Protection of BNT162b2 vaccine booster against Covid-19 in Israel
854,Safety monitoring of an additional dose of COVID-19 vaccine-United States
855,Supporting Information section at the end of this article. How to cite this article
856,"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and"
857,Thailand sticks with Sinovac vaccine after cases of''stroke-lik'' side effects
858,"World Health Organization. Recommendation for an emergency use listing of COVID-19 vaccine (Vero cell), inactivated submitted by Sinovac. Geneva: World Health Organization"
859,Amsterdam: European Medicine Agency
860,COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants
861,Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant
862,Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
863,Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans
864,"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial"
865,Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals
866,"Indonesia 2 Centre for Research and Development on Biomedical and Basic Health Technology, National Institute of Health Research and Development (NIHRD), Ministry of Health of Indonesia"
867,"*Based on adjusted multivariable logistic regression, accounting for age (continuous), sex, district of COVID-19 in adults (aged 18 years), by age group"
868,COVID-19 vaccination coverage in adults 18 years (any type of vaccines) during
869,Indonesia (Data source: Ministry of Health of Indonesia)
870,Trends in COVID-19 incidence in Bali over the period of study (Data source: Ministry 622 of Health of Indonesia)
871,Distribution of SARS-CoV-2 variants of concern (VOCs) in samples examined during 632
872,Variant proportions are estimated against total sequences of 633 collected samples of each month. Total samples are varied for each month. Data are subject to change 634 over time and will be updated as more data become available. Variant proportions may not represent 635 national estimates
873,Data source: Ministry of Health of Indonesia)
874,Good recovery of immunization stress-related responses presenting as cluster of stroke- 2 like events following CoronaVac and ChAdOx1 vaccinations
875,"Immunization stress-related response: a manual for program managers and 308 health professionals to prevent, identify and respond to stress-related responses following 309 immunization"
876,Current Concepts in 311 Diagnosis and Treatment of Functional Neurological Disorders
877,Complex regional pain syndrome and 313 functional neurological disorders -time for reconciliation
878,Acute prolonged motor aura resembling ischemic stroke after COVID -19 vaccination (CoronaVac): the 317 first case report
879,Abnormal parietal function in 319 conversion paresis
880,Motor cortical 321 activity during motor tasks is normal in patients with complex regional pain syndrome
881,324 Immunization stress-related responses presenting as psychogenic non-epileptic seizures following HPV 325 vaccination in Rio Branco
882,"HPV vaccine confidence and cases of mass 327 psychogenic illness following immunization in Carmen de Bolivar, Colombia. Human vaccines & 328 immunotherapeutics"
883,Mass psychogenic illness in nationwide in-school vaccination 330 for pandemic influenza A (H1N1)
884,Mass psychogenic response to human papillomavirus vaccination. The 333
885,Psychogenic illness following vaccination: exploratory study of 335 mass vaccination against pandemic influenza A (H1N1) in 2009 in South Korea. Clinical and experimental 336 vaccine research
886,Disorder After SARS-CoV-2 Vaccines: Two Case Reports and Discussion of Potential Public Health 339 Implications
887,Functional neurological disorder after COVID-341 19 vaccination
888,63rd ASH Annual Meeting Abstracts POSTER ABSTRACTS 642.CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICAL AND EPIDEMIOLOGICAL COVID-19 Infection in Vaccinated Adult Patients with Hematological Malignancies. Preliminary Results from Epicovideha (Epidemiology of COVID-19 infection in patients with hematological malignancies: A European Haematology Association Survey)
889,Cidara: Membership on an entity's Board of Directors or advisory committees
890,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis
891,"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"
892,Associations of baseline use of biologic or targeted synthetic DMARDs 16
893,Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
894,Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study
895,An mRNA Vaccine against SARS-CoV-2 -Preliminary Report
896,"SARS-CoV-2 vaccination in IBD: past lessons, current evidence and future challenges"
897,Antigen-specific antibody responses in lupus patients following immunization
898,The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis
899,Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
900,Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
901,PROSPERO's progress and activities 2012/13
902,JBI Manual for Evidence Synthesis
903,GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias)
904,Measuring inconsistency in meta-analyses
905,High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases
906,"Correspondence on ""SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response"
907,"but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases"
908,Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis
909,Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2
910,"Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients: An Observational, Prospective Cohort Study Interim Analysis"
911,Immunogenicity of the ChAdOx1 nCoV-19 and the BBV152 Vaccines in Patients with Autoimmune Rheumatic Diseases
912,Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel Disease
913,Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab
914,Spike-antibody responses to ChAdOx1 and BNT162b2 vaccines by demographic and clinical factors (Virus Watch study)
915,Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis
916,The importance of cell-mediated immunity in COVID-19 -An opinion
917,Preprint manuscripts and servers in the era of coronavirus disease 2019
918,"Heterogeneity: I 2 = 0%, Q = 1.65, P ="
919,"Heterogeneity: I 2 = 0%, Q = 1.33"
920,Heterogeneity: I 2 = 0%
921,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes
922,Vaccine-associated hypersensitivity
923,World Health Organization. Interim recommendations for use of the inactivated COVID-19 vaccine
924,Data from the Ministry of Public Health
925,"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data"
926,Why the 20% + 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome
927,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, Phase 1/2 trial"
928,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, Phase 3 trial in Turkey"
929,EAACI guideline: anaphylaxis (2021 update)
930,Aluminum hydroxide adjuvant differentially activates the three complement pathways with major involvement of the alternative pathway
931,Immunemediated adverse reactions to vaccines
932,Could aluminum be a new hidden allergen in type 1 hypersensitivity reactions when used as a drug additive?
933,Total and IgE antibody levels following booster immunization with aluminum absorbed and nonabsorbed tetanus toxoid in humans
934,Safety evaluation of the second dose of messenger RNA COVID-19 vaccines in patients with immediate reactions to the first dose
935,Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: don't give up on the second dose! Allergy
936,Administration of a second dose of the moderna COVID-19 vaccine after an immediate hypersensitivity reaction with the first dose: two case reports
937,First-dose mRNA COVID-19 vaccine allergic reactions: limited role for excipient skin testing
938,Safe administration of the Pfizer-BioNtTech COVID-19 vaccine following an immediate reaction to the first dose
939,Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19
940,International Consensus (ICON): allergic reactions to vaccines
941,Clinical Immunization Safety Assessment Network Hypersensitivity Working G. Irritant skin test reactions to common vaccines
942,Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group
943,"Progress of the COVID-19 Vaccine Effort: Viruses, Vaccines and Variants Versus Efficacy, Effectiveness and Escape"
944,Phase I/II Study of COVID-19 RNA Vaccine BNT162b1 in Adults
945,"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Treating Healthcare Professionals With the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac -PROFISCOV: A Structured Summary of a"
946,Interim Report : Safety and Immunogenicity of an Inactivated Vaccine
947,Ministerio de Salud Gobierno de Chile. Ficha Vacuna Contra Sars-Cov-2
948,Available at
949,"A Systematic Review of Antibody Mediated Immunity to Coronaviruses: Kinetics, Correlates of Protection, and Association With Severity"
950,Insights Into Neutralizing Antibody Responses in Individuals Exposed to SARS-CoV-2 in Chile
951,Prime and Boost Vaccination Elicit a Distinct Innate Myeloid Cell Immune Response
952,Cell-Mediated Immune Response to Respiratory Coronaviruses
953,SARS Coronavirus Spike Protein-Induced Innate Immune Response Occurs via Activation of the NF-kb Pathway in Human Monocyte Macrophages In Vitro
954,SARS-CoV-2 Nsp14 Activates NF-kb Signaling and Induces IL-8 Upregulation
955,"Dynamic Changes in Serum IL-6, IL-8, and IL-10 Are Associated With the Outcome of Patients With Severe COVID-19 in ICU"
956,Duration of Humoral Immunity to Common Viral and Vaccine Antigens
957,Immunology of COVID-19: Current State of the Science
958,COVID-19 Vaccine BNT162b1 Elicits Human Antibody and TH1 T Cell Responses
959,Changes of Lymphocyte Subsets in Patients With COVID-19 and Clinical Significance: A Case-Control Observational Study
960,Acute asthma exacerbation after SARS-CoV-2 vaccine (Sinovac®): a case report
961,World Health Organization. The Sinovac COVID-19 vaccine: What you need to know
962,What do we know about China's covid-19 vaccines?
963,A review of the progress and challenges of developing a vaccine for COVID-19
964,Sinovac COVID-19 vaccine: What are the side effects?
965,18)F-fluorodeoxyglucose PET/CT findings in a systemic inflammatory response syndrome after COVID-19 vaccine
966,Seasonal influenza vaccine-induced pneumonitis presenting with multiple pulmonary nodules
967,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine
968,An Interactive Web-Based Dashboard to Track COVID-19 in Real Time
969,SARS-CoV-2 Spike-Protein D614G Mutation Increases Virion Spike Density and Infectivity
970,SARS-CoV-2 D614G Spike Mutation Increases Entry Efficiency With Enhanced ACE2-Binding Affinity
971,COVID-19 mRNA Vaccine Induced Antibody Responses and Neutralizing Antibodies Against Three SARS
972,The Spike D614g Mutation Increases Sars-Cov-2 Infection of Multiple Human Cell Types
973,"SARS-CoV-2 Variants, Spike Mutations and Immune Escape"
974,The N501Y Spike Substitution Enhances SARS-CoV-2 Transmission
975,Resistance of SARS-CoV-2 Variants to Neutralization by Monoclonal and Serum-Derived Polyclonal Antibodies
976,"Neutralization of SARS-CoV-2 Spike 69/70 Deletion, E484K and N501Y Variants by BNT162b2 Vaccine-Elicited Sera"
977,Molecular Determinants and Mechanism for Antibody Cocktail Preventing SARS-CoV-2 Escape
978,Increased Transmissibility and Global Spread of SARS-CoV-2 Variants of Concern as at
979,SARS-CoV-2 Spike P681R Mutation Enhances and Accelerates Viral Fusion
980,"Transmission, Infectivity, and Neutralization of a Spike L452R SARS-CoV-2 Variant"
981,Plan Nacional De Vacunacioń
982,Surrogate Virus Neutralization Test Based on Antibody-Mediated Blockage of ACE2-spike Protein-Protein Interaction
983,"Tolerability, and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in Healthy Adults Aged 18-59 Years: A Randomised, Double-Blind, Placebo-Controlled, Phase 1/2 Clinical Trial"
984,Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis
985,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine
986,Immune Responses Against SARS-CoV-2 Variants After Heterologous and Homologous ChAdOx1 Ncov-19/BNT162b2 Vaccination
987,Effectiveness of the CoronaVac Vaccine in the Elderly Population During a P.1 Variant-Associated Epidemic of COVID-19 in Brazil: A Test-Negative Case-Control Study
988,"A Third Dose of Inactivated Vaccine Augments the Potency, Breadth, and Duration of Anamnestic Responses Against"
989,Neutralisation of SARS-CoV-2 Lineage P.1 by Antibodies Elicited Through Natural SARS-CoV-2 Infection or Vaccination With an Inactivated SARS-CoV-2 Vaccine: An Immunological Study
990,Infectivity and Immune Escape of the New SARS-CoV-2 Variant of Interest Lambda
991,"Neutralization of Alpha, Gamma, and D614G SARS-CoV-2 Variants by CoronaVac Vaccine-Induced Antibodies"
992,Structural and Functional Ramifications of Antigenic Drift in Recent SARS-CoV-2 Variants
993,CoronaVac Induces Lower Neutralising Activity Against Variants of Concern Than Natural Infection
994,Neutralizing Activity of BNT162b2-Elicited Serum
995,BNT162b2-Elicited Neutralization of B.1.617 and Other SARS-CoV-2 Variants
996,Reduced Sensitivity of SARS-CoV-2 Variant Delta to Antibody Neutralization
997,Development of Neutralizing Antibody Responses Against SARS-CoV-2 in COVID-19 Patients
998,Impact of SARS-CoV-2 Variants on the Total CD4+ and CD8+ T Cell Reactivity in Infected or Vaccinated Individuals
999,Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy
1000,WHO coronavirus disease (COVID-19) dashboard
1001,"Pregnancy, viral infection, and COVID-19"
1002,Characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status -United States
1003,COVID-19 vaccines: interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States
1004,"The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations"
1005,In-terim guidance for COVID-19 vaccination in children and adolescents
1006,CoV-2 IgG II. FDA emergency use authorization instructions manuscript
1007,Newborn antibodies to SARS-CoV-2 detected in cord blood after maternal vaccination -a case report. C Pediatr
1008,Cord blood antibodies following maternal COVID-19 vaccination during pregnancy
1009,Assessment of maternal and neonatal cord blood SARS-CoV-2 antibodies and placental transfer ratios. MA Pediatr
1010,Antibodies in the breast milk of a maternal woman with COVID-19. Emerg Microbes Infect
1011,SARS-CoV-2-specific antibodies in breast milk after COVID-19 vaccination of breastfeeding women
1012,Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons
1013,"Infectious diseases society of America. Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the infectious diseases society of America"
1014,"Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment"
1015,COVID-19 Vaccination Programme
1016,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"
1017,Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry
1018,view points on SARS-CoV-2 vaccination in patients with RMDs
1019,Safety of the first dose of SARS-CoV-2 vaccination in solid organ transplant recipients
1020,COVID-19) vaccination information for public health professionals
1021,European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
1022,The Hong Kong society of rheumatology consensus recommendations for COVID-19 vaccination in adult patients with autoimmune rheumatic diseases
1023,COVID-19 vaccination and antirheumatic therapy
1024,Vaccination against COVID-19: expectations and concerns of patients with autoimmune and rheumatic diseases
1025,Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries
1026,2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
1027,Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
1028,BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting
1029,Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases
1030,Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies
1031,Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
1032,Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2
1033,Impaired antibody response to the BNT162b2 messenger RNA coronavirus disease 2019 vaccine in patients with systemic lupus erythematosus and rheumatoid arthritis
1034,Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 global rheumatology alliance vaccine survey
1035,Challenges to vaccination against SARS-CoV-2 in patients with immune-mediated diseases
1036,Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations
1037,Evaluation of immune response and disease status in SLE patients following SARS-CoV-2 vaccination
1038,"Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies"
1039,COVID-19 vaccine tracker
1040,mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
1041,Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
1042,SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera
1043,Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera
1044,"Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera"
1045,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study. Lancet Microbe. 2021
1046,Development of neutralizing antibody responses against SARS-CoV-2 in COVID-19 patients
1047,Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition
1048,SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
1049,"Severe acute respiratory syndrome coronavirus 2 P.2 lineage associated with reinfection case, Brazil"
1050,A human monoclonal antibody blocking SARS-CoV-2 infection
1051,Human neutralizing antibodies elicited by SARS-CoV-2 infection
1052,Comparison of four SARS-CoV-2 Neutralization Assays
1053,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3"
1054,Draft landscape and tracker of COVID-19 candidate vaccines 415
1055,Assessing transmissibility 418 of SARS-CoV-2 lineage B.1.1.7 in England
1056,Model-420 based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant
1057,Increased mortality in 423 community-tested cases of SARS-CoV-2 lineage B.1.1.7
1058,Risk of 425 mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort 426 study
1059,Genomics and 428 epidemiology of the P.1 SARS-CoV-2 lineage in Manaus
1060,Sensitivity of 431 infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
1061,Neutralizing Antibodies Against SARS-CoV-434 2 Variants After Infection and Vaccination
1062,Resistance of SARS-CoV
1063,1.351 and B.1.1.7 to Antibody Neutralization
1064,Escape of SARS-CoV-2 501Y.V2 438 from neutralization by convalescent plasma
1065,V2 escapes neutralization by South African COVID-19 donor plasma
1066,Direct gene transfer into 443 mouse muscle in vivo
1067,History of vaccination
1068,Safety and Efficacy of 446 the BNT162b2 mRNA Covid-19 Vaccine
1069,Safety and Efficacy 448 of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
1070,Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
1071,Efficacy and Safety of the 454 mRNA-1273 SARS-CoV-2 Vaccine
1072,Efficacy of 457 the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
1073,Press release. CureVac Final Data from Phase 2b/3 Trial of First-Generation
1074,"Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60"
1075,Efficacy of ChAdOx1 nCoV-465 19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an 466 exploratory analysis of a randomised controlled trial. The Lancet [Internet]. 30 mars 2021
1076,"Safety and efficacy 470 of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four 471 randomised controlled trials in Brazil, South Africa, and the UK. The Lancet"
1077,Efficacy of the ChAdOx1 474 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
1078,AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 476 at interim analysis
1079,Effectiveness of 602 the Single-Dose Ad26.COV2.S COVID Vaccine
1080,FDA-606 authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across 607 a multi-state health system
1081,Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19
1082,MMWR 611 Morb Mortal Wkly Rep
1083,Effect of Vaccination on 614 Transmission of SARS-CoV-2
1084,An 616 Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome
1085,Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by 618
1086,Clin Infect Dis
1087,Impact of Delta 621 on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK 622
1088,BNT162b2 625 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar 626
1089,Comparison 629 of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant 630 prevalence
1090,Interim Estimates of 637 Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-638
1091,"CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and 639"
1092,MMWR Morb Mortal 640 Wkly Rep
1093,BNT162b2 643 mRNA Covid-19 vaccine effectiveness in the prevention of SARS-CoV-2 infection: a preliminary 644 report
1094,Effectiveness of BNT162b2 647 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers
1095,Multicentre Prospective Cohort Study (the SIREN Study)
1096,Social Science Research Network; 2021 févr
1097,BNT162b2 Vaccine 652 Effectiveness in Preventing Asymptomatic Infection with SARS-CoV-2 Virus: A Nationwide 653
1098,Historical Cohort Study
1099,Social Science Research Network; 2021 mars 654
1100,Vaccine 657 effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term 658 care facility residents and healthcare workers -a Danish cohort study
1101,Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened 662 Workforce
1102,Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural
1103,Molecular Screening
1104,SARS-CoV-2 Vaccine Effectiveness in a High-Risk 669 National Population in a Real-World Setting
1105,Prevention of COVID-19 by 671 mRNA-based vaccines within the general population of California
1106,"REACT-1 round 13 final report: 674 exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with 675 Delta variant in England during"
1107,Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among 678
1108,Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance -Eight
1109,Effectiveness of 682 mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the 683 USA: a retrospective cohort study. The Lancet
1110,Early Release -Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-686
1111,-687 Emerging Infectious Diseases journal -CDC
1112,Prevention and 690 Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
1113,Initial report of 693 decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine
1114,"SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by 696 Vaccination Status"
1115,"Brown CM. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough 700 Infections"
1116,Virological and serological 704 kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort 705 study
1117,Virological 708 characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers 709
1118,Effect of Vaccination on 712 Household Transmission of SARS-CoV-2 in England
1119,Vaccination with 714 BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
1120,High coverage COVID-19 mRNA vaccination 717 rapidly controls SARS-CoV-2 transmission in Long-Term Care Facilities
1121,Transmission dynamics and 720 epidemiological characteristics of Delta variant infections in China
1122,"Risk factors and disease 724 profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study 725 app: a prospective, community-based, nested, case-control study"
1123,Antibody 733 Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
1124,Dynamics of antibody 736 response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg 737 Health -Eur
1125,Durability of mRNA-1273 740 vaccine-induced antibodies against SARS-CoV-2 variants
1126,Comparative Effectiveness of Moderna
1127,Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without 743 Immunocompromising Conditions -United States
1128,No evidence for increased 747 transmissibility from recurrent mutations in SARS-CoV-2
1129,CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. 751 medRxiv
1130,Emergence 753 and rapid spread of a new severe acute respiratory syndrome
1131,CoV-2) lineage with multiple spike mutations in South Africa
1132,Estimated 757 transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
1133,Public Health England. SARS-CoV-2 variants of concern and variants under investigation
1134,Increased 763 transmissibility and global spread of SARS-CoV-2 variants of concern as at
1135,"Scientific Pandemic Influenza Group on Modelling, Operational sub-group (SPI-M-O) for 766 the Scientific Advisory Group for Emergencies (SAGE). SPI-M-O: Consensus statement on 767 COVID-19"
1136,SARS-CoV-2 B.1.1.7 and B.1.351 spike 771 variants bind human ACE2 with increased affinity
1137,The continuous 775 evolution of SARS-CoV-2 in South Africa: a new lineage with rapid accumulation of mutations 776 of concern and global detection
1138,Hospital 784 admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared 785 with alpha (B.1.1.7) variants of concern: a cohort study
1139,Neutralizing Activity of 789 BNT162b2-Elicited Serum
1140,"Neutralization of SARS-CoV-2 spike 791 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera"
1141,.351 and P.1 escape from neutralizing antibodies
1142,CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
1143,Two doses of 800 SARS-CoV-2 vaccination induce more robust immune responses to emerging SARS-CoV-2 801 variants of concern than does natural infection
1144,CoV-2 variants escape neutralization by vaccine-induced humoral immunity
1145,CoV-2 variants by convalescent and vaccinated serum. medRxiv. 9 avr 809 2021
1146,Reduced neutralization of 811 SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
1147,Qualitatively 814 distinct modes of Sputnik V vaccine-neutralization escape by SARS-CoV-2 Spike variants
1148,mRNA vaccine-elicited 817 antibodies to SARS-CoV-2 and circulating variants
1149,1 strain of SARS-CoV-2. Cell [Internet]. 30 mars 2021
1150,Neutralizing Response 822 against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2
1151,Ineffective 825 neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera
1152,mRNA-1273 vaccine 829 induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants
1153,Susceptibility of Circulating 832 SARS-CoV-2 Variants to Neutralization
1154,Neutralization of UK-834 variant VUI-202012/01 with COVAXIN vaccinated human serum. bioRxiv
1155,Serum neutralising activity against SARS-CoV-2 837 variants elicited by CoronaVac
1156,SARS-CoV-2 variant B.1.1.7 is 845 susceptible to neutralizing antibodies elicited by ancestral Spike vaccines
1157,Neutralization of SARS-CoV-2 VOC 501Y.V2 848 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD 849 ZF2001 vaccines
1158,"851 Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant 852 spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies"
1159,Infection-and 855 vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
1160,1.429 and B.1.351
1161,Reduced neutralisation of 860 the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination
1162,Infectious Diseases (except HIV/AIDS); 2021 juin
1163,S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of 865 concern
1164,Temporal 867 Increase in Neutralization Potency of SARS-CoV-2 Antibodies and Reduced Viral Variant Escape 868 after Sputnik V Vaccination
1165,Infection and Vaccine-871 Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants
1166,Comparison of 875 Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-876
1167,CoV-2 Variants. bioRxiv. 19 juill 2021
1168,Serum Neutralizing Activity of 878 mRNA-1273 against SARS-CoV-2 Variants
1169,BNT162b2-elicited neutralization of 880 B.1.617 and other SARS-CoV-2 variants
1170,Reduced 882 neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
1171,Neutralising capacity 886 against Delta (B.1.617.2) and other variants of concern following Comirnaty
1172,BioNTech/Pfizer) vaccination in health care workers
1173,SARS-CoV-2 B.1.617.2 890 Delta variant replication and immune evasion
1174,Reduced neutralization of SARS-CoV-2 B.1.617 893 variant by inactivated and RBD-subunit vaccine
1175,"Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern 896 (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants. 897 Vaccines"
1176,Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees. Clin Infect Dis
1177,CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection 903 and vaccination. bioRxiv. 5 mai 2021
1178,"Vaccine 905 effectiveness against infection with the Delta (B.1.617.2) variant, Norway"
1179,"Transmission, 908 infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California 909 carrying a L452R spike protein mutation"
1180,"A Novel and 911 Expanding SARS-CoV-2 Variant, B.1.526, Identified in New York"
1181,"Reduced 914 neutralizing activity of post-SARS-CoV-2 vaccination serum against variants B.1.617.2, B.1"
1182,B.1.1.7+E484K and a sub-variant of C.37 [Internet]. 2021 juill
1183,SARS-CoV-2 immune evasion 919 by variant B.1.427/B.1.429
1184,BNT162b2-Elicited Neutralization 921 against New SARS-CoV-2 Spike Variants
1185,CoV-2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine
1186,Disponible sur: 925
1187,SARS-CoV-2 Lambda 927 Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies
1188,Neutralizing antibody 931 levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
1189,BNT162b2 vaccine 934 induces neutralizing antibodies and poly-specific T cells in humans
1190,Low dose mRNA-937 1273 COVID-19 vaccine generates durable T cell memory and antibodies enhanced by pre-938 existing crossreactive T cell memory
1191,Evidence of SARS-Cov-2-942 specific memory B cells six months after vaccination with BNT162b2 mRNA vaccine
1192,COVID-19 vaccination: initial reactogenicity data. The Lancet
1193,Un ensayo clínico evaluará una segunda dosis de la vacuna de 950
1194,Pfizer en personas ya vacunadas con una dosis de AstraZeneca
1195,"Safety and 954 immunogenicity of heterologous versus homologous prime-boost schedules with an 955 adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, 956 non-inferiority trial. The Lancet"
1196,Induction of robust neutralizing antibodies 958 against the COVID-19 Delta variant with ChAdOx1 nCoV-19 or BNT162b2 as a booster 959 following a primary vaccination series with CoronaVac
1197,Single-dose 963 administration and the influence of the timing of the booster dose on immunogenicity and 964 efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. 965 The Lancet. 6 mars 2021
1198,Strong humoral 967 immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 968 sixteen-week interval between doses
1199,Extended interval 972 BNT162b2 vaccination enhances peak antibody generation in older people
1200,Safety 976 and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients 977 with cancer: interim analysis of a prospective observational study
1201,Immunogenicity of 981 a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. 982 JAMA
1202,High seroconversion rate 984 but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients 985 treated with chemotherapy for solid cancers
1203,Randomized Trial of a 989 Third Dose of mRNA-1273 Vaccine in Transplant Recipients
1204,Antibody 991 Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant 992 Recipients With Minimal Serologic Response to 2 Doses
1205,Short Term Reduction in 994 the Odds of Testing Positive for SARS-CoV-2; a Comparison Between Two Doses and Three 995 doses of the BNT162b2 Vaccine
1206,Protection 999 of BNT162b2 Vaccine Booster against Covid-19 in Israel
1207,SARS-CoV-2 1001 Neutralization with BNT162b2 Vaccine Dose 3
1208,Safety and immunogenicity of SARS-CoV-2 1003 variant mRNA vaccine boosters in healthy adults: an interim analysis
1209,mRNA vaccination 1006 boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
1210,Antibody 1010 Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
1211,Antibody Response in Persons with Past Natural Infection
1212,Distinct 1015 antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals 1016 following mRNA vaccination
1213,Poor 1019 antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-1020 experienced individuals
1214,Single Dose 1022 Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2. medRxiv
1215,COVID-19 vaccine safety update
1216,Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine 1029 Recipients: Update from the Advisory Committee on Immunization Practices -United States
1217,MMWR Morb Mortal Wkly Rep
1218,Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons
1219,Receipt of mRNA Covid-1036 19 Vaccines and Risk of Spontaneous Abortion
1220,"Clinical manifestations, risk 1038 factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living 1039 systematic review and meta-analysis"
1221,Surveillance for Adverse 1041
1222,Events After COVID-19 mRNA Vaccination
1223,1042 Disponible sur
1224,Coronavirus vaccine -weekly summary 1044 of Yellow Card reporting
1225,Safety of the BNT162b2 1048 mRNA Covid-19 Vaccine in a Nationwide Setting
1226,Safety Monitoring of COVID-19 Vaccines in Hong Kong
1227,Moderna COVID-19 Vaccine -United States
1228,A Retrospective observational survey of 1058 adverse events following immunization comparing tolerability of covishield and covaxin 1059 vaccines in the real world
1229,ROCCA observational 1063 study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San 1064 Marino using active surveillance
1230,Active monitoring of early safety of Sputnik V vaccine in
1231,Quinto Informe Estadistico: 1069 ESAVI asociados a la administracion de las vacunas SARS-CoV-2 en Chile
1232,Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines
1233,Potential adverse effects of COVID19 1076 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a 1077 retrospective cross-sectional study
1234,"Effectiveness of BNT162b2 and 1079 ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 1080 80 years: a test-negative, case-control study"
1235,Interim findings from first-1083 dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a 1084 national prospective cohort study
1236,Early rate reductions of SARS-CoV-2 1086 infection and COVID-19 in BNT162b2 vaccine recipients. The Lancet. 6 mars
1237,Experience of 1089 COVID-19 Vaccination of Healthcare Workers in a Hospital Setting
1238,Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two 1093 Skilled Nursing Facilities Experiencing COVID-19 Outbreaks -Connecticut
1239,Real-world effectiveness of Ad26.COV2.S adenoviral vector vaccine for 1098 COVID-19. medRxiv
1240,Association 1100 Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women
1241,"Effectiveness 1103 of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant 1104 transmission in Manaus, Brazil: A test-negative case-control study. Lancet Reg Health -Am 1105"
1242,The proximal origin of SARS-CoV-2
1243,Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2
1244,"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-An update on the status"
1245,Vírus emergentes e reemergentes
1246,Animal and Human Coronavirus Disease
1247,Invasion Science and the Global Spread of SARS-CoV-2
1248,History is repeating itself: Probable zoonotic spillover as the cause of the 2019 novel Coronavirus Epidemic
1249,The presence of SARS-CoV-2 RNA in human sewage
1250,Immunology of COVID-19: Current state of the science
1251,Polyclonal F(ab )2 fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency
1252,Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation
1253,Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a Hif-1a/Glycolysis Dependent Axis
1254,Antiviral activities of type I Interferons to SARS-CoV-2 infection
1255,Structural basis for the recognition of the SARS-CoV-2 by full length human ACE-2
1256,How to discover antiviral drugs quickly
1257,Mutations of SARS-CoV-2-What Do They Mean?
1258,Potential host range of multiple SARSlike coronaviruses and an improved ACE2-Fc variant that is potent against both SARS-CoV-2 and SARS-CoV-1
1259,Characterizing genomic variants and mutations in SARS-CoV-2 proteins from Indian isolates
1260,Microchip-based structure determination of low-molecular weight proteins using cryo-electron microscopy
1261,The 501.V2 and B.1.1.7 variants of coronavirus disease 2019 (COVID-19): A new time-bomb in the making?
1262,The high infectivity of SARS-CoV-2 B.1.1.7 is associated with increased interaction force between Spike-ACE2 caused by the viral N501Y mutation
1263,Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
1264,Genomic characterization of an emergent SARS-CoV-2 lineage in Manaus: Preliminary findings
1265,Imported SARS-CoV-2 Variant P.1 in Traveler Returning from Brazil to Italy
1266,"Convergent evolution of SARS-CoV-2 spike mutations L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra"
1267,Emergence in Southern France of a new SARS-CoV-2 variant of probably Cameroonian 5 origin harbouring both substitutions N501Y and E484K in the spike protein
1268,SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
1269,Severe acute respiratory coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response
1270,Coronavirus vaccine trials have delivered their first results-But their promise is still unclear
1271,The COVID-19 vaccine development landscape
1272,A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic
1273,ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
1274,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: Interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind"
1275,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: A double-blind, randomised, phase 1 trial"
1276,Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein
1277,Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model
1278,An mRNA Vaccine against SARS-CoV-2-Preliminary Report
1279,Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
1280,Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients
1281,Announce Positive Topline Results from Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
1282,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial"
1283,"Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: A dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial"
1284,A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques
1285,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia"
1286,First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
1287,Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults
1288,Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19. FDA News Release
1289,Immunogenicity of Heterologous Prime/Booster-Inactivated and Adenoviral-Vectored COVID-19 Vaccine: Real-World Data
1290,"Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection"
1291,Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination
1292,Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
1293,Association between 3 doses of mRNA COVID-19 Vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants
1294,Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection
1295,Malaysia: Ministry of Health Malaysia
1296,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: an observational study
1297,Computation and analysis of multiple structural change models
1298,"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study"
1299,Effectiveness of homologous and heterologous booster shots for an inactivated SARS-CoV-2 vaccine: a large-scale observational study
1300,TA B L E 1 Demographic characteristics and outcomes for the 3 participants Demographic and background clinical information Post-dose 1 Pre-dose 2 testing Post-dose 2 Post-dose 2 7-day electronic diary of symptoms Participants Age (Yrs) Sex Ethnicity Medical history Time to urticaria a Duration of urticaria Basophil activation test results a
1301,Fatal anaphylaxis in children in France: analysis of national data
1302,Practical guidance for the evaluation and management of drug hypersensitivity: specific drugs
1303,Maintaining safety with SARS-CoV-2 vaccines
1304,"Department of Health, the Government of Hong Kong Safety monitoring of COVID-19 vaccines in Hong Kong"
1305,Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy
1306,BÜHLMANN Laboratories AG. Flow CAST® Basophil Activation Test (BAT) Flow Cytometry
1307,Basophil activation test application in drug hypersensitivity diagnosis: an empirical approach
1308,Basophil reactivity as biomarker in immediate drug hypersensitivity reactions-potential and limitations
1309,Polyethylene glycol-induced systemic allergic reactions (anaphylaxis)
1310,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers
1311,The epidemiology and clinical information about COVID-19
1312,COVID-19: insight into the asymptomatic SARS-CoV-2 infection and transmission
1313,Asymptomatic patients as a source of COVID-19 infections: a systematic review and meta-analysis
1314,Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission
1315,COVID-19 pathophysiology: a review
1316,Can symptoms of anosmia and dysgeusia be diagnostic for COVID-19?
1317,A Review of coronavirus disease-2019 (COVID-19)
1318,Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19
1319,Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients
1320,"SARS-CoV-2/COVID-19: viral genomics, epidemiology, vaccines, and therapeutic interventions"
1321,A Review of the progress and challenges of developing a vaccine for COVID-19
1322,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial"
1323,"Eficácia global da Coronavac é de 50,38%, anuncia governo paulista"
1324,Present yourself! By MHC Class I and MHC Class II molecules
1325,"Serological testing for COVID-19, immunological surveillance, and exploration of protective antibodies"
1326,Development of low-cost serological immunoassay to detect antiviral antibodies to SARSars-Cov-2 Spike protein
1327,Relation between COVID-19 and Guillain-Barré syndrome in adults. Systematic review
1328,Guillain-Barré syndrome associated with SARS-CoV-2
1329,The effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on antibody response in participants aged 65 years and older
1330,SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study
1331,SARS-CoV-2 seroprevalence and risk factors among health care workers: estimating the risk of COVID-19 dedicated units
1332,Vaccination and induction of autoimmune diseases
1333,"Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence"
1334,Sequential IgG antibody monitoring for virusinactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers
1335,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers
1336,High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2
1337,World Health Organization. WHO coronavirus disease (COVID-19) dashboard. 2021
1338,The impact of the COVID-19 pandemic on medical education
1339,"Emotional, behavioral, and psychological impact of the COVID-19 pandemic"
1340,Observed impacts of the COVID-19 pandemic on global trade
1341,World Health Organization. Draft landscape of COVID-19 candidate vaccines
1342,World Health Organization. COVID-19 advice for the public: Getting vaccinated
1343,Viral targets for vaccines against COVID-19
1344,Current status of COVID-19 vaccine development: focusing on antigen design and clinical trials on later stages
1345,Approaches and challenges in SARS-CoV-2 vaccine development
1346,Overview of approved and upcoming vaccines for SARS-CoV-2: a living review
1347,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
1348,World Health Organization. Covid-19 vero cell inactivated
1349,Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
1350,"Food and Drug Administration, Ministry of Public Health, Thailand. Details of Medicinal Product"
1351,Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients
1352,ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
1353,Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273
1354,"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a singleblind, randomised, controlled, phase 2/3 trial"
1355,Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
1356,Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine
1357,Antibody status and incidence of SARS-CoV-2 infection in health care workers
1358,Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers
1359,Antibody response to SARS-CoV-2 infection in humans: a systematic review
1360,A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients
1361,Longitudinal assessment of anti-SARS-CoV-2 immune responses for six months based on the clinical severity of COVID-19
1362,Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection
1363,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study"
1364,A novel coronavirus from patients with pneumonia in China
1365,Immune responses to SARS-CoV-2 among patients with cancer: what can seropositivity tell us?
1366,• Comment about seropositivity in cancer patients
1367,WHO. WHO coronavirus (COVID-19) dashboard
1368,Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
1369,Determinants of COVID-19 disease severity in patients with cancer
1370,SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer
1371,Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies
1372,COVID-19 and cancer: current challenges and perspectives
1373,Impact of the COVID-19 pandemic on surgical oncology in Europe: results of a European survey
1374,Delays and disruptions in cancer health care due to COVID-19 pandemic: systematic review
1375,"Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study"
1376,Prevalence and outcome of COVID-19 infection in cancer patients: a National Veterans Affairs study
1377,Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
1378,SARS-CoV-2 testing for asymptomatic adult cancer patients before initiating systemic treatments: a systematic review
1379,National Comprehensive Cancer Network. Recommendations of the NCCN COVID-19 vaccination advisory committee
1380,Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19
1381,•• Study which evaluated antibody development in cancer patients after COVID-19 infection
1382,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, Phase 1/2 trial"
1383,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, Phase 3 trial in Turkey"
1384,•• Study which evaluated the efficacy and safety profile of CoronaVac
1385,Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine
1386,Immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with malignancy
1387,• Study which evaluated the efficacy and safety profile of CoronaVac in cancer patients
1388,Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer
1389,• Study which evaluated the mRNA vaccine BNT162b2 in cancer patients
1390,SARS-CoV-2-Immnuoassays
1391,AdviseDx SARS-CoV-2 IgG II package insert
1392,Impaired antibody response to pneumococcal vaccine after treatment for Hodgkin's disease
1393,Influenza vaccination in patients with breast cancer: a case-series analysis
1394,Association of SARS-CoV-2 seropositive antibody test with risk of future infection
1395,Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
1396,Epub ahead of print) future science group
1397,BNT162b2 mRNA COVID-19 Vaccine Effectiveness among Health Care Workers
1398,Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine
1399,Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center
1400,Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study
1401,SARS-CoV-2 Infection after Vaccination in Health Care Workers in California
1402,COVID-19 dynamics after a national immunization program in Israel
1403,Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization
1404,Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming
1405,Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
1406,"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19"
1407,Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. The Lancet. Infectious diseases 21
1408,Homologous and Heterologous Covid-19 Booster Vaccinations
1409,Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
1410,SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
1411,"International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted"
1412,mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
1413,"Balazs, mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant"
1414,"Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations"
1415,The T cell immune response against SARS-CoV-2
1416,"International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity"
1417,Mucosal immune response in BNT162b2 COVID-19 vaccine recipients
1418,Nasal and Salivary Mucosal Humoral Immune Response Elicited by mRNA BNT162b2 COVID-19 Vaccine Compared to SARS
1419,Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans
1420,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study
1421,"MRA and PPB were supported by Coordination for the Improvement of Higher Education Personnel (88887.356527/2019-00) fellowships, and DAT-T and LSM were supported by CNPq fellowships"
1422,MSD was supported by a grant from the National Institutes of Health (U01 grant AI151810). We thank Wendy Barclay for helpful discussions
1423,"all blood donors, vaccinated individuals, and SARS-CoV-2 patients who provided clinical specimens for this study"
1424,Thermo Fisher Scientific for provision of an EVOS inverted microscope for the biosafety level 3 facility at the Emerging Viruses Laboratory; the National Institute of Science and Technology of Photonics Applied to Cell Biology for confocal microscopy analysis; UNICAMP-Task-Force against COVID-19
1425,for technical support; all individuals involved in the diagnosis and generation of SARS-CoV-2 sequences as part of the CADDE-Genomic-Network; and the MCTI and all members of the Corona-ômica network for support
1426,A new coronavirus associated with human respiratory disease in China
1427,A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
1428,SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo
1429,A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2
1430,Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology
1431,Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
1432,Detection of a SARS-CoV-2 variant of concern in South Africa
1433,Antibody evasion by the P.1 strain of SARS-CoV-2
1434,Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
1435,"Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil"
1436,Virological assessment of hospitalized patients with COVID-2019
1437,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
1438,SARS-CoV-2 uses CD4 to infect T helper lymphocytes
1439,Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
1440,SARS-CoV-2 isolation from the first reported patients in Brazil and establishment of a coordinated task network
1441,SARS-CoV-2 reinfection by the new variant of concern (VOC) P.1 in Amazonas
1442,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic
1443,SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
1444,Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv 2021: published online
1445,Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study
1446,Mapping the antigenic and genetic evolution of influenza virus
1447,A human coronavirus evolves antigenically to escape antibody immunity
1448,Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome
1449,Delayed production of neutralizing antibodies correlates with fatal COVID-19
1450,Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection
1451,mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
1452,Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner
1453,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data"
1454,Concise report SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy
1455,Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: epidemiology and outcomes
1456,"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immunemediated inflammatory diseases"
1457,Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
1458,Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey
1459,"The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress"
1460,Systemic sclerosis and the COVID-19 pandemic: world Scleroderma Foundation preliminary advice for patient management
1461,2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
1462,Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV Study
1463,Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
1464,Pandemic non-adjuvanted influenza A H1N1 vaccine in a cohort of patients with systemic sclerosis
1465,American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 1
1466,American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 3
1467,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine"
1468,Sjögren's syndrome: a systemic autoimmune disease
1469,Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis
1470,The epidemiology of Sjögren's syndrome
1471,Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a crosssectional study from the Big Data Sjögren Project Consortium
1472,Clinical and prognostic characteristics of 573 cases of primary Sjögren's syndrome
1473,"Rate, risk factors and causes of mortality in patients with Sjögren's syndrome: a systematic review and meta-analysis of cohort studies"
1474,Mortality in patients with primary Sjögren's syndrome: a systematic review and meta-analysis. Rheumatology (Oxford) keab364
1475,Determinants of COVID-19 disease severity in patients with underlying rheumatic disease
1476,"COVID-19 in association with development, course, and treatment of systemic autoimmune rheumatic diseases"
1477,Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up
1478,SARS-CoV-2 infection in patients with systemic autoimmune diseases
1479,SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients
1480,Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis annrheumdis-2021-220503
1481,"Sinovac is the most used vaccine in the world, with 943M doses delivered"
1482,"Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel"
1483,"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases"
1484,Short and longterm effects of pandemic unadjuvanted influenza A(H1N1)pdm09 vaccine on clinical manifestations and autoantibody profile in primary Sjögren's syndrome
1485,Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group
1486,Research electronic data capture (REDCap)-a metadatadriven methodology and workflow process for providing translational research informatics support
1487,WHO. WHO Draft Guidelines for Adverse Event Reporting and Learning Systems
1488,Development of the ClinESSDAI: a clinical score without biological domain A tool for biological studies
1489,A new SARS-CoV-2 dual-purpose serology test: highly accurate infection tracing and neutralizing antibody response detection
1490,Sex differences in vaccine-induced humoral immunity
1491,Comparison of ESS-DAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry
1492,Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome
1493,"Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis"
1494,A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis
1495,Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial
1496,Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial
1497,Arthritis Foundation. ACR COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and Musculoskeletal Diseases
1498,Salivary glands are a target for SARS-CoV-2: a source for saliva contamination
1499,Will the COVID-19 pandemic trigger future occurrence of autoimmunity like Sjögren's syndrome?
1500,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination
1501,Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence
1502,Validation of real-time RT-PCR for detection of SARS-CoV-2 in the early stages of the COVID-19 outbreak in the Republic of Korea
1503,Characteristics of SARS-CoV-2 and COVID-19
1504,Dynamics prediction of emerging notable spike protein mutations in SARS-CoV-2 implies a need for updated vaccines
1505,Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
1506,Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
1507,Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. Cell Rep
1508,Late phase of COVID-19 pandemic in General Cardiology. A position paper of the ESC Council for Cardiology Practice
1509,COVID-Pain: Acute and Late-Onset Painful Clinical Manifestations in COVID-19-Molecular Mechanisms and Research Perspectives
1510,Association between IL-10 systemic low level and pain during symptomatic SARS-CoV-2 infection
1511,"Mask up to keep it up"": Preliminary evidence of the association between erectile dysfunction and COVID-19"
1512,Emergence of SARS-CoV-2 Variants in the World: How Could This Happen? Life
1513,Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination-Kentucky
1514,Efficacy and safety of COVID-19 vaccines: A systematic review
1515,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data"
1516,Do vaccines protect against long COVID? What the data say
1517,Data. Coronavirus Pandemic (COVID-19). 2022. Available online
1518,"Vacunas SARS CoV-2, estudios en fase III"
1519,Oxford-AstraZeneca COVID-19 vaccine efficacy
1520,"Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: An international, multicentre, randomised, double-blinded"
1521,Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection. Front. Public Health
1522,Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19
1523,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG Quantitative Reagent Pack
1524,CoV-2 nAb FIA
1525,IFN-Gamma) Technical Document
1526,Covid-19: AstraZeneca vaccine is approved in EU with no upper age limit
1527,Covid-19: Canada relaxes age limits on AstraZeneca vaccine as Ontario cases surge
1528,Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
1529,Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies
1530,Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients
1531,Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile
1532,"BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: A prospective, single-centre, longitudinal cohort study in health-care workers"
1533,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: An immunological study
1534,Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia
1535,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial"
1536,Dynamics of antibody response to CoronaVac vaccine Funding information
1537,A novel Coronavirus from patients with pneumonia in china
1538,WHO declares COVID-19 a pandemic
1539,SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
1540,Rapid COVID-19 vaccine development
1541,The race for coronavirus vaccines: a graphical guide
1542,An mRNA vaccine against SARS-CoV-2-preliminary Report
1543,A strategic approach to COVID-19 vaccine R&D
1544,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-inhuman trial"
1545,"COVID-19 in health-care workers: a living systematic review and metaanalysis of prevalence, risk factors, clinical characteristics, and outcomes"
1546,COVID-19: protecting health-care workers
1547,"World Health OrganizationInterim Recommendations for Use of the Inactivated COVID-19 Vaccine, CoronaVac, Developed by Sinovac: Interim Guidance"
1548,2 -Vaccine immunology. Plotkin's vaccines. 7th end. Elsevier
1549,Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
1550,"Decline of SARS-CoV-2-specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge"
1551,Cellular and humoral immune responses in Covid-19 and immunotherapeutic approaches
1552,SARS-CoV-2 Immunoassays: advancing diagnostics of COVID-19
1553,Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study
1554,Remembrance of things past: long-term b cell memory after infection and vaccination
1555,Sex differences in immune responses
1556,Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health
1557,Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VI-VALDI): a prospective cohort study
1558,COVID-19 mRNA vaccination generates greater immunoglobulin g levels in women compared to men
1559,Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile
1560,Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2
1561,Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine
1562,SARS-CoV-2 vaccines: anamnestic response in previously infected recipients
1563,Single dose vaccination in healthcare workers previously infected with SARS-CoV-2
1564,SARS-CoV-2 seropositivity after infection and antibody response to mRNA-based vaccination
1565,First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19
1566,Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection
1567,The impact of pre-existing comorbidities and therapeutic interventions on COVID-19
1568,How to cite this article: Fonseca MHG
1569,Dynamics of antibody response to CoronaVac vaccine
1570,"Short-term immune response after inactivated SARS-CoV-2 (CoronaVac(R), Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria(R), Oxford-AstraZeneca) vaccinations in health care workers. Asian Pac"
1571,mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
1572,"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): A single-blind, randomised, non-inferiority trial"
1573,Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
1574,"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: Interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials"
1575,Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine
1576,"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): A phase 4, non-inferiority, single blind, randomised study"
1577,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey
1578,Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1
1579,Suggested guidelines for convalescent plasma therapy for the treatment of COVID-19
1580,Neutralization assays for differential henipavirus serology using Bio-Plex Protein Array Systems
1581,Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance and Cognate Cross-Reactivity
1582,Peculiarities of the T Cell Immune Response in COVID-19
1583,Immunogenicity of ChAdOx1 nCoV-19 Booster Vaccination Following Two CoronaVac Shots in Healthcare Workers
1584,Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: The Dominican Republic Experience
1585,WHO international standard for SARS-CoV-2 antibodies to determine markers of protection
1586,"Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine"
1587,SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
1588,T cell responses to SARS-CoV-2 spike cross-recognize Omicron
1589,Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron
1590,Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies
1591,Heterologous prime-boost: Breaking the protective immune response bottleneck of COVID-19 vaccine candidates
1592,Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
1593,SARS-CoV-2 T-cell immunity to variants of concern following vaccination. bioRxiv 2021
1594,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review
1595,The Impact of COVID-19 Vaccination on the Italian Healthcare System: A Scenario Analysis
1596,Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination
1597,Skin reactions to COVID-19 vaccines: An American Academy of Dermatology/International League of Dermatological Societies registry update on reaction location and COVID vaccine type
1598,New-Onset Systemic Lupus Erythematosus after mRNA SARS-CoV-2 Vaccination. Case Rep Rheumatol
1599,ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review
1600,New-onset autoimmune phenomena post-COVID-19 vaccination
1601,"Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination"
1602,Oral pemphigus after COVID-19 vaccination
1603,"Autoimmune bullous skin diseases, pemphigus and pemphigoid"
1604,Blistering autoimmune skin reaction following SHINGRIX vaccination in an ulcerative colitis patient: Case report and literature review. Vaccine
1605,Diagnosis and management of pemphigus: Recommendations of an international panel of experts
1606,Food and Drug Administration Rituxan label
1607,Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2
1608,Development of pemphigus vulgaris after the second dose of the mRNA-1273 SARS-Cov-2 vaccine
1609,Development of pemphigus vulgaris following mRNA SARS-CoV-19 BNT162b2 vaccination in an 89-year-old patient
1610,An unusual presentation of pemphigus foliaceus following COVID-19 vaccination
1611,Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: a report and brief literature review
1612,Epub ahead of print
1613,Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine
1614,A case of bullous pemphigoid after the SARS-CoV-2 mRNA vaccine
1615,Bullous pemphigoid after SARS-CoV-2 vaccination: Spike protein-directed immunofluorescence confocal microscopy and T cell receptor studies
1616,Bullous pemphigoid and COVID-19 vaccine
1617,Case of bullous pemphigoid following coronavirus disease 2019 vaccination
1618,New-onset bullous pemphigoid after inactivated Covid-19 vaccine: Synergistic effect of the Covid-19 vaccine and vildagliptin
1619,Biphasic bullous pemphigoid starting after first dose and boosted by second dose of mRNA-1273 vaccine in an 84-year-old female with polymorbidity and polypharmacy
1620,Linear IgA bullous dermatosis following Oxford AstraZeneca COVID-19 vaccine
1621,Vesiculobullous skin reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature
1622,Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination
1623,Incident bullous pemphigoid in a psoriatic patient following mRNA-1273 SARS-CoV-2 vaccination
1624,Can Covid-19 vaccines cause or exacerbate bullous pemphigoid? A report of seven cases from one center
1625,Pemphigus vulgaris after SARS-CoV-2 vaccination: a case with new-onset and two cases with severe aggravation
1626,COVID-19) Dashboard
1627,The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?
1628,Autoimmune-and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination. Blood Adv
1629,Covid-19 and autoimmunity
1630,"Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to ""potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases"
1631,Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases
1632,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers
1633,Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants
1634,Risk of COVID-19 among frontline healthcare workers and the general community: a prospective cohort study
1635,BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting
1636,Effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 among hospitalized adults aged ≥65 years-United States
1637,The short-term effectiveness of coronavirus disease 2019 (COVID-19) vaccines among healthcare workers: a systematic literature review and meta-analysis
1638,Rapid metagenomic identification of viral pathogens in clinical samples by real-time nanopore sequencing analysis
1639,Practical Statistics for Medical Research
1640,Statistics in Clinical Vaccine Trials
1641,Survival Analysis: Techniques for Censored and Truncated Data
1642,R: A Language and Environment for Statistical Computing
1643,Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine
1644,"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 gamma-variant transmission in Manaus, Brazil: a test-negative case-control study"
1645,Effectiveness of COVID-19 vaccines against the B.1.617.2 (delta) variant
1646,Plano Nacional de Operacionalização da Vacinação contra a COVID-19. 2021. Ministério da Saúde website
1647,Clinical endpoints for evaluating efficacy in COVID-19 vaccine trials
1648,What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
1649,Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study
1650,Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
1651,Vaccine breakthrough infections with SARS-CoV-2 variants
1652,COVID-19 vaccine breakthrough infections reported to CDC-United States
1653,A systematic review of quasiexperimental study designs in the fields of infection control and antibiotic resistance
1654,Interim Public Health recommendations for fully vaccinated people
1655,Antibody testing is not currently recommended to assess immunity after COVID-19 vaccination. US Food and Drug Administration website
1656,Thailand Allows Emergency Use of Sinovac's COVID-19 Vaccine
1657,Vaxzevria (Previously COVID-19 Vaccne AstraZeneca)
1658,Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost
1659,Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
1660,Heterologous immunization with inactivated vaccine followed by mRNA booster elicits strong humoral and cellular immune responses against the SARS-CoV-2 Omicron variant
1661,Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination
1662,Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
1663,Antibody response and variant cross-neutralization after SARS-CoV-2 breakthrough infection
1664,Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa
1665,SARS-CoV-2 B. 1.1. 529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent individuals
1666,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021"
1667,Vacunación contra COVID-19 Bogotá D.C.2022
1668,"Comparing COVID-19 vaccines for their characteristics, efficacy, and effectiveness against SARS-CoV-2 and variants of concern: a narrative review"
1669,Low Neutralizing Antibody Titers against the Mu Variant of SARS-CoV-2 in 31 BNT162b2 Vaccinated Individuals in Colombia
1670,Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage
1671,COVID -2019) en Colombia: Instituto Nacional de Salud
1672,Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2
1673,Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum
1674,Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B
1675,Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians
1676,A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12
1677,Evaluation of Commercial Anti-SARS-CoV-2 Antibody Assays and Comparison of Standardized Titers in Vaccinated Health Care Workers
1678,"Association of SARS-CoV-2 Vaccinations with SARS-CoV-2 Infections, ICU Admissions and Deaths in Greece. Vaccines (Basel)"
1679,The Implementation of Mass-Vaccination against SARS-CoV-2: A Systematic Review of Existing Strategies and Guidelines. Vaccines (Basel)
1680,"Correlation Between SARS-Cov-2 Vaccination, COVID-19 Incidence and Mortality: Tracking the Effect of Vaccination on Population Protection in Real Time"
1681,High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals
1682,Intensity and Dynamics of Anti-SARS-CoV-2 Immune Responses after BNT162b2 mRNA Vaccination: Implications for Public Health Vaccination Strategies. Vaccines (Basel)
1683,Neutralizing antibody titres in SARS-CoV-2 infections
1684,Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection
1685,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19
1686,International COVID-19 vaccine inequality amid the pandemic: perpetuating a global crisis?
1687,Vaccination against COVID-19 and inequalities -avoiding making a bad situation worse. Public Health Pract (Oxf) 2:100101
1688,Strengthened health systems are needed to tackle COVID-19 in Africa
1689,"COVID-19 and postinfection immunity: limited evidence, many remaining questions"
1690,Covid-19 vaccines: delivering protective immunity
1691,Rapid generation of neutralizing antibody responses in COVID-19 patients
1692,COVID-19 Vaccines: a review of the safety and efficacy of current clinical trials
1693,Organization WH (2021) Draft landscape and tracker of COVID-19 candidate vaccines. World Health Organization
1694,SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
1695,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (Coro-naVac): interim results of a double-blind, randomised, placebocontrolled, phase 3 trial in Turkey"
1696,Balanced cellular and humoral immune responses targeting multiple antigens in adults receiving a quadrivalent inactivated influenza vaccine. Vaccines (Basel)
1697,Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial
1698,Current advances in the development of SARS-CoV-2 vaccines
1699,Inactivated COVID-19 vaccines to make a global impact
1700,First case of 2019 novel coronavirus in the United States
1701,"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2"
1702,"Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the"
1703,Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation
1704,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, doubleblind, placebo-controlled, phase 1/2 clinical trial"
1705,Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19
1706,Correlates of vaccine-induced protection against SARS-CoV-2. Vaccines (Basel)
1707,Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals
1708,Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19
1709,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines
1710,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-toperson transmission: a study of a family cluster
1711,"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape"
1712,Re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing
1713,"SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)"
1714,Serum antibody profile of a patient with coronavirus disease 2019 reinfection
1715,"SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact"
1716,COVID-19 vaccines: keeping pace with SARS-CoV-2 variants
1717,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study
1718,Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7
1719,Impact of SARS-CoV-2 variant-associated RBD mutations on the susceptibility to serum antibodies elicited by COVID-19 infection or vaccination
1720,National study group for C-E. Efficacy of natural immunity against SARS-CoV-2 reinfection with the beta variant
1721,Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta
1722,Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape
1723,Transmission of Omicron (B.1.1.529) -SARS-CoV-2 variant of concern in a designated quarantine hotel for travelers: a challenge of elimination strategy of COVID-19
1724,Enhanced readiness for Omicron (B.1.1.529): technical brief and priority actions for member states
1725,SARS-CoV-2 variants of concern and variants under investigation in England
1726,Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum
1727,The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic
1728,Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine
1729,Plasma neutralization of the SARS-CoV-2 Omicron variant
1730,SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 33
1731,Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa
1732,Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa
1733,Seroprevalence of SARS-CoV-2 in Hong Kong Special Administrative Region and our returnees evacuated from Hubei province of China: a multi-cohort study
1734,"Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study"
1735,Undiagnosed SARS-CoV-2 seropositivity during the first 6 months of the COVID-19 pandemic in the United States
1736,Antibody response of BNT162b2 and CoronaVac platforms in recovered individuals previously infected by COVID-19 against SARS-CoV-2 wild type and delta variant
1737,Performance of a surrogate SARS-CoV-2-neutralizing antibody assay in natural infection and vaccination samples
1738,On determining the most appropriate test cut-off value: the case of tests with continuous results
1739,SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and convalescent persons
1740,Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
1741,Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination
1742,Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
1743,"M on behalf of the VIPER (Vaccines IdP, and Epidemiology Research) group COVID-19 vaccine development and approvals tracker team, COVID-19 vaccine development and approvals tracker"
1744,China's COVID vaccines have been crucial -now immunity is waning
1745,Recognition of Variants of concern by antibodies and T cells induced by a SARS-CoV-2 inactivated vaccine
1746,Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike
1747,Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
1748,"SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay"
1749,Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum
1750,Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong
1751,Tracking coronavirus vaccinations around the world
1752,Multilateral leaders task force on COVID-19. Data. Available at
1753,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world
1754,Will SARS-CoV-2 become endemic?
1755,SARS-CoV-2 vaccines: status report
1756,Rapid field determination of SARS-CoV-2 by a colorimetric and fluorescent dual-functional lateral flow immunoassay biosensor
1757,"Assessment of S1-, S2-, and NCP-specific IgM, IgA, and IgG antibody kinetics in acute SARS-CoV-2 infection by a microarray and twelve other immunoassays"
1758,Serologic testing of US blood donations to identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-reactive antibodies
1759,ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
1760,Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
1761,Verification of precision and estimation of bias; approved guideline
1762,"Evaluation of the linearity of quantitative measurement procedures: a statistical approach; approved guideline. West Valley Road, Suite 2500"
1763,Interference Testing in Clinical Chemistry; Approved Guideline
1764,Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation
1765,"Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (KCONVAC) in healthy adults: two randomized, double-blind, and placebo-controlled phase 1/2 clinical trials. medRxiv"
1766,A thermostable mRNA vaccine against COVID-19
1767,Antibody titres decline 3-month post-vaccinationwith BNT162b2
1768,Evaluation of anti-SARS-Cov-2 S-RBD IgG antibodies after COVID-19 mRNA BNT162b2 vaccine
1769,Antibody titer kinetics and SARS-CoV-2 infections six months after administration with the BNT162b2 vaccine. Vaccines (Basel)
1770,Effect of COVID-19 on anti-S antibody response in health care workers six months post-vaccination. Vaccines (Basel)
1771,Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection
1772,Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers
1773,Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity
1774,"Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples"
1775,A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
1776,Potently neutralizing and protective human antibodies against SARS-CoV-2
1777,Publisher's Note
1778,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
1779,Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series
1780,Acute prolonged motor aura resembling ischemic stroke after COVID -19 vaccination (CoronaVac): the first case report
1781,Immunization related focal neurological syndrome after coronavac vaccination
1782,Evaluating and managing severe headache in the emergency department
1783,"Timing and topography of cerebral blood flow, aura, and headache during migraine attacks"
1784,Time course of cerebral perfusion changes in children with migraine with Aura mimicking stroke
1785,Migraine associated cerebral hyperperfusion with arterial spin-labeled MR imaging
1786,"Familial hemiplegic migraine: follow-up findings of diffusion-weighted magnetic resonance imaging (MRI), perfusion-MRI and [99mTc] HMPAO-SPECT in a patient with prolonged hemiplegic aura"
1787,Prolonged hemiplegic migraine associated with unilateral hyperperfusion on perfusion weighted magnetic resonance imaging
1788,Cerebral perfusion changes in hemiplegic migraine: illustrated by Tc-99m ECD brain perfusion scan
1789,Pathophysiology of migraine: a disorder of sensory processing
1790,The typical duration of migraine aura: a systematic review
1791,"Migraine, obesity and body fat distribution -a population-based study"
1792,"Triggers, protectors, and predictors in episodic migraine"
1793,COVID-19: is it just a lung disease? A casebased review
1794,"Time to re-evaluate. SN Compr Clin Med:1, 1-2. Advance online publication"
1795,Neutralizing antibody titres to SARS-CoV-2 Omicron variant and wild-type virus in those with past infection or vaccinated or boosted with mRNA BNT162b2 or inactivated CoronaVac vaccines
1796,Respirology Epub ahead of print
1797,Clin Infect Dis (2021) Epub ahead of print
1798,"Table Table: Age, sex and geometric mean 50% plaque reduction neutralization test (PRNT 50 ) titres vs"
1799,Epidemiology and Infection Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival
1800,COVID-19 Aşısı Ulusal Uygulama Stratejisi
1801,Summary of Clinical Trial Data of Sinovac's COVID-19 Vaccine (CoronaVac®)
1802,"Efficacy and safety of an inactivated wholevirion SARS-CoV-2 vaccine (CoronaVac): interim results of a doubleblind, randomised, placebo-controlled, phase 3 trial in Turkey"
1803,Effectiveness of Inactivated SARS-CoV-2 Vaccine (CoronaVac) on Survival at Intensive Care Unit: A Cross-sectional Study
1804,"Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac 2021"
1805,Naming SARS-CoV-2 variants
1806,"SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against COVID-19 in Sao Paulo, Brazil"
1807,"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: a test-negative case-control study"
1808,BNT162b2-Elicited Neutralization against New SARS-CoV-2 spike variants
1809,Vaccines highly effective against hospitalisation from Delta variant
1810,Michos A SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence
1811,Turkey: 85% of new COVID-19 cases due to UK variant
1812,"Hundreds of vaccinated Indonesian health workers get COVID-19, dozens in hospital"
1813,"Short-term immune response after inactivated SARS-CoV-2 (CoronaVac(R), Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria(R)"
1814,Influence of age on the effectiveness and duration of protection in Vaxzevria and CoronaVac vaccines medRxiv
1815,Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of COVID-19 in Brazil: test negative case-control study
1816,"Indonesia's Doctors Got Vaccinated With Sinovac, and Got Sick 2021"
1817,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics
1818,"A randomized, double-blind, placebocontrolled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial"
1819,Diagnosis of breast cancer with infrared spectroscopy from serum samples
1820,Ultrarapid on-site detection of sars-cov-2 infection using simple atr-ftir spectroscopy and an analysis algorithm: high sensitivity and specificity
1821,The global phosphorylation landscape of SARS-CoV-2 infection
1822,Screening of protective effect of amifostine on radiation-induced structural and functional variations in rat liver microsomal membranes by FT-IR spectroscopy
1823,The structural and functional damages of whole body ionizing radiation on rat brain homogenate membranes and protective effect of amifostine
1824,Understanding the symptoms of the common cold and influenza
1825,Multivariate Data Analysis: In Practice: an Introduction to Multivariate Data Analysis and Experimental Design
1826,Fouriertransform infrared spectroscopy coupled with a classification machine for the analysis of blood plasma or serum: a novel diagnostic approach for ovarian cancer
1827,Bladder cancer diagnosis from bladder wash by Fourier transform infrared spectroscopy as a novel test for tumor recurrence
1828,"Restoring effect of selenium on the molecular content, structure and fluidity of diabetic kidney brush border cell membrane"
1829,"Methylation, sugar puckering and Z-form status of DNA from a heavy metal-acclimated freshwater Gordonia sp"
1830,Principal Component Analysis. Springer Series in Statistics
1831,Use of FTIR spectroscopy and PCA-LDC analysis to identify cancerous lesions within the human colon
1832,Spectroscopy as a tool for detection and monitoring of Coronavirus (COVID-19)
1833,Disease recognition by infrared and Ramanspectroscopy
1834,Early diagnosis of Alzheimer's disease using infrared spectroscopy of isolated blood samples followed by multivariate analyses
1835,FTIR spectroscopy of whole cells for the monitoring of yeast apoptosis mediated by p53 over-expression and its suppression by Nigella sativa extracts
1836,Phosphorylation regulates the subcellular localization of Cucumber Mosaic Virus 2b protein
1837,Serum-based diagnostic prediction of oral submucous fibrosis using FTIR spectrometry
1838,Study of SH-SY5Y cancer cell response to treatment with polyphenol extracts using FT-IR spectroscopy
1839,ATR-FTIR spectroscopy for virus identification: a powerful alternative
1840,FT-IR spectroscopy in diagnosis of diabetes in rat animal model
1841,Introduction to vibrational spectroscopy in diagnosis and screening
1842,Early alterations in myocardia and vessels of the diabetic rat heart :An FTIR microspectroscopic study
1843,The importance of hydration and DNA conformation in interpreting infrared spectra of cells and tissues
1844,Virological assessment of hospitalized patients with COVID
1845,Plasma metabolomic and lipidomic alterations associated with COVID-19
1846,Relapsing-remitting multiple sclerosis diagnosis from cerebrospinal fluids via Fourier transform infrared spectroscopy coupled with multivariate analysis
1847,Immune phenotyping based on the Neutrophil-to-Lymphocyte ratio and IgG level predicts disease severity and outcome for patients with COVID-19
1848,World Health Organization. COVID-19 Vaccines WHO EUL Issued
1849,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
1850,BNT162b2 mRNA COVID-19 caccine in a nationwide mass vaccination setting
1851,"COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): A prospective, multicentre, cohort study"
1852,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study"
1853,Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): A prospective cohort study
1854,Updates on COVID-19 Variants of Concern
1855,SARS-CoV-2 variants of interest and concern naming scheme conducive for global discourse
1856,Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern
1857,Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
1858,Adaptive value of high mutation rates of RNA viruses: Separating causes from consequences
1859,The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity
1860,Will mutations in the spike protein of SARS-CoV-2 lead to the failure of COVID-19 vaccines?
1861,Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint
1862,SARS-CoV-2 Variants of Concern and Variants under Investigation in England. Technical Briefing 11. SARS-CoV-2 Variants of Concern and Variants under Investigation in England
1863,Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant
1864,Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
1865,Understanding interobserver agreement: The kappa statistic
1866,The Joanna Briggs Institute Critical Appraisal Tools for Use in JBI Systematic Reviews. Checklist for Qualitative Research
1867,"Null hypothesis significance testing, p-values, effects sizes and confidence intervals"
1868,"Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada. medRxiv 2021"
1869,Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study
1870,Effectiveness of BNT162b2 vaccine against Delta variant in adolescents
1871,"SARS-CoV-2 Delta VOC in Scotland: Demographics, risk of hospital admission, and vaccine effectiveness"
1872,Efficacy of vaccination against severe COVID-19 in relation to Delta variant and time since second dose: The REACT-SCOT case-control study
1873,"Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): A double-blind, randomised"
1874,Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection during a Delta variant epidemic surge in Multnomah County
1875,Sustained effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 associated hospitalizations among adults-United States
1876,Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: A multi-center cohort study
1877,"Progress of the Delta variant and erosion of vaccine effectiveness, a warning from Utah. medRxiv 2021"
1878,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study
1879,A review on current COVID-19 vaccines and evaluation of particulate vaccine delivery systems
1880,COVID-19 Treatment and Vaccination Trackers
1881,Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: A systematic review and meta-analysis
1882,Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence
1883,Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B. 1.617. 2 (Delta) variant-National Healthcare Safety Network
1884,"New COVID-19 cases and hospitalizations among adults, by vaccination status"
1885,BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B. 1.617. 2) variant in Qatar
1886,"Rapid increase in circulation of the SARS-CoV-2, B. 1.617. 2 (Delta) variant-Mesa County"
1887,"Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation"
1888,"What Scientists Know about New, Fast-Spreading Coronavirus Variants"
1889,"Vygen-Bonnet, S. Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B. 1.617. 2) variant: Second interim results of a living systematic review and meta-analysis"
1890,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: A systematic review and meta-analysis
1891,World Health Organization. WHO Target Product Profiles for COVID-19 Vaccines
1892,Efficacy and safety of COVID-19 vaccines: A systematic review and meta-analysis of randomized clinical trials
1893,Factors that influence the immune response to vaccination
1894,Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 vaccine in long-term care facility residents and healthcare workers-A Danish cohort study
1895,Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention
1896,The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus
1897,"Omicron SARS-CoV-2 variant: What we know and what we don't. Anaesth Crit Care Pain Med. 2021, 41, 100998"
1898,CLINICAL EXPERIMENTAL VACCINE RESEARCH
1899,SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
1900,Long-lasting neutralizing antibody responses in SARS-CoV-2 seropositive individuals are robustly boosted by immunization with the CoronaVac and BNT162b2 vaccines. medRxiv
1901,SARS-CoV-2 variants of concern exhibit reduced sensitivity to live-virus neutralization in sera from CoronaVac vaccinees and naturally infected COVID-19 patients. medRxiv
1902,The immunology of SARS-CoV-2 infections and vaccines
1903,"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls"
1904,Clinical and Experimental Dermatology Acute urticaria alone after CoronaVac COVID-19 vaccination should not be a contraindication for revaccination
1905,COVID-19 vaccine-associated anaphylaxis: a statement of the World Allergy Organization Anaphylaxis Committee
1906,Centers for Disease Control and Prevention What to do if you had an allergic reaction after getting a COVID-19 vaccine
1907,Basophil activation test: mechanisms and considerations for use in clinical trials and clinical practice
1908,Aluminiuminduced granulomas after inaccurate intradermal hyposensitisation injections of aluminium-adsorbed depot preparations
1909,SARS-CoV-2 spike protein positivity in pityriasis rosea-like and urticaria-like rashes of COVID-19
1910,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report"
1911,WHO remarks at the media briefing on COVID-19 -11
1912,COVID-19 Vaccine: Critical Questions with Complicated Answers
1913,Optic Neuritis After Influenza Vaccination
1914,"Optic Neuritis Complicating Measles, Mumps, and Rubella Vaccination"
1915,Bilateral optic neuritis complicating rabies vaccination
1916,Bilateral panuveitis and optic neuritis following Bacillus Calmette-Guérin (BCG) vaccination. Acta Paediatr Oslo Nor
1917,Bilateral retrobulbar optic neuritis with hepatitis B vaccination
1918,Optic neuritis after meningococcal vaccination
1919,Optic neuritis and myelitis after booster tetanus toxoid vaccination
1920,Coronavirus Disease
1921,Late emergence of macular sparing in a stroke patient
1922,Middle Cerebral Artery Stroke
1923,Posterior Cerebral Artery Stroke
1924,Reversible cerebral vasoconstriction syndrome
1925,Cerebral venous sinus thrombosis
1926,"Retinal, ophthalmic, or ocular migraine"
1927,Optic neuritis
1928,Multiple Evanescent White Dot Syndrome
1929,Acute Idiopathic Blind Spot Enlargement Syndrome: A Review of 27 New Cases
1930,Vascular wall imaging in reversible cerebral vasoconstriction syndrome -a 3-T contrast-enhanced MRI study
1931,Infectious optic neuropathies: a clinical update
1932,Multiple evanescent white dot syndrome following influenza immunization -A multimodal imaging study
1933,Acute idiopathic blind spot enlargement syndrome following influenza vaccination
1934,High-definition optical coherence tomography findings in acute idiopathic blind spot enlargement (AIBSE) syndrome
1935,Citation
1936,Association between short-term exposure to air pollution and COVID-19 infection: Evidence from China
1937,Part II-The Positive Sense Single Stranded RNA Viruses
1938,"Coronavirus disease 2019-Historical context, virology, pathogenesis, immunotherapy, and vaccine development. Hum. Vaccines Immunother"
1939,Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association
1940,Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues
1941,An overview of COVID-19
1942,"Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals"
1943,World Health Organization. COVID-9 Landscape of Novel Coronavirus Candidate Vaccine Development Worldwide
1944,COVID-19 Map-Johns Hopkins Coronavirus Resource Center
1945,"Secretaria Extraordinário de Enfrentamento à COVID-19, Secovid"
1946,Evolutionary Dynamics and Dissemination Pattern of the SARS-CoV-2 Lineage B.1.1.33 During the Early Pandemic Phase in Brazil
1947,ACE2-lentiviral transduction enables mouse SARS-CoV-2 infection and mapping of receptor interactions
1948,Complete protection by a single-dose skin patch-delivered SARS-CoV-2 spike vaccine
1949,Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses
1950,Long-lasting neutralizing antibody responses in SARS-CoV-2 seropositive individuals are robustly boosted by immunization with the CoronaVac and BNT162b2 vaccines
1951,Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild COVID-19
1952,Antibody responses to SARS-CoV-2 in patients with COVID-19
1953,Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity
1954,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses
1955,Predictors of Nonseroconversion after SARS-CoV-2 Infection
1956,Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals
1957,"Secretaria Extraordinário de Enfrentamento à COVID-19, Secovid. In Plano de Operacionalização da Vacinação Contra a COVID-19, 11 a ; Brasil. Ministério da Saúde: Brasília, Brazil"
1958,Differential Kinetics of Immune Responses Elicited by COVID-19 Vaccines
1959,Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study
1960,"Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: A retrospective, total population cohort study in Sweden"
1961,SARS-CoV-2 Variants of Concern and Variants Under Investigation in England
1962,WHO SAGE Roadmap for Prioritizing Uses of COVID-19 Vaccines in the Context of Limited Supply: An Approach to Inform Planning and Subsequent Recommendations Based on Epidemiological Setting and Vaccine Supply Scenarios
1963,SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
1964,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine
1965,BNT162b2 and ChAdOx1 nCoV-19 vaccine effectiveness against death from the Delta variant
1966,"Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review"
1967,Secondary cases of Delta-variant COVID-19 among vaccinated healthcare workers with breakthrough infections is rare
1968,An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam
1969,COVID-19 vaccine-breakthrough infections requiring hospitalization in Mayo Clinic Florida through
1970,Recognition of variants of concern by antibodies and T cells induced by a SARS-CoV-2 inactivated vaccine
1971,"TAG-VE), classification of omicron (B.1.1.529): SARS-CoV-2 variant of Concern"
1972,Neutralization of SARS-CoV-2 omicron by BNT162b2 mRNA vaccine-elicited human sera
1973,"Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis"
1974,Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis
1975,"Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies"
1976,Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region
1977,Distribution of total cases of COVID-19 in the United States as of
1978,Influence of immune aging on vaccine responses
1979,Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies
1980,Antibody response to influenza vaccination in the elderly: a quantitative review
1981,The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial
1982,The immune response to influenza in older humans: beyond immune senescence
1983,The immunogenicity and safety of different COVID-19 booster vaccination following CoronaVac or ChAdOx1 nCoV-19 primary serie. medRxiv
1984,Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2
1985,Thai Healthcare Workers. medRxiv
1986,Reduced mortality rate after coronavac vaccine among healthcare workers
1987,Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant
1988,"Public health S, the EIIC. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness"
1989,Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2. medRxiv
1990,Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates
1991,"WHO Health Emergencies Programme, Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States"
1992,BNT162b2 boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19. medRxiv
1993,A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
1994,IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis
1995,The protective and pathogenic roles of IL-17 in viral infections: friend or foe?
1996,Interleukin 17 is a chief orchestrator of immunity
1997,CD8+ T cells clear influenza virus by perforin or Fas-dependent processes
1998,Role of TNF-alpha in CD8+ cytotoxic T lymphocytemediated lysis
1999,Between immunomodulation and immunotolerance: the role of IFNgamma in SARS-CoV-2 disease
2000,The dual nature of type I and type II interferons
2001,Interferongamma is a master checkpoint regulator of cytokine-induced differentiation
2002,COVID-19 vaccines: modes of immune activation and future challenges
2003,Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action
2004,Many Th cell subsets have Fas ligand-dependent cytotoxic potential
2005,Cytomegalovirus infection leads to development of high frequencies of cytotoxic virus-specific CD4+ T cells targeted to vascular endothelium
2006,Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity
2007,Cytomegalovirus-specific CD4 T cells are Cytolytic and mediate vaccine protection
2008,High efficiency of antiviral CD4(+) killer T cells
2009,Vaccination against persistent viral infection exacerbates CD4+ T-cell-mediated immunopathological disease
2010,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine"
2011,Differential CD147 functional epitopes on distinct leukocyte subsets
2012,"Lastest news, COVID-19 Coronavirus pandamic"
2013,The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised data
2014,Vaccines against the B.1.617.2 (Delta) Variant
2015,Thailand Medicines Regulation Division
2016,SARS-CoV-2 IgG Antibody Response after Immunization of Healthcare Workers with Inactivated COVID-19 Vaccine
2017,Phyathai 3 Hospital. The. Bangkok
2018,"All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted"
2019,Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern
2020,Confronting the Delta Variant of SARS-CoV-2
2021,Delta to dominate world
2022,Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2
2023,Correlation of SARS-CoV-2-breakthrough infections to time-fromvaccine
2024,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving twodose inactivated vaccines in healthy adults
2025,"Boosting with heterologous vaccines effectively improves protective All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted"
2026,"Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2"
2027,Boosting immunity to COVID-19 vaccines
2028,China's COVID vaccines have been crucial-now immunity is waning
2029,The level of Ig anti-RBD SARS-CoV-2 after two doses of CoronaVac vaccine
2030,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population
2031,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults
2032,Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19
2033,Humoral Responses and Serological Assays in SARS-CoV-2 Infections
2034,A SARS-CoV-2 antibody curbs viral nucleocapsid proteininduced complement hyperactivation
2035,A functional assay for serum detection of antibodies against SARS-CoV-2 nucleoprotein
2036,Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern
2037,T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire
2038,BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
2039,Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an
2040,Down-regulation of SARS-CoV-2 neutralizing antibodies in vaccinated smokers
2041,Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
2042,"Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion"
2043,Cigarette smoke exposure exacerbates lung inflammation and compromises immunity to bacterial infection
2044,"SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against COVID-19 in São Paulo, Brazil"
2045,Second wave of COVID-19 in Brazil: Younger at higher risk
2046,Governo do Estado
2047,Efficacy and safety of a COVID-19 inactivated vaccine in health care professionals in Brazil: The PROFISCOV study
2048,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomized trials
2049,Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) -preliminary report
2050,Um ano de pandemia da COVID-19: Diversidade genética do SARS-CoV-2 no Brasil
2051,SARS-CoV-2 monitoramento atualizado em 21 de maio
2052,SARS-CoV-2: monitoramento -vigilância epigenômica
2053,SES/SP; 2021
2054,A review on the immune responses against novel emerging coronavirus (SARS-CoV-2)
2055,The increase in the risk of severity and fatality rate of COVID-19 in southern Brazil after the emergence of the variant of concern (VOC) SARS-CoV-2 P.1 was greater among young adults without pre-existing risk conditions
2056,Genomic surveillance tracks the first communitary outbreak of Delta (B.1.617.2) variant in Brazil. SARS-CoV-2 coronavirus / nCoV-2019
2057,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study
2058,"Overview of EU/EEA country recommendations on COVID-19 vaccination with Vaxzevria, and a scoping review of evidence to guide decision-making. Stockholm: European Centre for Disease Prevention and Control"
2059,Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination
2060,"Serendipitous COVID-19 vaccine-mix in Uttar Pradesh, India: safety and immunogenicity assessment of a heterologous regime. medRxiv preprint"
2061,Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv
2062,"World Health Organization. Immunization stress-related response: a manual for program managers and health professionals to prevent, identify and respond to stress-related responses following immunization. Geneva: World Health Organization"
2063,Immunogenicity of heterologous prime/booster-inactivated and adenoviral-vectored COVID-19 vaccine: real-world data. Res Sq
2064,"A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: an interim analysis in Indonesia"
2065,Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients. Res Sq
2066,Development of an inactivated vaccine candidate for SARS-CoV-2. Science
2067,Evolution of antibody immunity to SARS-CoV-2. bioRxiv
2068,Safety and Immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile
2069,COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses
2070,Preliminary evaluation of QuantiFERON SARS-CoV-2 and QIAreach anti-SARS-CoV-2 total test in recently vaccinated individuals
2071,Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine
2072,Limited and short-lasting virus neutralizing titers induced by inactivated SARS-CoV-2 vaccine. Emerg Infect Dis
2073,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants
2074,COVID-19) Situation Report
2075,Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
2076,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
2077,Safety and Efficacy of NVX-CoV2373 COVID-19 Vaccine
2078,"Progress of the COVID-19 vaccine effort: Viruses, vaccines and variants versus efficacy, effectiveness and escape"
2079,Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine through 6 Months
2080,Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19. Vaccines
2081,"The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines"
2082,Efficacy of NVX-CoV2373 COVID-19 Vaccine against the B.1.351 Variant
2083,Efficacy of the ChAdOx1 nCoV-19 COVID-19 Vaccine against the B.1.351 Variant
2084,"Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers"
2085,"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): A randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial"
2086,Could mixing COVID vaccines boost immune response?
2087,"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: A prospective cohort study"
2088,Performance of a Surrogate SARS-CoV-2-Neutralizing Antibody Assay in Natural Infection and Vaccination Samples
2089,"mRNA vaccines for COVID-19: What, why and how"
2090,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
2091,Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates
2092,Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: A national prospective cohort study
2093,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant
2094,Principles for designing an optimal mRNA lipid nanoparticle vaccine
2095,Effectiveness of COVID-19 vaccines BNT162b2 and mRNA-1273 by days from vaccination: A reanalysis of clinical trial data
2096,SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
2097,Effectiveness of COVID-19 Vaccines against the B.1.617.2 (Delta) Variant
2098,"COVID-19 vaccination: What's the evidence for extending the dosing interval? Bmj 2021, 372, n18"
2099,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases
2100,"COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study"
2101,Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study
2102,CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
2103,Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients
2104,Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
2105,Exercise and the Regulation of Immune Functions
2106,"Effects of Regular Physical Activity on the Immune System, Vaccination and Risk of Community-Acquired Infectious Disease in the General Population: Systematic Review and Meta-Analysis"
2107,World Health Organization 2020 guidelines on physical activity and sedentary behaviour
2108,"Does physical activity attenuate, or even eliminate, the detrimental association of sitting time with mortality? A harmonised meta-analysis of data from more than 1 million men and women"
2109,Causal diagrams in systems epidemiology
2110,"Data, design, and background knowledge in etiologic inference"
2111,The effects of exercise on vaccination responses: a review of chronic and acute exercise interventions in humans
2112,Vaccines in historic evolution and perspective: a narrative of vaccine discoveries
2113,Methodological quality of studies and patient age as major sources of variation in efficacy estimates of influenza vaccination in healthy adults: a meta-analysis
2114,"World Health Organization, Strategic Advisory Group of Experts (SAGE) on Immunization, SAGE Working Group on COVID-19 Vaccines. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac"
2115,Cardiovascular exercise intervention improves the primary antibody response to keyhole limpet hemocyanin (KLH) in previously sedentary older adults
2116,"Higher antibody, but not cell-mediated, responses to vaccination in high physically fit elderly"
2117,Exercise and psychosocial factors modulate immunity to influenza vaccine in elderly individuals
2118,Moderate exercise improves antibody response to influenza immunization in older adults
2119,Effect of physical activity on the production of specific antibody in response to the 1998-99 influenza virus vaccine in older adults
2120,Influence of age and physical activity on the primary in vivo antibody and T cell-mediated responses in men
2121,Cardiovascular Exercise Training Extends Influenza Vaccine Seroprotection in Sedentary Older Adults: The Immune Function Intervention Trial
2122,Effects of a Taiji and Qigong intervention on the antibody response to influenza vaccine in older adults
2123,"Sitting Time, Physical Activity, and Risk of Mortality in Adults"
2124,Effects of exercise on vaccine-induced immune responses
2125,Acute exercise enhancement of pneumococcal vaccination response: A randomised controlled trial of weaker and stronger immune response
2126,The acute stressinduced immunoenhancement hypothesis
2127,Stress as an endogenous adjuvant: augmentation of the immunization phase of cell-mediated immunity
2128,"Physical activity and influenza-coded outpatient visits, a population-based cohort study"
2129,Worldwide Effect of COVID-19 on Physical Activity: A Descriptive Study
2130,"Rcommendation for an Emergency Use Listing of COVID-19 Vaccine (Vero Cell), Inactivated Submitted by Sinovac"
2131,Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients
2132,"Seroconversion was defined as a positive serology (IgG titer ≥ 15 AU/ml) for anti-SARS-CoV-2 S1/S2 IgG antibodies after vaccination (Indirect ELISA, LIAISON® SARS-CoV-2 S1/S2 IgG, DiaSorin, Italy)"
2133,Adjusted risk factors for immunogenicity data in non-autoimmune rheumatic diseases (non-ARD) individuals
2134,"CIs) with binary data was used for frequency of seroconversion rates of total anti-SARS-Cov-2 S1/S2 IgG (SC) and neutralizing antibodies (NAb) positivity. Tobit regression was used for natural log transformed GMT, FI-GMT and neutralizing activity. *P<.05, **P<.01, ***P<.001. Seroconversion was defined as a positive serology (IgG titer ≥ 15 AU/ml) for anti-SARS-CoV-2 S1/S2 IgG antibodies after vaccination"
2135,Positivity for NAb was defined as a neutralizing activity ≥ 30% (cPass sVNT Kit
2136,Morbidity and Mortality Weekly Report COVID-19 Mortality and Vaccine Coverage -Hong Kong Special Administrative
2137,"000 (82) 2,751,916/3,443,000 (80) 171,899/3,443,000 (5.0) 30-39 889"
2138,hk * Total persons vaccinated divided by total population in the age group
2139,booster doses are considered third and fourth doses after the 2-dose primary COVID-19 vaccination series vaccines
2140,The Government of the Hong Kong Special Administrative Region. CHP investigates six cases tested positive for SARS-CoV-2 virus involving Silka Seaview Hotel Hong Kong
2141,The Government of the Hong Kong Special Administrative Region
2142,"The Government of the Hong Kong Special Administrative Region. Together we fight the virus. Hong Kong, China: The Government of the Hong Kong Special Administrative Region"
2143,Coronavirus pandemic (COVID-19)
2144,Policy notes: interpretation of the protocol for prevention and control of COVID-19 in China
2145,New Zealand Ministry of Health
2146,"Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China"
2147,Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in
2148,World Health Organization
2149,Understanding the social determinants of vaccine acceptance and hesitancy: evidence from Hong Kong
2150,Willingness to accept COVID-19 vaccine among the elderly and the chronic disease population in China
2151,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients
2152,Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and Risk at different exposure periods before and after symptom onset
2153,"Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study"
2154,Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
2155,Effectiveness of an inactivated SARS-CoV-2 Vaccine in Chile
2156,"Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine"
2157,Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study
2158,COVID-19 vaccine type and humoral immune response in patients receiving dialysis
2159,"COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study"
2160,Hydroxychloroquine inhibits the trained innate immune response to interferons
2161,Review: ischemia reperfusion injury-A translational perspective in organ transplantation
2162,COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration
2163,COVID-19 and kidney transplantation: results from the TANGO International Transplant Consortium
2164,Vaccination in chronic kidney disease
2165,COVID-19 vaccination in kidney transplant recipients
2166,Waning humoral response 3 to 6 months after vaccination with the SARS-COV-2 BNT162b2 mRNA vaccine in dialysis patients
2167,"The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis or living with a kidney transplant"
2168,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients
2169,Antibody responses to the SARS-CoV-2 vaccines in hemodialysis patients: is inactivated vaccine effective? Ther Apher Dial
2170,Short-term immunogenicity profiles and predictors for suboptimal immune responses in patients with end-stage kidney disease immunized with inactivated SARS-CoV-2 vaccine
2171,Humoral response after SARS-CoV-2 mRNA vaccination in a cohort of hemodialysis patients and kidney transplant recipients
2172,Humoral and cellular responses to mRNA-1273 and BNT162b2 SARS-CoV-2 vaccines administered to hemodialysis patients
2173,"The RECOVAC immune-response Study: the immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. Transplantation. 2021. Online ahead of print"
2174,"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials"
2175,Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients
2176,Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients
2177,The type of SARS-CoV-2 vaccine influences serological response in kidney transplant recipients
2178,Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients
2179,Adverse events report of inactivated COVID-19 vaccine from 4040 healthcare workers
2180,Clinical Infectious Diseases BRIEF REPORT • cid 2021:XX (XX XXXX) • 1 Clinical Infectious Diseases ® 2021;XX(XX):0-0 False Coronavirus Disease 2019 Cases due to Contamination by Inactivated Virus Vaccine
2181,Unique SARS-CoV-2 clusters causing a large COVID-19 outbreak in Hong Kong
2182,Phylogenomic analysis of COVID-19 summer and winter outbreaks in Hong Kong: an observational study
2183,Government of the Hong Kong Special Administration Region. Government tightens restrictions and compulsory quarantine requirements for persons arriving at Hong Kong who have stayed in places outside China
2184,Air and environmental sampling for SARS-CoV-2 around hospitalized patients with coronavirus disease 2019 (COVID-19)
2185,"Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens"
2186,Intra-host non-synonymous diversity at a neutralizing antibody epitope of SARS-CoV-2 spike protein N-terminal domain
2187,Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction
2188,Lessons learned one year after SARS-CoV-2 emergence leading to COVID-19 pandemic
2189,Anomalous COVID-19 tests hinder researchers
2190,New recommendation policies for pathogen surveillance testing of researchers and improved stewardship of diagnostic DNA
2191,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines
2192,Guillain-Barré syndrome and influenza vaccines: A meta-analysis
2193,Guillain-Barré syndrome
2194,The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review
2195,The unequal scramble for coronavirus vaccines -by the numbers
2196,"Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study"
2197,Incidencia de casos nuevos de enfermedad por grupos de edad Estados Unidos Mexicanos
2198,Advisory Committee on Immunization Practices -United States
2199,COVID-19 vaccines and treatments nationalism: Challenges for low-income countries and the attainment of the SDGs
2200,Política nacional rectora de vacunación contra el SARS-CoV-2 para la prevención de la COVID-19 en México
2201,Criteria for diagnosis of Guillain-Barré syndrome
2202,Global manual on surveillance of adverse events following immunization
2203,Stroke Among SARS-CoV-2 Vaccine Recipients in Mexico: A Nationwide Descriptive Study
2204,Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study
2205,The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
2206,Controlled trial prednisolone in acute polyneuropathy
2207,Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria
2208,Early recognition of poor prognosis in Guillain-Barre syndrome
2209,Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group
2210,"Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data"
2211,"Probable Inference, the Law of Succession, and Statistical Inference"
2212,Modern epidemiology
2213,Quantitative Contrasts: The Magnitude of Distinctions
2214,Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program
2215,Guillain-Barré Syndrome After High-Dose Influenza Vaccine Administration in the United States
2216,"Adverse events following adenovirus type 4 and type 7 vaccine, live, oral in the Vaccine Adverse Event Reporting System (VAERS)"
2217,Vaccines and the risk of Guillain-Barré syndrome
2218,Estimation of the Incidence of Guillain-Barré Syndrome During Pregnancy in the United States
2219,Surveillance for Adverse Events After COVID-19 mRNA Vaccination
2220,Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection
2221,Guillain-Barré Syndrome after COVID-19 Vaccination in the Vaccine Safety Datalink
2222,Neurological Events Reported after COVID
2223,A variant of Guillain-Barre syndrome after SARS-CoV-2 vaccination
2224,"UNESCO Office Montevideo and Regional Bureau for Science in Latin America and the Caribbean. COVID-19 and vaccination in Latin America and the Caribbean: challenges, needs and opportunities"
2225,Prognostic Factors in Elderly Patients With Guillain-Barré Syndrome: Does Age Matter?
2226,Guillain-Barré syndrome in low-income and middle-income countries: challenges and prospects
2227,Clinical Characteristics and Predictors of Short-Term Outcome in Mexican Adult Patients with Guillain-Barré Syndrome
2228,Predictors of mechanical ventilation in Guillain-Barré syndrome with axonal subtypes
2229,"Electrophysiological subtypes and associated prognosis factors of Mexican adults diagnosed with Guillain-Barré syndrome, a single center experience"
2230,NCAM protein and SARS-COV-2 surface proteins: In-silico hypothetical evidence for the immunopathogenesis of Guillain-Barré syndrome
2231,Post-adenoviral-based vaccines Guillain-Barre Syndrome: A proposed mechanism
2232,Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients
2233,Maintaining Safety with SARS-CoV-2 Vaccines
2234,Regional variation of Guillain-Barré syndrome
2235,279 non-serious AEFI 81
2236,Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant
2237,Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants
2238,Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil
2239,Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
2240,Strategic Advisory Group of Experts on Immunization -SAGE (WHO). Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization
2241,Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
2242,Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression
2243,Omicron thwarts some of the world's most-used COVID vaccines
2244,Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong
2245,Epidemiologic Surveillance Guide. National Emergency of Public Health Concern due to the COVID-19 disease
2246,Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings
2247,Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness
2248,R: A language and environment for statistical computing
2249,Austria: R Foundation for Statistical Computing
2250,"Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients. Clinical Infectious Diseases systems**, n (%) 17564 (25.4) 11866 (17.2) and RT-PCR testing, median (p25-p75)"
2251,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina
2252,La OMS caracteriza a COVID-19 como una pandemia
2253,"Organización Panamericana de la Salud,organización Mundial de la Salud"
2254,COVID-19) -the data -Statistics and Research
2255,Actualización Epidemiológica Enfermedad por coronavirus (COVID-19) [Internet] Washington DC: Organización Panamericana de la Salud
2256,Reino Unido comienza vacunación masiva contra la covid-19: cómo es el proceso y qué se puede esperar
2257,Data. Coronavirus (COVID-19) Vaccinations -Statistics and Research
2258,COVID-19 vaccine tracker and landscape [Internet]Ginebra:Organización Mundial de Salud
2259,Manual para la elaboración de análisis de impacto presupuestal
2260,The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization
2261,Economic evaluation for mass vaccination against COVID-19
2262,Centre for the Mathematical Modelling of Infectious Diseases COVID-19 working group. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation
2263,Principles of good practice for budget impact analysis: Report of the ISPOR Task Force on Good Research Practices -Budget Impact Analysis. Value Heal
2264,Coronavirus y realidad: los imposibles costos de internarse en una clínica privada
2265,Mortalidad y factores pronósticos en pacientes hospitalizados por COVID-19 en la Unidad de Cuidados Intermedios de un hospital público de Lima
2266,Se define valores de referencia a pagar por servicios UCI de covid-19 [Internet]Bogóta: Ministerio de de Salud y Protección Social
2267,Períodico el Contribuyente México. Éstos son los costos de atención médica en el IMSS en
2268,COVAX anuncia un nuevo acuerdo y previsiones sobre las primeras entregas de vacunas
2269,Bogóta: Ministerio de Saud y Protección Social
2270,SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines
2271,ENSEMBLE Study Group. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
2272,"Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial"
2273,Evidence Assessment: Sinovac/CoronaVac COVID-19 vaccine
2274,NMPA Accepts the Application for Conditional Marketing Authorization of CanSinoBIO's COVID-19 Vaccine ConvideciaTM
2275,Evidence assessment: Sinopharm/BBIBP COVID-19 vaccine
2276,Plan Estratégico Para La Vacunación Contra La Covid-19 En La república de Argentina
2277,Los modelos de Markov probabilísticos en la evaluación económica de tecnologías sanitarias: Una guía práctica
2278,La salud pública en la primera ola: una agenda para la cooperación ante Covid-19
2279,Vacunas e inmunización: ¿qué es la vacunación? [Internet] Ginebra: Organización Mundial de la Salud
2280,El COVID-19 como renovado detonador del acaparamiento y la depredación comercial: ¿el multilaterismo en coma? Glob Trade Alert Rep
2281,Disponible en: www.globaltradealert.org/reports 35. ForoALC2030. Cuarta reunión virtual del Foro de los Países de América Latina y el Caribe sobre el Desarrollo Sostenible
2282,"Aceptado para su publicación, tras revisión, el 13 de octubre del 2021. coronavirus-vacuna-plan-estrategico-vacunacion-covid-19-diciembre -2020.pdf 26. Ministério da Saúde"
2283,Operacionalização Da Vacinação Contra a Covid-19
2284,Planificación: vacunación contra sars-cov-2
2285,Plan Nacional de Vacunación contra el SARS-CoV-2. 2021;Bogóta: Ministerio de de Salud y Protección Social
2286,Plan Nacional Actualizado contra la COVID-19
2287,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China
2288,Interım report: safety and immunogenicity of an inactivated vaccine agaınst SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv
2289,SINOVAC科兴. 2021. 为人类消除疾病提供疫苗. Accessed
2290,US authorization of first COVID vaccine marks new phase in safety monitoring
2291,mRNA vaccination induces durable immune memory to SARS-CoV-2 with continued evolution to variants of concern
2292,Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant
2293,Ocular Surface Erosion after Suspected Exposure to Evaporated COVID-19 Vaccine Somporn Chantra a Pareena Chaitanuwong a Kasem Seresirikachorm a Keywords COVID-19 vaccine · Ocular surface erosion · Skin rash · Health worker · Case report
2294,The long road toward COVID-19 herd immunity: vaccine platform technologies and mass immunization strategies. Front Immunol
2295,WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations
2296,Grading of corneal and conjunctival staining in the context of other dry eye tests
2297,The Short Time Exposure (STE) test for predicting eye irritation potential: intra-laboratory reproducibility and correspondence to globally harmonized system (GHS) and EU eye irritation classification for 109 chemicals
2298,Eye complaints in the office environment: precorneal tear film integrity influenced by eye blinking efficiency
2299,Hazardous Substances Data Bank: PubChem data source
2300,TOXBASE: poisons information database for clinical toxicology advice
2301,Exhaled particles and small airways
2302,Characteristics of endothelial corneal transplant rejection following immunisation with SARS-CoV-2 messenger RNA vaccine
2303,Association of ocular adverse events with inactivated COVID-19 vaccination in patients in Abu Dhabi
2304,Neutralizing Activities against the Omicron Variant after a 2 Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination
2305,"Progress of the COVID-19 365 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape"
2306,Waning Immunity after the BNT162b2
2307,Vaccine in Israel
2308,Emerging SARS-CoV-2 variants of concern and potential 388 intervention approaches
2309,Structural and 390 functional insights into the spike protein mutations of emerging SARS-CoV-2 variants
2310,"The Global Epidemic of the SARS-CoV-2 delta variant, 393 key spike mutations and immune escape"
2311,Delta spike P681R mutation enhances SARS-CoV-2 395 fitness over Alpha variant. bioRxiv
2312,CoronaVac induces lower 398 neutralising activity against variants of concern than natural infection
2313,Reduced neutralization of SARS-CoV-2 B.1.617 401 by vaccine and convalescent serum
2314,Omicron escapes the majority of existing SARS-CoV-2 403 neutralizing antibodies
2315,Omicron (B. 1.1. 529) variant of concern and its global perspective
2316,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome"
2317,"COVID-19 coagulopathy, thrombosis, and bleeding"
2318,Inflammation and coagulation
2319,Immunopathology of hyperinflammation in COVID-19
2320,Thrombosis and COVID-19 pneumonia: the clot thickens!
2321,Pulmonary embolism and deep vein thrombosis in COVID-19: A systematic review and meta-analysis
2322,Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis
2323,Treatment of antiphospholipid syndrome
2324,"Lessons from the ""Euro-Phospholipid"" project"
2325,International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
2326,COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS AC-TION)
2327,Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots
2328,Viral coagulopathy in patients with COVID-19: Treatment and care
2329,Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19
2330,Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review
2331,Pathogenesis of the antiphospholipid syndrome
2332,The pathogenesis of the antiphospholipid syndrome
2333,"COVID-19, Antiphospholipid Antibodies, and Catastrophic Antiphospholipid Syndrome: A Possible Association?"
2334,Vaccine-induced immune thrombocytopenia and thrombosis (VITT). Res Practice
2335,WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic
2336,Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: The PROFISCOV study
2337,A new SARS-CoV-2 dual-purpose serology test: Highly accurate infection tracing and neutralizing antibody response detection
2338,World Health Organization. World alliance for patient safety: WHO draft guidelines for adverse event reporting and learning systems: from information to action. World Health Organization
2339,The REDCap consortium: Building an international community of software platform partners
2340,Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support
2341,GAPSS: the Global Anti-Phospholipid Syndrome Score
2342,The adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction
2343,Update of the guidelines for lupus anticoagulant detection
2344,"Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients"
2345,Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases
2346,New and upcoming treatments in antiphospholipid syndrome: A comprehensive review
2347,Importance of COVID-19 vaccine efficacy in older age groups
2348,"COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations"
2349,The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort
2350,Common risk factors for both arterial and venous thrombosis
2351,Thrombosis after covid-19 vaccination
2352,Pandemic influenza immunization in primary antiphospholipid syndrome (PAPS): a trigger to thrombosis and autoantibody production?
2353,Inactivated SARS-CoV-2 vaccine does not influence the profile of prothrombotic antibody nor increase the risk of thrombosis in a prospective Chinese cohort
2354,Antiphospholipid antibodies in patients with COVID-19: A relevant observation?
2355,The epidemiology of antiphospholipid syndrome: A populationbased study
2356,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access"
2357,"Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review"
2358,Covid-19 in Brazil: a sad scenario
2359,condicionantes e desafios de coordenação do Estado federativo brasileiro no contexto da COVID-19
2360,COVID-19 Vaccine Tracker: Latest Updates -The New York Times. The New York Times
2361,Agência Brasil -Vacinação contra COVID-19 começa em todo país
2362,COVID-19) Vaccinations. Our World in Data
2363,Monitor da COVID: Vacinação. Lagom Data
2364,Introducing COVID-19 vaccination: Guidance for determining priority groups and microplanning. Version 1
2365,Plano Nacional de Operacionalização da Vacinação contra Covid-19 -Português (Brasil)
2366,DATASUS -TabNet Win32 3.0: CNES -Recursos Humanos -Profissionais -Indivíduos -segundo CBO 2002 -Brasil
2367,"Cerca de 570 mil profissionais de saúde se infectaram e 2,5 mil morreram por COVID-19 nas Américas"
2368,Censo 2010 IBGE
2369,Levantamento -Plano de Vacinação nos Estados e nas Cidades do Brasil
2370,Covid Performance Index: Deconstructing pandemic responses -Methodology
2371,The hindrances to perform the COVID-19 vaccination in Brazil
2372,A beacon for the COVID-19 epidemic control in Brasil: seroepidemiological population-based surveys
2373,What policy makers need to know about COVID-19 protective immunity
2374,World Health Organization. Population-based age-stratified seroepidemiological investigation protocol for COVID-19 virus infection
2375,National COVID-19 vaccination plan: using artificial spatial intelligence to overcome challenges in Brazil
2376,"Estabelece diretrizes gerais para a instituição de Regiões de Saúde no âmbito do Sistema Único de Saúde (SUS), nos termos do Decreto n. 7.508, de 28 de junho de 2011"
2377,A spatial scan statistic
2378,Interactive spatial data analysis in medical geography
2379,46 anos do Programa Nacional de Imunizações: uma história repleta de conquistas e desafios a serem superados
2380,"Brasileiro perdeu quase 2 anos de expectativa de vida na pandemia, e 2021 deve ser pior, diz demógrafa de Harvard. BBC News Brasil"
2381,COVID-19 and Older Adults: What We Know
2382,Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up
2383,COVID-19 in the elderly people and advances in vaccination approaches
2384,Saúde do idoso em tempos de pandemia COVID-19
2385,Secretaria de Vigilância em Saúde
2386,Demographic and Social Factors Associated with COVID-19 Vaccination Initiation Among Adults Aged ≥65 Years-United States
2387,Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalised Adults Aged ≥65 Years -United States
2388,Boletim do Observatório Covid-19 -semanas epidemiológicas 16 e 17 de 2021
2389,Brasil receberá as primeiras vacinas contra COVID-19 por meio do Mecanismo COVAX neste domingo
2390,Vacina de Oxford ultrapassa CoronaVac e é a mais usada no Brasil
2391,Lira diz que inclusão de pessoas com comorbidades diminuiu ritmo de vacinação no Brasil. Valor Econômico
2392,COVID-19 and comorbidities in the Americas: Hands-on tool to estimate the population at increased and high risk of severe COVID-19 due to underlying health conditions for the Americas
2393,dos que não tomaram segunda dose. Agência Brasil
2394,Boletim do Observatório Covid-19 -semanas 31 e 32 de 2021
2395,"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac -PROFISCOV: A structured summary of a"
2396,The Brazilian Government's mistakes in responding to the COVID-19 pandemic
2397,One Year of Coronavirus Disease 2019 (COVID-19) in Brazil: a political and social overview
2398,A partisan pandemic: state government public health policies to combat COVID-19 in
2399,"convenient online submission • thorough peer review by experienced researchers in your field • rapid publication on acceptance • support for research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year submit your research ?"
2400,Data. Statistics and Research -Coronavirus (COVID-19) Vaccinations. 2021
2401,"Disparities in COVID-19 Vaccination Coverage Among Health Care Personnel Working in Long-Term Care Facilities, by Job Category, National Healthcare Safety Network -United States"
2402,Inferring the effectiveness of government interventions against COVID-19
2403,The Implementation of Mass-Vaccination against SARS-CoV-2: A Systematic Review of Existing Strategies and Guidelines
2404,Considerations for fair prioritisation of COVID-19 vaccine and its mandate among healthcare personnel
2405,Physician COVID-19 Vaccination Study (Final Report)
2406,Is It Lawful and Ethical to Prioritise Racial Minorities for COVID-19 Vaccines?
2407,Indigenous and tribal peoples' health (The Lancet-Lowitja Institute Global Collaboration): a population study
2408,COVID-19 mortality among Indigenous people in Brazil: a nationwide register-based study
2409,Análise da distribuição e tendência de coberturas vacinais para crianças indígenas menores de cinco anos de idade. Brasil
2410,"STF obriga governo a priorizar indígenas urbanos em vacinação, mas medida ainda tem obstáculos"
2411,Menos de 7% das áreas quilombolas no Brasil foram tituladas. Agência Brasil
2412,Brazil vaccine drive faces challenges in remote communities
2413,Quilombolas têm que recorrer à Justiça e até comprar geladeira para conseguir vacina. Brasil de Fato
2414,Instituto Brasileiro de Geografia e Estatística (IBGE)
2415,Fundação Cultural Palmares. Informações Quilombolas. 2021
2416,Covid-19 vaccination hesitancy
2417,Healthcare workers' (HCWs) attitudes and related factors towards COVID-19 vaccination: a rapid systematic review
2418,COVID-19 Vaccination Hesitancy in the United States: A Rapid National Assessment
2419,Desafios das Fake News com Idosos durante Infodemia sobre Covid-19: Experiência de Estudantes de Medicina
2420,"Por conta de fake news, 70% dos índigenas do Tapajós resistem à vacinação. CNN Brasil"
2421,62% dos indígenas na Amazônia estão vacinados contra COVID; AC e PA têm aldeias com baixa adesão. G1 Globo/ Instituto Socioambiental
2422,"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study"
2423,"COVID-19) Dashboard, Overview of all Countries"
2424,"The current COVID-19 situation, Iran (Islamic Republic of)"
2425,COVID-19: Prevention and control measures in community
2426,COVID-19 transmission through asymptomatic carriers is a challenge to containment. Influenza Other Respir. Viruses
2427,Vaccine confidence in the time of COVID-19
2428,The advisory committee on immunization practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine-United States
2429,Identifying airborne transmission as the dominant route for the spread of COVID-19
2430,Estimation of basic reproduction number for COVID-19 and the reasons for its differences
2431,The vaccine journey for COVID-19: A comprehensive systematic review of current clinical trials in humans
2432,The Covid-19 Candidate Vaccine Landscape and Tracker
2433,Covid-19 Vaccines
2434,Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: Interim results of a living systematic review
2435,Tracking Coronavirus Vaccination Around the World
2436,The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections
2437,SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse
2438,Mutation D614G increases SARS-CoV-2 transmission
2439,An Observational Laboratory-Based Assessment of SARS-CoV-2 Molecular Diagnostics in
2440,Genomics and epidemiology of the P. 1 SARS-CoV-2 lineage in Manaus
2441,"Delta variant: What is happening with transmission, hospital admissions, and restrictions? BMJ 2021"
2442,Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection among Frontline Workers Before and During B. 1.617. 2 (Delta) Variant Predominance-Eight US Locations
2443,The Equitable Distribution of COVID-19 Therapeutics and Vaccines
2444,"Population and Housing Census, Census"
2445,WHO. COVID-19 Clinical Management: Living Guidance
2446,"COVID-19 Attributable Deaths on Longevity, Premature Mortality and DALY: Estimates of"
2447,Reductions in 2020 US life expectancy due to COVID-19 and the disproportionate impact on the Black and Latino populations
2448,How Much is the Cost of Each Covid-19 Patient? Available online
2449,How Much Will a Covid-19 Vaccine Cost? The Financial Times
2450,The Cost per Jab of Covid-19 Vaccine Candidates
2451,The Price Tags on the COVID-19 Vaccines
2452,Sinovac Shot Shown 78% Effective in Brazil after Data Confusion. Bloomberg News
2453,Turkey Finds Chinese Vaccine Efficacy Rate of 91.25% in Trial
2454,Sinovac's Vaccine Approved by Indonesia for Emergency Use
2455,Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: Test negative case-control study
2456,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial"
2457,Assessment: Sinopharm/BBIBP COVID-19 vaccine
2458,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials
2459,Mounting evidence suggests Sputnik COVID vaccine is safe and effective
2460,"Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: Test negative design study"
2461,Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
2462,Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
2463,"Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years-COVID-NET, 13 States"
2464,Safety and Potency of COVIran Barekat Inactivated Vaccine Candidate for SARS-CoV-2: A Preclinical Study
2465,Results of the Coviran Barekat Vaccine Trials
2466,"Gholamzadeh Baeis, M. The challenge of deciding between home-discharge versus hospitalization in COVID-19 patients: The role of initial imaging and clinicolaboratory data"
2467,Morbidity and mortality from COVID-19 post-vaccination breakthrough infections in association with vaccines and the emergence of variants in Bahrain
2468,COVID-19 Vaccines: Current Status and Implication for Use in Indonesia
2469,The Role of Cost-Effectiveness in U.S. Vaccination Policy
2470,"The World Bank, Data. GDP per Capita (Current US$)-Iran, Islamic Rep"
2471,COVID-19 Vaccination Scenarios: A Cost-Effectiveness Analysis for Turkey
2472,Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa. medRxiv 2021
2473,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine
2474,Respiratory follow-up of patients with COVID-19 pneumonia
2475,PMCID:PMC7447111)
2476,The socio-economic implications of the coronavirus pandemic (COVID-19): a review
2477,"COVID-19 vaccine: a recent update in pipeline vaccines, their design and development strategies"
2478,C4591001 Clinical Trial Group (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine
2479,COVE Study Group (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
2480,Thrombotic events and COVID-19 vaccines
2481,Shedding the light on post-vaccine myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients
2482,Guillain-Barré syndrome following BNT162b2 COVID-19 vaccine
2483,Antibody response to COVID-19 vaccination in adults with hematologic malignant disease
2484,"Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: a web-based survey"
2485,Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry
2486,Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study
2487,Adverse events after first COVID-19 vaccination in patients with autoimmune diseases
2488,PMCID:PMC8213359)
2489,Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine
2490,Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis
2491,Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus
2492,A flare of Still's disease following COVID-19 vaccination in a 34-year-old patient
2493,Autoimmune phenomena following SARS-CoV-2 vaccination
2494,ANCA-associated vasculitis following Pfizer-BioNTech COVID-19 vaccine
2495,Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination
2496,Uveitis and other ocular complications following COVID-19 vaccination
2497,PMCID:PMC8704915)
2498,International Study Group for Behçet's Disease (1990) Criteria for diagnosis of Behçet's disease
2499,Criteria for the diagnosis of familial Mediterranean fever
2500,Behçet's-like adverse event or inaugural Behçet's disease after SARS-CoV-2 mRNA-1273 vaccination?
2501,Emergence of Behçet's disease post-SARS-CoV2-vaccination: two clinical cases in Japan
2502,"Pathogenesis of Behçet's syndrome: genetic, environmental and immunological factors"
2503,Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Behçet's disease-a multicenter study
2504,Induction of Behçet's disease symptoms after dental treatment and streptococcal antigen skin test
2505,Behcet's disease and severe inflammatory reaction to 23-valent pneumococcal polysaccharide vaccine: a case report and review of literature
2506,Streptococcal hypersensitivity reloaded: severe inflammatory syndrome in Behcet's disease following 23-valent polysaccharide Streptococcus pneumoniae vaccine
2507,"The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet's syndrome"
2508,Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: a single-center study
2509,COVID-19 and autoinflammatory diseases: prevalence and outcomes of infection and early experience of vaccination in patients on biologics
2510,Occurrence of Henoch-Schönlein purpura in a patient treated with secukinumab
2511,Autoinflammatory disease reloaded: a clinical perspective
2512,Surveillance for adverse events after COVID-19 mRNA vaccination
2513,Guillain-Barré syndrome associated with COVID-19 vaccination
2514,PMCID:PMC8632191)
2515,Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
2516,Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study
2517,Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting
2518,The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety
2519,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis
2520,The psychological state and changes in the routine of the patients with rheumatic diseases during the coronavirus disease (COVID-19) outbreak in Turkey: a web-based cross-sectional survey
2521,Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
2522,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome
2523,Endocrine Conditions and COVID-19
2524,"Endocrine Involvement in COVID-19: Mechanisms, Clinical Features, and Implications for Care"
2525,"Thyroid Dysfunction in Relation to Immune Profile, Disease Status, and Outcome in 191 Patients with COVID-19"
2526,SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves' disease after COVID-19
2527,Is Subacute Thyroiditis an Underestimated Manifestation of SARS-CoV-2 Infection? Insights From a Case Series
2528,Viruses and thyroiditis: an update
2529,COVID-19: vaccine's progress. Microb Biotechnol
2530,The SARS-CoV-2 as an instrumental trigger of autoimmunity
2531,ASIA syndrome and endocrine autoimmune disorders
2532,Subacute thyroiditis following the H1N1 vaccine
2533,Subacute thyroiditis following seasonal influenza vaccination
2534,Subacute thyroiditis following influenza vaccine (Vaxigrip) in a young female
2535,Subacute thyroiditis and dyserythropoesis after influenza vaccination suggesting immune dysregulation
2536,Subacute thyroiditis after hepatitis B vaccination
2537,Occurrence of Subacute Thyroiditis following Influenza Vaccination
2538,Two cases of Graves' disease following SARS-CoV-2 vaccination: An autoimmune/inflammatory syndrome induced by adjuvants
2539,"double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial"
2540,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind"
2541,Endocrine Significance of SARS-CoV-2's Reliance on ACE2
2542,COVID-19-associated ophthalmoparesis and hypothalamic involvement
2543,Adrenal Vascular Changes in COVID-19 Autopsies
2544,Bilateral Adrenal Hemorrhage in Coronavirus Disease 2019 Patient: A Case Report
2545,Pathological Findings in the Testes of COVID-19 Patients: Clinical Implications
2546,Clinical characteristics of subacute thyroiditis classified according to human leukocyte antigen typing
2547,Autoimmune/Inflammatory Syndrome Induced by Adjuvants and Thyroid Autoimmunity
2548,Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome): clinical and immunological spectrum
2549,Severe manifestations of autoimmune syndrome induced by adjuvants (Shoenfeld's syndrome)
2550,Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases
2551,Approach to the patient with postpartum thyroiditis
2552,Journal Pre-proof Type 1 Kounis syndrome induced by inactivated SARS-CoV-2 vaccine Type 1 Kounis syndrome induced by inactivated SARS- CoV-2 vaccine
2553,Recombinant vaccines for COVID-19
2554,Histamine-induced coronary artery spasm: the concept of allergic angina
2555,Allergic myocardial infarction following recombinant human insulin
2556,"Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations. Vaccines. 2021, 9"
2557,Kounis Syndrome in a patient after administration of influenza vaccine
2558,A Rarely Seen Type-I Kounis Syndrome Caused By Tetanus Vaccine
2559,Coronary hypersensitivity disorder: the Kounis syndrome
2560,"Myocardial infarction after aspirin treatment, and Kounis syndrome"
2561,Treatment of Kounis syndrome
2562,Allergic acute coronary syndrome (Kounis syndrome)
2563,Allergic reaction reveals a non-lethal late stent thrombosis. A new subtype of Kounis syndrome?
2564,"Kounis syndrome: an update on epidemiology, pathogenesis, diagnosis and therapeutic management"
2565,Current understanding of Kounis syndrome
2566,Vasospastic angina induced by nonsteroidal antiinflammatory drugs
2567,Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech
2568,Vaccine -United States
2569,IMPact of the COVID-19 epidemic on the moRTAlity of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT)
2570,COVID-19 among US dialysis patients: risk factors and outcomes from a national dialysis provider
2571,"Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey"
2572,Covid-19 and kidney transplantation
2573,COVID-19 in kidney transplant recipients: a multicenter experience in Istanbul
2574,At least 156 reasons to prioritize COVID-19 vaccination in patients receiving in-centre haemodialysis
2575,COVID-19 and solid organ transplantation: a review article
2576,The impact of COVID-19 on kidney transplantation and the kidney transplant recipient -One year into the pandemic
2577,Antibody response to 2-Dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients
2578,Safety and immunogenicity of anti-sars-cov-2 messenger RNA vaccines in recipients of solid organ transplants
2579,Antibody and T cell response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and hemodialysis patients
2580,Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus
2581,High immunogenicity of a messenger RNA based vaccine against SARS-CoV-2 in chronic dialysis patients
2582,Betjes MGH. Protective cytomegalovirus (CMV)-Specific T-Cell immunity is frequent in kidney transplant patients without serum anti-CMV antibodies
2583,"Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation"
2584,Serologic vaccination response after solid organ transplantation: a systematic review
2585,Vaccination of solid organ transplant candidates and recipients: guidelines from the American society of transplantation infectious diseases community of practice
2586,Three doses of an mRNA covid-19 vaccine in solid-organ transplant recipients
2587,Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac
2588,Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients
2589,Impaired humoral response in renal transplant recipients to SARS-CoV-2 vaccination with BNT162b2 (Pfizer-BioNTech)
2590,Impact of prior influenza and pneumoccocal vaccines on humoral and cellular response to SARS-CoV-2 BNT162b2 vaccination. Vaccines (Basel)
2591,"Cutaneous adverse reactions from 35,229 doses of Sinovac and AstraZeneca COVID-19 vaccination: a prospective cohort study in healthcare workers Letter to the Editor Data availability statement Letter to the Editor Letter to the Editor"
2592,Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases
2593,Incidence of cutaneous reactions after messenger RNA COVID-19 vaccines
2594,The health of the healthcare workers
2595,Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS)
2596,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint
2597,Neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination: a systematic review and pooled meta-analysis
2598,Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections
2599,Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months
2600,Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for COVID-19
2601,Durable humoral and cellular immune responses 8 months after Ad26. COV2.S vaccination
2602,Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
2603,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/ 2 clinical trial"
2604,"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, doubleblind, randomised, placebo-controlled phase 2 clinical trials"
2605,MICE: multivariate imputation by chained equations in R
2606,SARS-CoV-2 variants: levels of neutralisation required for protective immunity
2607,Correlates of vaccine-induced protection against SARS-CoV-2. Vaccines
2608,Moderna 2Q 2021 Earnings Call
2609,Second Quarter 2021 Financial Results and Operational Highlights
2610,SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3
2611,Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months
2612,Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine
2613,Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in elderly people over 85 years of age in Greece
2614,COVID-19 dashboard
2615,Clinical manifestations of COVID-19 in the general population: systematic review
2616,Mild or moderate Covid
2617,Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases
2618,"Vaccine hesitancy: definition, scope and determinants"
2619,COVID-19 vaccine acceptance and hesitancy in low-and middle-income countries
2620,"Cross-sectional analysis of COVID-19 vaccine intention, perceptions and hesitancy across Latin America and the Caribbean"
2621,SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists
2622,COVID-19 vaccine hesitancy in patients with systemic autoimmune rheumatic disease: an interview-based survey
2623,"Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: a webbased survey"
2624,Reporting survey based studies-a primer for authors
2625,Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children
2626,Centro de Vigilância Epidemiológica
2627,"Documento técnico: campanha de vacinação contra a COVID-19: 23 de julho de 2021, 18ª atualização"
2628,Head-to-head evaluation on diagnostic accuracies of six SARS-CoV-2 serological assays
2629,Prevalence and types of vaccination errors from 2009 to 2018: a systematic review of the medical literature
2630,Incidence of post-vaccination adverse events in children
2631,"Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children"
2632,"Children and adolescents with SARS-CoV-2 infection: epidemiology, clinical course and viral loads"
2633,Multisystem inflammatory syndrome in children (MIS-C) with COVID-19: insights from simultaneous familial Kawasaki disease cases
2634,The importance of advancing severe acute respiratory syndrome coronavirus 2 vaccines in children
2635,The Turkish Ministry of Health Covid19 information page n.d
2636,SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans
2637,Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19
2638,Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection
2639,Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study
2640,Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac. The Lancet Infectious Diseases
2641,BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
2642,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled"
2643,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in health care workers
2644,Long-lived plasma cells are contained within the CD19− CD38hiCD138+ subset in human bone marrow
2645,Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
2646,A single-cell atlas of the peripheral immune response in patients with severe COVID-19
2647,"Correlation of the units (U) of the Elecsys® Anti-SARS-CoV-2 S assay to the ""binding antibody units"" (BAU) of the first WHO International Standard for anti-SARS-CoV-2 immunoglobulin"
2648,"Immune Assays Team § Moderna, Inc. Team § Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team § United States Government (USG)/CoVPN Biostatistics Team § Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial"
2649,Weak correlation between antibody titers and neutralizing activity in sera from SARS-CoV-2 infected subjects
2650,"BNT162b2 Vaccine-Induced Immune Responses and Dynamics Vary Among Age Groups, Sex and Co-Morbidities: A Longitudinal Prospective Cohort Study n"
2651,"Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study"
2652,Immunogenicity After Two Doses of Inactivated Virus Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: Prospective Observational Study
2653,Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine
2654,"Peripheral innate and adaptive immune cells during COVID-19: Functional neutrophils, pro-inflammatory monocytes and halfdead lymphocytes"
2655,B cell memory and Plasma cell development
2656,Age-associated changes in counts and detailed characterization of circulating normal CD138− and CD138+ plasma cells
2657,Germinal center reaction: antigen affinity and presentation explain it all
2658,"Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus"
2659,Extrafollicular responses in humans and SLE
2660,Maturation trajectories and transcriptional landscape of plasmablasts and autoreactive B cells in COVID-19
2661,Fundamental Immunology. Fundamental Immunology
2662,"Type I and type III interferons-induction, signaling, evasion, and application to combat COVID-19"
2663,Side effects and antibody response of an inactive severe acute respiratory syndrome coronavirus 2 vaccine among health care workers
2664,Report of the SAGE Working Group on Vaccine Hesitancy
2665,World Health Organization. Ten Threats to Global Health in 2019
2666,Understanding Vaccine Hesitancy around Vaccines and Vaccination from a Global Perspective: A Systematic Review of Published Literature
2667,Confidence and Receptivity for COVID-19 Vaccines: A Rapid Systematic Review. Vaccines
2668,Using the Internet for Surveys and Health Research
2669,Twitter as a Tool for Health Research: A Systematic Review
2670,Social Media Vaccine Websites: A Comparative Analysis of Public and Moderated Websites
2671,Analysis of the Anti-Vaccine Movement in Social Networks: A Systematic Review
2672,Content Themes and Influential Voices within Vaccine Opposition on Twitter
2673,The Ministry of Health of Turkey Health Statistics Yearbook 2019; General Directorate of Health Information Systems
2674,Vaccine hesitancy in turkey
2675,Systematic review of studies to determine factors affecting vaccine rejection/instability/contrast
2676,An analysis on the anti-vaccination movement in Turkish digital platforms: Ekşisözlük and Facebook. Eskişehir Türk Dünyası Uygul. Araştırma Merk. Halk Saglıgı Derg
2677,Youtube'daki Aşılarlaİlgili Türkçe Videolar Neler Söylüyor? Birİçerik Analizi
2678,Social media and vaccine hesitancy: New updates for the era of COVID-19 and globalized infectious diseases. Hum. Vaccines Immunother
2679,Digital 2021: Turkey. Available online
2680,What is an adequate sample size? Operationalising data saturation for theory-based interview studies
2681,A simple method to assess and report thematic saturation in qualitative research
2682,Lessons learned from frontline skilled nursing facility staff regarding COVID-19 vaccine hesitancy
2683,High Rates of COVID-19 Vaccine Hesitancy and Its Association with Conspiracy Beliefs: A Study in Jordan and Kuwait among Other Arab Countries
2684,COVID-19 vaccine hesitancy is associated with beliefs on the origin of the novel coronavirus in the UK and Turkey
2685,"COVID-19 vaccination hesitancy, misinformation and conspiracy theories on social media: A content analysis of Twitter data"
2686,European Centre for Disease Prevention and Control. Rapid Literature Review on Motivating Hesitant Population Groups in Europe to Vaccinate; ECDC Technical Report
2687,COVID-19 Vaccine Hesitancy in Canada: Content Analysis of Tweets Using the Theoretical Domains Framework
2688,COVID-19 vaccine hesitancy and resistance: Correlates in a nationally representative longitudinal survey of the Australian population
2689,Relational ethical approaches to the COVID-19 pandemic
2690,Diyanet: Salgında Aşı Yaptırmamak Kul Hakkına Girer
2691,"The relationship of COVID-19 vaccine attitude with life satisfaction, religious attitude and COVID-19 avoidance in Turkey. Hum. Vaccines Immunother"
2692,The anti-vaccination infodemic on social media: A behavioral analysis
2693,Republic of Turkey Ministry of Health. COVID-19 Vaccination Information Platform
2694,Myths and conspiracy theories on vaccines and COVID-19: Potential effect on global vaccine refusals
2695,Resistance to COVID-19 vaccination has increased in Ireland and the United Kingdom during the pandemic
2696,Vaccinating against COVID-19: The Correlation between Pro-Vaccination Attitudes and the Belief That Our Peers Want to Get Vaccinated
2697,"Mapping the Dutch vaccination debate on Twitter: Identifying communities, narratives, and interactions"
2698,Optimal control of the COVID-19 pandemic: Controlled sanitary deconfinement in Portugal
2699,Cost Utility of Vaccination Against COVID-19 in Brazil
2700,and Author Information Accepted for Publication
2701,"França Acquisition of data: Fernandes, Magliano, Macedo, Padila, Braga Analysis and interpretation of data: Fernandes, Santos, Tura, Macedo, Padila, França Drafting of the manuscript: Fernandes, Magliano, Macedo, Padila, França, Braga Critical revision of the paper for important intellectual content: Fernandes"
2702,Novel coronavirus 2019 (COVID-19) pandemic outbreak: a comprehensive review of the current literature
2703,The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review of the current global status
2704,COVID-19 hospitalizations in Brazil's Unified Health System (SUS)
2705,"Risk factors for hospitalization and mortality due to COVID-19 in Espírito Santo state, Brazil"
2706,Epidemiologic and clinical features of patients with COVID-19 in Brazil. Einstein (São Paulo)
2707,Evolution and epidemic spread of SARS-CoV-2 in Brazil
2708,"Wię ckiewicz M. Demographic, clinical, laboratory, and genetic risk factors associated with COVID-19 severity in adults: a narrative review"
2709,"Characteristics and factors associated with COVID-19 infection, hospitalization, and mortality across race and ethnicity"
2710,COVID-19). World Health Organization
2711,Ten months of COVID-19 in metropolitan region of Curitiba: the pandemic in the territory and the mitigation damage public policies in 2020
2712,"Bases técnicas para decisão do uso emergencial, Em caráter experimental de vacinas contra a COVID-19. ANVISA, Relatório"
2713,FDA Briefing Document-Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19. US Food and Drug Administration
2714,Waiting vaccines. FGV IBRE
2715,Health Vigilance
2716,Flu -Severe respiratory syndrome notifications
2717,Mortality National Information System
2718,"Drugs prosthesis and procedures -(management system of SUS procedures, drugs, and orthotics, prostheses and materials data). SIGTAP, Management System of Procedures Table"
2719,Health system accounts in the international accountability perspective: Brazil
2720,Health prices database
2721,Outcomes for patients with COVID-19 and acute kidney injury: a systematic review and meta-analysis
2722,Economic value of treatment and vaccine to address the COVID-19 pandemic
2723,Cost-effectiveness and budget impact analysis
2724,Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation
2725,"Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study)"
2726,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais
2727,"Studies on viral pneumonia related to novel coronavirus SARS-CoV-2, SARS-CoV, and MERS-CoV: a literature review"
2728,Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a Report of 72 314 cases from the Chinese Center for Disease Control and Prevention
2729,Offline: COVID-19 is not a pandemic
2730,Role of genetic variants and gene expression in the susceptibility and severity of COVID-19
2731,Geneva: WHO
2732,Secretaria de Vigilância em Saúde. Painel Coronavírus
2733,Coordenação Geral do Programa Nacional de Imunizações. Plano Nacional de Operacionalização da Vacinação contra a Covid-19. Brasil Imunizado Somos Uma Só Nação 2020
2734,Estratégia de Vacinação contra o Vírus SARS-CoV-2 COVID-19: Protocolo de Vigilância Epidemiológica e Sanitária de Eventos Adversos Pós-Vacinação 2020
2735,World Health Organization; Council for International Organizations of Medical Sciences. Definition and application of terms for vaccine pharmacovigilance: report of CIOMS/WHO Work Group on Vaccine Pharmacovigilance. Geneva: WHO/CIOMS
2736,"Secretaria de Vigilância em Saúde, Departamento de Imunizações e Doenças Transmissíveis. Manual de Vigilância Epidemiológica de Eventos Adversos Pós-Vacinação"
2737,BR). e-SUS Notifica
2738,Efficacy and safety of COVID-19 vaccines: a systematic review
2739,The Brazilian National Immunization Program: 46 years of achievements and challenges
2740,Herd immunity -estimating the level required to halt the COVID-19 epidemics in affected countries
2741,Rio de Janeiro: IBGE
2742,Estimativas da população residente no Brasil e unidades da federação com data de referência em 1º de julho de 2019. Rio de Janeiro: IBGE
2743,"Situação epidemiológica dos eventos adversos pós-vacinação contra a covid-19, Brasil"
2744,"Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac -PROFISCOV: a structured summary of a study protocol for a randomised controlled trial"
2745,Perfil da Enfermagem no Brasil: relatório final. Rio de Janeiro: Fiocruz/COFEN
2746,"World Health Organization. GACVS COVID-19 Vaccine Safety subcommittee meeting to review reports of deaths of very frail elderly individuals vaccinated with Pfizer BioNTech COVID-19 vaccine, BNT162b2. Geneva: WHO; 2021"
2747,"Secretaria de Vigilância em Saúde, Departamento de Imunização e Doenças Transmissíveis, Coordenação-Geral do Programa Nacional de Imunizações. Nota Informativa Nº 11/2021-CGPNI/DEIDT/SVS/MS. Esclarecimentos sobre eventos adversos supostamente atribuíveis à vacinação contra a covid-19"
2748,Análise da ocorrência de evento adverso pós-vacinação decorrente de erro de imunização
2749,Avaliação do sistema brasileiro de vigilância de eventos adversos pós-vacinação
2750,Coordenação-Geral do Programa Nacional de Imunizações. Nota Informativa Nº 21/2021-CGPNI/DEIDT/SVS/MS. Orientações referentes aos erros de imunização relacionados às vacinas COVID-19
2751,COVID-19 vaccine response in pregnant and lactating women: a cohort study
2752,"Secretaria de Atenção Primária à Saúde, Departamento de Açõe Programáticas Estratégicas. Nota Técnica Nº 1/2021-DAPES/SAPS/MS. Recomendações referentes a administração de vacinas covid 19 em gestantes, puérperas e lactantes, incluindo os esclarecimentos que devem ser fornecidos para tomada de decisão"
2753,The tragedy of COVID-19 in Brazil: 124 maternal deaths and counting
2754,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study
2755,REFERENCES 1. WHO Health Emergency Dashboard.WHO (COVID-19). Homepage; 2021. Accessed
2756,Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
2757,For recommendatıon by the Strategıc Advısory Group of Experts (Sage) on Immunızatıon. Prepared by the SAGE Working Group on COVID-19 vaccines; 2021. Accessed
2758,World Health Organization.WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations
2759,Commercial serology assays predict neutralization activity against SARS-CoV-2
2760,Public attention; 2021
2761,COVID-19 clinical management: living guidance; 2021. Accessed
2762,SARS-CoV-2 IgG II Quant Assay User Manual
2763,Susceptibility of circulating SARS-CoV-2 variants to neutralization
2764,SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects
2765,Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19
2766,"A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity"
2767,Kinetics of viral load and antibody response in relation to COVID-19 severity
2768,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: prospective observational study
2769,SARS-CoV-2 vaccines
2770,Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination
2771,Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination
2772,Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination
2773,Adverse effect after COVID-19 vaccination in Thailand
2774,An observational study to identify the prevalence of thrombocytopenia and anti-PF4/ polyanion antibodies in Norwegian health care workers after COVID-19 vaccination
2775,Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2
2776,Low prevalence of heparin-induced thrombocytopenia after cardiac surgery in Thai patients
2777,"Allele frequency net database (AFND) 2020 update. How to cite this article: Noikongdee P, Police P"
2778,Prevalence of anti-platelet factor 4/ polyanionic antibodies after COVID-19 vaccination with ChAdOx1 nCoV-19 and CoronaVac in Thais
2779,"Anti-PF4/polyanionic antibodies were positive in five participants in the ChAdOx1 nCoV-19, and four participants in the CoronaVac group by ELISA. The highest OD was 0.9. OD of >0.3 indicates positive result. Black dots indicate OD after first-dose vaccination, and red diamonds indicate OD after second-dose vaccination. Gray shading indicates negative range. OD; optical density"
2780,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile
2781,Weekly epidemiological update on COVID-19 -27
2782,COVID-19 vaccines for low-and middle-income countries
2783,Plan Nacional de Vacunacion Covid
2784,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18&#x2013;59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases"
2785,BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated hospitalized COVID-19 patients in Israel
2786,Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US
2787,Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants
2788,Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines. Vaccines (Basel)
2789,Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients
2790,Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic
2791,Occurrence of severe COVID-19 in vaccinated transplant patients
2792,Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies
2793,Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
2794,Vaccination in the Adult Patient Infected with HIV: A Review of Vaccine Efficacy and Immunogenicity
2795,Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
2796,The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living with HIV. Clinical Infectious Diseases
2797,"The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment"
2798,vaccine BNT162b1 elicits human antibody and TH1 T cell responses
2799,Implications of defective immune responses in SARS-CoV-2 vaccinated organ transplant recipients
2800,Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses
2801,"TNF inhibitors: infliximab, golimumab, adalimumab, etanercept, certolizumab pegol 2. Other cancers: peritoneum, gastric, liver, ovarium, testicular and small bowel 3. HSC: hematopoietic stem cell transplant"
2802,O R I G I N A L A R T I C L E Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study
2803,Isolation of whole mononuclear cells from peripheral blood and cord blood
2804,Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection
2805,Trimmed Spearman-Karber method for estimating median lethal concentrations in toxicity bioassays
2806,Two detailed plaque assay protocols for the quantification of infectious SARS-CoV-2
2807,Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine
2808,Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: the Dominican Republic Experience
2809,Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients
2810,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine. Vaccines (Basel)"
2811,CD8(+) T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity
2812,Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report
2813,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/ 2 clinical trial"
2814,China COVID vaccine reports mixed results-what does that mean for the pandemic?
2815,Pityriasis rosea and pityriasis rosea-like eruptions: how to distinguish them?
2816,Pityriasis rosea: an update with a critical appraisal of its possible herpesviral etiology
2817,Vaccine-induced pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature
2818,Vaccine allergy
2819,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
2820,Nosocomial Outbreak of Coronavirus Disease 2019 by Possible Airborne Transmission Leading to a Superspreading Event
2821,The World Health Organzation. COVD-19 vaccine tracker
2822,RBD mutations on the susceptibility to serum antibodies elicited by COVID-19 infection or vaccination
2823,The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum
2824,COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants
2825,Transmission of
2826,529) -SARS-CoV-2 Variant of Concern in a designated quarantine hotel for travelers: a challenge of elimination strategy of COVID-19
2827,Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic
2828,Antibody response of BNT162b2 and CoronaVac platforms in COVID-19 recovered individuals against SARS-CoV-2 wild type and delta variant
2829,Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection
2830,B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes
2831,Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
2832,Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016
2833,Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
2834,SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms
2835,Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies
2836,"SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2"
2837,Omicron likely to weaken COVID vaccine protection
2838,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access"
2839,Delayed second dose versus standard regimen for COVID-19 vaccination
2840,What is the evidence for extending the SARS-CoV-2 (COVID-19) vaccine dosing schedule
2841,"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a twodose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials"
2842,Evaluation of COVID-19 vaccination strategies with a delayed second dose
2843,Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study
2844,Self-reported real-world safety and reactogenicity of COVID-19 vaccines: a vaccine recipient survey
2845,The how's and what's of vaccine reactogenicity
2846,"Side effects of BNT162b2 mRNA COVID-19 vaccine: a randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers"
2847,Myocarditis and pericarditis after vaccination for COVID-19
2848,"Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: a nationwide descriptive study"
2849,Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study
2850,COVID-19 vaccine adverse reactions bring patients to emergency departments
2851,"Impacts of side effects to BNT162b2 and the first dose of ChAdOx1 anti-SARS-CoV-2 vaccination on work productivity, the need for medical attention, and vaccine acceptance: a multicenter survey on healthcare workers in referral teaching hospitals in the Republic of"
2852,Real-time analysis of a mass vaccination effort confirms the safety of FDAauthorized mRNA COVID-19 vaccines
2853,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong
2854,Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents following Comirnaty vaccination
2855,Multimorbidity and adverse events of special interest associated with COVID-19 vaccines in Hong Kong
2856,Carditis after COVID-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine: a case-control study
2857,COVID-19 vaccines and risks of hematological abnormalities: nested case-control and selfcontrolled case series study
2858,Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: a self-controlled case series and nested case-control study
2859,Post-COVID-19-vaccination adverse events and healthcare utilization among individuals with or without previous SARS-CoV-2 infection
2860,Lack of inflammatory bowel disease flare-up following two-dose BNT162b2 vaccine: a population-based cohort study
2861,Safety of inactivated and mRNA COVID-19 vaccination among patients treated for hypothyroidism: a population-based cohort study
2862,The Government of the Hong Kong Special Administrative Region. Government announces 2019 COVID-19 vaccination programme
2863,The Government of the Hong Kong Special Administrative Region. Government expands scope of priority groups and opens more CVCs
2864,The Government of the Hong Kong Special Administrative Region. Vaccination priority groups to be expanded to cover people aged 30 or above
2865,The Government of the Hong Kong Special Administrative Region. COVID-19 Vaccination Programme opens to persons aged 16 or above
2866,The Government of the Hong Kong Special Administrative Region. Secretary for Food and Health approves lowering age limit for receiving Comirnaty vaccine
2867,nsus_ inter im_ recom menda tions_ on_ the_ use_ of_ covid 19_ vacci nes_ inhk
2868,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine • fast, convenient online submission • thorough peer review by experienced researchers in your field • rapid publication on acceptance • support for research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year submit your research ?"
2869,gclid= CjwKC Ajwvu GJBhB 1EiwA CU1Ai dX-t9s2o kQDMm PxKmJ-pL9iA zrq0L ZrTJb GcmQx mWAzg D6yCi Jjbxo CZl4Q AvD_ BwE
2870,Accessed 28
2871,Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners
2872,COVID-19 vaccine second-dose completion and interval between first and second doses among vaccinated persons -United States
2873,National Health Commission of the People's Republic of China. Novel coronavirus vaccine technical guide
2874,The Bonferonni and `idák corrections for multiple comparisons
2875,Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England
2876,Immunogenicity of inactivated COVID-19 vaccines at different vaccination intervals. Hum Vaccines Immunother
2877,Extended interval BNT162b2 vaccination enhances peak antibody generation
2878,Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
2879,Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials
2880,The safety of COVID-19 mRNA vaccines: a review
2881,Association of total and neutralizing SARS-CoV-2 spike -receptor binding domain antibodies with epidemiological and clinical characteristics after immunization with the 1(st) and 2(nd) doses of the BNT162b2 vaccine
2882,"Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: data from 3,078 health care workers"
2883,Pfizer-BioNTech COVID-19 vaccine tolerance in allergic versus non-allergic individuals
2884,"Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1"
2885,Myocarditis occurring after immunization with mRNA-based COVID-19 vaccines
2886,Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
2887,Why promoting a COVID-19 vaccine booster dose?
2888,Protection against COVID-19 by BNT162b2 booster across age groups
2889,Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
2890,Third doses of COVID-19 vaccines reduce infection and transmission of SARS-CoV-2 and could prevent future surges in some populations: a modeling study
2891,Serological responses to COVID-19 Comirnaty booster vaccine
2892,Antibody response of combination of BNT162b2 and CoronaVac platforms of COVID-19 vaccines against omicron variant
2893,The emergence of new SARS-CoV-2 variant (omicron) and increasing calls for COVID-19 vaccine boosters-the debate continues
2894,Comparative Effectiveness of mRNA and Inactivated Whole Virus Vaccines against COVID-19 1 Infection and Severe Disease in Singapore
2895,Considerations in boosting COVID-19 vaccine immune 4 responses
2896,Accessed 12
2897,& Johnson) Vaccines in Preventing
2898,Hospitalizations Among Adults Without Immunocompromising Conditions -United States
2899,Comparing the clinical efficacy of COVID-19 14 vaccines: a systematic review and network meta-analysis
2900,A systematic review of COVID-19 vaccine efficacy and 17 effectiveness against SARS-CoV-2 infection and disease
2901,"Comparing COVID-19 vaccines for their 21 characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern"
2902,Efficacy and Safety of the mRNA-1273 SARS-CoV-2
2903,Comparative immunogenicity of mRNA and inactivated 7 vaccines against COVID-19
2904,/fulltext#coronavirus-linkback-header
2905,Effectiveness of an Inactivated SARS-CoV-2 Vaccine 11 in Chile
2906,Comparison of antibody and T cell responses elicited 14 by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in 15 healthy adult humans
2907,Pfizer-BioNTech and Sinopharm: A 19 Comparative Study on Post-Vaccination Antibody Titers
2908,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
2909,Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations
2910,"Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil"
2911,SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape
2912,A leading coronavirus vaccine trial is on hold: scientists react
2913,Novavax offers first evidence that COVID vaccines protect people against variants
2914,"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: Pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials"
2915,"A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS"
2916,Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells
2917,Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
2918,Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite
2919,Structure-based development of human antibody cocktails against SARS-CoV-2
2920,N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
2921,Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy
2922,Article
2923,Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies
2924,Structural basis of a shared antibody response to SARS-CoV-2
2925,An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain
2926,Evolution of antibody immunity to SARS-CoV-2
2927,Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
2928,Circular RNA vaccines against SARS-CoV-2 and emerging variants
2929,Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
2930,Phaser crystallographic software
2931,"Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix"
2932,Features and development of Coot
2933,Automated electron microscope tomography using robust prediction of specimen movements
2934,MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy
2935,CTFFIND4: fast and accurate defocus estimation from electron micrographs
2936,New tools for automated high-resolution cryo-EM structure determination in RELION-3
2937,UCSF Chimera -a visualization system for exploratory research and analysis
2938,Comprehensive integration of single-cell data
2939,Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage
2940,RNA-Seq signatures normalized by mRNA abundance allow absolute deconvolution of human immune cell types
2941,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1
2942,The Nucleocapsid protein triggers the main humoral immune response in COVID-19 patients
2943,Antibody response to Covıd-19 infectıon clinical variables at play. medRxiv
2944,SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response
2945,Factors That Influence the Immune Response to Vaccination
2946,COVID-19: Characteristics and Therapeutics
2947,SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease
2948,Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies
2949,Anti-Spike protein assays to determine SARS-CoV-2 antibody levels: a head-to-head comparison of five quantitative assays
2950,Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization
2951,Substitutions in Spike and Nucleocapsid proteins of SARS-CoV-2 circulating in South America
2952,The potential danger of suboptimal antibody responses in COVID-19
2953,Immunological considerations for COVID-19 vaccine strategies
2954,Evaluation of a SARS-CoV-2 vaccine NVX-CoV2373 in younger and older adults. medRxiv
2955,Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers
2956,Vaccines for the elderly
2957,"Antibody response after COVID-19 mRNA vaccination in relation to age, sex, and side effects. medRxiv"
2958,The relationship between influenza vaccine-induced specific antibody responses and vaccine-induced nonspecific autoantibody responses in healthy older women
2959,Obesity is associated with impaired immune response to influenza vaccination in humans
2960,Obesity and COVID-19: The Two Sides of the Coin
2961,Serological reconstruction of COVID-19 epidemics through analysis of antibody kinetics to SARS-CoV-2 proteins. medRxiv
2962,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (Coronavac): interim results of a double blind, randomised, placebocontrolled, phase 3 trial in Turkey"
2963,Quantitation of antibodies against SARS-CoV-2 spike proteinafter two doses of CoronaVac in healthcare workers
2964,Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection
2965,Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals with and without COVID-19 vaccination: A method comparison of two different commercially available serological assays from the same manufacturer
2966,Measurement of multiple SARS-CoV-2 antibody titer after vaccination represents individual vaccine response and contributes to individually appropriate vaccination schedules. medRxiv
2967,Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine
2968,Evaluation of antibody response after COVID-19 vaccination of healthcare workers
2969,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology
2970,World alliance for patient safety: WHO draft guidelines for adverse event reporting and learning systems: from information to action 2021
2971,"Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: meta-analysis with 55 studies and 10014 cases"
2972,A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19
2973,Prevalence of comorbidities and their association with mortality in patients with COVID-19: a systematic review and metaanalysis
2974,Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study
2975,Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19
2976,Global Rheumatology Alliance physician-reported registry
2977,Inflammatory muscle diseases
2978,European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups
2979,Immune-mediated necrotizing myopathy
2980,COVID-19 and myositis -unique challenges for patients
2981,Infectious complications in polymyositis and dermatomyositis: a series of 279 patients
2982,Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies
2983,Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a postvaccination cross-sectional survey
2984,Immunogenicity and safety of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases
2985,A prospective cross-sectional study of serum IL-17A in antisynthetase syndrome
2986,Defining clinical improvement in adult and juvenile myositis
2987,"Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis"
2988,Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies
2989,Considering how biological sex impacts immune responses and COVID-19 outcomes
2990,Sex differences in immunity: implications for the development of novel vaccines against emerging pathogens
2991,Pandemic unadjuvanted influenza A (H1N1) vaccine in dermatomyositis and polymyositis: immunogenicity independent of therapy and no harmful effect in disease
2992,Guideline on risk management systems for medicinal products for human use
2993,Guidance for Industry: Clinical data needed to support the licensure of pandemic influenza vaccines. U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research
2994,WHO. WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations 2021
2995,American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 1
2996,A recommended paradigm for vaccination of rheumatic disease patients with the SARS-CoV-2 vaccine
2997,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay
2998,"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"
2999,"Epidemiology, genetic recombination, and pathogenesis of coronaviruses"
3000,Prevention is better than the cure: risk management of COVID-19
3001,"Covid-19: WHO declares pandemic because of ""alarming levels"" of spread, severity, and inaction"
3002,"Cochrane COVID-19 Diagnostic Test Accuracy Group. Rapid, point-ofcare antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection"
3003,Rapid SARS-CoV-2 antigen detection assay in comparison with realtime RT-PCR assay for laboratory diagnosis of COVID-19 in ailand
3004,Understanding the most important facilitators and barriers for online education during COVID-19 through online photovoice methodology
3005,"Validation of the STANDARD Q COVID-19 antigen test in Vojvodina, Serbia"
3006,"Students' views towards sarscov-2 mass asymptomatic testing, social distancing and selfisolation in a university setting during the COVID-19 pandemic: a qualitative study"
3007,Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients
3008,"Case-control study of use of personal protective measures and risk for SARS-CoV 2 infection, ailand"
3009,Seoul metropolitan government COVID-19
3010,"Coronavirus disease exposure and spread from nightclubs, South Korea"
3011,What other countries can learn from Italy during the COVID-19 pandemic
3012,Characteristics of SARS-CoV-2 positive cases beyond health-care professionals or social and health-care facilities
3013,Evaluation of a rapid antigen test (Panbio ™ COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients
3014,"Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 Years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial"
3015,Draft Landscape of COVID-19 Candidate Vaccines
3016,COVID-19 vaccines (revisited) and oral-mucosal vector system as a potential vaccine platform
3017,AstraZeneca's COVID-19 vaccine authorised in five other countries
3018,Medical studies during the COVID-19 pandemic; the impact of digital learning on medical students' murnout and metal health
3019,"High seroprevalence of SARS-CoV-2 (COVID-19)-Specific antibodies among healthcare workers: a cross-sectional study in guilan, Iran"
3020,COVID-19 in longterm care facilities: an upcoming threat that cannot be ignored
3021,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS-CoV-2 vaccines
3022,Execution of laboratory tests were performed by Rosemeire Yamashiro and Marcia J. Castejon. Samples management was performed by
3023,Statistical analysis was performed by
3024,The manuscript was written by Valéria O. Silva and Luís F. de Macedo Brígido
3025,Anonymized datasets generated for the current study are available from the corresponding author upon reasonable request
3026,Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study
3027,SARS-CoV-2 reinfection and implications for vaccine development
3028,Severe COVID-19: what have we learned with the immunopathogenesis?
3029,The effectiveness of the twodose BNT162b2 vaccine: analysis of real-world data
3030,Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview
3031,"COVID-19): serology, antibodies and immunity. World Health Organization"
3032,Throat wash as source of SARS-CoV-2 RNA to monitor community spread of COVID-19
3033,CoV-2 Neutralization Antibody Detection Kit. Food and Drug Administration
3034,The coronavirus is here to stay-here's what that means
3035,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/ Oxford's AZD1222 SARS-CoV-2 vaccines
3036,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study
3037,HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform
3038,"Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety"
3039,Immunogenicity of pneumococcal vaccination in HIV infected individuals: a systematic review and meta-analysis
3040,Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis
3041,CD4/CD8 ratio and KT ratio predict yellow fever vaccine immunogenicity in HIV-infected patients
3042,Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV
3043,Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1
3044,"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial"
3045,Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy
3046,Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study
3047,"COVID-19 vaccination in people living with HIV (PLWH) in China: a cross sectional study of vaccine hesitancy, safety, and immunogenicity"
3048,Vacina adsorvida covid-19 (inativada)
3049,A new SARS-CoV-2 dualpurpose serology test: highly accurate infection tracing and neutralizing antibody response detection
3050,World alliance for patient safety: WHO draft guidelines for adverse event reporting and learning systems: from information to action
3051,Pathogenesis of HIV infection: what the virus spares is as important as what it destroys
3052,Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. medRxiv 2021
3053,Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease
3054,Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients
3055,Change in COVID-19 risk over time following vaccination with CoronaVac: a test-negative case-control study
3056,Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults
3057,Influenza and HIV: lessons from the 2009 H1N1 influenza pandemic
3058,Anvisa faz recomendações sobre doses de reforço de vacinas contra Covid-19
3059,Coronavirus vaccine tracker
3060,WHO approval of Chinese coronaVac COVID vaccine will be crucial to curbing pandemic
3061,Effectiveness of an inactivated SARS-CoV-2 vaccine
3062,"CoronaVac Study Group. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
3063,The full spectrum of COVID-19 development and recovery among kidney transplant recipients
3064,Antibody response to the Janssen COVID-19 vaccine in solid organ transplant recipients
3065,Safety and immunogenicity of anti-SARS-CoV-2 messenger RNA vaccines in recipients of solid organ transplants
3066,Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine
3067,"Clinical impact, reactogenicity, and immunogenicity after the first CoronaVac dose in kidney transplant recipients"
3068,"Kidney transplantation in the time of COVID-19: dilemmas, experiences, and perspectives"
3069,AdviseDx SARS-CoV-2 IgG II instructions for use
3070,SARS-CoV-2 surrogate virus neutralization test (sVNT) kit (RUO)
3071,Interrupted time series regression for the evaluation of public health interventions: a tutorial
3072,Review of early immune response to SARS-CoV-2 vaccination among patients with CKD
3073,"Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine"
3074,Prevalence of frailty among kidney transplant candidates and recipients in the United States: Estimates from a National Registry and Multicenter Cohort Study
3075,Boletim completo SP contra o coronavirus
3076,Implication of in silico studies in the search for novel inhibitors against SARS-CoV-2
3077,"active site C, respectively"
3078,"examined 19 hydrolysable tannins against 3CLpro of SARS-CoV-2, and they found that of these (Figure 25), pedunculagin (205), tercatain (206) and castalin (207) showed the best binding affinities of −18.58, −23.11 and −14.04 kcal/mol, respectively, on the selected target"
3079,"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, china"
3080,Seroprevalence study of SARS-CoV-2 antibodies in healthcare workers following the first wave of the COVID-19 pandemic in a tertiary-level hospital in the south of ireland
3081,Challenges to the system of reserve medical supplies for public health emergencies: Reflections on the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in china
3082,Risk of COVID-19 among front-line health-care workers and the general community: A prospective cohort study
3083,Prevalence of SARS-CoV-2 infection in previously undiagnosed health care workers in new jersey
3084,Seroprevalence of hospital staff in a province with zero COVID-19 cases
3085,COVID-19 seroprevalence among hospital staff and preprocedural patients in thai community hospitals: A cross-sectional study
3086,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (coronavac) in healthy adults aged 60 years and older: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
3087,Comparison of the immunogenicity of bnt162b2 and coronavac COVID-19 vaccines in hong kong
3088,Dynamic igg seropositivity after rollout of coronavac and bnt162b2 COVID-19 vaccines in chile: A sentinel surveillance study
3089,Should a third booster dose be scheduled after two doses of coronavac? A single-center experience
3090,"Immunogenicity and safety of a third dose of coronavac, and immune persistence of a two-dose schedule, in healthy adults: Interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials"
3091,SARS-CoV-2 specific antibody responses after third coronavac or bnt162b2 vaccine following two-dose coronavac vaccine regimen
3092,Antibody responses to COVID-19 vaccines in older adults
3093,Coronavac induces lower neutralising activity against variants of concern than natural infection
3094,Serum neutralising activity against SARS-CoV-2 variants elicited by coronavac
3095,Reactogenicity and immunogenicity after a late second dose or a third dose of chadox1 ncov-19 in the uk: A substudy of two randomised controlled trials (cov001 and cov002)
3096,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of chadox1 ncov-19 or bnt162b2 in the uk (cov-boost): A blinded, multicentre, randomised, controlled, phase 2 trial"
3097,"Immunogenicity, safety and reactogenicity of a heterogeneous booster following the coronavac inactivated SARS-CoV-2 vaccine in patients with sle: A case series"
3098,Intradermal chadox1 vaccine following two coronavac shots: A case report
3099,SARS-CoV-2 igg antibody response after immunization of healthcare workers with inactivated COVID-19 vaccine (coronavac) at phyathai 3 hospital
3100,"Safety and immunogenicity of coronavac and chadox1 against the SARS-CoV-2 circulating variants of concern (alpha, delta, beta) in thai healthcare workers"
3101,Title: A randomized clinical trial of a booster dose with low versus standard dose of 1 AZD1222 in adult after 2 doses of inactivated vaccines 2 3
3102,Immune responses against SARS-CoV-2 variants after heterologous and 479 homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
3103,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after 483 receiving two-dose inactivated vaccines in healthy adults
3104,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA
3105,Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population
3106,A serological assay to detect SARS-CoV-2 seroconversion in humans
3107,Correlates of protection 494 against symptomatic and asymptomatic SARS-CoV-2 infection
3108,A SARS-CoV-2 surrogate virus 497 neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein 498 interaction
3109,Funding information WHO Regional Office for Europe
3110,"Confronting the Delta Variant of SARS-CoV-2, Summer 2021"
3111,Infection and mortality of healthcare workers worldwide from COVID-19: a systematic review
3112,The nature and extent of COVID-19 vaccination hesitancy in healthcare workers
3113,COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates
3114,Factors associated with COVID-19 vaccine hesitancy
3115,Seasonal influenza vaccine dose distribution in 157 countries
3116,Vaccination-Protection for those most at risk of Influenza Denmark: World Health Organization; 2022 [Protection for those most at risk of Influenza
3117,Barriers of influenza vaccination intention and behavior-a systematic review of influenza vaccine hesitancy
3118,Determinants of self-perceived health for Canadians aged 40 and older and policy implications
3119,Acceptability of vaccination against COVID-19 among healthcare workers in the Democratic Republic of the Congo. Pragmatic and Observational Research
3120,Vaccine hesitancy of the COVID-19 by health care personnel
3121,Intention to get vaccinations against COVID-19 in French healthcare workers during the first pandemic wave: a cross-sectional survey
3122,COVID-19 vaccine hesitancy among medical students
3123,Nurses' voices matter in decisions about dismissing vaccine-refusing families
3124,Assessment of U.S. health care personnel (HCP) attitudes towards COVID-19 vaccination in a large university health care system
3125,Factors associated with early uptake of COVID-19 vaccination among healthcare workers in Azerbaijan
3126,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants
3127,"A comparative study between the severe acute respiratory syndrome-coronavirus-2, severe acute respiratory syndrome coronavirus, and the Middle East respiratory syndrome coronavirus"
3128,"Evolution, mode of transmission, and mutational landscape of newly emerging SARS-CoV-2 variants"
3129,"Present variants of concern (VOC) and variants of interest (VOI) of SARS-CoV-2: their significant mutations in S-glycoprotein, infectivity, re-infectivity, immune escape, and vaccines activity"
3130,Effectiveness of BNT162b2 vaccine against omicron variant in South Africa
3131,How bharat biotech's vaccine works. The New York Times
3132,Emerging SARS-CoV-2 variants: shooting the messenger
3133,Identification of a novel coronavirus in patients with severe acute respiratory syndrome
3134,Omicron SARS-CoV-2 variant: what we know and what we don't
3135,COVID-19 vaccines: where we stand and challenges ahead
3136,Emerging SARS-CoV-2 variants and impact in global vaccination programs against SARS-CoV-2/COVID-19. Vaccines (basel)
3137,Profiles of current COVID-19 vaccines
3138,Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19
3139,History and recent advances in coronavirus discovery
3140,Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine
3141,A novel coronavirus associated with severe acute respiratory syndrome
3142,"Overview of the main anti-SARS-CoV-2 vaccines: mechanism of action, efficacy and safety"
3143,Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic
3144,A review on the effectivity of the current COVID-19 drugs and vaccines: are they really working against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants?
3145,"A comparative review of pathogenesis and host innate immunity evasion strategies among the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV)"
3146,Developmental status of the potential vaccines for the mitigation of the COVID-19 pandemic and a focus on the effectiveness of the Pfizer-BioNTech and Moderna mRNA vaccines
3147,A review on the induction of host immunity by the current COVID-19 vaccines and a brief non-pharmaceutical intervention to mitigate the pandemic
3148,A brief outline of respiratory viral disease outbreaks: 1889-till date on the public health perspectives
3149,"Recombinant protein vaccines, a proven approach against coronavirus pandemics"
3150,Highly mutated SARS-CoV-2 Omicron variant sparks significant concern among global experts-what is known so far
3151,Advances in gene-based vaccine platforms to address the COVID-19 pandemic
3152,"COVID-19 vaccine makers plan for annual boosters, but it's not clear they'll be needed"
3153,"Recent advances in SARS-CoV-2 Spike protein and RBD mutations comparison between new variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil)"
3154,Abdel-Moneim AS (2021) Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective
3155,Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant
3156,Immunogenicity of the Ad26.COV2.S vaccine for COVID-19
3157,Emerging SARS-CoV-2 variants of concern (VOCs): an impending global crisis
3158,SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
3159,Cultivation of viruses from a high proportion of patients with colds
3160,New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates
3161,Novavax vaccine delivers 89 % efficacy against COVID-19 in U.K.-but is less potent in South Africa
3162,Coronavirus diseases (COVID-19) Dashboard (2022) Updated on 5:13pm CET
3163,Situation report 1. World Health Organization
3164,Imported SARS-CoV-2 V501Y.V2 variant (B.1.351) detected in travelers from South Africa and Tanzania to India
3165,The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity
3166,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study
3167,Interim findings from firstdose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study
3168,The impact of vaccination on coronavirus disease 2019 (COVID-19) outbreaks in the United States
3169,I mmunosenescence and inflammaging: risk factors of severe COVID-19 in older people
3170,Vaccination in the elderly: the challenge of immune changes with aging
3171,Efficacy and effectiveness of influenza vaccines: a systematic review and metaanalysis
3172,Plano Nacional de Operacionalização da Vacinação Contra a COVID-19
3173,"SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness"
3174,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study"
3175,"Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study"
3176,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: analyzes of routinely-collected data on vaccine coverage and mortality
3177,Time interval between onset of symptoms and COVID-19 testing in Brazilian state capitals
3178,Clinical characteristics and risk factors for death among hospitalised children and adolescents with COVID-19 in Brazil: an analysis of a nationwide database
3179,Use of recently vaccinated individuals to detect bias in test-negative case-control studies of COVID-19 vaccine effectiveness
3180,Small-area Deprivation Measure for Brazil: Data Documentation. University of Glasgow
3181,Efficacy and safety of highdose influenza vaccine in elderly adults: a systematic review and meta-analysis
3182,Collapse of the public health system and the emergence of new variants during the second wave of the COVID-19 pandemic in Brazil
3183,The effectiveness of the two-dose BNT162b2 vaccine: analysis of real-world data
3184,Assessment of effectiveness of 1 dose of BNT162b2 vaccine for SARS-CoV-2 infection 13 to 24 days after immunization
3185,Medidas de distanciamento social no controle da pandemia de COVID-19: potenciais impactos e desafios no Brasil
3186,Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine
3187,"Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the bnt162b2 mrna covid-19 vaccine: Real-world evidence from healthcare workers, israel"
3188,Immune responses against sars-cov-2 variants after heterologous and homologous chadox1 ncov-19/bnt162b2 vaccination
3189,Neutralizing antibodies against the sars-cov-2 omicron variant following homologous and heterologous coronavac or bnt162b2 vaccination
3190,"Heterologous versus homologous covid-19 booster vaccination in previous recipients of two doses of coronavac covid-19 vaccine in brazil (rhh-001): A phase 4, non-inferiority, single blind, randomised study"
3191,"Antibody response to the inactivated sars-cov-2 vaccine among healthcare workers, indonesia"
3192,Waning antibody levels after vaccination with mrna bnt162b2 and inactivated coronavac covid-19 vaccines in hong kong blood donors
3193,Comparison of the immunogenicity of bnt162b2 and coronavac covid-19 vaccines in hong kong
3194,"Safety and immunogenicity of seven covid-19 vaccines as a third dose (booster) following two doses of chadox1 ncov-19 or bnt162b2 in the uk (cov-boost): A blinded, multicentre, randomised, controlled, phase 2 trial"
3195,Neutralizing antibodies against the sars-cov-2 delta and omicron variants following heterologous coronavac plus bnt162b2 booster vaccination
3196,Personalized vaccinology: A review
3197,Convalescent plasma anti-sars-cov-2 spike protein ectodomain and receptor-binding domain igg correlate with virus neutralization
3198,Comparison of sars-cov-2 antibody response following vaccination with bnt162b2 and mrna-1273
3199,"Efficacy and safety of an inactivated whole-virion sars-cov-2 vaccine (coronavac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in turkey"
3200,"Safety, tolerability, and immunogenicity of an inactivated sars-cov-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
3201,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers
3202,Surveillance on emerging coronavirus variant of concern (VOCs) on
3203,WHO. WHO Coronavirus Disease (COVID-19) Dashboard
3204,Thailand Guideline for COVID-19 vaccination 2021 second edition
3205,COVID-19 Response in Thailand and Its Implications on Future Preparedness
3206,CoronaVac induces lower neutralising activity against variants of concern than natural infection. The Lancet Infectious Diseases
3207,Immunogenicity of a third dose viralvectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults
3208,Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
3209,mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
3210,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
3211,AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC
3212,Serological response to mRNA and inactivated COVID-19 vaccine in healthcare workers in Hong Kong: preliminary results
3213,Laboratory diagnosis of COVID-192021
3214,Vaccine xxx (xxxx) xxx
3215,Anti-spike protein assays to determine SARS-CoV-2 antibody levels: a head-to-head comparison of five quantitative assays
3216,Abbott SARS-CoV-2 IgG II Quant for Use with ARCHITECT
3217,cPass TM SARS-CoV-2 Neutralization Antibody Detection Kit. Instructions for Use
3218,Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients
3219,Antibody response to the inactivated SARS-CoV-2 vaccine among healthcare workers
3220,Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. The Lancet Regional Health -Europe
3221,The immunogenicity and safety of different COVID-19 booster vaccination following CoronaVac or ChAdOx1 nCoV-19 primary series
3222,The influence of sex and gender on the immune response
3223,The effect of estrogen in coronavirus disease 2019
3224,"Antibody titers against SARS-CoV-2 decline, but do not disappear for several months"
3225,Rapidly declining SARS-CoV-2 antibody titers within 4 months after BNT162b2 vaccination
3226,Interleukin-21 is a critical cytokine for the generation of virus-specific longlived plasma cells
3227,Vaccine sideeffects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study
3228,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study
3229,Maternal immunological adaptation during normal pregnancy
3230,"Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis"
3231,"Study to evaluate the safety, tolerability, and immunogenicity of SARS CoV-2 RNA vaccine candidate (BNT162b2) against COVID-19 in healthy pregnant women 18 years of age and older"
3232,Perspectives on administration of COVID-19 vaccine to pregnant and lactating women: a challenge for low-and middle-income countries
3233,Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings
3234,Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of Covid-19 in Brazil: test negative case-control study
3235,Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy
3236,Association between BNT162b2 vaccination and incidence of SARS-CoV-2 infection in pregnant women
3237,Early exploration of COVID-19 vaccination safety and effectiveness during pregnancy: interim descriptive data from a prospective observational study
3238,SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women
3239,Brazilian Ministry of Health. Campanha Nacional de Vacinação contra a Covid-1. Décimo oitavo informe técnico
3240,Nota Técnica N° 1/2021-DAPES/SAPS/MS -Vaccination for pregnant and postpartum women with comorbities
3241,Nota Técnica N° 467/2021-CGPNI/DEIDT/ SVS/MS -Vaccination for pregnant and postpartum women without comorbidities
3242,COVID-19 Vacinação Doses Aplicadas
3243,Coronavirus update (live) COVID-19 virus pandemic
3244,"Impact of COVID-19 pandemic on time series of maternal mortality ratio in Bahia, Brazil: analysis of period 2011-2020"
3245,Brazilian Ministry of Health
3246,Genomic Surveillance of SARS-CoV-2 in Brazil
3247,Developing a Small-Area Deprivation Measure for Brazil
3248,"Test-negative designs: differences and commonalities with other case-control studies with ""other patient"
3249,A test-negative design with additional population controls can be used to rapidly study causes of the SARS-CoV-2 epidemic
3250,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based study
3251,"COVID-19 mRNA vaccines drive differential Fc-functional profiles in pregnant, lactating, and non-pregnant women"
3252,Is the host viral response and the immunogenicity of vaccines altered in pregnancy? Antibodies (Basel)
3253,Análise da qualidade das estatísticas vitais brasileiras: a experiência de implantação do SIM e do SINASC. Ciência & Saúde Coletiva
3254,WHO. The Sinovac-CoronaVac COVID-19 vaccine: what you need to know. 2021
3255,"Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series"
3256,"Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2"
3257,Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients
3258,Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series
3259,"Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebocontrolled phase 2 clinical trial"
3260,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola
3261,Dexamethasone in hospitalized patients with Covid-19
3262,Merck and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study
3263,COVID-19 vaccine trials in Africa
3264,Africa's preparedness towards COVID-19 vaccines: Demand and acceptability challenges
3265,Interim statement on COVID-19 vaccination for children and adolescents
3266,Epidemiological and clinical characteristics of COVID-19 in children: a systematic review and meta-analysis
3267,The differential impact of pediatric COVID-19 between high-income countries and low-and middle-income countries: a systematic review of fatality and ICU admission in children worldwide
3268,"World Health Organization. WHO coronavirus disease (COVID-19) Dashboard, data table, and detailed surveillance data"
3269,COVID-19) update: FDA Authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic
3270,FDA Authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age
3271,Philippines approves emergency use of Moderna's COVID-19 vaccine for 12-17 year olds
3272,Covaxin shot recommended for children in India
3273,Hong Kong authorises Sinovac Covid vaccine for children aged 3 to 17
3274,China approves emergency use of Sinopharm COVID-19 vaccine for children aged 3-17
3275,China authorises CoronaVac Covid-19 vaccine for children above 3 years
3276,COVID-19 vaccine Spikevax Approved for children aged 12 to 17 in EU
3277,World Health Organization. COVID-19 vaccine Tracker and landscape
3278,Regulation and Prequalification: Emergency Use Listing (EUL)-COVID-19 Vaccines
3279,Children and COVID-19 vaccinations trends
3280,US Centers for Disease Control and Prevention. COVID-19 vaccine booster Shots
3281,Things must not fall apart: the ripple effects of the COVID-19 pandemic on children in sub-Saharan Africa
3282,Available: https:// africacdc.org/download/covid-19-scientific-and-public-healthpolicy-update
3283,Assessment of clinical outcomes among children and adolescents hospitalized with COVID-19 in 6 sub-Saharan African countries
3284,The critical need for pooled data on coronavirus disease 2019 in African children: an AFREhealth call for action through multicountry research collaboration
3285,"African COVID-19 Critical Care Outcomes Study (ACCCOS) Investigators. Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre, prospective, observational cohort study"
3286,Strategy to achieve global COVID-19 vaccination by mid-2022
3287,Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern
3288,"Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) -highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts"
3289,Omicron-fuelled COVID-19 surge in African plateaus
3290,Vaccine Advocacy Infographics: What age groups do AU Member States need to target to reach 70% COVID-19 vaccination coverage?
3291,The Tribune. India gets its 1st vaccine for children above 12
3292,Zydus's 3-dose ZyCoV-D approved
3293,Uganda to start inoculating children under 15 with Pfizer vaccine
3294,Mauritius orders Covid-19 doses to cover remaining population
3295,Vaccination campaign for Seychellois children begins Friday
3296,SAHPRA update on section 21 Authorisation for Pfizer Comirnaty vaccine
3297,Xinhuanet News. Namibia to start vaccinating teens against COVID-19
3298,Ghana: FDA authorizes Pfizer vaccine for 15 to 17-year-olds
3299,"Egypt to vaccinate children aged between 15, 18 against COVID-19"
3300,Egypt authorizes Pfizer's COVID-19 vaccine for 12 to 15 year-olds
3301,NPHCDA: 16-year-olds can receive COVID vaccine if required for educational purposes
3302,Zimbabwe starts vaccinating teens against COVID-19
3303,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old
3304,Estimating the Early Impact of Vaccination Against COVID-19 on Deaths Among Elderly People in Brazil: Analyses of Routinely-Collected Data on Vaccine Coverage and Mortality
3305,"High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related Deaths in Over 75-Year-Olds, CearáState, Brazil"
3306,"Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?"
3307,Antibody Response to Inactivated COVID-19 Vaccine (CoronaVac) in Immune-Mediated Diseases: A Controlled Study Among Hospital Workers and Elderly
3308,Immunosenescence: Influenza Vaccination and the Elderly
3309,Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
3310,AS03-Adjuvanted Versus Non-Adjuvanted Inactivated Trivalent Influenza Vaccine Against Seasonal Influenza in Elderly People: A Phase 3 Randomised Trial
3311,A Minimal Common Outcome Measure Set for COVID-19 Clinical Research
3312,Immunodominant B Cell Epitope in a Hotspot Mutation Site and Mechanism of Immune Escape for SARS-CoV-2. medRxiv (2021)
3313,Screening for SARS-CoV-2 Antibodies in Convalescent Plasma in Brazil: Preliminary Lessons From a Voluntary Convalescent Donor Program
3314,SARS-CoV-2 Isolation From the First Reported Patients in Brazil and Establishment of a Coordinated Task Network
3315,Identification of Novel Consensus CD4 T-Cell Epitopes From Clade B HIV-1 Whole Genome That Are Frequently Recognized by HIV-1 Infected Patients
3316,Algorithm AS 136 A K-Means Clustering Algorithm
3317,Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals
3318,Early Programming and Late-Acting Checkpoints Governing the Development of CD4 T-Cell Memory
3319,Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection
3320,Male Sex Identified by Global COVID-19 Meta-Analysis as a Risk Factor for Death and ITU Admission
3321,The X-Files in Immunity: Sex-Based Differences Predispose Immune Responses
3322,Sex and Gender Differences in the Outcomes of Vaccination Over the Life Course
3323,Immunosenescence and Human Vaccine Immune Responses
3324,Antibody Response to Influenza Vaccination in the Elderly: A Quantitative Review
3325,Safety and Immunogenicity of
3326,"Vaccine Administered in a Prime-Boost Regimen in Young and Old Adults (COV002): A Single-Blind, Randomised, Controlled, Phase 2/3 Trial"
3327,T-Cell Mediated Immunity After AZD1222 Vaccination: A Polyfunctional Spike-Specific Th1 Response With a Diverse TCR Repertoire
3328,An mRNA Vaccine Against SARS-CoV-2 -Preliminary Report
3329,Age-Related Immune Response Heterogeneity to SARS-CoV-2 Vaccine BNT162b2
3330,Safety and Immunogenicity of the SARS-CoV-2 BNT162b1 mRNA Vaccine in Younger and Older Chinese Adults: A Randomized
3331,Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay
3332,Clinical Performance of a Standardized SARS-CoV-2 Interferon-g Release Assay for Simple Detection of T-Cell Responses After Infection or Vaccination
3333,Interferon-gRelease Assay for Accurate Detection of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Response
3334,Spike Is the Most Recognized Antigen in the Whole-Blood Platform in Both Acute and Convalescent COVID-19 Patients
3335,Rapid Measurement of SARS-Cov-2 Spike T Cells in Whole Blood From Vaccinated and Naturally Infected Individuals
3336,Linhagens do SARS-CoV-2 Em Circulacão
3337,Influence of Age on the Effectiveness and Duration of Protection of Vaxzevria and CoronaVac Vaccines
3338,A 'Mix and Match' Approach to SARS-CoV-2 Vaccination
3339,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population
3340,"History of the COVID-19 pandemic: origin, explosion, worldwide spreading"
3341,A pneumonia outbreak associated with a new coronavirus of probable bat origin
3342,SARS-CoV-2 was already spreading in France in late
3343,Dating first cases of COVID-19
3344,An mRNA vaccine against SARS-CoV-2 -preliminary report
3345,Russia announces positive COVID-vaccine results from controversial trial
3346,National Guiding Policy for Vaccination Against SARS-CoV-2 for the Prevention of COVID-19 in Mexico
3347,"Acceptance, refusal and hesitancy of Covid-19 vaccination in Mexico: Ensanut 2020 Covid-19"
3348,data. Coronavirus (COVID-19) Vaccinations. Available online at
3349,Mexico -COVID-19 -Vaccines administered
3350,Coronavirus Vaccine -Weekly Summary of Yellow Card Reporting
3351,Centers for Disease Control and Prevention. Pfizer-BioNTech COVID-19 Vaccine Reactions & Adverse Events
3352,"Vaccine's Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events"
3353,"The Janssen COVID-19 Vaccine's Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events"
3354,"Impacts of side effects to BNT162b2 and the first dose of ChAdOx1 Anti-SARS-CoV-2 vaccination on work productivity, the need for medical attention, and vaccine acceptance: a multicenter survey on healthcare workers in referral teaching hospitals in the Re"
3355,Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among saudi residents: a retrospective cross-sectional study
3356,Mild adverse events of Sputnik V vaccine in Russia: social media content analysis of telegram via deep learning
3357,Adverse reactions following the first dose of ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine for healthcare workers in South Korea
3358,Side effects of mRNA-based COVID-19 vaccine: nationwide phase IV study among healthcare workers in Slovakia
3359,Patients with history of covid-19 had more side effects after the first dose of covid-19 vaccine
3360,Adverse Effects When Being Vaccinated Against Covid-19
3361,Side effects of mRNA-based and viral vector-based COVID-19 vaccines among german healthcare workers
3362,Side effects following administration of the first dose of Oxford-AstraZeneca's covishield vaccine in Bangladesh: a cross-sectional study
3363,BMI-based body size guides for women and men: development and validation of a novel pictorial method to assess weight-related concepts
3364,BNT162b2 and ChAdOx1 SARS-CoV-2 post-vaccination side-effects among Saudi vaccinees
3365,A retrospective cross-sectional study assessing self-reported adverse events following immunization (AEFI) of the COVID-19 vaccine in Bangladesh
3366,Vaxzevria (previously COVID-19 Vaccine AstraZeneca): EPAR -Product information (updated). (2021)
3367,Associations between geographic region and immune response variations to pneumococcal conjugate vaccines in clinical trials: a systematic review and meta-analysis
3368,Advisory Committee on Imunization Practices (ACIP) (2021)
3369,Survey data of COVID-19 vaccine side effects among hospital staff in a national referral hospital in Indonesia
3370,Sex differences in immunity to viral infections
3371,The Xs and Y of immune responses to viral vaccines
3372,Population and Housing Census
3373,National Health and Nutrition Survey 2020 on Covid-19. National results
3374,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil
3375,Coronavirus Disease (COVID-2019) Situation Reports. 2020. Available online
3376,Multiple forms of mass anxiety in coronavirus disease-2019 pandemic
3377,COVID-19 Vaccines vs. Variants-Determining How Much Immunity Is Enough
3378,Delivery Routes for COVID-19 Vaccines. Vaccines
3379,Synthesis and immunological evaluation of synthetic peptide based anti-SARS-CoV-2 vaccine candidates
3380,COVID-19 Vaccine Tracker and Landscape
3381,COVID-19 vaccine hesitancy: A survey in a population highly compliant to common vaccinations
3382,"Challenges and Issues of Anti-SARS-CoV-2 Vaccines. Front. Med. 2021, 8, 664179"
3383,Influence of age on the effectiveness and duration of protection in Vaxzevria and CoronaVac vaccines
3384,Vacinas-COVID-19
3385,Sexual dimorphism in SARS-COV-2 infection
3386,Immune system and COVID-19 by sex differences and age. Women's Health
3387,Neutralizing Antibodies against SARS-CoV-2 Variants after Infection and Vaccination
3388,G-test of goodness-of-fit
3389,Vacina Adsorvida COVID-19 (Inativada)
3390,SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines
3391,Herd Immunity and Implications for SARS-CoV-2 Control
3392,Sex-and age-specific clinical and immunological features of coronavirus disease 2019
3393,Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion
3394,1 Special Administrative Region
3395,COVID-19 vaccines: under evaluation
3396,WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations. Geneva: WHO; 2021
3397,Travel and covid: rules and restrictions. Brussels: Your Europe
3398,COVID-19: travel into the EU. Brussels: European Council 2022
3399,Serological response to mRNA and inactivated COVID-19 vaccine in healthcare workers in Hong Kong: decline in antibodies 12 weeks after two doses
3400,Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine
3401,SARS-CoV-2 Testing in Elective Surgery Collaborators. A dual-antigen enzyme-linked immunosorbent assay allows the assessment of severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in a low-transmission setting
3402,"Optimization, comparison, and application of colorimetric vs. chemiluminescence based indirect sandwich ELISA for measurement of human IL-23"
3403,The Government of Hong Kong Special Administrative Region. Hong Kong vaccination dashboard. Hong Kong: The Government of Hong Kong Special Administrative Region
3404,"Evaluation of a SARS-CoV-2 surrogate virus neutralization test for detection of antibody in human, canine, cat, and hamster sera"
3405,"License, supplementary material and copyright"
3406,Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine
3407,Psoriasiform disorders. Fitzpatrick's Dermatology
3408,Possible triggering effect of influenza vaccination on psoriasis
3409,"Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial"
3410,Widespread psoriasis flare following influenza vaccination
3411,New onset guttate psoriasis following pandemic H1N1 influenza vaccination
3412,COVID-19 vaccination intention among patients with psoriasis compared with immunosuppressed patients with other skin diseases and factors influencing their decision
3413,Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine
3414,A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: case report
3415,Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single centre
3416,What do we know about India's Covaxin vaccine
3417,Generalized exacerbation of psoriasis vulgaris induced by pneumococcal polysaccharide vaccine
3418,Impact of yellow fever vaccine on patients with psoriasis: preliminary results
3419,New-onset guttate psoriasis following intravesical immunotherapy of Bacillus Calmette-Guerin. Dermatol Sin
3420,"National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: version 2-advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments"
3421,Vaccinations in patients receiving systemic drugs for skin disorders: what can we learn for SARS-Cov-2 vaccination strategies
3422,Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine
3423,A Novel Coronavirus From Patients With Pneumonia in China
3424,Symptoms and Symptom Clusters Associated With SARS-CoV-2 Infection in Communitybased Populations: Results From a Statewide Epidemiological Study
3425,SARS-CoV-2 Vaccines in Development
3426,Covid-19. Draft Landscape of COVID-19 Candidate Vaccines
3427,SARS-CoV-2 Vaccines Strategies: A Comprehensive Review of Phase 3
3428,"Safety and Immunogenicity of the ChAdOx1 Ncov-19 Vaccine Against SARS-CoV-2: A Preliminary Report of a Phase 1/2, Single-Blind, Randomised Controlled Trial"
3429,Genomic Survey of SARS-CoV-2 Vaccine Breakthrough Infections in Healthcare Workers From Kerala
3430,Vaccine Breakthrough Infections With SARS-CoV-2 Variants
3431,"Tolerability, and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Healthy Adults Aged 60 Years and Older: A Randomised, Double-Blind, Placebo-Controlled, Phase 1/2 Clinical Trial"
3432,Interim Report: Safety and Immunogenicity of an Inactivated Vaccine Against Sars-Cov-2 in Healthy Chilean Adults in A Phase 3 Clinical Trial 2 3 Brief Title: Coronavac03cl Phase 3 Interim Analysis of Safety and Immunogenicity
3433,Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study
3434,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans With COVID-19 Disease and Unexposed Individuals
3435,Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials
3436,Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
3437,WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A Minimal Common Outcome Measure Set for COVID-19 Clinical Research
3438,Statement -Older People are at Highest Risk From COVID-19
3439,Comorbidities in the Elderly and Their Possible Influence on Vaccine Response
3440,Clinical Features of COVID-19 in Elderly Patients: A Comparison With Young and Middle-Aged Patients
3441,Gender Differences in Patients With COVID-19: Focus on Severity and Mortality
3442,Considering How Biological Sex Impacts Immune Responses and COVID-19 Outcomes
3443,Risk of COVID-19 for Patients With Obesity
3444,Clinical Characteristics of 30 Medical Workers Infected With New Coronavirus Pneumonia
3445,Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2
3446,Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19
3447,Inflammatory Response Cells During Acute Respiratory Distress Syndrome in Patients With Coronavirus Disease 2019 (COVID-19)
3448,Risk and Course of SARS-CoV-2 Infection in Patients Treated for Hypothyroidism and Hyperthyroidism
3449,Single-Cell Landscape of Bronchoalveolar Immune Cells in Patients With COVID-19
3450,Multi-Omics Resolves a Sharp Disease-State Shift Between Mild and Moderate COVID-19
3451,Thyroid Disease Is Associated With Severe Coronavirus Disease 2019 (COVID-19) Infection
3452,Evidence for Antibody as a Protective Correlate for COVID-19
3453,Case Study of Two Post Vaccination SARS-CoV-2 Infections With P1 Variants in Coronavac Vaccinees in Brazil
3454,"Interim Recommendations for Use of the Inactivated COVID-19 Vaccine, CoronaVac"
3455,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines
3456,The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak
3457,"Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak"
3458,Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
3459,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study"
3460,Clinical features of patients infected with 2019 novel coronavirus in
3461,Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in
3462,Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies
3463,Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients
3464,TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes
3465,Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
3466,"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial"
3467,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia
3468,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial"
3469,Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine
3470,Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials
3471,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: A randomised, double-blind"
3472,Letter to the editor: Autoimmune hepatitis after COVID-19 vaccination. A rare adverse effect? Hepatology
3473,Autoimmune hepatitis after COVID-19 vaccination
3474,Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: one or even several swallows do not make a summer
3475,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity"
3476,"Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)"
3477,The interplay between HIV and COVID-19: Summary of the data and responses to date
3478,HIV/SARS-CoV-2 coinfection: A global perspective
3479,"Description of COVID-19 in HIV-infected individuals: A single-centre, prospective cohort"
3480,An updated meta-analysis on the association between HIV infection and COVID-19 mortality
3481,Associations between HIV infection and clinical spectrum of COVID-19: A population level analysis based on US National COVID Cohort Collaborative (N3C) data
3482,Fear of Adverse Effects and COVID-19 Vaccine Hesitancy: Recommendations of the Treatment Expectation Expert Group
3483,Attitudes Toward a Potential SARS-CoV-2 Vaccine: A Survey of U.S. Adults
3484,Factors Associated with US Adults' Likelihood of Accepting COVID-19 Vaccination
3485,COVID-19 Vaccination Willingness among Chinese Adults under the Free Vaccination Policy
3486,A Proactive Approach for Managing COVID-19: The Importance of Understanding the Motivational Roots of Vaccination Hesitancy for SARS-CoV2
3487,COVID-19 Vaccine Hesitancy among French People Living with HIV. Vaccines
3488,Expert recommendation for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients with HIV infection
3489,Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: Results from the IQOLA Project. International Quality of Life Assessment
3490,Guidelines for Standard Criteria for Adverse Events in Clinical Trials of Vaccines
3491,Inference and missing data
3492,Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen
3493,Complete Course COVID-19 Vaccinal Rate in Beijing Exceeded 90%
3494,HIV-positive gay men's knowledge and perceptions of Human Papillomavirus (HPV) and HPV vaccination: A qualitative study
3495,Predictors for and coverage of influenza vaccination among HIV-positive patients: A cross-sectional survey
3496,"High prevalence of syphilis, HBV, and HCV co-infection, and low rate of effective vaccination against hepatitis B in HIV-infected patients in West China hospital"
3497,COVID-19 Vaccine Hesitancy Among PLWH in South India: Implications for Vaccination Campaigns
3498,"COVID-19 Related Medical Mistrust, Health Impacts, and Potential Vaccine Hesitancy Among Black Americans Living With HIV"
3499,Severe Acute Respiratory Syndrome Coronavirus 2: Vaccine Hesitancy Among Underrepresented Racial and Ethnic Groups with HIV in
3500,Association of provider recommendation and offer and influenza vaccination among adults aged >/=18years-United States
3501,Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications
3502,Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV-1
3503,"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: An interim analysis of a randomised, double-blind"
3504,The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living with Human Immunodeficiency Virus (HIV)
3505,Safety surveillance after BNT162b2 mRNA COVID-19 vaccination: Results from a cross-sectional survey among staff of a large Italian teaching hospital
3506,Comparison of the effects of acute Influenza infection and Influenza vaccination on HIV viral load and CD4 cell counts
3507,COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2
3508,Association of time since pneumococcal polysaccharide vaccine receipt and CD4 count with antibody response to the 13-valent pneumococcal conjugate vaccine in HIV-infected adults
3509,Germinal centers B-cell reaction and T follicular helper cells in response to HIV-1 infection
3510,Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19
3511,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adult
3512,Effectiveness of an Inactivated SARS-CoV-2 Vaccine
3513,"India's Coronavirus Death Toll Tops 400,000 as the Delta Variant Spreads Globally, Including in the United States-The Washington Post"
3514,Tracking SARS-CoV-2 Variants
3515,AstraZeneca to Deliver Six Million COVID-19 Vaccine Doses in THAILAND
3516,Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria). medRxiv 2021
3517,"Production, Titration, Neutralisation, Storage and Lyophilisation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Lentiviral Pseudotypes"
3518,The R Project for Statistical Computing
3519,Pipe-Friendly Framework for Basic Statistical
3520,DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus
3521,The Immunogenicity and Safety of Different COVID-19 Booster Vaccination Following CoronaVac or ChAdOx1 nCoV-19 Primary Series
3522,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: A prospective cohort
3523,Cell Memory and Plasma Cell Development
3524,SARS-CoV-2 variants of concern exhibit reduced sensitivity to live-virus neutralization in sera from CoronaVac vaccinees and naturally infected COVID-19 patients
3525,Reduced serum neutralization capacity against SARS-CoV-2 variants in a multiplex ACE2 RBD competition assay
3526,Interim Recommendations for Heterologous COVID-19 Vaccine Schedules
3527,Cohort study of COVID-19 vaccine effectiveness among healthcare workers in Finland
3528,Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination
3529,Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2. Vaccine in a Subgroup of Healthy Adults in Chile
3530,"T follicular helper cell differentiation, function, and roles in disease"
3531,SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19
3532,"Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins"
3533,Age-related changes in lymphocyte development and function
3534,Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses
3535,Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity
3536,Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion
3537,SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans
3538,"SARS-CoV-2-Specific T Cells Exhibit Phenotypic Features of Helper Function, Lack of Terminal Differentiation, and High Proliferation Potential"
3539,Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination
3540,MAIT cells are activated in acute Dengue virus infection and after in vitro Zika virus infection
3541,T follicular helper cells in human autoimmunity
3542,Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses
3543,Clinical performance of different SARS-CoV-2 IgG antibody tests
3544,SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor
3545,SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses. medRxiv
3546,SARS-CoV-2 Immunoassays: Advancing diagnostics of COVID-19
3547,Discrete SARS-CoV-2 antibody titers track with functional humoral stability
3548,Vaccines: correlates of vaccine-induced immunity
3549,Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. medRxiv
3550,A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
3551,How to cite this article
3552,Symptomatic recurrence of SARS-CoV-2 infection in healthcare workers recovered from COVID-19
3553,The Turkish Ministry of Health Covid19 information page
3554,Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States
3555,Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
3556,The use of social network in daily pediatric practice and education: Turkish pediatric atelier
3557,A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses
3558,What do we know about India's Covaxin vaccine?
3559,"Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: A phase 1, randomised, double-blind, placebo-controlled trial"
3560,"B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance. arXiv 2021"
3561,"Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: An observational study"
3562,Omicron: Call for updated vaccines
3563,The emergence of new SARS-CoV-2 variant (Omicron) and increasing calls for COVID-19 vaccine boosters-The debate continues
3564,"BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection, but recognition of mutant viruses is up to 10-fold reduced"
3565,Revista da Sociedade Brasileira de Medicina Tropical Case Report Vertical transmission of maternal COVID-19 antibodies after CoronaVac vaccine: A case report
3566,Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status
3567,Pregnancy and COVID-19
3568,Suspected COVID-19 case definition: a narrative review of the most frequent signs and symptoms among confirmed cases
3569,Worldwide maternal deaths due to COVID-19: A brief review
3570,We have Vaccine for COVID-19! What to Recommend for Pregnant Women?
3571,Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants
3572,Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals
3573,Antigen-specific immune responses to influenza vaccine in utero
3574,Impact of maternal immunization on influenza hospitalizations in infants
3575,A Case Report to Assess Passive Immunity in a COVID Positive Pregnant Patient
3576,"Tropical Medicine and Infectious Disease High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related Deaths in over 75-Year-Olds, Ceará State, Brazil"
3577,"Impact of vaccination by priority group on UK deaths, hospital admissions and intensive care admissions from COVID-19"
3578,First month of COVID-19 vaccine safety monitoring-United States
3579,"Health system collapse 45 days after the detection of COVID-19 in Ceará, Northeast Brazil: A preliminary analysis"
3580,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study"
3581,"Decreases in COVID-19 Cases, Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Introduction of COVID-19 Vaccine-United States"
3582,"The Influence of Covid-19 Vaccine on Daily Cases, Hospitalization, and Death Rate in Tennessee: A Case Study in the United States"
3583,Take-Home Messages from the COVID-19 Pandemic: Strengths and Pitfalls of the Italian National Health Service from a Medico-Legal Point of View
3584,Vaccines for a healthy future: 21st DCVMN Annual General Meeting 2020 report
3585,The Difficult Balance between Ensuring the Right of Nursing Home Residents to Communication and Their Safety
3586,International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Accelerator and the COVAX Facility. Milbank Q. 2021
3587,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study
3588,Ministry of Public Health of Thailand. SARS-CoV-2 variants in Thailand
3589,"Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands"
3590,Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months
3591,Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase
3592,BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 delta variant in Qatar
3593,Vaccine effectiveness against infection with the delta (B.1.617.2) variant
3594,Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617.2 (delta) variant predominance -eight U.S. locations
3595,Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (delta) variant -national healthcare safety network
3596,Online ahead of print
3597,Guangdong's study of the effectiveness of China's inactivated vaccines against the SARS-CoV-2 B.1.617.2 (delta) variant
3598,Effectiveness of inactivated SARS-CoV-2 vaccines against the delta variant infection in Guangzhou: a test-negative case-control real-world study
3599,"Short-term immune response after inactivated SARS-CoV-2 (CoronaVac®, Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) vaccinations in health care workers"
3600,Safety and immunological response following heterologous primary series of COVID-19 vaccination: the preliminary report focusing on the delta variant
3601,Evaluation of postintroduction COVID-19 vaccine effectiveness: summary of interim guidance of the World Health Organization
3602,"Guidelines on diagnosis, treatment and prevention of Covid-19 in hospitals, the revised version"
3603,"Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 delta VOC in Guangzhou. China EClinicalMedicine"
3604,World Health Organization. COVID-19 clinical management: living guidance
3605,Evaluation of COVID-19 vaccine effectiveness
3606,Viral loads of delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2
3607,"Safety and immunogenicity of heterologous versus homologous primeboost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a singleblind, randomised, non-inferiority trial"
3608,Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report
3609,Sinovac: Coronavac. Inactivated Vaccine. Available online
3610,Effectiveness of an inactivated SARS-CoV-2 vaccine in chile
3611,"Immunogenicity and reactogenicity of bnt162b2 booster in chadox1-s-primed participants (combivacs): A multicentre, open-label, randomised, controlled, phase 2 trial"
3612,Intradermal vaccination: A potential tool in the battle against the COVID-19 pandemic? Risk Manag
3613,Immunogenicity and safety of reduced-dose intradermal vs intramuscular influenza vaccines: A systematic review and meta-analysis
3614,Pseudotype neutralization assays: From laboratory bench to data analysis
3615,Studies on the level of neutralizing antibodies produced by inactivated COVID-19 vaccines in the real world. medRxiv 2021. preprint
3616,Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine
3617,"Daily Corona Virus Disease (COVID-19) Vaccine Situation Report. Department of Disease Control, Ministry of Public Health"
3618,"Safety and immunogenicity of a DNA SARS-CoV-2 vaccine (zycov-d): Results of an open-label, non-randomized phase i part of phase i/ii clinical study by intradermal route in healthy subjects in india"
3619,"Safety and immunogenicity of ino-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, phase 1 clinical trial"
3620,safety and immunogenicity of intradermal delivery of a fractional dose mrna-1273 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy. medRxiv 2021. preprint
3621,"Immunogenic potential of DNA vaccine candidate, zycov-d against SARS-CoV-2 in animal models"
3622,Immunogenicity of a DNA vaccine candidate for COVID-19
3623,Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals. medRxiv 2021. preprint
3624,Thrombocytopenia and splenic platelet directed immune responses after intravenous chadox1 ncov-19 administration
3625,The adjuvant gla-af enhances human intradermal vaccine responses
3626,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant
3627,COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium
3628,COVID-19-related mortality in kidney transplant and dialysis patients: Results of the ERACODA collaboration
3629,Respiratory and Gastrointestinal COVID-19 Phenotypes in Kidney Transplant Recipients
3630,COVID-19 infection in kidney transplant recipients: Disease incidence and clinical outcomes
3631,Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe
3632,Antibody response to 2-dose sars-cov-2 mrna vaccine series in solid organ transplant recipients
3633,mRNA Vaccine in a Cohort of Hemodialysis Patients and Kidney Transplant
3634,Antibody response to SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients and in-centre and satellite centre haemodialysis patients
3635,SARS-CoV-2 breakthrough infections in vaccinated kidney transplant recipients: an issue of concern
3636,Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients
3637,Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients
3638,Impaired humoral and cellular immunity after SARS-CoV2 BNT162b2 (Tozinameran) prime-boost vaccination in kidney transplant recipients
3639,Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273
3640,SARS-CoV-2 vaccine
3641,Impaired humoral response in renal
3642,"Clinical Impact, Reactogenicity, and Immunogenicity After the First CoronaVac Dose in Kidney Transplant Recipients"
3643,Weak antibody response to 3 doses of mRNA vaccine in kidney transplant recipients treated with belatacept
3644,Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients
3645,"Lymphocyte count, cells/L, median (IQR)"
3646,"Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate using CKD EPI Formula"
3647,"Receptor Binding Domain of SARS-CoV-2 spike protein; SD, standard deviation"
3648,Interstitial Lung Disease and Transverse Myelitis: A Possible Complication of COVID-19 Vaccine
3649,Transverse myelitis
3650,"Transverse myelitis: pathogenesis, diagnosis and treatment"
3651,Acute transverse myelitis -A rare clinical manifestation of Lyme neuroborreliosis
3652,Transverse myelitis after vaccination
3653,Drug-induced interstitial lung disease: a systematic review
3654,COVID-19 vaccine-related interstitial lung disease: a case study
3655,Acute transverse myelitis following COVID-19 vaccination. Vaccines (Basel)
3656,Adverse events reported from COVID-19 vaccine trials: a systematic review
3657,ANA investigates: neurological complications of COVID-19 vaccines
3658,SARS-CoV-2 vaccinationinduced transverse myelitis
3659,Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature (PREPRINT)
3660,COVID-19 vaccine induced interstitial lung disease
3661,A case of severe interstitial lung disease after COVID-19 vaccination
3662,Acute exacerbation of idiopathic pulmonary fibrosis after pandemic influenza A (H1N1) vaccination
3663,Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches
3664,Coronavirus vaccine-associated lung immunopathology-what is the significance
3665,"Comparative systematic review and metaanalysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2"
3666,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines
3667,COVID-19 Weekly Epidemiological Update Edition 68
3668,Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants
3669,WHO. Interim statement on COVID-19 vaccine booster doses 2021
3670,WHO. Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19 2021
3671,"Short-term immune response after inactivated SARS-CoV-2 (CoronaVac(R), Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria(R), Oxford-AstraZeneca) vaccinations in health care workers"
3672,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The"
3673,Optimize Prime/Boost Vaccine Strategies: trained Immunity as a New Player in the Game
3674,Prime-boost vaccine strategy against viral infections: mechanisms and benefits
3675,Guidance for Industry Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials
3676,"WHO. Guidelines on clinical evaluation of vaccines: regulatory expectations, WHO Technical Report Series 1004"
3677,Immunological memory cells
3678,Correlation of sample-to-cut-off ratio of anti-SARS-CoV-2 IgG antibody chemiluminescent assay with neutralization activity: a prospective multi-centric study in India
3679,To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination
3680,Coronavirus Pandemic (COVID-19) 2020
3681,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: a randomized controlled trial
3682,Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India
3683,Novel coronavirus (2019-nCoV) cases in Hong Kong and implications for further spread
3684,WHO Coronavirus (COVID-19) Dashboard. Available online
3685,Hong Kong Special Administrative Region. CHP Local Situation Dashboard
3686,Hong Kong Special Administrative Region. CHP Vaccination Dashboard
3687,Evaluation of the QuantiFERON SARS-CoV-2 interferon-G release assay in mRNA-1273 vaccinated health care workers
3688,Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total Test in Recently
3689,Humoral and Cellular Immunogenicity of the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Nursing Home Residents
3690,Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response
3691,R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing
3692,Serological response to mRNA and inactivated COVID-19 vaccine in healthcare workers in Hong Kong: Decline in antibodies 12 weeks after two doses
3693,"RHH-001 study team. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): A phase 4, non-inferiority, single blind, randomised study"
3694,DMID 21-0012 Study Group
3695,Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa
3696,Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters
3697,Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses
3698,"SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection"
3699,Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants
3700,Global burden of COVID-19: situational analysis and review
3701,American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 3
3702,Potential false-positive reasons for SARS-CoV-2 antibody testing and its solution
3703,IDSA clinical practice guideline for vaccination of the immunocompromised host
3704,"Clinical impact, reactogenicity, and immunogenicity after the first coronavac dose in kidney transplant recipients"
3705,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy
3706,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial"
3707,WHO. Coronavirus disease (COVID19): Vaccines. 2021
3708,Duration of protection against mild and severe disease by Covid19 vaccines
3709,Emergence of a novel SARSCoV2 variant in southern California
3710,"Safety and immunogenicity of seven COVID19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov19 or BNT162b2 in the UK (COVBOOST): a blinded, multicentre, randomised, controlled, phase 2 trial"
3711,Protection of BNT162b2 vaccine booster against Covid19 in Israel
3712,Interim recommendations for heterologous COVID19 vaccine schedules. Interim guidance
3713,Highlights from the meeting of the strategic advisory group of experts (SAGE) on immunization
3714,SARSCoV2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following twodose CoronaVac vaccine regimen
3715,A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac
3716,Heterologous AD5nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
3717,"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type5 vectorbased COVID19 vaccine (Ad5nCoV) in adults: preliminary report of an openlabel and randomised phase 1 clinical trial"
3718,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type5 vectored COVID19 vaccine: a doseescalation, openlabel, nonrandomised, firstinhuman trial"
3719,Notice of the state food and drug administration on issuing the guidelines for the grading standards for adverse events in clinical trials of prophylactic vaccines
3720,Heterologous primeboost immunization with CoronaVac and Convidecia
3721,"Development of an inactivated vaccine candidate, BBIBPCorV, with potent protection against SARSCoV2"
3722,"Immunogenicity and safety of a recombinant adenovirus type5vectored COVID19 vaccine in healthy adults aged 18 years or older: a randomised, doubleblind, placebocontrolled, phase 2 trial"
3723,Quantifying adenovirusneutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors
3724,Correlates of protection against symptomatic and asymptomatic SARSCoV2 infection
3725,Antibody titers measured by commercial assays are correlated with neutralizing antibody titers calibrated by international standards
3726,"Safety and immunogenicity of CpG 1018 and aluminium hydroxideadjuvanted SARSCoV2 S2P protein vaccine MVCCOV1901: interim results of a large scale, doubleblind, randomised, placebocontrolled phase 2 trial in Taiwan"
3727,Clover's COVID19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
3728,"Immunogenicity, safety, and reactogenicity of heterologous COVID19 primary vaccination incorporating mRNA, viralvector, and proteinadjuvant vaccines in the UK (ComCOV2): a singleblind, randomised, phase 2, noninferiority trial"
3729,"Safety and immunogenicity of heterologous versus homologous primeboost schedules with an adenoviral vectored and mRNA COVID19 vaccine (ComCOV): a singleblind, randomised, noninferiority trial"
3730,Heterologous ChAdOx1 nCoV19 and mRNA1273 vaccination
3731,Respiratory mucosal delivery of nextgeneration COVID19 vaccine provides robust protection against both ancestral and variant strains of SARSCoV2
3732,T resident helper cells promote humoral responses in the lung
3733,Mucosal vaccines-fortifying the frontiers
3734,"Safety, mucosal and systemic immunopotency of an aerosolized adenovirusvectored vaccine against SARSCoV2 in rhesus macaques"
3735,T cell immunity to SARSCoV2 following natural infection and vaccination
3736,Considerable escape of SARSCoV2 Omicron to antibody neutralization
3737,mRNAbased COVID19 vaccine boosters induce neutralizing immunity against SARSCoV2 Omicron variant
3738,Erythema multiforme after SARS-CoV-2 vaccine
3739,Localized cutaneous reaction to an mRNA COVID-19 vaccine
3740,New-onset cutaneous lichen planus triggered by COVID-19 vaccination
3741,Erythema multiforme after Corona-Vac vaccination
3742,Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: an Italian single-centre case series
3743,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong
3744,Psychobehavioral responses and likelihood of receiving COVID-19 vaccines during the Pandemic
3745,Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military
3746,Incidence of cerebral venous thrombosis and COVID-19 vaccination: possible causal effect or just chance? Eur
3747,Thromboembolic events in the South African Ad26.COV2.S vaccine study
3748,Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?
3749,Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study
3750,COVID-19 vaccine and myocarditis
3751,The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: a monocentric experience
3752,Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
3753,Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): a multicenter study
3754,Are vaccines against COVID-19 tailored to the most vulnerable people? Vaccine
3755,"Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study"
3756,"Multimorbidity in middle age predicts more subsequent hospital admissions than in older age: A nine-year retrospective cohort study of 121,188 discharged in-patients"
3757,Sociodemographic moderation of the association between depression and stroke incidence in a retrospective cohort of 0.4 million primary care recipients with hypertension
3758,"Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity"
3759,"Multimorbidity, polypharmacy, referrals, and adverse drug events: are we doing things well?"
3760,"Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: a cross-sectional UK Biobank study"
3761,Learning from the past: development of safe and effective COVID-19 vaccines
3762,Age and multimorbidity predict death among COVID-19 patients
3763,BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting
3764,Interim Guidance Notes On Common Medical Diseases and COVID-19 Vaccination In Primary Care Settings
3765,Centre for Health Protection. Hong Kong Vaccination Dashboard
3766,Evaluation of the safety profile of COVID-19 vaccines: a rapid review
3767,Coverage of COVID-19 Vaccines In Electronic Healthcare Databases: A Protocol Template From The ACCESS Project
3768,Prevalence of multimorbidity in community settings: A systematic review and meta-analysis of observational studies
3769,"COVID-19 vaccine hesitancy and acceptance among individuals with cancer, autoimmune diseases, and other serious comorbid conditions: a cross-sectional internet-based survey"
3770,Differential impacts of multimorbidity on COVID-19 severity across the socioeconomic ladder in Hong Kong: a syndemic perspective
3771,An evaluation of universal vouchers as a demand-side subsidy to change primary care utilization: a retrospective analysis of longitudinal services utilisation and voucher claims data from a survey cohort in Hong Kong
3772,Redistribution or horizontal equity in Hong Kong's mixed public-private health system: a policy conundrum
3773,Cardiovascular outcomes associated with use of clarithromycin: population based study
3774,Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation
3775,Prenatal antidepressant use and risk of attention-deficit/ hyperactivity disorder in offspring: population based cohort study
3776,Influenzarelated hospitalizations among children in Hong Kong
3777,Methods for identifying 30 chronic conditions: application to administrative data
3778,Background paper on Covid-19 disease and vaccines: prepared by the Strategic Advisory Group of Experts (SAGE) on immunization working group on COVID-19 vaccines
3779,Entropy balancing is doubly robust
3780,Comparing measures of multimorbidity to predict outcomes in primary care: a cross sectional study
3781,World Health Organization. Coronavirus Disease (COVID-19) Dashboard
3782,Our World in Data. Coronavirus (COVID-19) Vaccinations
3783,China Sinovac says it reached two billion doses annual capacity for COVID-19 vaccine | Reuters
3784,Plan Nacional de Vacunación contra COVID-19
3785,"Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID-19 en establecimientos de atención de la salud Recomendaciones basadas en consenso de expertos e informadas en la evidencia"
3786,World Health Organization. Clinical management of COVID-19
3787,COVID-19 vaccine: critical questions with complicated answers
3788,Sinovac Announces Phase III Results of Its
3789,"New mutations raise specter of ""immune escape"
3790,"COVID-19 vaccines: current understanding on immunogenicity, safety, and further considerations"
3791,"Reporte COVID-19: Vacuna CoronaVac tiene un 90,3% de efectividad para prevenir el ingreso a UCI"
3792,El virus se adaptó para transmitirse rápidamente
3793,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis
3794,References: 'metafor' P. Package 'metafor'
3795,National Study Group for C-V. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
3796,Effectiveness and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
3797,Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks
3798,Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization
3799,Vaccination in the elderly: The challenge of immune changes with aging
3800,mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
3801,Effectiveness of COVID-19 vaccines: From clinical trials to real life
3802,Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans
3803,Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19. Vaccines (Basel)
3804,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using 19 national surveillance data"
3805,Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection
3806,Spread of a Variant SARS-CoV-2 in
3807,Long-Term Care Facilities in England
3808,Interpreting vaccine effectiveness trial results for infection and transmission
3809,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults 20 in England: test negative case-control study"
3810,Effectiveness of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B
3811,AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial
3812,The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
3813,"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Effectiveness and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac -PROFISCOV: A structured summary of a study protocol for a randomised controlled trial"
3814,Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization
3815,FDA-authorized mRNA COVID-19 vaccines are effective per 21
3816,real-world evidence synthesized across a multi-state health system
3817,A systematic review assessing the under-representation of elderly adults in COVID-19 trials
3818,Proportion of SARS-CoV-2 positive tests and vaccination in Veterans Affairs Community Living Centers
3819,Safety and Effectiveness of Single-Dose Ad26.COV2.S Vaccine against Covid-19
3820,Efectividad de la vacuna CoronaVac con virus inactivo contra SARS-CoV-2 en Chile
3821,VIVALDI): a prospective cohort study. The Lancet Infectious Diseases
3822,Safety and Effectiveness of the BNT162b2 mRNA Covid-19 Vaccine
3823,Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening
3824,Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) -United States
3825,"-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The"
3826,The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses
3827,Tracking SARS-CoV-2 variants
3828,Retrieved
3829,Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention
3830,BNT162b2 Vaccine Effectiveness in Preventing Asymptomatic Infection With SARS-CoV-2 Virus: A Nationwide Historical Cohort Study
3831,The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout
3832,"To cite: Saygılı ES, Karakilic E"
3833,Mini-Review Discussing the reliability and efficiency of COVID-19 vaccines
3834,Clinical characteristics of 852 patients with subacute thyroiditis before treatment
3835,Thyroiditis and SARS-CoV-2 pandemic: a review
3836,Diagnostic value of nuclear medicine imaging and ultrasonography in subacute thyroiditis
3837,Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis
3838,Endocrine significance of SARS-CoV-2's reliance on ACE2
3839,Sars vaccines: where are we?
3840,Occurrence of subacute thyroiditis following influenza vaccination
3841,Asia syndrome and endocrine autoimmune disorders
3842,Three cases of subacute thyroiditis following SARS-CoV-2 vaccine: postvaccination Asia syndrome
3843,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine
3844,Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19
3845,E.a. The COVID-19 pandemic and global environmental change: emerging research needs
3846,"Associations of ambient coarse particulate matter, nitrogen dioxide, and carbon monoxide with the risk of kidney disease: a cohort study"
3847,Immunotoxicity and environment: immunodysregulation and systemic inflammation in children
3848,Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis
3849,Elevated biomarkers of sympatho-adrenomedullary activity linked to ewaste air pollutant exposure in preschool children
3850,The role of air pollution (PM and NO2) in COVID-19 spread and lethality: a systematic review
3851,Systemic inflammatory markers associated with cardiovascular disease and acute and chronic exposure to fine particulate matter air pollution (PM2.5) among US NHANES adults with metabolic syndrome
3852,Evaluation of masks' internal and external surfaces used by health care workers and patients in coronavirus-2 (SARS-CoV-2) wards
3853,Investigation of SARS-CoV-2 virus in environmental surface
3854,"Co-variance nexus between COVID-19 mortality, humidity, and air quality index in Wuhan, China: new insights from partial and multiple wavelet coherence"
3855,Source apportionment and health risk assessment of air pollution particles in eastern district of Chengdu
3856,"SARS-CoV-2 in municipal wastewater treatment plant, collection network, and hospital wastewater"
3857,Moradi-Asl E (2021b) Investigation of SARS-CoV-2 virus on nozzle surfaces of fuel supply stations in North West of Iran
3858,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis
3859,Decreased vaccine antibody titers following exposure to multiple metals and metalloids in e-waste-exposed preschool children
3860,"Considerable decrease of antibody titers against measles, mumps, and rubella in preschool children from an e-waste recycling area"
3861,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised
3862,Air pollution exposure and COVID-19: a look at mortality in Mexico City using individual-level data
3863,Elevated inflammatory Lp-PLA2 and IL-6 link e-waste Pb toxicity to cardiovascular risk factors in preschool children
3864,"Nurture to nature via COVID-19, a self-regenerating environmental strategy of environment in global context"
3865,Air pollution by NO 2 and PM 2.5 explains COVID-19 infection severity by overexpression of angiotensinconverting enzyme 2 in respiratory cells: a review
3866,Spike in pollution to ignite the bursting of COVID-19 second wave is more dangerous than spike of SAR-CoV-2 under environmental ignorance in long term: a review
3867,Characterization of water soluble inorganic ions and their evolution processes during PM2.5 pollution episodes in a small city in southwest China
3868,Association between changes in air pollution levels during the Beijing Olympics and biomarkers of inflammation and thrombosis in healthy young adults
3869,Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19
3870,Investigating the relationship between occupation and SARS-CoV2
3871,A study on the effects of meteorological and climatic factors on the COVID-19 spread in Canada during 2020
3872,Effects of climatological parameters on the outbreak spread of COVID-19 in highly affected regions of Spain
3873,Does environmental quality and weather induce COVID-19: case study of Istanbul
3874,Fluctuations in environmental pollutants and air quality during the lockdown in the USA and China: two sides of COVID-19 pandemic
3875,"Lamon-Fava S (2021) EPA and DHA differentially modulate monocyte inflammatory response in subjects with chronic inflammation in part via plasma specialized pro-resolving lipid mediators: a randomized, double-blind, crossover study"
3876,COVID-19 and air pollution and meteorology-an intricate relationship: a review
3877,Links between air pollution and COVID-19 in England
3878,Long-term residential exposure to air pollution is associated with hair cortisol concentration and differential leucocyte count in Flemish adolescent boys
3879,Investigation of SARS-CoV-2 in hospital indoor air of COVID-19 patients' ward with impinger method
3880,"Seasonal characteristics, formation mechanisms and source origins of PM<sub>2.5</sub> in two megacities in Sichuan Basin"
3881,"Combined toxicity of outdoor air pollution on kidney function among adult women in Mianyang City, southwest China"
3882,"Children and increased susceptibility to environmental carcinogens: evidence or empathy? Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research"
3883,"SARS-CoV-2 infection, COVID-19 pathogenesis, and exposure to air pollution: what is the connection?"
3884,Exposure to air pollution and COVID-19 mortality in the United States: a nationwide cross-sectional study
3885,Decreased blood hepatitis B surface antibody levels linked to ewaste lead exposure in preschool children
3886,Inflammatory response to fine particulate air pollution exposure: neutrophil versus monocyte
3887,Assessing the mechanism of DNA damage induced by lead through direct and indirect interactions
3888,Analysis of efficacy of intervention strategies for COVID-19 transmission: a case study of Hong Kong
3889,"Particulate air pollution and respiratory Haemophilus influenzae infection in Mianyang, southwest"
3890,Ambient fine particulate matter inhibits innate airway antimicrobial activity in preschool children in e-waste areas
3891,The association of PM2.5 with airway innate antimicrobial activities of salivary agglutinin and surfactant protein D
3892,Associations between air pollution and COVID-19 epidemic during quarantine period in China
3893,Ambient air heavy metals in PM2.5 and potential human health risk assessment in an informal electronic-waste recycling site of China
3894,Association between short-term exposure to air pollution and COVID-19 infection: evidence from China
3895,Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
3896,Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers
3897,Ministry of Health
3898,WHO. Coronavirus disease (COVID-19): Vaccines
3899,The Capacity of the Indonesian Healthcare System to Respond to COVID-19
3900,Efficacy of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study
3901,WHO. Coronavirus disease (COVID-19
3902,Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers
3903,The complementary roles of Phase 3 trials and postlicensure surveillance in the evaluation of new vaccines
3904,Real world effectiveness of covid-19 vaccines
3905,WHO. Interim statement on COVID-19 vaccine booster doses
3906,Turkish Society of Clinical Microbiology and Infectious Diseases
3907,"Vaccination status, acceptance, and knowledge toward a COVID-19 vaccine among healthcare workers: a cross-sectional survey in China"
3908,"Covid-19 vaccine acceptance, hesitancy, and refusal among Canadian healthcare workers: A multicenter survey"
3909,"Hazal Cansu Acar, Sumeyye Nur Aydin et al. Vaccine xxx (xxxx) xxx"
3910,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil"
3911,"), and National Institute of Allergy and Infectious Diseases (ZIA AI001273). JDS, LRG and BMA have received postdoctoral fellowships by the Brazilian Ministry of Health while conducting this study. References Artic Network"
3912,The importance and challenges of identifying SARS-CoV-2 reinfections
3913,"Centers for Disease Control and Prevention, 2020. CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel"
3914,Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
3915,2020. The N501Y and K417N mutations in the spike protein of SARS-CoV-2 alter the interactions with both hACE2 and human derived antibody: a free energy of perturbation study
3916,Confirmed reinfection with SARS-CoV-2 variant VOC-202012/01
3917,SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. The Lancet Microbe
3918,ModelFinder: fast model selection for accurate phylogenetic estimates
3919,Longitudinal analysis of human memory T-cell response according to the severity of illness up to 8 months after SARS-CoV-2 infection
3920,Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques
3921,A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity
3922,"Oxford University Hospitals Staff Testing, G, 2021. Antibody status and incidence of SARS-CoV-2 infection in health care workers"
3923,SARS-CoV-2 infection of BNT162b2(mRNA)-vaccinated individuals is not restricted to variants of concern or high-risk exposure environments
3924,SARS-CoV-2 immune evasion by variant B.1.427/B.1.429
3925,Portal do COVID-19 -Coronavírus Brasil
3926,Three SARS-CoV-2 Reinfection Cases by the New Variant of Concern (VOC) P.1/501Y.V3. PREPRINT Available at Research Square
3927,IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies
3928,"CoG-UK), o.b.o.C.-G.C.U, 2020. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations"
3929,Rede Genômica Fiocruz. Presença das linhagens por estado
3930,SARS-CoV-2 genomic analyses in cancer patients reveal elevated intrahost genetic diversity
3931,Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding
3932,Association between SARS-CoV-2 neutralizing antibodies and commercial serological assays
3933,Genomic evidence for reinfection with SARS-CoV-2: a case study
3934,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine
3935,reactive T cells in healthy donors and patients with COVID-19
3936,Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
3937,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with
3938,Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence
3939,Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients
3940,Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection
3941,Correlates of protection from SARS-CoV-2 infection
3942,"A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients"
3943,Unique phenotypes and clonal expansions of human CD4 effector memory T cells re-expressing CD45RA
3944,Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
3945,Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination
3946,Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19
3947,Dengue-specific CD8+ T cell subsets display specialized transcriptomic and TCR profiles
3948,Extended interval BNT162b2 vaccination enhances peak antibody generation in older people
3949,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study
3950,Age-specific mortality and immunity patterns of SARS-CoV-2
3951,Genomic surveillance of SARS-CoV-2 tracks early interstate transmission of P.1 lineage and diversification within P.2 clade in Brazil
3952,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study
3953,Projeções populacionais por sexo e idade para pequenas áreas no Brasil
3954,"Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls"
3955,"Case-control vaccine effectiveness studies: Data collection, analysis and reporting results"
3956,Definition of COVID-19 cases and recommendations for COVID-19 surveillance in Brazil
3957,Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial
3958,COVID-19 epidemic in the Brazilian state of Amazonas was driven by long-term persistence of endemic SARS-CoV-2 lineages and the recent emergence of the new Variant of Concern P.1
3959,Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus
3960,Novel SARS-CoV-2 Variant Identified in Travelers from Brazil to Japan
3961,Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation
3962,The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera
3963,"Supplementary Figure 1. Reported RT-PCR or Antigen confirmed COVID-19 in the general population of the São Paulo State, Brazil from"
3964,"Reported RT-PCR or Antigen confirmed COVID-19 rates in the general population of the São Paulo State, Brazil from"
3965,Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers
3966,Dominance of alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City
3967,Infection with the SARS-CoV-2 delta variant is associated with higher infectious virus loads compared to the alpha variant in both unvaccinated and vaccinated individuals. medRxiv
3968,"Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections"
3969,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort"
3970,"Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participants"
3971,"Aging in COVID-19: vulnerability, immunity and intervention"
3972,Safety and efficacy of singledose Ad26.COV2.S vaccine against Covid-19
3973,Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine
3974,Socioeconomic inequalities associated with mortality for COVID-19 in Colombia: a cohort nationwide study
3975,"COVID-19 clinical characteristics, and sex-specific risk of mortality: systematic review and meta-analysis"
3976,Public health surveillance for COVID-19. Interim guidance
3977,Pan American Health Organization. Case definitions for COVID-19 surveillance
3978,Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents
3979,Associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes and healthcare workers in Catalonia: prospective cohort study
3980,mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal
3981,Preparing for a pandemic: accelerating vaccine availability
3982,Frailty: implications for clinical practice and public health
3983,Effectiveness of the CoronaVac vaccine in the elderly population during a gamma variant-associated epidemic of COVID-19 in Brazil: a test-negative case-control study
3984,"A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
3985,Tolerability and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 (AZD1222)
3986,Introduction to the analysis of survival data in the presence of competing risks
3987,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review"
3988,Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies
3989,A rare case of shingles after covid-19 vaccine: is it a possible adverse effect?
3990,Myocarditis following COVID-19 vaccination
3991,Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
3992,The 2020 pandemic: current SARS-CoV-2 vaccine development
3993,Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates
3994,Cancer immunology and canine malignant melanoma: a comparative review
3995,AZD1222 US Phase III primary analysis confirms safety and efficacy
3996,Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV
3997,Review on up-to-date status of candidate vaccines for COVID-19 disease
3998,The 2019-new coronavirus epidemic: evidence for virus evolution
3999,Vaccines and drug therapeutics to lock down novel coronavirus disease 2019 (COVID-19): a systematic review of clinical trials
4000,Evolutionary reversion of live viral vaccines: can genetic engineering subdue it? Virus Evol
4001,Combinatorial nano-bio interfaces
4002,"Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute?"
4003,"Update on the angiotensin converting enzyme 2-angiotensin (1-7)-Mas receptor axis: fetal programing, sex differences, and intracellular pathways"
4004,mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.3.5.1 variants and severe COVID-19 disease in Qatar
4005,The world health organization international clinical trials registered organization registered platform
4006,Chinese COVID-19 vaccine candidate the first to start phase 3 clinical trials worldwide-Global Times
4007,Reported orofacial adverse effects of COVID-19 vaccines: the knowns and the unknowns
4008,Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals-Full Text View-ClinicalTrials.gov
4009,Aurisicchio L (2020) Are genetic vaccines the right weapon against COVID-19?
4010,SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness
4011,Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in nonhuman primates
4012,Covid-19 Latest News: Sinopharm Virus Vaccine Safe in Testing-Bloomberg
4013,COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection-Full Text View-ClinicalTrials.gov. (2021)
4014,Personalized medicine case report a rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporally associated to the COVID-19 vaccine administration
4015,West Nile virus: recent trends in diagnosis and vaccine development
4016,Eong Ooi E (2020) A single dose of self-transcribing and replicating RNA based SARS-CoV-2 1 vaccine produces protective adaptive immunity
4017,Polyethylene glycol and polysorbate testing in twelve patients prior to or after COVID-19 vaccine administration
4018,Singledose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates
4019,Tuberculosis vaccine: a journey from BCG to present
4020,"Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?"
4021,Recent advances in design of immunogenic and effective naked DNA vaccines against cancer
4022,SARS-CoV-2 variants and ending the COVID-19 pandemic
4023,Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit?
4024,Nonviral delivery of self-amplifying RNA vaccines
4025,A decade after SARS: strategies for controlling emerging coronaviruses
4026,Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19
4027,A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2
4028,Making sense of mutation: what D614G means for the COVID-19 pandemic remains unclear
4029,Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report
4030,Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B117 variant
4031,Cytokine gene expression in epidermis with biological effects following injection of naked DNA
4032,Lymphadenopathy associated with the COVID-19 vaccine
4033,DNA vaccines-how far from clinical use?
4034,The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells
4035,Recognizing vaccine-induced immune thrombotic thrombocytopenia
4036,COVID-19 spike-host cell receptor GRP78 binding site prediction
4037,Indonesia Testing Location for China's Sinovac Phase 3 Clinical Trial (2021) https:// trial siten ews. com/ indon esia-testi ng-locat ion-forchinas-sinov ac-phase-3-clini cal-trial/. Accessed 30 Mar 2021 Investigating a Vaccine Against COVID-19-Full Text View-Clini-calTrials.gov
4038,COVID-19: a review of therapeutic strategies and vaccine candidates
4039,Preparation of viruslike particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells
4040,Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle
4041,Role of nanotechnology behind the success of mRNA vaccines for COVID-19
4042,COVID-19 vaccination and glomerulonephritis
4043,Montefiori DC (2020) Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2
4044,Status report on COVID-19 vaccines development. Curr Infect Dis Rep
4045,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges
4046,Next generation vaccine platform: polymersomes as stable nanocarriers for a highly immunogenic and durable SARS-CoV-2 spike protein subunit vaccine
4047,Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against middle east respiratory syndrome coronavirus challenge
4048,How could a COVID vaccine cause blood clots? Scientists race to investigate
4049,Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
4050,SARS-CoV-2 and viral sepsis: observations and hypotheses
4051,Pseudo-anaphylactic reactions to pfizer bnt162b2 vaccine: report of 3 cases of anaphylaxis post pfizer bnt162b2 vaccination
4052,Vaccines against COVID-19
4053,Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
4054,Epitopes for a 2019-nCoV vaccine
4055,Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses
4056,Updated recommendations from the advisory committee on immunization practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients-United States
4057,"AstraZeneca vaccine: blood clots are ""extremely rare"" and benefits outweigh risks, regulators conclude"
4058,Epidemiological impact of SARS-CoV-2 vaccination: mathematical modeling analyses
4059,India's DNA COVID vaccine is a world firstmore are coming
4060,Cationic liposome-mediated RNA transfection
4061,Skeletal muscle cells: from local inflammatory response to active immunity
4062,Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices-United States
4063,Vaccines for emerging infectious diseases: lessons from MERS coronavirus and Zika virus
4064,"COVID-19 vaccine causing Guillain-Barre syndrome, a rare potential side effect"
4065,Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
4066,Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: a case report
4067,Unilateral axillary adenopathy in the setting of COVID-19 vaccine
4068,"SARS-CoV-2, from its current highly contagious spreading toward the global development of an effective and safe vaccine: challenges and uncertainties"
4069,Live attenuated vaccines: historical successes and current challenges
4070,Vaccine-induced immune thrombotic thrombocytopenia after vaccination against Covid-19: a clinical dilemma for clinicians and patients
4071,Cross-reactive neutralizing antibody responses elicited by SARS-CoV-2 501Y. V2 (B.1.351)
4072,Lipid nanoparticle formulation increases efficiency of DNA-vectored vaccines/immunoprophylaxis in animals including transchromosomic bovines
4073,Nanotechnology shows promise for nextgeneration vaccines in the fight against COVID-19
4074,Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: Interim report. medRxiv (p. 2020.06.30
4075,Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncologic patients
4076,Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
4077,mRNA vaccinesa new era in vaccinology
4078,Non-viral COVID-19 vaccine delivery systems
4079,Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection
4080,"COVID-19 vaccine anaphylaxis : IgE, complement or what else ? A reply to"
4081,"Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection"
4082,Phase I/II study of intracutaneous inoculation of COVID-19 DNA vaccine (AG0302-COVID19)
4083,Phase II/III Study of COVID-19 DNA Vaccine (AG0302-COVID19)-Full Text View-ClinicalTrials.gov
4084,Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization
4085,Single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice
4086,Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses
4087,A peptide-based subunit candidate vaccine against SARS-CoV-2 delivered by biodegradable mesoporous silica nanoparticles induced high humoral and cellular immunity in mice
4088,Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2
4089,Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein
4090,Functional SARS-CoV-2-specific immune memory persists after mild COVID-19
4091,Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination
4092,Safety and efficacy of single-dose Ad26COV2S vaccine against covid-19
4093,DNA and mRNA vaccination against allergies
4094,ANCA glomerulonephritis after the Moderna COVID-19 vaccination
4095,Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioN-Tech mRNA COVID-19 vaccine
4096,An overview of vaccine development for COVID-19
4097,ANCA-associated vasculitis following pfizer-BioNTech COVID-19 vaccine
4098,COVID-19 vaccination in developing nations: challenges and opportunities for innovation
4099,A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
4100,Allergic reactions including anaphylaxis after receipt of the first dose of moderna COVID-19 vaccine-United States
4101,Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine-United States
4102,COVID-19 vaccine development and a potential nanomaterial path forward
4103,Generation of influenza A viruses as live but replication-incompetent virus vaccines
4104,Cerebral vein thrombosis with vaccine-induced immune thrombotic thrombocytopenia
4105,The clinical development process for a novel preventive vaccine: an overview
4106,Sinovac says its Covid-19 vaccine generated immune responses-STAT
4107,Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine
4108,Orofacial adverse effects of COVID-19 vaccines exist but are rare
4109,The biological characteristics of SARS-CoV-2 spike protein Pro330-Leu650
4110,A novel concept for treatment and vaccination against Covid-19 with an inhaled chitosan-coated DNA vaccine encoding a secreted spike protein portion
4111,Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform
4112,Emerging vaccine delivery systems for COVID-19: functionalised silica nanoparticles offer a potentially safe and effective alternative delivery system for DNA/RNA vaccines and may be useful in the hunt for a COVID-19 vaccine
4113,Varicella zoster virus reactivation following COVID-19 vaccination: a systematic review of case reports
4114,COVID-19: learning from lessons to guide treatment and prevention interventions
4115,"The current and future state of vaccines, antivirals and gene therapies against emerging coronaviruses"
4116,"SARS-CoV-2/ COVID-19: viral genomics, epidemiology, vaccines, and therapeutic interventions"
4117,Understanding Viral Vector COVID-19 Vaccines|CDC
4118,Engineering attenuated virus vaccines by controlling replication fidelity
4119,Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men
4120,Neurological complications of COVID-19: guillain-barre syndrome following pfizer COVID-19 vaccine
4121,Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
4122,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2
4123,"Veesler D (2020b) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein"
4124,RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study
4125,Longitudinal dynamics of the neutralizing antibody response to severe acute respiratory syndrome coronavirus
4126,Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome
4127,Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
4128,Neutrilizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patients cohort and their implications
4129,"Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product"
4130,An infectious cDNA clone of SARS-CoV-2
4131,Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
4132,Childhood vaccination: implications for global and domestic public health
4133,Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan
4134,Wilson IA (2020) A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
4135,Leveraging mRNA sequences and nanoparticles to deliver SARS-CoV-2 antigens in vivo
4136,Recent advances in the development of vaccines for chronic inflammatory autoimmune diseases
4137,Progress and prospects on vaccine development against sars-cov-2
4138,"Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, doubleblind, and placebo-controlled phase 2 clinical trial"
4139,Assessment of the immune responses to Treponema pallidum Gpd DNA vaccine adjuvanted with IL-2 and chitosan nanoparticles before and after Treponema pallidum challenge in rabbits
4140,A novel liposome-polymer hybrid nanoparticles delivering a multi-epitope self-replication DNA vaccine and its preliminary immune evaluation in experimental animals
4141,Single-cell RNAseq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection
4142,COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data
4143,"Vaccine Development, Testing, and Regulation | History of Vaccines"
4144,The SARS-CoV-2 spike glycoprotein as a drug and vaccine target: structural insights into its complexes with ACE2 and antibodies
4145,Safety and efficacy of single-dose Ad2.6COV2.S vaccine against COVID-19
4146,Safety and efficacy of NVX-CoV2373 Covid-19 vaccine
4147,"Molecular sciences mRNA vaccine era-mechanisms, drug platform and clinical prospection"
4148,"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy"
4149,Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: A randomized clinical trial
4150,Efficacy and safety of COVID-19 vaccines in phase III trials: a meta-analysis
4151,Network meta-analysis: an introduction for clinicians
4152,Factors influencing the efficacy of COVID-19 vaccines: a quantitative synthesis of phase III trials
4153,Systematic reviews and meta-analyses CHECK LIST: The PRISMA statement
4154,Rayyan-a web and mobile app for systematic reviews
4155,The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
4156,The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations
4157,"Systematic review, meta-analysis, and network meta-analysis of the cardiovascular safety of macrolides"
4158,Fluoroquinolones and cardiovascular risk: a systematic review Meta-analysis and Network Meta-analysis
4159,Selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) during pregnancy and the risk for autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in the offspring: A true effect o
4160,"Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis"
4161,Ranking treatments in frequentist network meta-analysis works without resampling methods
4162,Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses
4163,Janssen Vaccines & Prevention B.V. A Study of Ad26.COV2.S in Adults
4164,Novavax COVID-19 Vaccine Demonstrates 89 . 3 % Efficacy in UK Phase 3 Trial
4165,Vaccines and Related Biological Products Advisory Committee
4166,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. www. thela ncet"
4167,Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
4168,mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants
4169,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE
4170,COVID-19) Dashboard with Vaccination Data
4171,Outcomes of COVID-19 in patients with rheumatoid arthritis: a multicenter research network study in the United States. InSeminars in Arthritis and Rheumatism
4172,Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
4173,"Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. Rmd Open"
4174,Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases
4175,Lb0003 Immunogenicity and Safety of the BNT162B2 mRNA Covid-19 Vaccine in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases and General Population: a Multicenter Study
4176,"Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis"
4177,Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis
4178,The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
4179,Optimal time between the last methotrexate administration and seasonal influenza vaccination in rheumatoid arthritis: post hoc analysis of a randomised clinical trial
4180,Effect of short-term methotrexate discontinuation on rheumatoid arthritis disease activity: post-hoc analysis of two randomized trials
4181,American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3. Arthritis Rheumatol
4182,rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
4183,The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis
4184,"Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate"
4185,Predictors of disease flare after discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab
4186,Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry
4187,Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study
4188,"Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomized controlled, non-inferiority trial"
4189,A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection
4190,Draft Guidelines for Adverse Event Reporting and Learning Systems
4191,Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice
4192,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil
4193,2021. 2. WHO. Draft Landscape and Tracker of COVID-19 Candidate Vaccines
4194,Efficacy and SAFETY of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study
4195,CoV-2 Variant Classifications and Definitions
4196,Lineage Assignment in An Emerging Pandemic as An Epidemiological Tool
4197,COVID-19 Vaccine Breakthrough Infections Reported to CDC-United States
4198,"Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice"
4199,BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT
4200,"MAFFT online service: Multiple sequence alignment, interactive sequence choice and visualization"
4201,Laboratory findings of COVID-19: A systematic review and meta-analysis. Scand
4202,"Clinical presentations, laboratory and radiological findings, and treatments for 11,028 COVID-19 patients: A systematic review and meta-analysis"
4203,the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak
4204,who-director-general-s-opening-remarks-at-the-media-briefing-on-covid
4205,Informativo da Sociedade Brasileira de Infectologia: Primeiro Caso Confirmado de Doença Pelo Novo Coronavírus (COVID-19) No Brasil-26/02/2020. Soc. Bras. Infectol. Sao Paulo Brasil 2020
4206,Explosion in mortality in the Amazonian epicenter of the COVID-19 epidemic 19. Cad
4207,Have deaths from COVID-19 in Europe plateaued due to herd immunity?
4208,Genomic Characterisation of an Emergent SARS-CoV-2 Lineage in Manaus: Preliminary Findings
4209,"Ministério da Saúde: Brazilia, Brazil"
4210,Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding
4211,Spike mutation D614G alters SARS-CoV-2 fitness
4212,SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies
4213,Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: Matched cohort study
4214,Plano Nacional da Operacionalização da Vacinação Contra a COVID-19
4215,A systematic review of SARS-CoV-2 vaccine candidates
4216,A cross-country database of COVID-19 testing
4217,"Characterisation of the first 250,000 hospital admissions for COVID-19 in Brazil: A retrospective analysis of nationwide data"
4218,Did pangolins spread the China coronavirus to people? Nature 2020
4219,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster
4220,World Health Organization Draft Landscape of COVID-19 Candidate Vaccines
4221,The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines
4222,COVID-19 vaccine: Where are we now and where should we go?
4223,Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for COVİD-19
4224,Five things to know about: Mixing and Matching Coronavirus Vaccines
4225,Oxford Vaccine Group COM-COV Comparing COVID-19 Vaccine Schedule Combinations
4226,Southampton University COV-BOOST Evaluating COVID-19 Vaccine Boosters
4227,BioNTech Product Monograph including Patient Medication Information Comirnaty(R) COVID-19 Vaccine
4228,Diagnostic Snibe MAGLUMI 2019-nCoV IgM/IgG Immunoassay 2020
4229,Snibe Diagnostic Fact Sheet for Healthcare Providers-MAGLUMI 2019-nCoV IgM/IgG 2020
4230,COVID-19) Emergency Use Authorizations for Medical Devices; Food and Drug Administration
4231,Heterologous prime-boost COVID-19 vaccination: Initial reactogenicity data
4232,R-Pharm) Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19
4233,"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): A multicentre, open-label, randomised, controlled, phase 2 trial"
4234,"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1-nCoV19 and BNT162b2: A prospective cohort study. medRxiv 2021"
4235,Mixing COVID-19 Vaccines Appears to Boostİmmune Responses
4236,Outbreak of SARS-CoV-2 B.1.617.2 (Delta) variant ınfections among ıncarcerated persons in a federal prison-Texas
4237,Breakthrough ınfections of SARS-CoV-2 gamma variant in fully vaccinated gold miners
4238,"COVID-19-associated hospitalizations mong vaccinated and unvaccinated adults ≥18 years -COVID2 NET, 13 states"
4239,Vaccination reduces need for emergency care in breakthrough COVID-19 infections: A multicenter cohort study
4240,Prevention and attenuation of COVİD-19 with the BNT162b2 and mRNA-1273 Vaccines
4241,Royal College of Physicians. National Early Warning Score (NEWS) 2. 2021. Available online
4242,World Health Organization. WHO R&D Blueprint Novel Coronavirus COVID-19 Therapeutic Trial Synopsis
4243,BNT162b2 vaccine breakthrough: Clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel
4244,Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
4245,COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): A prospective cohort study
4246,Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity
4247,Clinical outcomes in vaccinated individuals hospitalized with Delta variant of SARS-CoV-2
4248,Clinical characteristics of hospitalized COVID-19 patients who received at least one dose of COVID-19 vaccine
4249,Virological and serological kinetics of 1 SARS-CoV-2 Delta variant vaccine breakthrough infections: A multi-center cohort study
4250,"Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections"
4251,The overlooked superpower of mRNA vaccines
4252,Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents and healthcare workers-A Danish cohort study
4253,Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2
4254,Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants
4255,Waning ımmune humoral response to BNT162b2 COVİD-19 vaccine over 6 months
4256,Correlation of SARS-CoV-2 breakthrough infections to time-from-vaccine; preliminary study
4257,Waning of BNT162b2 vaccine protection against SARS-CoV-2 ınfection in Qatar
4258,Prediction of long-term kinetics of vaccine-elicitedneutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint
4259,SARS-CoV-2 infection in fully vaccinated individuals of old age strongly boosters the humoral immune response
4260,Vaccine breakthrough ınfections with SARS-CoV-2 variants
4261,Anti-SARS-CoV-2 antibody levels measured by the AdviseDx SARS-CoV-2 assay are concordant with previously available serologic assays but are not fully predictive of sterilizing ımmunity
4262,SARS-CoV-2 breakthrough infections in fully vaccinated individuals
4263,Virological characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers
4264,COVİD-19 breakthrough ınfections in vaccinated health care workers
4265,Vaccinated and unvaccinated individuals have similar viral loads in communities with a high prevalence of the SARS-CoV-2 delta variant
4266,"No significant difference in viral load between vaccinated and unvaccinated, asymptomatic and symptomatic groups ınfected with SARS-CoV-2 delta variant"
4267,The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency
4268,Effectiveness of an ınactivated SARS-CoV-2 vaccine in Chile
4269,Effectiveness of an ınactivated SARS-CoV-2 vaccine
4270,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus
4271,Risk of adverse outcomes in hospitalized patients with autoimmune disease and COVID-19: a matched cohort study from New York City
4272,A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center
4273,SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study
4274,Leveraging the United States Epicenter to provide insights on COVID-19 in patients with systemic lupus erythematosus
4275,Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy?
4276,Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
4277,Evaluation of Immune Response and Disease Status in SLE Patients Following SARS-CoV-2 Vaccination
4278,Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support
4279,The REDCap consortium: building an international community of software platform partners
4280,Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus
4281,World Health Organization. WHO Draft Guidelines for Adverse Event Reporting and Learning Systems
4282,Systemic lupus erythematosus disease activity index
4283,The development and initial validation of the systemic lupus international collaborating clinics/American College of Rheumatology damage index for systemic lupus erythematosus
4284,SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease
4285,Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort
4286,Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination
4287,One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19
4288,Dynamics of inactivated SARS-CoV-2 vaccine antibody response in SARS-CoV-2-seropositive autoimmune rheumatic disease patients
4289,"Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers"
4290,The immunogenicity and safety of different COVID-19 booster vaccination following 1
4291,"*The post primary series GMC was derived from the study in the same setting as the current study 620 (Reference: Angkasekwinai, N. et al. Safety and Immunogenicity of CoronaVac and ChAdOx1 Against 621 the SARS-CoV-2 Circulating Variants of Concern"
4292,The post primary series GMC 623 (95% CI) at 2 weeks after the second dose of the 2-dose homologous CoronaVac
4293,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population
4294,Ethics and execution of developing a 2nd wave COVID vaccine-Our interim phase I/II VSV-SARS-CoV2 vaccine experience
4295,COVID-19 vaccine trial ethics once we have efficacious vaccines
4296,Threat assessment brief: emergence of SARS CoV 2 B. 1.617 variants in India and situation in the EU/EEA
4297,Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis
4298,"Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 -COVID-NET, 14 states"
4299,"BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers"
4300,Declining levels of neutralizing antibodies against SARS-CoV-2 in convalescent COVID-19 patients one year post symptom onset
4301,"SARS-CoV-2 neutralizing antibodies: longevity, breadth, and evasion by emerging viral variants"
4302,Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants
4303,Strategies for vaccine prioritization and mass dispensing
4304,"Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial"
4305,Antiviral effect of high-dose ivermectin in adults with COVID-19: a proof-of-concept randomized trial
4306,Intradermal vaccination: a potential tool in the battle against the COVID-19 pandemic? Risk Manag
4307,Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination -A systematic review and meta-analysis
4308,Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A
4309,Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model
4310,Protective CD8(+) T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
4311,Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector
4312,COVID-19 vaccine dose sparing: strategies to improve vaccine equity and pandemic preparedness
4313,T cell response to SARS-CoV-2 infection in humans: a systematic review
4314,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebocontrolled, phase 3 trial in Turkey"
4315,"Ministry of Public Health, a goverment organization. The Coronavirus disease 2019 situation"
4316,Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity
4317,The race to a COVID-19 vaccine: opportunities and challenges in development and distribution
4318,"Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India"
4319,Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label
4320,Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine
4321,Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen
4322,Mechanisms of innate events during skin reaction following intradermal injection of seasonal influenza vaccine
4323,Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus
4324,Skin infection generates non-migratory memory CD8+ T(RM) cells providing global skin immunity
4325,Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine: preclinical studies
4326,Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
4327,SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
4328,T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
4329,Identification and evaluation of novel protective antigens for the development of a candidate TB subunit vaccine
4330,Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission
4331,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques"
4332,"5′-TCGTTTCGGAAGAGA-CAGGT-3′; reverse primer, 5′-GCGCAGTAAGGATGGCTAGT-3′. gradient centrifugation, and peripheral blood mononuclear cells (PBMCs) were isolated using conventional Ficoll-Hypaque density-gradient centrifugation (GE Healthcare"
4333,"Hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC) microscope. For IHC staining, to identify the expression of SARS-CoV-2 S protein"
4334,dehydrated paraffin sections (3-4 µm in thickness) were treated with an antigen retrieval kit
4335,"After blocking in 1% normal goat serum for 1 h at 37°C, the sections were stained with anti-SARS-CoV-2 rabbit monoclonal antibody at 4°C overnight, followed by incubation with a horseradish peroxidase HRP-labeled goat anti-rabbit IgG secondary antibody (ZDR-5306, 1:200; ZSGB Bio) for 1 h at 37°C. Finally, the sections were visualized by incubation with 3,3′-diaminobenzidine tetrahydrochloride (DAB) and viewed carefully by an Olympus microscope. CT Macaques were anesthetized with 2% isoflurane. CT imaging was conducted by using an IRIS XL-260 CT scanner"
4336,Infection with the SARS-CoV-2 delta variant is associated with higher infectious virus loads compared to the alpha variant in both unvaccinated and vaccinated individuals
4337,Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
4338,Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron
4339,Analysis of the delta variant B.1.617.2 COVID-19
4340,mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant
4341,Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants
4342,"A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2"
4343,Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: Sequential immunizations confer cross-protection against variants of
4344,"two randomised, double-blind, placebo-controlled, phase 1 and 2 trials"
4345,Transcriptome-wide off-target effects of steric-blocking oligonucleotides
4346,Heavily mutated Omicron variant puts scientists on alert
4347,Relative instantaneous reproduction number of Omicron SARS-CoV-2 variant with respect to the Delta variant in Denmark
4348,micron extensively but incompletely escapes Pfizer BNT162b2 neutralization
4349,Culture and identification of a Deltamicron SARS-CoV-2 in a three cases cluster in southern France
4350,The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
4351,Primary exposure to SARS-CoV-2 protects against reinfection in Rhesus macaques
4352,Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in Rhesus macaques
4353,"which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder"
4354,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci
4355,Infective endocarditis in adults
4356,Acute pericarditis
4357,"Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study"
4358,Myocarditis and inflammatory cardiomyopathy: current evidence and future directions
4359,Symptomatic acute myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination
4360,Myocarditis following COVID-19 mRNA vaccination
4361,"Myocarditis following mRNA vaccination against SARS-CoV-2, a case series"
4362,Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military
4363,C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
4364,Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel
4365,Myocarditis with COVID-19 mRNA vaccines
4366,Approval letter-Comirnaty. Accessed atwww.fda.gov/media/151710/download on 10
4367,"Association between treatment with apixaban, dabigatran, rivaroxaban, or warfarin and risk for osteoporotic fractures among patients with atrial fibrillation: ORIGINAL RESEARCH"
4368,Carditis Risk After Messenger RNA and Inactivated Virus Vaccination a population-based cohort study
4369,EMA commissions independent research to prepare for real-world monitoring of COVID-19 vaccines
4370,Myocarditis/pericarditis case definition
4371,The Government of the Hong Kong Special Administrative Region. Hong Kong vaccination dashboard
4372,Analysis of matched case-control studies
4373,Unconditional or Conditional logistic regression model for age-matched case-control data. Front Public Health
4374,"C4591001 Clinical Trial Group. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents"
4375,"CombiVacS Study Group. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, openlabel, randomised, controlled, phase 2 trial"
4376,Association of myocarditis with BNT162b2 messenger RNA COVID-19 vaccine in a case series of children
4377,Gender differences in myocarditis: a nationwide study in Finland
4378,Association between COVID-19 and myocarditis using hospital-based administrative data -United States
4379,Characterising the background incidence rates of adverse events of special interest for Covid-19 vaccines in eight countries: multinational network cohort study
4380,Intravenous injection of COVID-19 mRNA vaccine can induce acute myopericarditis in mouse model
4381,Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study
4382,Critical revision of the article for important intellectual content
4383,Collection and assembly of data
4384,Clinical Outcomes in Hospitalized Vaccine-Breakthrough Coronavirus Disease 2019 Cases Compared With Contemporary Unvaccinated Hospitalized Adults
4385,COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
4386,Chilean Ministry of Health. Daily official report
4387,Effectiveness of the SARS-CoV-2 vaccine program
4388,"Monitoring incidence of COVID-19 cases, and deaths, by vaccination status 13 US jurisdictions"
4389,World Health Organization. WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations
4390,Effectiveness of homologous and heterologous booster shots for an inactivated SARS-CoV-2 vaccine: a large-scale observational study. SSRN [Preprint
4391,63rd ASH Annual Meeting Abstracts ONLINE PUBLICATION ONLY 632.CHRONIC MYELOID LEUKEMIA: CLINICAL AND EPIDEMIOLOGICAL A Survey Conducted during COVID-19 Pandemic Among Brazilian Chronic Myeloid Leukemia and Philadelphia-Negative Myeloproliferative Neoplasms Patients
4392,"COVID-19 incidence was higher in the CML than in the MPN population, probably because MPN patients were less exposed, and the older pts were the rst to receive vaccines"
4393,"Pagnano: Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Astellas: Membership on an entity's Board of Directors or advisory committees"
4394,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile
4395,World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2022
4396,Association between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women
4397,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled"
4398,Evaluation of mRNA-1273 SARS-CoV-2
4399,Vaccine in Adolescents
4400,Evaluation of the BNT162b2
4401,Covid-19 Vaccine in Children 5 to 11 Years of Age
4402,Clinical and epidemiological features of 36 children
4403,China: an observational cohort study
4404,Report: Case Series of Children With Multisystem Inflammatory Syndrome Following SARS-CoV-2
4405,"Clinical validation of the Siemens All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers"
4406,Improvements and limits of anti SARS-CoV-2 antibodies assays by WHO (NIBSC 20/136) standardization
4407,Impact of SARS-CoV-2 variants on the
4408,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study"
4409,The Covid-19 world-Are we there yet?
4410,Characterization of the Second Wave of COVID-19 in India
4411,SARS-CoV-2 variants of concern and variants under investigation in England-Technical briefing 17
4412,"Population Movement, City Closure in Wuhan, and Geographical Expansion of the COVID-19 Infection in China in"
4413,Countries of origin of imported COVID-19 cases into China and measures to prevent onward transmission
4414,Guangzhou Municipal Health Commission. COVID-19 situation update in Guangzhou on 21
4415,US Centers for Disease Control and Prevention. Delta Variant: What We Know About the Science
4416,Suspending social vaccination against COVID-19 and concentrating on case findings
4417,National Health Commission of the People's Republic of China. Diagnosis and treatment protocols of pneumonia caused by a novel coronavirus (trial version 8)
4418,Transmission dynamics and control of two epidemic waves of SARS-CoV-2 in South Korea
4419,Serial Interval of COVID-19 among Publicly Reported Confirmed Cases
4420,A new framework and software to estimate time-varying reproduction numbers during epidemics
4421,How generation intervals shape the relationship between growth rates and reproductive numbers
4422,Serial interval of SARS-CoV-2 was shortened over time by nonpharmaceutical interventions
4423,Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta-analysis
4424,The incubation period distribution of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis
4425,International Expansion of a Novel SARS-CoV-2 Mutant
4426,Does incubation period of COVID-19 vary with age? A study of epidemiologically linked cases in Singapore
4427,Forward-looking serial intervals correctly link epidemic growth to reproduction numbers
4428,Alternative methods of estimating an incubation distribution: examples from severe acute respiratory syndrome
4429,"Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study"
4430,Transmission dynamics and epidemiological characteristics of Delta variant infections in China
4431,The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application
4432,Increased household transmission of COVID-19 cases associated with SARS-CoV-2 Variant of Concern B.1.617.2: a national case-control study
4433,SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 14
4434,Serial interval of novel coronavirus (COVID-19) infections
4435,"Transmission dynamics of the delta variant of SARS-CoV-2 infections in Daejeon, South Korea"
4436,Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom
4437,Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
4438,Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study
4439,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings"
4440,BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel
4441,"Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study"
4442,Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong
4443,COVID-19 Outbreak Associated with Air Conditioning in Restaurant
4444,Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine 1
4445,Correlates of protection against symptomatic and 185 asymptomatic SARS-CoV-2 infection
4446,Longer intervals and extra doses of ChAdOx1 188 nCoV-19 vaccine
4447,"SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, 192 placebo-controlled, phase 1/2 clinical trial"
4448,Effectiveness of an Inactivated SARS-CoV-2 196
4449,IgA dominates the early neutralizing antibody 199 response to SARS-CoV-2
4450,Role of Immunoglobulin M and A Antibodies in the 202
4451,Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2
4452,Enhanced SARS-CoV-2 neutralization by 205 dimeric IgA
4453,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for"
4454,SARS-CoV-2 vaccines: a triumph of science and collaboration
4455,"A review of novel coronavirus disease ( COVID -19 ): based on genomic structure , phylogeny , current shreds of evidence , candidate vaccines , and drug repurposing"
4456,SARS-CoV-2 vaccines: Lights and shadows
4457,Biochemical characterization of SARS-CoV-2 nucleocapsid protein
4458,Evaluation of the performance of SARS-CoV--2 antibody assays for the longitudinal population-based study of COVID-19 spread in
4459,Single-domain antibodies make a difference. Science (80-)
4460,SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses
4461,Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay
4462,Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay
4463,Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: Comparison with neutralization titers
4464,Immunity to SARS-CoV-2: Lessons Learned. Front Immunol
4465,The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development
4466,Coronavirus disease (COVID-19) advice for the public
4467,"Local Transmission of SARS-CoV-2 Lineage B.1.1.7, Brazil"
4468,Emergence and rapid spread of a new severe acute respiratory syndromerelated coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa
4469,Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. medRxiv
4470,Suppression of normal immune responses after treatment with rituximab
4471,Quadrivalent inactivated influenza vaccine (VaxigripTetra™)
4472,"Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers"
4473,The Effects of Heterologous Immunization with Prime-Boost
4474,Vaccination against SARS-CoV-2. Vaccines
4475,SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following twodose CoronaVac vaccine regimen
4476,"Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern, Emerging Microbes & Infections"
4477,Negligible impact of SARS-CoV-2 variants on CD4 + and CD8 + T cell reactivity in COVID-19 exposed donors and vaccinees
4478,Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid
4479,Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary report
4480,Autorização de Uso Emergencial de Vacinas contra a COVID-19
4481,A Primer on Effectiveness and Efficacy Trials
4482,Dados abertos. Registro de casos e óbitos por município e data de notificação no Estado de São Paulo
4483,Adesão ao isolamento social em SP. Available at: synthesized across a multi-state health system
4484,Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS
4485,13-Aran D. Estimating real-world COVID-19 vaccine effectiveness in Israel
4486,"Science in 5. Episode #31-Vaccines, variants & doses"
4487,Covid-19 deaths in Africa: prospective systematic postmortem surveillance study
4488,Tracking excess deaths associated with the COVID-19 epidemic as an epidemiological surveillance strategy-preliminary results of the evaluation of six Brazilian capitals
4489,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination"
4490,Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine
4491,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil. Vaccines (Basel)
4492,"The impact of Vaccination worldwide on SARS-CoV-2 infection: A Review on Vaccine Mechanisms, Results of Clinical Trials, Vaccinal Coverage and Interactions with Novel Variants"
4493,Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection. Vaccine
4494,Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
4495,Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials
4496,Risk Factors of Healthcare Workers With Coronavirus Disease 2019: A Retrospective Cohort Study in a Designated Hospital of Wuhan in China
4497,SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines. Vaccines (Basel)
4498,Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14
4499,Months After SARS-CoV-2 Infection. Front Immunol
4500,"Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2"
4501,The COVID-19 pandemic: major risks to healthcare and other workers on the front line
4502,"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein"
4503,Vaccination drive against coronavirus begins with health care workers in Turkey
4504,COVID-19 Vaccine National Implementation Strategy
4505,COVID-19 (SARS-CoV-2 INFECTION) LABORATORY BIOSAFETY GUIDE
4506,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines
4507,Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2
4508,"Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: An ecological study"
4509,CMMID COVID-19 Working Group
4510,Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature
4511,"Local Transmission of SARS-CoV-2 Lineage, B.1.1.7, Brazil"
4512,"Epidemic Spread of SARS-CoV-2 Lineage, B.1.1.7 in Brazil"
4513,Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
4514,COVID-19: Medical community split over vaccine interval policy as WHO recommends six weeks
4515,Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2
4516,Hospitalisation among vaccine breakthrough COVID-19 infections
4517,Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine
4518,Post-vaccination COVID-19: A case-control study and genomic analysis of 119 breakthrough infections in partially vaccinated individuals
4519,Accurate spliced alignment of long RNA sequencing reads
4520,Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools
4521,Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool
4522,MAFFT multiple sequence alignment software version 7: Improvements in performance and usability
4523,IQ-TREE: A fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies
4524,Fast model selection for accurate phylogenetic estimates
4525,RDP4: Detection and analysis of recombination patterns in virus genomes
4526,Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in
4527,AdviseDx SARS-CoV-2 IgG II
4528,Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs
4529,"Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: An observational cohort study"
4530,Connecting clusters of COVID-19: An epidemiological and serological investigation
4531,Temporal spread and evolution of SARS-CoV-2 in the second pandemic wave in Brazil
4532,Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy
4533,SARS-CoV-2 outbreak in a long-term care facility after vaccination with BNT162b2
4534,"Spike-antibody responses following first and second doses of ChAdOx1 and BNT162b2 vaccines by age, gender, and clinical factors-A prospective community cohort study (Virus Watch)"
4535,"Features, Evaluation, and Treatment of Coronavirus (COVID-19). In StatPearls"
4536,Determine the most common clinical symptoms in COVID-19 patients: A systematic review and meta-analysis
4537,Current and innovative methods for the diagnosis of COVID 19 infection (Review)
4538,World Health Organization. COVID-19 Weekly Epidemiological Update-Edition 64
4539,World Health Organization. COVID-19 Vaccine Tracker and Landscape
4540,Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
4541,Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
4542,World Health Organization. Considerations for Evaluation of COVID-19 Vaccines
4543,Looking beyond COVID-19 vaccine phase 3 trials
4544,Effectiveness of COVID-19 vaccines against the B. 1.617. 2 (delta) variant
4545,COVID-19 Vaccine Tracker. Sinovac: CoronaVac. Available online
4546,World Health Organization. Evidence Assessment: Sinovac/CoronaVac COVID-19 Vaccine
4547,Open data on Malaysia's National COVID-19 Immunisation Programme
4548,COVID-19 Situation Report for the Western Pacific Region #70: 8-14
4549,Kenyataan Media Pejabat Perdana Menteri
4550,The Special Committee for Ensuring Access to COVID-19 Vaccine
4551,Open Data on the COVID-19 Epidemic in Malaysia
4552,"Sirotkin, B. Field evaluation of vaccine efficacy"
4553,Estimating rotavirus vaccine effectiveness in Japan using a screening method
4554,An assessment of the screening method to evaluate vaccine effectiveness: The case of 7-valent pneumococcal conjugate vaccine in the United States
4555,Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany
4556,Confounding by indication in non-experimental evaluation of vaccine effectiveness: The example of prevention of influenza complications
4557,Government of Chile. Effectiveness of the SARS-CoV-2 Vaccination Program
4558,Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at
4559,World Health Organization. Tracking SARS-CoV-2 Variants
4560,"COVID-19 Epidemic in Malaysia: Epidemic Progression, Challenges, and Response. Front. Public Health"
4561,Malaysia's third COVID-19 wave-a paradigm shift required
4562,World Health Organization. COVID-19 in Malaysia Situation Report 45
4563,Institute for Public Health (IPH); National Institutes of Health; Ministry of Health Malaysia
4564,Evidence Used to Update the List of Underlying Medical Conditions that Increase a Person's Risk of Severe Illness from COVID-19
4565,National Pharmaceutical Regulatory Agency (NPRA); Ministry of Health Malaysia. Frequently Asked Questions (FAQ) about COVID-19 Vaccine
4566,A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker)
4567,Three SARS-CoV-2 reinfection cases by the new Variant of Concern (VOC) P.1/501Y.V3. In Review
4568,COVID-19 data in Brazil
4569,Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
4570,Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. Infectious Diseases (except HIV/AIDS)
4571,Summary of Clinical Trial Data of Sinovac's COVID-19 Vaccine (CoronaVac®)-SINOVAC -Supply Vaccines to Eliminate Human Diseases
4572,Fundação de Vigilância em Saúde do Amazonas. BOLETIM DIÁRIO COVID-19 NO AMAZONAS
4573,Brazilian Ministry of Health. Definition of COVID-19 cases and recommendations for COVID-19
4574,Sinovac Announces Phase III Results of Its COVID-19 Vaccine-SINOVAC -Supply Vaccines to Eliminate Human Diseases
4575,Erythema multiforme after CoronaVac vaccination
4576,"Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist"
4577,"Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination"
4578,Cutaneous adverse reactions after m-RNA COVID-19 vaccine: early reports from Northeast Italy
4579,Prompt onset of Rowell's syndrome following the first BNT162b2 SARS-CoV-2 vaccination
4580,Vaccine allergies
4581,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19
4582,Herd immunity: understanding COVID-19
4583,Herd immunity or suppression strategy to combat COVID-19
4584,Pandemic preparedness: developing vaccines and therapeutic antibodies for COVID-19
4585,The hallmarks of COVID-19 disease
4586,Bats as reservoirs of severe emerging infectious diseases
4587,"Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis"
4588,"The Mysterious Disappearance of the First SARS Virus, and Why we need a Vaccine for the Current One But Didn't for the Other"
4589,The reproductive number of COVID-19 is higher compared to SARS coronavirus
4590,Cells Found in COVID-19 Patients Bode Well for Long-Term Immunity
4591,Sentinel surveillance of SARS-CoV-2 in waste water anticipates the occurrence of COVID-19 cases. medRxiv
4592,"SARS-CoV-2 specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls"
4593,Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv
4594,Antibody testing for COVID-19: a report from the national COVID scientific advisory panel. medRxiv
4595,Immunology of COVID-19: current state of the science
4596,Twoyear prospective study of the humoral immune response of patients with severe acute respiratory syndrome
4597,Coronavirus vaccines leap through safety trials -but which will work is anybody's guess
4598,Clinical vaccine development
4599,Are genetic vaccines the right weapon against COVID-19?
4600,The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world
4601,Developing Covid-19 vaccines at pandemic speed
4602,Coronavirus Vaccine Tracker
4603,Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19
4604,COVID-19: learning from lessons to guide treatment and prevention interventions. mSphere
4605,SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
4606,An Infectious Disease Expert Explains The Results from Moderna's Latest Vaccine Trials
4607,"Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older"
4608,"Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older"
4609,Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report. medRxiv
4610,Studies at Pirbright Demonstrate Two Doses of Oxford University's COVID-19
4611,Vaccine Boosts Immune Response In Pigs
4612,"A phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers"
4613,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized control trial"
4614,Vaccine (ChAdOx1 nCoV-19) trial in South African Adults with and without HIV-Infection
4615,Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19
4616,A Phase III Study to Investigate a Vaccine Against COVID-19
4617,"Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19"
4618,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomized, first-in-human trial"
4619,"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 2 trial"
4620,CanSino's COVID-19 Vaccine Candidate Approved for Military use in China
4621,"Why One Vaccine is Already a Sure Loser, and also a Sure Winner, in the Race to Inoculate the World"
4622,Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes
4623,Placebo Parallel-Controlled Phase I/II Clinical Trial for Inactivated Novel Coronavirus Pneumonia Vaccine (Vero cells). (2020)
4624,Sinopharm Says Second Covid Vaccine Found to Be Safe
4625,Chinese COVID-19 Vaccine Candidate the First to Start Phase 3 Clinical Trials Worldwide
4626,Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy and Safety in Healthcare Professionals of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac
4627,Indonesia Testing Location for China's Sinovac Phase 3 Clinical Trial
4628,Sinovac Says Early Data Show its Covid-19 Vaccine Generated Immune Responses
4629,"Immunogenicity and Safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, double-blind, and placebo-controlled Phase 2 clinical trial. medRxiv"
4630,Available online at: https:// www.gatesfoundation.org/Media-Center/Press-Releases/2020/04/Gates-Foundation-Expands-Commitment-to-COVID-19-Response-Calls-for-International-Collaboration
4631,Fear Mounts Trump May Pressure FDA to Rush Covid-19 Vaccine by Election
4632,Don't rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees
4633,Russia's fast track coronavirus vaccine draws outrage over safety
4634,A review of Dengvaxia R : development to deployment
4635,COVID-19 human challenge studies: ethical issues
4636,"From Oxford to an Italian Lab, One Race for Coronavirus Vaccine is gaining Backers"
4637,Multivalue ethical framework for fair global allocation of a COVID-19 vaccine
4638,Epidemiological impact of SARS-CoV-2 vaccination: mathematical modeling analyses. medRxiv
4639,Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv
4640,The improbability of the rapid development of a vaccine for SARS-CoV-2
4641,Coronavirus Vaccine Developers Wary of Errant Antibodies
4642,US Anti-Vaxxers Aim to Spread Fear Over Future Coronavirus Vaccine
4643,Half of Americans would get a COVID-19 Vaccine
4644,Disruption of healthcare: Will the COVID pandemic worsen non-COVID outcomes and disease outbreaks?
4645,Ensuring uptake of vaccines against SARS-CoV-2
4646,Older Adults May Be Left Out Of Some COVID-19 Trials
4647,What you always needed to know about electroporation based DNA vaccines
4648,Global Vaccine Summit 2020
4649,Accelerating development of SARS-CoV-2 vaccines -the role for controlled human infection models
4650,Coronavirus disease pandemic (COVID-19): challenges and a global perspective
4651,WHO. WHO coronavirus disease (COVID-19) dashboard. 2021
4652,"Coronavirus infections in children including COVID-19: An overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children"
4653,European Centre for Disease Prevention and Control. Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children
4654,"Children and adolescents with SARS-CoV-2 Infection: epidemiology, clinical course and viral loads"
4655,COVID-19 in children and young people
4656,COVID-19 vaccine development: a pediatric perspective
4657,The importance of advancing SARS-CoV-2 vaccines in children
4658,Association of age with SARS-CoV-2 antibody response
4659,COVID-19 vaccines in children: research to guide your news coverage
4660,National Institutes of Health. Safety and immunogenicity study of inactivated vaccine for prevention of COVID-19
4661,Pfizer-Biontech announce positive topline results of pivotal COVID-19 vaccine study in adolescents
4662,Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv 2021
4663,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial"
4664,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial"
4665,"Safety and immunogenicity of a novel human enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, phase I clinical trial"
4666,Comparison of the effect of increased hepatitis B vaccine dosage on immunogenicity in healthy children and adults
4667,Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: an integrated analysis
4668,SARS-CoV-2-Specific T cell responses in patients with COVID-19 and unexposed individuals
4669,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant
4670,The biological and clinical significance of emerging SARS-CoV-2 variants
4671,SARS-CoV-2 variants and vaccines
4672,Omicron and Delta variant of SARS-CoV-2: a comparative computational study of spike protein
4673,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (Coron-aVac): interim results of a double-blind, randomised, placebocontrolled, phase 3 trial in Turkey"
4674,Effectiveness of COVID-19 vaccines over a 9-month period in North Carolina
4675,Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant
4676,Protection of BNT162b2 vaccine booster against COVID-19 in Israel
4677,Safety and efficacy of a third dose of BNT162b2 COVID-19 vaccine
4678,Homologous and heterologous COVID-19 booster vaccinations
4679,mRNAbased COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
4680,Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: evidence from Danish Households. medRxiv
4681,Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
4682,SARS-CoV-2 spreads through cell-to-cell transmission
4683,Assessment of infectivity and the impact on neutralizing activity of immune sera of the COVID-19 variant
4684,Molecular basis of receptor binding and antibody neutralization of Omicron
4685,Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity
4686,The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
4687,SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells
4688,Is there a link between the pathogenic human coronavirus envelope protein and immunopathology? A review of the literature
4689,Antibody evasion properties of SARS-CoV-2 Omicron sublineages
4690,"Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study"
4691,"Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study"
4692,"Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: a randomised, doubleblind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)"
4693,Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern
4694,Universal coronavirus vaccines-an urgent need
4695,Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study
4696,Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay
4697,"Title Safety and efficacy of two immunization schedules with an inactivated SARS- 2 CoV-2 vaccine in adults. A randomized non-inferiority clinical trial. Affiliations Hospital Félix Bulnes, Facultad de Medicina y Ciencia y Facultad de Ciencias para el Short running title: CoronaVac ® safety and efficacy in adults by two immunization"
4698,CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
4699,Development of an inactivated vaccine candidate for 484 SARS-CoV-2
4700,"Safety, tolerability, and immunogenicity of an 486 inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a 487 randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4701,"vaccine (CoronaVac) in healthy adults aged 60 years and older: a 491 randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4702,Sinovac's coronavirus vaccine candidate approved for emergency use in 494
4703,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1
4704,Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
4705,Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective
4706,Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients
4707,Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
4708,An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
4709,Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects
4710,Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
4711,SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron
4712,Immunosequencing and epitope mapping reveal substantial preservation of the T cell immune response to Omicron generated by SARS-CoV-2 vaccines. medRxiv
4713,SARS-CoV-2 T cell responses elicited by COVID-19 vaccines or infection are expected to remain robust against Omicron
4714,T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant
4715,T-cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals
4716,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans
4717,Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4+ T cells in COVID-19
4718,Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and variants of concern
4719,Vaccine booster efficiently inhibits entry of SARS-CoV-2 Omicron variant
4720,Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: a systematic review
4721,Transmission dynamics and mutational prevalence of the novel Severe acute respiratory syndrome coronavirus-2 Omicron variant of concern
4722,HLA common and well-documented alleles in China. HLA
4723,NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data
4724,Understanding T-cell responses to COVID-19 is essential for informing public health strategies
4725,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile
4726,COVID-19 Vaccine Surveillance Report-Week 41
4727,The impact of vaccination to control COVID-19 burden in the United States: a simulation modeling approach
4728,International Vaccine Access Center's. COVID-19 Vaccine Effectiveness Forest Plots
4729,Decreased infectivity following BNT162b2 vaccination: a prospective cohort study in Israel
4730,COVID-19 Vaccine Tracker
4731,Weekly Epidemiological Update on COVID-19 -31
4732,A cluster of the new SARS-CoV-2 B1621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine
4733,Neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine serum
4734,Analysis by real-time pcr of five transport and conservation medium of nasopharyngeal swab samples to covid-19 diagnosis in Santiago of Chile
4735,Coronavirus disease (covid-19) associated mucormycosis (CAM): case report and systematic review of literature
4736,Efficient SARS-CoV-2 detection in unextracted oro-nasopharyngeal specimens by rRT-PCR with the Seegene Allplex TM 2019-nCoV assay
4737,Effectiveness of covid-19 vaccines against the B16172 (Delta) variant
4738,SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against
4739,Arterial hypertension as a risk comorbidity associated with covid-19 pathology
4740,Identification of symptoms prognostic of COVID-19 severity: multivariate data analysis of a case series in Henan Province
4741,"Aging and the immune system: the impact of immunosenescence on viral infection, immunity and vaccine immunogenicity"
4742,SARS-CoV-2 vaccine breakthrough infections are asymptomatic or mildly symptomatic and are infrequently transmitted
4743,Vaccines: Correlates of vaccine-induced immunity
4744,Beyond binding: Antibody effector functions in infectious diseases
4745,SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2
4746,"The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry. bioRxiv"
4747,Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters. bioRxiv
4748,Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
4749,Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
4750,Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design
4751,Broadly neutralizing antiinfluenza antibodies require Fc receptor engagement for in vivo protection
4752,"Alter, A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus"
4753,Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant
4754,Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity
4755,Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality
4756,COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions
4757,"The Fcmediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody"
4758,"Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo"
4759,Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
4760,Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy
4761,IgG subclasses and allotypes: From structure to effector functions
4762,Mouse and human FcR effector functions
4763,CD107a as a functional marker for the identification of natural killer cell activity
4764,SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution
4765,T cell responses to SARS-CoV-2 spike crossrecognize Omicron
4766,Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: A data linkage study
4767,Severity of Omicron variant of concern and vaccine effectiveness against symptomatic disease: national cohort with nested test negative design study in Scotland
4768,"Beigel; mRNA-1273 Study Group, An mRNA Vaccine against SARS-CoV-2 -Preliminary Report"
4769,Distinct conformational states of SARS-CoV-2 spike protein
4770,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5
4771,Rapid epidemic expansion of the SARS-CoV-2
4772,Omicron variant in southern Africa
4773,"SARS-CoV-2 variants, spike mutations and 384 immune escape"
4774,Omicron escapes the majority of existing SARS-CoV-2 386 neutralizing antibodies
4775,Striking antibody evasion manifested by the Omicron 388 variant of SARS-CoV-2
4776,Increased risk of SARS-CoV-2 390 reinfection associated with emergence of Omicron in South Africa
4777,Omicron (BA. 1) and Sub-Variants (BA
4778,BA. 2 and BA. 3) of SARS-CoV-2 Spike Infectivity and Pathogenicity: A Comparative 394
4779,Sequence and Structural-based Computational Assessment
4780,Overview of Variants/Mutations
4781,Accessed 16
4782,Efficacy of Antibodies and Antiviral 399 Drugs against Covid-19 Omicron Variant
4783,Efficacy of Antiviral Agents against the 401
4784,Waning immune humoral response to BNT162b2
4785,Covid-19 vaccine over 6 months
4786,Neutralizing antibody levels are highly 405 predictive of immune protection from symptomatic SARS-CoV-2 infection
4787,Considerable escape of SARS-CoV-2 Omicron to 408 antibody neutralization
4788,Safety and immunogenicity of seven COVID-19 412 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or
4789,"BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, 414 phase 2 trial"
4790,Correlates of protection against SARS-CoV-2 in 416 rhesus macaques
4791,Antigen-specific adaptive immunity to
4792,SARS-CoV-2 in acute COVID-19 and associations with age and disease severity
4793,Divergent SARS CoV-2 Omicron-421
4794,reactive T-and B cell responses in COVID-19 vaccine recipients
4795,T cell responses to SARS-CoV-2 spike cross-424 recognize Omicron
4796,"Age in years (mean, IQR) in age between groups using one-way ANOVA. c represents the comparison in dosing 473 interval between groups using Kruskal-Wallis H test"
4797,The effectiveness of Vaxzevria and CoronaVac vaccines: A nationwide longitudinal retrospective study of 61 million Brazilians (VigiVac-COVID19). Short Title: Effectiveness of Vaxzevria and CoronaVac vaccines in Brazil
4798,The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States
4799,Tracking Coronavirus Vaccinations Around the World
4800,The New York Times
4801,Plano nacional de operacionalização da vacinação contra a covid-19: 9ª edição
4802,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
4803,"Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. medRxiv"
4804,CoVariants: SARS-CoV-2 Mutations and Variants of Interest
4805,Department of Statistics Malaysia
4806,Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
4807,Expert Committee on COVID-19 Vaccination: Updated Recommendation on Use of COVID-19 Vaccines
4808,Comparison of the Immunogenicity of BNT162b2 and CoronaVac COVID-19 Vaccines in Hong Kong: An Observational Cohort Study
4809,Ministry of Health Malaysia
4810,Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio
4811,the USA: a retrospective cohort study
4812,"World Health Organization. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac"
4813,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics
4814,Accessed on 22 nd February 2022 499 2. The New York Times. Tracking Coronavirus Vaccinations Around the World
4815,How COVID vaccines shaped 2021 in eight powerful charts
4816,Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a 505 systematic review and meta-analysis
4817,mRNA-based COVID-19 vaccine boosters induce 507 neutralizing immunity against SARS-CoV-2 Omicron variant
4818,SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273
4819,The immunogenicity and safety of different COVID-19 512 booster vaccination following CoronaVac or ChAdOx1 nCoV-19 primary series
4820,Effectiveness of a third dose of the BNT162b2 mRNA COVID-19
4821,vaccine for preventing severe outcomes in Israel: an observational study
4822,Neutralizing antibody levels are highly predictive of immune and Hospitalizations Among Adults During Periods of Delta and Omicron Variant 570
4823,10 States
4824,Heterologous versus homologous COVID-19 booster 573 vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in 574
4825,"RHH-001): a phase 4, non-inferiority, single blind, randomised study"
4826,Neutralizing antibodies against the SARS-CoV-2 Omicron variant 577
4827,BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination
4828,Neutralizing antibodies against the SARS-CoV-2 Delta and 580
4829,Omicron variants following heterologous CoronaVac plus BNT162b2 booster 581 vaccination
4830,"Department of Health and Human Services, Food and Drug Administration"
4831,Guidance for Industry Toxicity Grading 584
4832,Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine 585
4833,A Single-Cycle Influenza A Virus-Based SARS-CoV-2 Vaccine 587
4834,Elicits Potent Immune Responses in a Mouse Model
4835,Interferon-γ Release Assay for Accurate Detection of Severe Acute 589
4836,Respiratory Syndrome Coronavirus 2 T-Cell Response
4837,Commercialized kit to assess T-cell responses against SARS-592
4838,CoV-2 S peptides. A pilot study in Health Care Workers
4839,"Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination"
4840,High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape
4841,SARS-CoV-2 B.1.1.529 (Omicron) Variant -United States
4842,Virus isolation and quantitation
4843,Combination of ELISA screening and seroneutralisation tests to expedite Zika virus seroprevalence studies
4844,Screening for SARSCoV-2 antibodies in convalescent plasma (CCP) in Brazil: preliminary lessons from a voluntary convalescent donor program
4845,Correlation between SARS-COV-2 antibody screening by immunoassay and neutralizing antibody testing
4846,Essential medical statistics. 2 nd ed. Massachusetts: Blackwell Science
4847,Generalized linear models. 2 nd ed
4848,Applied linear statistical models. 4 th ed. Ilinois: Richard D. Irwing
4849,Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma
4850,"SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster"
4851,Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. medRxiv
4852,Understanding neutralizing antibodies against SARS-CoV-2 and their implications in clinical practice
4853,Special features of SARS-CoV-2 in daily practice
4854,Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay
4855,Modes of transmission of SARS-CoV-2 and evidence for preventive behavioral interventions
4856,Current and innovative methods for the diagnosis of COVID19 infection (Review)
4857,Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production
4858,Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: A population-level observational study
4859,COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing
4860,Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
4861,Serum Antibody Profile of a Patient With Coronavirus Disease
4862,B cell memory: Understanding COVID-19
4863,Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer
4864,Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity
4865,Factsheet on COVID-19 Vaccination for Persons with Prior COVID-19 Infection
4866,The Effects of Pre-Existing Antibodies on Live-Attenuated Viral Vaccines
4867,Two novel SARS-CoV-2 surrogate virus neutralization assays are suitable for assessing successful immunization with mRNA-1273
4868,SARS-Cov-2 infection: Response of human immune system and possible implications for the rapid test and treatment
4869,Assessing Immune Response to SARS-CoV-2 Infection
4870,"Evaluating ELISA, Immunofluorescence, and Lateral Flow Assay for SARS-CoV-2 Serologic Assays"
4871,What can the world learn from China's response to covid-19?
4872,Interpretation of the Protocol for Prevention and Control of COVID-19 in China
4873,National Health Commission of China. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 8)
4874,Sinopharm's BBIBP-CorV vaccine effectiveness on preventing hospital admission and deaths: results from a retrospective study in the Emirate of Abu Dhabi
4875,"Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded"
4876,Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples
4877,Outbreak of SARS-CoV-2 B.1.617.2 (Delta) Variant Infections Among Incarcerated Persons in a Federal Prison -Texas
4878,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022"
4879,Emergence of Omicron third lineage BA.3 and its importance
4880,Transmission of SARS-CoV-2 Omicron VOC subvaraints BA.1 and BA.2: Evidence from from Danish households
4881,Van Noorden R. How COVID vaccines shaped 2021 in eight powerful charts
4882,Does the world need an Omicron vaccine? What researchers say
4883,Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variantdependent manner
4884,A Randomized Clinical Trial Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac
4885,Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells
4886,Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection
4887,Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement
4888,"COVID-19 Genomics UK (COG-UK) Consortium. SARS-CoV-2 variants, spike mutations and immune escape"
4889,An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies
4890,Virological characteristics of SARS-CoV-2 BA.2 variant.2022. February152022
4891,Omicron BA.1 and BA.2 are antigenically distinct SARS-CoV-2 variants
4892,Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern
4893,SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity
4894,COVID-19) in the UK. Updated Wednesday 27
4895,Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2
4896,To appear in: Public Health
4897,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, openlabel, non-randomised, first-in-human trial"
4898,SARS-CoV-2 immunity: review and applications to phase 3
4899,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study"
4900,Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China
4901,The role of antibody testing for SARS-CoV-2: is there one?
4902,A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations
4903,Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID19 patients
4904,SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area
4905,Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers
4906,Quantitative measurement of anti-SARS-CoV-2 antibodies: analytical and clinical evaluation
4907,A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses
4908,Phase 1-2 trial of a SARSCoV-2 recombinant spike protein nanoparticle vaccine
4909,Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients
4910,Diagnostic accuracy of serological tests for Covid-19: systematic review and metaanalysis
4911,mRNA-1273 Study Group. An mRNA vaccine against SARS-CoV-2-preliminary report
4912,Humoral immune response to SARS-CoV-2 in Iceland
4913,A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report
4914,"Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes"
4915,Vaccinations in patients with immunemediated inflammatory diseases
4916,New-onset guttate psoriasis following intravesical immunotherapy of Bacillus Calmette-Guerin
4917,National survey of psoriasis flares after 2009 monovalent H1N1/seasonal vaccines
4918,Interferon-alpha and viral triggers promote functional maturation of human monocyte-derived dendritic cells
4919,IL-17-expressing cells as a potential therapeutic target for treatment of immunological disorders
4920,Th17 cytokines and vaccineinduced immunity
4921,"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against 1 SARS-CoV-2 across four different countries. 2 3 Running Title: Immunization of 7 vaccines vs SARS.CoV-2 4"
4922,Director-General's opening remarks at the media briefing on COVID-19 -11
4923,COVID-19 (Novel Coronavirus 2019) -418 recent trends
4924,"Morphology, Genome Organization, Replication, 421 and Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)"
4925,Covid-19 Vaccine Tracker: Latest Updates -The New York Times
4926,Overview of the Main Anti-SARS-CoV-429 2 Vaccines: Mechanism of Action
4927,STROBE 432 Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 433 statement: guidelines for reporting observational studies
4928,Safety of SARS-CoV-2 436 vaccines: a systematic review and meta-analysis of randomized controlled trials
4929,Clinical and Analytical Performance of an
4930,Test That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively
4931,One dose of 443 SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from 444 symptomatic COVID-19
4932,The antibody response to SARS-CoV-2 infection persists over at least 448 8 months in symptomatic patients
4933,Immunogenicity and Safety of the COVID-19 Vaccines Compared With 458 Control in Healthy Adults: A Qualitative and Systematic Review
4934,Comparing the clinical efficacy of 461 COVID-19 vaccines: a systematic review and network meta-analysis
4935,Robust spike antibody responses and 464 increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA 465 vaccine
4936,Antibody Responses in Seropositive 468 Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
4937,Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers 472 Previously Infected With SARS-CoV-2
4938,Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine 476 against Covid-19
4939,BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals
4940,Safety and efficacy of an 483 rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis 484 of a randomised controlled phase 3 trial in Russia
4941,Age-sex population adjusted analysis of disease severity 487 in epidemics as a tool to devise public health policies for COVID-19
4942,"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine 491 administered in a prime-boost regimen in young and old adults (COV002): a single-blind, 492 randomised, controlled, phase 2/3 trial"
4943,The dependent variable is the delta of antibodies. Time and personal variability are 602 random effects. Reference group BNT162b2 mRNA
4944,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs
4945,World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19-11
4946,World Health Organization. Coronavirus disease (COVID-19) pandemic
4947,"Endocrinology adult and pediatric, 7th edn"
4948,"Subacute (de Quervain's) thyroiditis: association with HLA-Bw35 antigen and abnormalities of the complement system, immunoglobulins and other serum proteins"
4949,Subacute thyroiditis after SARS-CoV-2 infection
4950,COVID-19-associated subacute thyroiditis: evidence-based data from a systematic review
4951,Potential ınteraction between SARS-CoV-2 and thyroid: a review. Endocrinology
4952,Subacute thyroiditis after mRNA vaccine for COVID-19
4953,Subacute thyroiditis following COVID-19 vaccination in a 67-year-old male patient: a case report
4954,Thyroiditis following vaccination against COVID-19: Report of two cases and review of the literature
4955,Williams textbook of endocrinology
4956,American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis
4957,Graves' disease following acute (subacute) thyroiditis
4958,Graves' disease with thyrotoxicosis following subacute thyroiditis
4959,Occurrence and spontaneous remission of Graves' hyperthyroidism preceded by painless thyroiditis
4960,Clinical characteristics of subacute thyroiditis is different than it used to be -current state based on 15 years own material
4961,"Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study"
4962,Recurrence of subacute thyroiditis over 10 years after the first attack in three cases
4963,COVID-19 autopsy cases: detection of virus in endocrine tissues
4964,Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series
4965,Case Report: two cases of subacute thyroiditis following SARS-CoV-2 vaccination
4966,Evidence refuting the existence of Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants (ASIA)
4967,"Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality"
4968,CDC Centre for Disease Control and Prevention. Adjuvants and Vaccines
4969,European Centre for Disease Prevention and Control. Types of seasonal influenza vaccine
4970,Efficacy and safety of COVID-19 Vaccines: a systematic review and meta-analysis of randomized clinical trials
4971,COVID-19 bilgilendirme platformu
4972,Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants
4973,Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
4974,SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination
4975,Improved neutralization of the SARS-CoV-2 Omicron variant after Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting
4976,Real-time public health communication of local SARS-CoV-2 genomic epidemiology
4977,A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice
4978,"designed, managed and monitored the quality of the epidemiological data collected in the REDCap database"
4979,secured funds and supervised the project
4980,"Vaccinated participants plasma reactivity to RBD measured by ELISA. b, Plasma neutralization titers measured at baseline, previously to BNT162b2 booster shot against ancestral virus, Delta and Omicron variants. Regression lines are shown over time as days post 2 CoronaVac dose vaccination, as purple (ancestral), dark green (Delta) and light green (Omicron)"
4981,"Extended Data Table 1 | Patient data: Dominican Republic SARS-CoV-2-vaccinated cohort Exact counts for each demographic category are displayed in N cell. Percentages of total, where applicable, are displayed in (%) cell. The mean with accompanying standard deviations for each measurement are displayed in Mean and SD cells respectively"
4982,"Extended Data Table 2 | Patient data: Yale healthcare worker SARS-CoV-2-vaccinated cohort Exact counts for each demographic category are displayed in N cell. Percentages of total, where applicable, are displayed in (%) cell. The mean with accompanying standard deviations for each measurement are displayed in Mean and SD cells respectively"
4983,Case Report Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19
4984,Vaccines Against RNA Viruses
4985,Keeping track of the SARS-CoV-2 vaccine pipeline
4986,"Technological approaches to streamline vaccination schedules, progressing towards single-dose vaccines"
4987,Differential chemokine expression following respiratory virus infection reflects 1-or 2-biased immunopathology
4988,e cytokine storm and COVID-19
4989,SARS-CoV-2 viral load is associated with increased disease severity and mortality
4990,Antibody-dependent enhancement of coronavirus
4991,COVID-19 vaccines: should we fear ADE
4992,Dexamethasone in hospitalized patients with covid-19
4993,Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in recovered COVID-19 patients: studies based on cellular and structural biology analysis
4994,Socio-demographic and health factors drive the epidemic progression and should guide vaccination strategies for best COVID-19 containment
4995,Optimal governance and implementation of vaccination programmes to contain the COVID-19 pandemic
4996,Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals
4997,The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine
4998,WHO. 2022. WHO Coronavirus (COVID-19) Dashboard
4999,COVID-19 Vaccine Effectiveness
5000,"Vaccine efficacy, effectiveness and protection"
5001,Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
5002,The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 $7 days after the 2nd dose
5003,Fomites and the environment did not have an important role in COVID-19 transmission in a Brazilian mid-sized city
5004,Lastest news. COVID-19 Coronavirus pandemic
5005,"Keinan-Boker, L. The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised data"
5006,Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) Variant
5007,SARS-CoV-2 IgG antibody response after immunization of healthcare workers with inactivated COVID-19 vaccine (CoronaVac) at Phyathai 3 Hospital
5008,Safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern
5009,Confronting the Delta variant of SARS-CoV-2
5010,Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
5011,China's COVID vaccines have been crucial-Now immunity is waning
5012,Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: An observational study
5013,Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: A substudy of two randomised controlled trials (COV001 and COV002)
5014,"Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: Interim results from a double-blind, randomized"
5015,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA vaccine booster after two doses of inactivated SARS-CoV-2 vaccine in healthy population
5016,Humoral responses and serological assays in SARS-CoV-2 infections
5017,The coronavirus infectious bronchitis virus nucleoprotein localizes to the nucleolus
5018,A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation
5019,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine
5020,Covid-19: a brief overview of the discovery clinical trial
5021,The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
5022,Naming the coronavirus disease (COVID-19) and the virus that causes it
5023,Global public health COVID-19 vaccines and treatments nationalism: challenges for low-income countries and the attainment of the SDGs
5024,"Access to COVID-19 vaccines and medicines-a Global Public Good Zur Verfügung Gestellt in Kooperation Mit/ provided in cooperation with: GIGA German Institute of Global and Area Studies Vaccines and Medicines -a Global Public Good. (GIGA Focus Global, 4)"
5025,Mental health and the covid-19 pandemic
5026,US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination
5027,"EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines"
5028,safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine -United States
5029,COVID-19 Vaccine Janssen: Guillain-Barré Syndrome Listed as a Very Rare Side Effect. European Medicines Agency
5030,Reactive arthritis after COVID-19 vaccination
5031,Myocarditis and pericarditis after mRNA COVID-19 vaccination
5032,Electron microscopy of SARS-CoV-2: a challenging task
5033,One year update on the COVID-19 pandemic: where are we now?
5034,SARS and MERS: recent insights into emerging coronaviruses
5035,Origin and evolution of pathogenic coronaviruses
5036,"Structure, function, and evolution of coronavirus spike proteins"
5037,Structure analysis of the receptor binding of 2019-nCoV
5038,Structural insights into coronavirus entry
5039,The N501Y and K417N mutations in the spike protein of SARS-CoV-2 alter the interactions with both hACE2 and human derived antibody: a free energy of perturbation study
5040,"Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: an insight from structural data"
5041,A tale of three SARS-CoV-2 variants with independently acquired P681H mutations in New York State
5042,Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein 1 triggers recent massive expansion of SARS-Cov-2 variants 2
5043,Identification of a SARS-CoV-2 variant with L452R and E484Q neutralization resistance mutations
5044,Covid-19: what new variants are emerging and how are they being investigated?
5045,Distinct patterns of emergence of SARS-CoV-2 spike variants including N501Y in clinical samples in Columbus Ohio
5046,Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the Severe acute respiratory syndrome coronavirus 2 501Y Variant 1 and Variant 2
5047,The British variant of the new coronavirus-19 (SARS-CoV-2) should not create a vaccine problem
5048,"Origin, evolution and global spread of SARS-CoV-2"
5049,D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity
5050,Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus
5051,Genetic Characteristics and Phylogeny of 969-bp S Gene Sequence of SARS-CoV-2 from Hawai'i Reveals the Worldwide Emerging P681H Mutation FDA = Food and Drug Administration VOC = Variant of Concern VTM = Viral Transport Media
5052,Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant
5053,SARS-CoV-2 spike P681R mutation enhances and accelerates viral fusion
5054,Influenza vaccine: where are we and where do we go
5055,"Polio vaccination: past, present and future"
5056,Safety and immunogenicity of novel adenovirus type 26-and modified vaccinia Ankaravectored Ebola vaccines: a randomized clinical trial
5057,Ebola vaccine trials: progress in vaccine safety and immunogenicity
5058,A comparison of plasmid DNA and mRNA as vaccine technologies
5059,RNA vaccines: a suitable platform for tackling emerging pandemics? Front Immunol
5060,Characterization of Coxsackievirus B4 virus-like particles VLP produced by the recombinant baculovirus-insect cell system expressing the major capsid protein
5061,Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis b vaccine with a novel adjuvant
5062,Safety and efficacy of singledose Ad26.COV2.S vaccine against covid-19
5063,Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine
5064,The arrival of Sputnik V
5065,COVID vaccine excitement builds as Moderna reports third positive result
5066,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Artic Lancet Infect Dis"
5067,Safety and immunogenicity of two RNA-based covid-19 vaccine candidates
5068,Safety and efficacy of NVX-CoV2373 covid-19 vaccine
5069,"Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques"
5070,"Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the Syrian hamster model. iScience"
5071,ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques
5072,Early-stage trial data on AstraZeneca COVID-19 vaccine due Monday -Lancet. Race for a cure
5073,Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters
5074,A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates
5075,NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge
5076,Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in
5077,Brazil: the PROFISCOV study
5078,Interim results of a phase 1-2a trial of Ad26.COV2.S covid-19 vaccine
5079,Antibody and T cell responses to Sinopharm/BBIBP-CorV in naïve and previously infected individuals in Sri Lanka. medRxiv
5080,"Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine 1 (BBV152): a, double-blind, randomised"
5081,Levels of SARS-CoV-2 lineage P.1 neutralization by antibodies elicited after natural infection and vaccination
5082,Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2
5083,Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152. bioRxiv
5084,Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine
5085,Effectiveness of the ChAdOx1 vaccine in the elderly during SARS-CoV-2 Gamma variant transmission in Brazil. medRxiv
5086,Efficacy of the ChAdOx1 nCoV-19 covid-19 vaccine against the B.1.351 variant
5087,"Sweden joins Germany, France, and 15 other countries in suspending AstraZeneca's vaccine over possible side effects"
5088,Expert suspects causal link between AstraZeneca jab and rare blood clots
5089,Prothrombotic immune thrombocytopenia after COVID-19 vaccine
5090,COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern
5091,A one-shot COVID-19 vaccine
5092,Thrombotic thrombocytopenia after Ad26.COV2.S vaccination -response from the manufacturer
5093,COVID-19 vaccine-induced myocarditis: case report with literature review
5094,Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Res Sq
5095,"Russia's Sputnik V shot around 90% effective against Delta variant, developers say. Reuters"
5096,SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
5097,Serum neutralizing activity of mRNA-1273 against SARS-CoV-2 variants
5098,Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine -United States
5099,RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv
5100,Effectiveness of the BNT162b2 covid-19 vaccine against the B.1.1.7 and B.1.351 variants
5101,BNT162b2 vaccination in people over 80 years of age induces strong humoral immune responses with cross neutralisation of P.1 Brazilian variant
5102,Efficacy of NVX-CoV2373 covid-19 vaccine against the B.1.351 variant
5103,"Zydus receives EUA from DCGI for ZyCoV-D, the only needle-free COVID vaccine in the world"
5104,"A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the ""EpiVacCorona"" vaccine for the prevention of COVID-19"
5105,"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, doubleblind, placebo-controlled, phase 1 and 2 trials"
5106,CureVac's mRNA-based vaccine candidate against COVID-19. CureVac; 2021
5107,Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models
5108,"Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models"
5109,Assessment of immunogenicity and protective efficacy of ZyCoV-D DNA vaccine candidates in Rhesus macaques against SARS-CoV-2 infection
5110,mRNA vaccine CVnCoV protects nonhuman primates from SARS-CoV-2 challenge infection
5111,mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents
5112,Optimization of non-coding regions improves protective efficacy of an mRNA SARS-CoV-2 vaccine in nonhuman primates
5113,Immunogenicity and protectivity of the peptide vaccine against SARS-CoV-2
5114,"Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India-NC-ND license. EClini-calMedicine"
5115,Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2
5116,China's single-dose COVID vaccine has efficacy similar to Johnson & Johnson's. Fortune
5117,"s first COVID-19 vaccine for those above 12, gets nod. The Hindu"
5118,"Efficacy and Safety of the CVnCoV SARS-CoV-2 mRNA Vaccine Candidate: Results from Herald, a Phase 2b/3, randomised, observer-blinded, placebocontrolled clinical trial in ten countries in Europe and Latin America"
5119,Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants
5120,How to cite this article: Hadj Hassine I. Covid-19 vaccines and variants of concern: A review
5121,Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required
5122,WHO (2022) WHO director-general's opening remarks at the media briefing on COVID-19
5123,Republic of Turkey Ministry of Health (2022) COVID-19 vaccination information platform
5124,"Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study"
5125,SARS-CoV-2 variant classifications and definitions
5126,World Health Organization (2022) Variants of concern (VOC)
5127,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: a testnegative case-control study. The Lancet Regional Health -Americas. 1:100025
5128,Establishment of the WHO International standard and reference panel for anti-SARS-CoV-2 antibody
5129,Dynamic of humoral response to SARS-CoV-2 anti-nucleocapsid and spike proteins after CoronaVac vaccination
5130,Waning antibody levels after vaccination with mRNA BNT162b2 and inactivated CoronaVac COVID-19 vaccines in Hong Kong blood donors
5131,"Shortterm immune response after inactivated SARS-CoV-2 (CoronaVac ® , Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria ® , Oxford-AstraZeneca) vaccinations in health care workers"
5132,Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection
5133,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
5134,Status of COVID-19 vaccines within WHO EUL/PQ evaluation process
5135,COVID-19 WHO Thailand Situation Reports
5136,Phase 3 safety and efficacy of AZD1222 (ChAdox1 nCov-19) Covid-19 vaccine
5137,Department of Disease Control MoPH. Thailand. a guide to COVID-19 vaccines in Thailand
5138,A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus
5139,Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdox1 nCov-19/bnt162b2 vaccination
5140,Correlation between commercial anti-RBD IgG titer and neutralization titer against SARS-CoV-2 beta variant
5141,Correlation of the commercial anti-SARS-CoV-2 receptor binding domain antibody test with the chemiluminescent reduction neutralizing test and possible detection of antibodies to emerging variants
5142,COVID-19 antibody tests and their limitations
5143,Effectiveness of heterologous ChAdox1 nCov-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: a nationwide cohort study
5144,Immunogenicity and efficacy of heterologous ChAdox1-BNT162b2 vaccination
5145,Innate responses induced by whole inactivated virus or subunit influenza vaccines in cultured dendritic cells correlate with immune responses in vivo
5146,HLA-Class II artificial antigen presenting cells in CD4+ T cell-based immunotherapy. Front Immunol
5147,Immunological mechanisms of vaccine-induced protection against SARS-CoV-2 in humans
5148,Cross-Presentation by dendritic cells
5149,Can complementary prime-boost immunization strategies be an alternative and promising vaccine approach against dengue virus? Front Immunol
5150,"Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group"
5151,Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses
5152,"A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
5153,Is prime boost strategy a promising approach in HIV vaccine development?
5154,From vaccines to memory and back
5155,Optimize prime/boost vaccine strategies: trained immunity as a new player in the game. Front Immunol
5156,Single-Dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdox1 nCov-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
5157,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study
5158,Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron. medRxiv : the preprint server for health sciences
5159,Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics
5160,Clinical Characteristics of 40 Patients Infected With the SARS-CoV-2 Omicron Variant in Korea
5161,Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province
5162,Will Omicron finally overpower China's COVID defences?
5163,Provisional Analysis of the First 6748 Reported Death Cases in the 5th Wave
5164,Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study
5165,COVID-19 vaccines and vaccine administration
5166,"Aging in COVID-19: Vulnerability, immunity and intervention"
5167,Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland
5168,A global survey of potential acceptance of a COVID-19 vaccine
5169,"Change of Willingness to Accept COVID-19 Vaccine and Reasons of Vaccine Hesitancy of Working People at Different Waves of Local Epidemic in Hong Kong, China: Repeated Cross-Sectional Surveys"
5170,Acceptance of COVID-19 Vaccination during the COVID-19
5171,Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination
5172,"Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review"
5173,BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study
5174,Immunogenicity and safety of two doses of the
5175,CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study
5176,Evidence-Based Strategies for Clinical Organizations to Address COVID-19 Vaccine Hesitancy
5177,Influence of a COVID-19 vaccine&#x2019;s effectiveness and safety profile on vaccination acceptance
5178,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18&#x2013;59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
5179,A third dose of inactivated SARS-CoV-2 vaccine induces robust antibody responses in people with inadequate response to two-dose vaccination
5180,Vaccines and related biological products advisory committee meeting
5181,COVID-19 Vaccination for People with Comorbidities
5182,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines
5183,"Triple combination of interferon beta-1b, lopinavirritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial"
5184,Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial
5185,Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma
5186,C4591001 Clinical Trial Group. 2020. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
5187,Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. Lancet Microbe 2:e423
5188,A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between sex
5189,Half-vs full-dose trivalent inactivated influenza vaccine
5190,Genetic control of the CD4/CD8 T-cell ratio in humans
5191,Sex differences in autoimmune disease
5192,Correlation of Side Effects and Neutralizing Antibody mSphere
5193,Reactogenicity following receipt of mRNA-Based COVID-19 vaccines
5194,Age-and sex-graded data evaluation of vaccination reactions after initial injection of the BNT162b2 mRNA vaccine in a local vaccination center in Germany
5195,Prevalence and risk factors of coronavac side effects: an independent cross-sectional study among healthcare workers in Turkey
5196,Immunogenicity of intradermal trivalent influenza vaccine with topical imiquimod: a double blind randomized controlled trial
5197,Comparative reactogenicity of enhanced influenza vaccines in older adults
5198,"Systemic IL-15, IFN-gamma, and IP-10/ CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients"
5199,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach
5200,Covid-19 vaccines: where we stand and challenges ahead
5201,Covid-19 vaccine tracker
5202,"Coronavac has overall efficacy of 50.4 percent, says butantan"
5203,Técnicos da anvisa recomendam uso emergencial da vacina de oxford
5204,Vacinas contra a covid-19
5205,"The brazilian health system: history, advances, and challenges"
5206,Brazil's unified health system: the first 30 years and prospects for the future
5207,Programa nacional de imunizações (pni) e covid-19: desafios a uma história de quase meio século de sucesso | cee fiocruz
5208,São paulo passa para fase vermelha a partir de hoje
5209,Update i. a systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for covid-19
5210,Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (sarscov-2) infection: a randomized clinical trial
5211,Mapa da vacinação contra covid-19 no brasil
5212,Informes e notas técnicas
5213,Estados · observatório covid-19 br
5214,Infectivity of asymptomatic versus symptomatic covid-19
5215,Spread and dynamics of the covid-19 epidemic in italy: Effects of emergency containment measures
5216,Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (sarscov-2)
5217,The implications of silent transmission for the control of covid-19 outbreaks
5218,Temporal dynamics in viral shedding and transmissibility of covid-19
5219,"Estimating the asymptomatic proportion of coronavirus disease 2019 (covid-19) cases on board the diamond princess cruise ship, yokohama, japan, 2020"
5220,"Asymptomatic and presymptomatic sarscov-2 infections in residents of a long-term care skilled nursing facility-king county, washington"
5221,Estimation of the asymptomatic ratio of novel coronavirus infections (covid-19)
5222,"Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019-covidnet, 14 states"
5223,Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 -united states
5224,"The novel coronavirus, 2019-ncov, is highly contagious and more infectious than initially estimated"
5225,"Clinical course and outcomes of critically ill patients with sars-cov-2 pneumonia in wuhan, china: a single-centered, retrospective, observational study"
5226,"Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (covid-19): a review"
5227,Coronavírus -dados completos
5228,Plano nacional de operacionalização da vacinação contra a covid-19
5229,Projecting contact matrices in 177 geographical regions: an update and comparison with empirical data for the covid-19 era
5230,Aspectos demográficos e socioeconômicos dos adultos brasileiros e a covid-19: uma análise dos grupos de risco a partir da pesquisa nacional de saúde
5231,Threequarters attack rate of sars-cov-2 in the brazilian amazon during a largely unmitigated epidemic
5232,Access to vaccines in brazil and the global dynamics of the health economic-industrial complex
5233,Knowledge about cervical cancer and hpv immunization dropout rate among brazilian adolescent girls and their guardians
5234,"Population-based estimates of chronic conditions affecting risk for complications from coronavirus disease, united states"
5235,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review"
5236,CDC. Vaccines: The Basics. Available online
5237,Population Ages 0-14 (% of Total Population)
5238,Vaccines 2021
5239,Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
5240,Vaccination against COVID-19: A systematic review and meta-analysis of acceptability and its predictors
5241,COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals)-A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergology (AeDA)
5242,Canadian Rheumatology Association Recommendation for the Use of COVID-19 Vaccination for Patients with Autoimmune Rheumatic Diseases
5243,"Interim Recommendations for Use of the Inactivated COVID-19 Vaccine, CoronaVac, Developed by Sinovac"
5244,Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections
5245,Should We Mandate a COVID-19 Vaccine for Children?
5246,Guidelines for the Management of Children and Adolescent with COVID-19: Protocol for an update
5247,Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
5248,Cochrane Handbook for Systematic Reviews of Interventions
5249,The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses
5250,Methodological quality and synthesis of case series and case reports
5251,Checklist for Analytical Cross Sectional Studies
5252,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: A double-blind, randomised, controlled, phase 1/2 clinical trial"
5253,BNT162b2 mRNA COVID-19 Vaccine in AYA with cancer: A monocentric experience
5254,Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine
5255,Recurrence of Acute Myocarditis Temporally Associated With Receipt of the mRNA COVID-19 Vaccine in an Adolescent Male
5256,Myopericarditis in a Previously Healthy Adolescent Male Following COVID-19 Vaccination: A Case Report
5257,Symptomatic acute myocarditis in seven adolescents following Pfizer-BioNTech COVID-19 vaccination
5258,Myopericarditis after the Pfizer mRNA COVID-19 Vaccine in Adolescents
5259,A systematic review of factors affecting vaccine uptake in young children
5260,The burden of seasonal and pandemic influenza in infants and children
5261,Safety of pandemic H1N1 vaccines in children and adolescents
5262,Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents
5263,Hyperinflammatory shock in children during COVID-19 pandemic
5264,SARS-CoV-2-Induced Kawasaki-Like Hyperinflammatory Syndrome: A Novel COVID Phenotype in Children
5265,An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study
5266,Clinical Characteristics of 58 Children with a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2
5267,A Systematic Review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 Infection
5268,Kawasaki disease and immunisation: A systematic review
5269,Vaccines Candidates by Trial Phase
5270,Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review
5271,"World Health Organization. Interim Recommendations for Use of the Pfizer-BioNTech COVID-19 Vaccine, BNT162b2, under Emergency Use Listing: Interim Guidance, First Issued"
5272,COVID-19 Vaccines for Children and Teens
5273,"Pfizer-BioNTech COVID-19 Vaccine Emergency Use Authorization; US Department of Health and Human Services, Food and Drug Administration: Silver Spring"
5274,The Canadian Paediatric Society. COVID-19 Vaccine for Children
5275,COVID-19 Vaccine Spikevax Approved for Children Aged 12 to 17 in EU
5276,Interim Public Health Considerations for COVID-19 Vaccination of Adolescents in the EU/EEA
5277,Factors Associated with Parents' Willingness to Enroll Their Children in Trials for COVID-19 Vaccination
5278,"Vaccine Hesitancy: COVID-19 and Influenza Vaccine Willingness among Parents in Wuxi, China-A Cross-Sectional Study"
5279,"A Systematic Review of Methods to Improve Attitudes towards Childhood Vaccinations. Cureus 2019, 11, e5067"
5280,Correspondence on 'EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs
5281,Flare of rheumatoid arthritis after COVID-19 vaccination
5282,Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested casecontrol study
5283,Association of risk of suicide attempts with methylphenidate treatment
5284,The Government of the Hong Kong Special Administrative Region. COMIRNATY COVID-19 mRNA vaccine (BNT162b2) 2021
5285,Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
5286,Statistical power analysis for the behavioral sciences
5287,Arthritis of the left elbow joint after vaccination against SARS-CoV-2 infection
5288,Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City
5289,"Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges"
5290,Factors associated with COVID-19-related death using OpenSAFELY
5291,Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot
5292,COVID-19 vaccine clinical guidance summary for patients with rheumatic and musculoskeletal diseases 2021
5293,Acceptance of COVID-19 vaccination during the COVID-19 pandemic in China. Vaccines (Basel)
5294,Willingness of the general population to accept and pay for COVID-19 vaccination during the early stages of COVID-19 pandemic: a nationally representative survey in mainland China
5295,An online survey of the attitude and willingness of Chinese adults to receive COVID-19 vaccination
5296,The changing acceptance of COVID-19 vaccination in different epidemic phases in china: a longitudinal study
5297,but the intention of immediate vaccination declined substantially due to concerns about the vaccine's safety. The results implied that information about vaccination safety was important in addressing vaccine hesitancy and promoting successful herd immunity for the general population in China
5298,Willingness to receive novel coronavirus vaccine and factors influencing willingness among healthcare workers in Zhejiang province. Zhongguo Yi Miao He Mian Yi
5299,The low acceptance rate of COVID-19 vaccines suggested that both the public and health professionals need to sufficient evidence and accurate information about COVID-19 vaccines to boost confidence in vaccination
5300,Understanding COVID-19 vaccine demand and hesitancy: a nationwide online survey in China
5301,"Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (Inactivated) vaccine manufactured by sinovac -PROFISCOV: a structured summary of a study protocol for a randomised controlled trial"
5302,This phase 3 clinical trial conducted in healthcare professionals in Brazil demonstrated that the inactivated CoronaVac vaccine has a good safety profile and is efficacious against any symptomatic SARS-CoV-2 infections and highly protective against moderate and severe COVID-19
5303,Draft landscape and tracker of COVID-19 candidate vaccines-30
5304,"Oxford COVID vaccine trial group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial"
5305,"Oxford COVID vaccine trial group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial"
5306,A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge
5307,"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials"
5308,mRNA vaccines -a new era in vaccinology
5309,C4591001 clinical trial group. safety and efficacy of the BNT162b2 mRNA covid-19 vaccine
5310,COVE study group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
5311,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †
5312,The impact of the COVID-19 pandemic on cancer patients
5313,"Centre for Health Protection, Hong Kong Department of Health. Interim Guidance Notes On Common Medical Diseases and COVID-19 Vaccination In Primary Care Settings"
5314,COVID-19 Vaccines for Moderately or Severely Immunocompromised People
5315,Temporal changes in factors associated with COVID-19 vaccine hesitancy and uptake among adults in Hong Kong: serial cross-sectional surveys
5316,Cancer patients' willingness to take COVID-19 vaccination: a nationwide multicenter survey in Korea
5317,Acceptance of COVID-19 vaccination in cancer patients in Hong Kong: approaches to improve the vaccination rate. Vaccines (Basel)
5318,COVID-19 vaccination acceptance and its associated factors among cancer patients in Tunisia
5319,COVID-19 vaccine safety in cancer patients: a single centre experience
5320,Immunogenicity and safety of COVID-19 vaccine BNT162b2 for patients with solid cancer: a large cohort prospective study from a single institution
5321,Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine among actively treated cancer patients
5322,Immunogenicity and safety of the coronavac vaccine in patients with cancer receiving active systemic therapy
5323,Safety of COVID-19 mRNA vaccines in patients with cancer enrolled in early-phase clinical trials
5324,Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options: a retrospective singlecenter study
5325,"Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: a multicenter, prospective, observational study. Thorac Cancer"
5326,Commentary: SARS-CoV-2 vaccines and cancer patients
5327,Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: The PROFISCOV Study. SSRN
5328,Bell's Palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study
5329,Carditis after COVID-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine : a case-control study
5330,Post-Covid-19-vaccination adverse events and healthcare utilization among individuals with or without previous SARS-CoV-2 infection
5331,Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH
5332,COVID-19 Vaccines: Safety Surveillance Manual
5333,"Report on Evaluation of Safety, Efficacy and Quality of Comirnaty COVID-19 mRNA Vaccine (BNT162b2) Concentrate for Dispersion for Injection"
5334,World Health Organization. Coronavirus (COVID-19) dashboard
5335,"Anti-SARS-CoV-2 antibodies testing in recipients of COVID-19 vaccination: why, when, and how?"
5336,Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study
5337,Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
5338,Interim statement on COVID-19 vaccine booster doses
5339,FDA authorizes booster dose of Pfizer-BioNTech COVID-19 vaccine for certain populations
5340,World Health Organization Reference Panel. First WHO international reference panel for anti-SARS-CoV-2 immunoglubulin NIBSC code: 20/268 instructions for use
5341,Humoral immune response in inactivated SARS-CoV-2 vaccine: when should a booster dose be administered? medRxiv
5342,Anti-SARS-CoV-2 receptor-binding domain total antibodies response in seropositive and seronegative healthcare workers undergoing COVID-19 mRNA BNT162b2 vaccination
5343,COVID-19: why we can't use antibody tests to show that vaccines are working
5344,Impact of age and sex on antibody response following the second dose of COVID-19
5345,BNT162b2 mRNA vaccine in Greek healthcare workers. Microorganisms
5346,"Early onset of SARS-COV-2 antibodies after first dose of BNT162b2: correlation with age, gender and BMI"
5347,HLA does not impact on shortmedium-term antibody response to preventive anti-SARS-Cov-2 vaccine
5348,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac
5349,"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A testnegative case-control study"
5350,Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers. Vaccines (Basel) 2021
5351,Intradermal Vaccination: A Potential Tool in the Battle Against the COVID-19 Pandemic?
5352,"Vaccination into the Dermal Compartment: Techniques, Challenges, and Prospects. Vaccines (Basel) 2020"
5353,Immunogenicity and Safety of Reduced-Dose Intradermal vs Intramuscular Influenza Vaccines: A Systematic Review and Meta-analysis
5354,World Health Organization. Polio vaccines: WHO position paper
5355,Intradermal vaccine delivery: will new delivery systems transform vaccine administration?
5356,T cell-oriented strategies for controlling the COVID-19 pandemic
5357,Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific Immune Response
5358,Multiplex analysis of antigen-specific memory B cells in humans using reversed B-cell FluoroSpot
5359,Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine
5360,"Immunogenicity and safety of two-visit, intradermal preexposure rabies prophylaxis simultaneously administrated with chimeric liveattenuated Japanese encephalitis vaccine in children living in rabies and Japanese encephalitis endemic country"
5361,Rapid healing with topical INH powder
5362,Comparison of intradermal and intramuscular administration of hepatitis B vaccine in neonates
5363,Key roles of adjuvants in modern vaccines
5364,Sanctioned countries in the global COVID-19 vaccination campaign: the forgotten 70
5365,Inequalities in coverage of COVID-19 vaccination: A population register based cross-sectional study in Wales
5366,Low COVID-19 vaccination coverage and high COVID-19 mortality rates in Brazilian elderly
5367,Coronavirus Pandemic (COVID-19): Our World in Data
5368,"A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines"
5369,Intradermal covid-19 vaccination could solve supply problems
5370,A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex
5371,A simple protein-based surrogate neutralization assay for SARS-CoV-2
5372,Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)
5373,Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
5374,Testing fractional doses of COVID-19 vaccines
5375,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study"
5376,Joint investigation of 2-month post-diagnosis IgG antibody levels and psychological measures for assessing longer term multi-faceted recovery among COVID-19 cases in northern Cyprus
5377,Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes
5378,"COVID-19: structural considerations for virus pathogenesis, therapeutic strategies and vaccine design in the novel SARS-CoV-2 variants era"
5379,Under the COVID-19 lockdown: rapid review about the unique case of north Cyprus
5380,Effectiveness of COVID-19 vaccines against omicron or delta infection
5381,Age-dependent immune response to the Biontech/Pfizer BNT162b2 coronavirus disease 2019 vaccination
5382,COVID-19 breakthrough infections in vaccinated health care workers
5383,Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients
5384,Heterologous primeboost vaccination with ChAdOx1 nCoV-19 and BNT162b2
5385,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (Coronavacâ) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
5386,Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine
5387,Cutaneous reactions after SARS-COV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases
5388,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study
5389,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, doubleblind, placebo-controlled, phase 1/2 trial"
5390,Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine
5391,Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination
5392,"Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study"
5393,"First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland"
5394,Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study
5395,Use of the selfcontrolled case-series method in vaccine safety studies: review and recommendations for best practice
5396,Hospital Authority. Hospital Authority Statistical Report
5397,Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population-based cohort study
5398,"Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy"
5399,The Government of the Hong Kong Special Administrative Region. COVID-19 Vaccination Programme
5400,Clinical characteristics of coronavirus disease 2019 in China
5401,Prevalence and clinical significance of neutropenia discovered in routine complete blood cell counts: a longitudinal study
5402,"Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes"
5403,Department of Health and Human Services NIH National Cancer Institute Common terminology criteria for adverse events (CTCAE) Version 4.0
5404,Self-controlled case series studies: A modelling guide with R
5405,MMR vaccine and idiopathic thrombocytopaenic purpura
5406,Incidence and risk estimate of drug-induced agranulocytosis in Hong Kong Chinese. A population-based case-control study
5407,Haematological changes associated with influenza vaccination in people aged over 65: case report and prospective study
5408,Vaccination induced neutropenia
5409,Hematologic toxicity of sodium valproate
5410,Delayed onset of clozapineinduced leucopenia
5411,Benign ethnic neutropenia
5412,Population By-census-Thematic Report: Ethnic Minorities
5413,Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic
5414,"European Centre for Disease Prevention and Control. COVID-19 Situation Update Worldwide, as of Week 49"
5415,The SARS-CoV-2 B.1.1.7 variant and increased clinical severity-the jury is out
5416,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: A cohort study
5417,Available online
5418,Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants
5419,Host genetic factors determining COVID-19 susceptibility and severity
5420,"Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence -China, 2021"
5421,COVID-19 Vaccine Technical Working Group. Technical vaccination recommendations for COVID-19 vaccines in China
5422,Interpretation of the protocol for prevention and control of COVID-19 in China (Edition 8)
5423,Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 8)
5424,BBIP-CorV vaccine effectiveness for preventing infection and death of health workers
5425,Effectiveness of inactivated COVID-19 vaccines against COVID-19 pneumonia and severe illness caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Guangdong
5426,Effectiveness of COVID-19 vaccines against the B. 1.617.2 (Delta) variant
5427,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study
5428,WHO. WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations
5429,Brazilian Ministry of Health. COVID-19 vaccination applied doses
5430,Antibody responses boosted in seropositive healthcare workers after single dose of SARS-CoV-2 mRNA vaccine
5431,Persistence and evolution of SARS-CoV-2 in an immunocompromised host
5432,Coronavirus (COVID-19) update: FDA authorizes additional vaccine dose for certain immunocompromised individuals
5433,World alliance for patient safety: WHO draft guidelines for adverse event reporting and learning systems: from information to action. Geneva: World Health Organization
5434,Multiplex qPCR discriminates variants of concern to enhance global surveillance of SARS-CoV-2
5435,Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: an up-to-date review
5436,Prevalence of asymptomatic SARS-CoV-2 infection : a narrative review
5437,Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate
5438,"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokinetreated patients with immune-mediated inflammatory diseases"
5439,Comparison of two commercial surrogate ELISAs to detect a neutralising antibody response to SARS-CoV-2
5440,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics
5441,WHO. WHO Coronavirus (COVID-19). 2022. Accessed
5442,"COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. The Lancet"
5443,Transmission of SARS-CoV-2 variant B. 1.1. 7 among vaccinated health care workers
5444,Effectiveness of first dose of COVID-19 vaccines against hospital admissions in Scotland: national prospective cohort study of 5.4 million people
5445,"Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers-eight US locations"
5446,Effectiveness of the Pfizer-BioNTech COVID-19 vaccine among residents of two skilled nursing facilities experiencing COVID-19 outbreaks-Connecticut
5447,Turkey begins mass COVID-19 vaccination with Sinovac's jabs. 2021
5448,Turkey OKs emergency use of Sputnik-V vaccine
5449,Anadolu Agency.1st Doses of Pfizer-BioNTech Jab Administered in Turkey
5450,C4591001 clinical trial group: safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine
5451,Early evidence of the effect of SARS-CoV-2 vaccine at one medical center
5452,Healthcare workers should be recieved with the highest effective vaccine available
5453,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18−59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
5454,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P. 1 variant transmission in Brazil: a test-negative case-control study. medRxiv
5455,Predictors for severe COVID-19 infection
5456,Correlations of clinical and laboratory characteristics of COVID-19: a systematic review and meta-analysis
5457,Ferritin as prognostic marker in COVID-19: the FerVid study
5458,"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China"
5459,"C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis"
5460,Respiratory support for adult patients with COVID-19
5461,WHO coronavirus (COVID-19) dashboard
5462,A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19
5463,"Swords and Shields"" against COVID-19 for patients with cancer at ""clean"" and ""pandemic"" hospitals: are we ready for the second wave?"
5464,Impact of coronaphobia on treatment and follow-up compliance of cancer patients
5465,The ESMO call to action on COVID-19 vaccinations and patients with cancer: vaccinate. Monitor. Educate
5466,• Discusses the importance of COVID-19 vaccines in patients with cancer
5467,• Discusses phase I and II CoronaVac trial results
5468,Discusses news about approval of CoronaVac by WHO
5469,Seasonal influenza vaccine in immunocompromised persons
5470,Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study
5471,Turkish Medical Oncology Society COVID-19 pandemic advisory board updated recommendations for medical oncologists: included vaccination
5472,ESMO statements for vaccination against COVID-19 in patients with cancer
5473,Siemens Healthcare Diagnostics Atellica IM SARS-CoV-2 total (COV2T) ELISA assay for the detection of total antibodies to SARS-CoV-2
5474,Discusses the immunogenicity of CoronaVac in patients with rheumatological disease receiving immunomodulator drugs
5475,Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients
5476,Discusses the immunogenicity of mRNA vaccines in cancer patients
5477,Influenza vaccines in immunosuppressed adults with cancer
5478,"Aging, cancer, and antitumor immunity"
5479,Allocation of COVID-19 vaccination: when public prioritisation preferences differ from official regulations
5480,Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations
5481,Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors
5482,CoronaVac (2x) DR + Pfizer (1x) DR
5483,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses
5484,A novel coronavirus outbreak of global health concern
5485,data. Coronavirus (COVID-19) Vaccinations. Available online
5486,"SAGE Working Group on Vaccine Hesitancy Vaccine hesitancy: Definition, scope and determinants"
5487,"The Royal Society and The British Academy. Covid-19 Vaccine Deployment: Behaviour, Ethics, Misinformation and Policy Strategies"
5488,The Policy Institute. Coronavirus: Vaccine Misinformation and the Role of Social Media
5489,Covid-19: Global Attitudes towards a COVID-19 Vaccine
5490,International estimates of intended uptake and refusal of COVID-19 vaccines: A rapid systematic review and meta-analysis of large nationally representative samples
5491,"Compulsory COVID-19 Vaccination? Only as a Policy of Last Resort. Voices Bioeth. 2020, 6"
5492,Incentives for Immunity-Strategies for Increasing Covid-19 Vaccine Uptake
5493,Change of willingness to accept COVID-19 vaccine and reasons of vaccine hesitancy of working people at different waves of local epidemic in Hong Kong
5494,Acceptance of the COVID-19 vaccine based on the health belief model: A population-based survey in Hong Kong
5495,Department of Health. Hong Kong Vaccination Dashboard
5496,"Office of the Communications Authority. The Numbering Plan for Telecommunications Services in Hong Kong (SAR), China. Available online"
5497,The Census and Statistics Department of the Hong Kong Government
5498,Our World in Data: Statistics and Research-Cornavirus (COVID-19) Vaccinations
5499,"Vaccine Among Healthcare Workers in the Kingdom of Saudi Arabia. Front. Med. 2021, 8, 644300"
5500,COVID-19: Wäre eine Impfpflicht rechtlich möglich?
5501,Will COVID-19 Vaccinations End Discrimination against COVID-19 Patients in China?
5502,Vaccine hesitancy: The next challenge in the fight against COVID-19
5503,Intention of nurses to accept coronavirus disease 2019 vaccination and change of intention to accept seasonal influenza vaccination during the coronavirus disease 2019 pandemic: A cross-sectional survey
5504,A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation
5505,Department of Health
5506,Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study
5507,Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines
5508,Populist politics and vaccine hesitancy in Western Europe: An analysis of national-level data
5509,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring
5510,Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey
5511,Comparative systematic review and meta-analysis of reactogenicity. immunogenicity and efficacy of vaccines against SARS-CoV-2 npj Vaccines
5512,The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data
5513,Predictors of COVID-19 vaccine hesitancy in the UK household longitudinal study
5514,Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility
5515,"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-Sprimed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial"
5516,Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose
5517,"Understanding the Prevalence and Associated Factors of Behavioral Intention of COVID-19 Vaccination Under Specific Scenarios Combining Effectiveness, Safety, and Cost in the Hong Kong Chinese General Population"
5518,Measures of multimorbidity and morbidity burden for use in primary care and community settings: A systematic review and guide
5519,Sample size for binary logistic prediction models: Beyond events per variable criteria
5520,What can countries learn from Hong Kong's response to the COVID-19 pandemic?
5521,Safety and efficacy of an rAd26 and rAd5 vectorbased heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
5522,"Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers -eight U.S. locations"
5523,Evolution of the COVID-19 vaccine development landscape
5524,Threat assessment brief: emergence of SARS-CoV-2 B.1.617 variants in India and situation in the EU/EEA
5525,Multiple SARS-CoV-2 variants escape neutralization by vaccineinduced humoral immunity
5526,SARS-CoV-2 variants of concern in the United States-challenges and opportunities
5527,Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
5528,Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis
5529,Effectiveness of COVID-19 vaccines against Delta variant (B.1.617.2): a metaanalysis
5530,Effectiveness of COVID-19 vaccines against Delta (B.1.617.2) variant: a systematic review and meta-analysis of clinical studies
5531,RoB 2: a revised tool for assessing risk of bias in randomised trials
5532,Meta-analysis in clinical trials
5533,Interpretation of subgroup analyses in systematic reviews: a tutorial
5534,"Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial"
5535,Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
5536,Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico
5537,"Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HER-ALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial"
5538,Final analysis of efficacy and safety of single-dose Ad26.COV2.S
5539,Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study
5540,Interim estimates of COVID-19 vaccine effectiveness in a mass vaccination setting: data from an Italian province. Vaccines (Basel)
5541,Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617.2 (Delta) variant predominance -eight U.S. locations
5542,"Effectiveness of BNT162b2 vaccine in adolescents during outbreak of SARS-CoV-2 Delta variant infection, Israel, 2021. Emerg Infect Dis"
5543,"Effectiveness of inactivated COVID-19 vaccines against illness caused by the B.1.617.2 (Delta) variant during an outbreak in Guangdong, China: a cohort study"
5544,Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI)
5545,An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status
5546,Interim estimate of vaccine effectiveness of BNT162b2 (Pfizer-BioNTech) vaccine in preventing SARS-CoV-2 infection among adolescents aged 12-17 years -Arizona
5547,Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant -National Healthcare Safety Network
5548,Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland
5549,Comparative effectiveness of COVID-19 vaccines against the Delta variant
5550,"Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway"
5551,COVID-19 outbreak associated with a SARS-CoV-2 P.1 lineage in a longterm care home after implementation of a vaccination program -Ontario
5552,"Effectiveness of inactivated COVID-19 vaccines against symptomatic, pneumonia, and severe disease caused by the Delta variant: real world study and evidence -China"
5553,Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants
5554,"Effectiveness of COVID-19 booster vaccines against covid-19 related symptoms, hospitalisation and death in England"
5555,Duration of protection against mild and severe disease by Covid-19 vaccines
5556,Association of COVID-19 vaccination with symptomatic SARS-CoV-2 infection by time since vaccination and Delta variant predominance
5557,"Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada"
5558,"Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France"
5559,"Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance -VISION Network, 10 States"
5560,Interim estimates of COVID-19 vaccine effectiveness against COVID-19-associated emergency department or urgent care clinic encounters and hospitalizations among adults during SARS-CoV-2 B.1.617.2 (Delta) variant predominance -nine states
5561,"Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: results from a nationwide case-control study in France"
5562,Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in São Paulo
5563,"Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 years -VISION Network, 10 States"
5564,Efficacy of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study
5565,Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario
5566,Assessment of clinical effectiveness of BNT162b2 COVID-19 vaccine in US adolescents
5567,BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
5568,"Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses"
5569,Considerations for evaluation of COVID19 vaccines
5570,Neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants induced by natural infection or vaccination: a systematic review and pooled analysis
5571,Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccineinduced sera
5572,SARS-CoV-2 501Y. V2 variants lack higher infectivity but do have immune escape
5573,Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
5574,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times
5575,The SARS-CoV-2 outbreak: What we know
5576,Epidemiology and public health in the COVID-19 epidemic
5577,Depression and Anxiety in Hong Kong during COVID-19
5578,Mental health outcomes of the CoViD-19 pandemic
5579,Science and Evidence-Based Review and Approval of COVID-19 Vaccines: A Statement of Support for the US FDA
5580,Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding
5581,"SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions"
5582,The Architecture of SARS-CoV-2 Transcriptome
5583,A Genomic Perspective on the Origin and Emergence of SARS-CoV-2
5584,Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK
5585,Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom
5586,Novel SARS-CoV-2 Variant in Travelers from Brazil to Japan
5587,Structural basis of receptor recognition by SARS-CoV-2
5588,The Nonstructural Proteins Directing Coronavirus RNA Synthesis and Processing
5589,Properties of Coronavirus and SARS-CoV-2
5590,"Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, United States"
5591,The pulmonary pathology of COVID-19
5592,COVID-19 and the elderly: Insights into pathogenesis and clinical decision-making
5593,COVID-19 and non-communicable diseases
5594,COVID-19 and comorbidities: Deleterious impact on infected patients
5595,Maternal and Perinatal Outcomes in Patients with Suspected COVID-19 and Their Relationship with a Negative RT-PCR Result
5596,The Profile of the Obstetric Patients with SARS-CoV-2 Infection according to Country of Origin of the Publication: A Systematic Review of the Literature
5597,Antibody Responses to SARS-CoV-2 in Patients with Novel Coronavirus Disease
5598,IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study
5599,The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection
5600,Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
5601,Why the immune system fails to mount an adaptive immune response to a COVID-19 infection
5602,A Predictive Model and Risk Factors for Case Fatality of COVID-19
5603,COVID-19 treatment: Close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2)
5604,Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches
5605,Brief History of Pandemics (Pandemics Throughout History). In Psychiatry of Pandemics
5606,"The last major outbreak of smallpox (Yugoslavia, 1972): The importance of historical reminders"
5607,"The swine flu vaccine, public attitudes, and researcher interpretations: A systematic review of qualitative research"
5608,Countering Vaccine Hesitancy
5609,Historical aspects of immunization and vaccine safety communication
5610,Vaccine Safety: Evidence-based research must prevail
5611,The state of vaccine safety science: Systematic reviews of the evidence
5612,"Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses"
5613,Herd Immunity: Understanding COVID-19
5614,Immunological mechanisms of vaccination
5615,Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network-12 States
5616,Animal models for highly pathogenic emerging viruses
5617,Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period
5618,Duration of Antibody Responses after Severe Acute Respiratory Syndrome
5619,Lessons for COVID-19 Immunity from Other Coronavirus Infections
5620,Barriers to Vaccination for COVID-19 Control-Experience from the United States
5621,Intention to Receive the COVID-19 Vaccination in China: Application of the Diffusion of Innovations Theory and the Moderating Role of Openness to Experience
5622,COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates
5623,"Challenges in ensuring global access to COVID-19 vaccines: Production, affordability, allocation, and deployment"
5624,Tanzania refuses COVID-19 vaccines
5625,Impact of COVID-19 Pandemic on Flu and COVID-19 Vaccination Intentions among University Students
5626,Change of Willingness to Accept COVID-19 Vaccine and Reasons of Vaccine Hesitancy of Working People at Different Waves of Local Epidemic in Hong Kong
5627,COVID-19 vaccines: Breaking record times to first-in-human trials
5628,COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology
5629,The clinical development process for a novel preventive vaccine: An overview
5630,"Covid-19, and the debunking of conspiracy theories"
5631,The Strategies to Support the COVID-19 Vaccination with Evidence-Based Communication and Tackling Misinformation. Vaccines
5632,A Rapid Systematic Review of Public Responses to Health Messages Encouraging Vaccination against Infectious Diseases in a Pandemic or Epidemic
5633,The US Regulatory System and COVID-19 Vaccines
5634,"Global, regional, and national estimates of target population sizes for covid-19 vaccination: Descriptive study"
5635,The plight of essential workers during the COVID-19 pandemic
5636,Genetics of healthy aging and longevity
5637,The Disproportionate Impact of COVID-19 on Racial and Ethnic Minorities in the United States
5638,Making a COVID-19 vaccine that works for everyone: Ensuring equity and inclusivity in clinical trials
5639,Is there a role for childhood vaccination against COVID-19? Pediatr
5640,Coronavirus Disease 2019 and Vaccination of Children and Adolescents: Prospects and Challenges
5641,Vaccinating Children against Covid-19-The Lessons of Measles
5642,Why It Is Important to Develop an Effective and Safe Pediatric COVID-19 Vaccine. Vaccines
5643,"Detection of breastmilk antibodies targeting SARS-CoV-2 nucleocapsid, spike and receptor-binding-domain antigens"
5644,CDC's COVID-19 Vaccine Rollout Recommendations | CDC
5645,Covid-19: Vaccine roll out could take a year and will require difficult prioritisation decisions
5646,Israel's rapid rollout of vaccinations for COVID-19
5647,Covid-19 vaccination rollout: A commentary from England
5648,Who should be vaccinated first? Comparing vaccine prioritization strategies in Israel and European countries using the Covid-19 Health System Response Monitor
5649,What can we learn from Israel's rapid roll out of COVID-19 vaccination?
5650,"Covid-19: How the UK vaccine rollout delivered success, so far"
5651,The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies
5652,Landscape of COVID-19 Candidate Vaccines
5653,"A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease"
5654,COVID-19 Vaccination: From Interesting Agent to the Patient. Vaccines
5655,Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach
5656,"Optimising Vaccine Dose in Inoculation against SARS-CoV-2, a Multi-Factor Optimisation Modelling Study to Maximise Vaccine Safety and Efficacy"
5657,Direct gene transfer into mouse muscle in vivo
5658,Developing mRNA-vaccine technologies
5659,Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand
5660,Advancements in mRNA Encoded Antibodies for Passive Immunotherapy
5661,mRNA vaccines-A new era in vaccinology
5662,Advanced Nanomaterials for Preparedness Against (Re-)Emerging Viral Diseases
5663,The Use of Nanobiotechnology in Immunology and Vaccination
5664,Nanomaterial Delivery Systems for mRNA Vaccines
5665,COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses
5666,COVID-19 Vaccine Frontrunners and Their Nanotechnology Design
5667,Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate
5668,Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity
5669,"Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans"
5670,SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. Vaccines
5671,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
5672,"A Novel Synonymous Mutation of SARS-CoV-2: Is This Possible to Affect Their Antigenicity and Immunogenicity? Vaccines 2020, 8, 220"
5673,Development of mRNA Vaccines: Scientific and Regulatory Issues. Vaccines
5674,Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19
5675,Allergische Reaktionen auf COVID-19-Impfstoffe-Evidenz und praxisorientiertes VorgehenAllergic reactions to COVID-19 vaccines: Evidence and practice-oriented approach
5676,Severe allergic reactions to the COVID-19 vaccine-Statement and practical consequences
5677,Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine
5678,The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic
5679,"Covid-19: What do we know about Sputnik V and other Russian vaccines? BMJ 2021, 372, n743"
5680,Adenovirus-Based Vaccines for Fighting Infectious Diseases and Cancer: Progress in the Field
5681,Adenoviruses as vaccine vectors
5682,Novel viral vectors in infectious diseases
5683,Chimpanzee-origin adenovirus vectors as vaccine carriers
5684,A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong Kong
5685,Effects of a SARS-associated coronavirus vaccine in monkeys
5686,Pros and Cons of Adenovirus-Based SARS-CoV-2 Vaccines
5687,Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine
5688,Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots
5689,WHO Statement on AstraZeneca COVID-19 Vaccine Safety Signals
5690,Inactivated Virus Vaccine-An Overview | ScienceDirect Topics
5691,Inactivated Viral Vaccines
5692,"Inactivated virus vaccines from chemistry to prophylaxis: Merits, risks and challenges"
5693,Adjuvantation helps to optimise COVID-19 vaccine candidate
5694,Immunogenicity and safety of a SARS-CoV-2
5695,SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. Front
5696,Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
5697,"Whole proteome screening and identification of potential epitopes of SARS-CoV-2 for vaccine design-an immunoinformatic, molecular docking and molecular dynamics simulation accelerated robust strategy"
5698,Bioinformatics prediction of B and T cell epitopes within the spike and nucleocapsid proteins of SARS-CoV2
5699,Passive immunotherapy of viral infections: 'super-antibodies' enter the fray
5700,Structural and functional analysis of a potent sarbecovirus neutralizing antibody
5701,Rational Vaccine Design in the Time of COVID-19
5702,Heterologous vaccination regimens with self-amplifying RNA and Adenoviral COVID vaccines induce superior immune responses than single dose vaccine regimens in mice
5703,Comparing COVID-19 Vaccine Schedule Combinations-Com-COV
5704,Disposable face masks and reusable face coverings as non-pharmaceutical interventions (NPIs) to prevent transmission of SARS-CoV-2 variants that cause coronavirus disease (COVID-19): Role of new sustainable NPI design innovations and predictive mathematical modelling
5705,Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis
5706,Physical activity: Benefits and challenges during the COVID-19 pandemic. Scand
5707,Sleeping when the world locks down: Correlates of sleep health during the COVID-19 pandemic across 59 countries
5708,COVID-19: Imbalanced Immune Responses and Potential Immunotherapies
5709,Therapeutic potential of medicinal plants against COVID-19: The role of antiviral medicinal metabolites
5710,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation
5711,International Nonproprietary Names Programme. Messenger RNA Encoding the Full-Length SARS-CoV-2 Spike Glycoprotein. World Health Organization (2020)
5712,Interim Report: Safety and Immunogenicity of an Inactivated Vaccine Against SARS-CoV-2 in Healthy Chilean Adults in a Phase 3 Clinical Trial. medRxiv
5713,Comparative Immunogenicity of mRNA and Inactivated Vaccines Against COVID-19
5714,Serological Response to mRNA and Inactivated COVID-19 Vaccine in Healthcare Workers in Hong Kong: Preliminary Results
5715,BNT162b2 Vaccine Induces Neutralizing Antibodies and Poly-Specific T Cells in Humans
5716,mRNA Vaccine-Elicited Antibodies to SARS-CoV-2 and Circulating Variants
5717,Comprehensive Assessment of Humoral Response After Pfizer BNT162b2 mRNA Covid-19 Vaccination: A Three-Case Series
5718,Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva
5719,SARS-CoV-2 Detection by Nasal Strips: A Superior Tool for Surveillance of Paediatric Population
5720,Molecular Diagnosis of a Novel Coronavirus (2019-Ncov) Causing an Outbreak of Pneumonia
5721,Inhalable Nanovaccine With Biomimetic Coronavirus Structure to Trigger Mucosal Immunity of Respiratory Tract Against COVID-19
5722,Bronchus-Associated Lymphoid Tissue (BALT) Is Not Present in the Normal Adult Lung But in Different Diseases
5723,"Lymphocyte Homing to Bronchus-Associated Lymphoid Tissue (BALT) Is Mediated by L-Selectin/PNAd, Alpha4beta1 Integrin/VCAM-1, and LFA-1 Adhesion Pathways"
5724,Regional Induction of Adhesion Molecules and Chemokine Receptors Explains Disparate Homing of Human B Cells to Systemic and Mucosal Effector Sites: Dispersion From Tonsils
5725,Mucosal Immunity in COVID-19: A Neglected But Critical Aspect of SARS-CoV-2 Infection
5726,Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines Against H10N8 and H7N9 Influenza Viruses
5727,Systemic and Mucosal Antibody Responses Specific to SARS
5728,During Mild Versus Severe COVID-19
5729,Surrogate Virus Neutralization Test Based on Antibody-Mediated Blockage of ACE2-Spike Protein-Protein Interaction
5730,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4
5731,Effectiveness 476 of an Inactivated SARS-CoV-2 Vaccine in Chile
5732,Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2
5733,Health Am 2021:100025
5734,CoronaVac induces lower neutralising activity against variants of concern 484 than natural infection
5735,"Safety and 486 immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral 487 vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-488 inferiority trial"
5736,ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses 491 among Health Care Workers. Vaccines (Basel) 2021
5737,Intradermal Vaccination: 493 A Potential Tool in the Battle Against the COVID-19 Pandemic?
5738,Vaccination into the Dermal Compartment: Techniques
5739,Vaccines (Basel) 2020
5740,Immunogenicity and Safety of Reduced-Dose Intradermal vs Intramuscular Influenza Vaccines: 499 A Systematic Review and Meta-analysis
5741,World Health O. Polio vaccines: WHO position paper
5742,505 12. World Health O. Rabies vaccines: WHO position paper
5743,"Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273"
5744,SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy. medRxiv 510 2021:2021.07.27.21261116
5745,"preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted December 14"
5746,Vaccine Following Two CoronaVac Shots: A Case Report
5747,Correlates of protection 523 against symptomatic and asymptomatic SARS-CoV-2 infection
5748,A SARS-CoV-2 surrogate virus 526 neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein 527 interaction
5749,Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive 530
5750,Vaccine Clinical Trials
5751,Correlates of protection 533 against symptomatic and asymptomatic SARS-CoV-2 infection
5752,Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination -A 537 systematic review and meta-analysis
5753,SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy
5754,COVID-19 pandemic
5755,Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific
5756,Multiplex 549 analysis of antigen-specific memory B cells in humans using reversed B-cell FluoroSpot
5757,Evidence of 552 SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2
5758,SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months 556 after the infection
5759,"Immunogenicity and safety of two-visit, intradermal pre-exposure rabies 559 prophylaxis simultaneously administrated with chimeric live-attenuated Japanese encephalitis 560 vaccine in children living in rabies and Japanese encephalitis endemic country"
5760,Comparison of intradermal and 565 intramuscular administration of hepatitis B vaccine in neonates
5761,Sanctioned countries in the global COVID-19 568 vaccination campaign: the forgotten 70
5762,Inequalities in 571 coverage of COVID-19 vaccination: A population register based cross-sectional study in Wales
5763,Low COVID-19 vaccination coverage and high COVID-19 mortality rates in 574 Brazilian elderly
5764,Our World in Data
5765,"A focused 581 review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines"
5766,A comparison study of SARS-CoV-2 IgG 589 antibody between male and female COVID-19 patients: A possible reason underlying different 590 outcome between sex
5767,A simple 592 protein-based surrogate neutralization assay for SARS-CoV-2
5768,Validation and 595 clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)
5769,Evaluation of a commercially-available surrogate virus neutralization test for severe acute 599 respiratory syndrome coronavirus-2 (SARS-CoV-2)
5770,"COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia"
5771,Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)
5772,"Understanding the epidemiology, diagnosis and management of"
5773,Cancer treatment during COVID-19 pandemic
5774,"COVID-19 in patients with sickle cell disease: A single center experience from Ohio, United States"
5775,The severity of COVID-19 among pregnant women and the risk of adverse maternal outcomes
5776,COVID-19 Vaccines: Special Considerations for the Obese Population
5777,Risk for SARS-CoV-2 infection in healthcare workers
5778,Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium
5779,Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital
5780,SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients
5781,Airborne or droplet precautions for health workers treating COVID-19?
5782,Peraturan Presiden Republik Indonesia Nomor 14 Tahun 2021
5783,Interim national immunization technical advisory group for covid-19 vaccines resolution no
5784,Sinovac reports positive data from Phase I/II trials of CoronaVac
5785,Sinovac Biotech Limited; 2020. Sinovac COVID-19 Vaccine Collaboration with Butantan Receives Approval from Brazilian Regulator for Phase III Trial
5786,Current state of the first covid-19 vaccines
5787,Glossopharyngeal nerve and vagus nerve palsies associated with influenza vaccination
5788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines
5789,Cultivation of a novel type of common-cold virus in organ cultures
5790,Human Coronavirus Types
5791,"FDA, Coronavirus Treatment Acceleration Program (CTAP)"
5792,Clinical efficacy of antivirals against novel coronavirus (COVID-19): a review
5793,Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections
5794,A summary of the SARS-CoV-2 vaccines and technologies available or under development
5795,Spontaneous abortion following COVID-19 vaccination during pregnancy
5796,Safety of COVID-19 vaccines administered in the EU: should we be concerned?
5797,e epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak
5798,Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data
5799,"COVID-19: progress in diagnostics, therapy and vaccination"
5800,Recent advances in mRNA vaccine technology
5801,Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination
5802,B and T cell immune responses elicited by the BNT162b2 (Pfizer BioNTech) COVID-19 vaccine in nursing home residents
5803,Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial
5804,Effectiveness of CoronaVac in the setting of high SARS
5805,1 variant transmission in Brazil: a test-negative case-control study
5806,"Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial"
5807,rombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination
5808,1 skewed immune response of whole virion inactivated SARS cov 2 vaccine and its safety evaluation
5809,A Tandem-repeat dimeric RBD protein-based COVID-19 vaccine ZF2001 protects mice and nonhuman primates
5810,Immunogenicity and protectivity of the peptide candidate vaccine against SARS-CoV-2
5811,"A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the ""Epi-VacCorona"" vaccine for the prevention of COVID-19, in volunteers aged 18-60 years (phase I-II)"
5812,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, nonrandomised, first-in-human trial"
5813,Ad26 vectorbased COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 spike immunogen induces potent humoral and cellular immune responses
5814,Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19
5815,romboembolic events in the South African Ad26.COV2.S vaccine study
5816,"Safety and immunogenicity of the Chadox1 ncov-19 vaccine against SARS-cov-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial"
5817,"Development of an inactivated vaccine candidate, BBIBP-corv, with potent protection against SARS-cov-2"
5818,Effects of COVID-19 and mRNA vaccines on human fertility
5819,Efficacy of Important COVID-19 Vaccine in Real-World
5820,Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients
5821,COVID-19 infection in solid organ transplant recipients after SARS-CoV-2 vaccination
5822,Preliminary findings of mRNA COVID-19 vaccine safety in pregnant persons
5823,e vaccine-elicited immunoglobulin profile in milk after COVID-19 mRNA-based vaccination is IgGdominant and lacks secretory antibodies
5824,Antibody response after second-dose of ChAdOx1-nCOV (CovishieldTM) and BBV-152 (CovaxinTM) among health care workers in India: final results of cross-sectional coronavirus vaccine
5825,Module 2: Types of Vaccine and Adverse Reactions
5826,"CDC, Vacines and immunizations. Local Reactions, Systemic Reactions, Adverse Events, And Serious Adverse Events: Janssen COVID-19 Vaccine"
5827,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico
5828,Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and Diabetes
5829,Unequal Impact of
5830,Structural Health Determinants and Comorbidity on COVID-19 Severity and Lethality in Older Mexican Adults: Considerations Beyond Chronological Aging
5831,The Impact of Vaccination on
5832,COVID-19) Outbreaks in the United States
5833,Safety and Efficacy of the BNT162b2
5834,mRNA Covid-19 Vaccine
5835,Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
5836,Safety and efficacy of the ChAdOx1
5837,"nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
5838,"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial"
5839,COVID-19 Vaccine: Promoting Vaccine Acceptance
5840,Impact and effectiveness of mRNA
5841,"BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data"
5842,Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of longterm care facilities in England (VIVALDI): a prospective cohort study
5843,Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel -33
5844,Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19
5845,"Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines"
5846,Effectiveness of the first component of
5847,"Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina"
5848,CoV-2 Vaccine in Chile
5849,Diagnostic performance and clinical implications of rapid SARS-CoV-2 antigen testing in Mexico using real-world nationwide COVID-19 registry data
5850,Epicardial adipose tissue thickness is associated with increased COVID-19 severity and mortality
5851,Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina
5852,Waning Effectiveness of SARS-CoV-2 mRNA Vaccines in Older Adults: A Rapid Review
5853,Independent risk factors of COVID-19 pneumonia in vaccinated Mexican adults
5854,"CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) and spread of the potential variant of interest (VOI) B.1.1.519 of SARS-CoV-2 predominantly present in Mexico"
5855,Antibody response following SARS-CoV-2 vaccination among patients with type 2 diabetes mellitus: A systematic review
5856,Epidemiology of diabetes mellitus in Mexico
5857,Profiling Cases With Nonrespiratory Symptoms and Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Mexico City
5858,Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2
5859,Omicron and Delta Variants
5860,"Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance -VISION Network, 10 States"
5861,Protection against SARS-CoV-2 after Covid-19
5862,The granting of emergency use designation to COVID-19 candidate vaccines: Implications for COVID-19 vaccine trials
5863,Threat Assessment Brief: Emergence of SARS CoV 2 B. 1.617 Variants in India and Situation in the EU/EEA
5864,Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019-COVID-NET
5865,"Neutralising antibody activity against SARS-CoV-2 VOCs, B.1.617.2 and B.1.351 by BNT162b2 vaccination"
5866,"BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: Aprospective, single-centre, longitudinal cohort study in health-care workers"
5867,Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset
5868,Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine
5869,"SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants"
5870,Strategies for Vaccine Prioritization and Mass Dispensing. Vaccines
5871,Intradermal Vaccination: A Potential Tool in the Battle Against the COVID-19 Pandemic? Risk Manag
5872,Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination-A systematic review and meta-analysis
5873,Clinical assessment of a recombinant simian adenovirus ChAd63: A potent new vaccine vector
5874,Safety and Immunogenicity of Intradermal Delivery of a Fractional Dose mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults as a Dose Sparing Strategy
5875,T cell response to SARS-CoV-2 infection in humans: A systematic review
5876,The Coronavirus Disease
5877,The race to a COVID-19 vaccine: Opportunities and challenges in development and distribution
5878,"Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India"
5879,Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label
5880,Targeting skin dendritic cells to improve intradermal vaccination
5881,Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies. Vaccines 2021
5882,T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals
5883,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil"
5884,World Health Organization. WHO Coronavirus (COVID-19) Dashboard.; 2021
5885,Vaccinating people who have had covid-19: why doesn't natural immunity count in the US?
5886,Is one vaccine dose enough if you've had COVID? What the science says
5887,SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors
5888,SARS-CoV-2 Omicron Has Extensive but Incomplete Escape of Pfizer BNT162b2 Elicited Neutralization and Requires ACE2 for
5889,Increased Risk of SARS-CoV-2 Reinfection Associated with Emergence of the Omicron Variant in South Africa
5890,Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections
5891,Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination -Kentucky
5892,Comparing SARS-CoV-2 Natural Immunity to Vaccine-Induced Immunity: Reinfections versus Breakthrough Infections
5893,Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar
5894,Effectiveness and Durability of Protection against Future SARS-CoV-2 Infection Conferred by COVID-19 Vaccination and Previous Infection; Findings from the UK SIREN Prospective Cohort Study of Healthcare Workers
5895,Direct and Indirect Effectiveness of mRNA Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 in Long-Term Care Facilities
5896,Reduced Odds of SARS-CoV-2 Reinfection after Vaccination among New York City Adults
5897,Use of Recently Vaccinated Individuals to Detect Bias in Test-Negative Case-Control Studies of COVID-19 Vaccine Effectiveness
5898,Welcome to the Tidyverse
5899,MatchIt: Nonparametric Preprocessing for Parametric Causal Inference
5900,Simultaneous inference in general parametric models
5901,A Package for Survival Analysis in R.; 2021
5902,Coronavirus: Vaccination
5903,Proof of Vaccination as Defined in the COVID-19 Protective Measures Exemption Directive and the Directive on Coronavirus Entry Regulations
5904,Stratégie de Vaccination Contre Le SARS-CoV-2 -Vaccination Des Personnes Ayant Un Antécédent de Covid-19.; 2021
5905,T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. The Lancet Microbe
5906,Hybrid immunity versus vaccine-induced immunity against SARS-CoV-2 in patients with autoimmune rheumatic diseases. The Lancet Rheumatology
5907,Evaluation of COVID-19 Vaccine Effectiveness: Interim Guidance
5908,Categorical variables reported as number (%)
5909,The psychological impact of quarantine and how to reduce it: rapid review of the evidence
5910,"COVID-19 and the workplace: implications, issues, and insights for future research and action"
5911,"Health inequity and the effects of COVID-19: assessing, responding to and mitigating the socioeconomic impact on health to build a better future"
5912,COVID-19 exacerbating inequalities in the US
5913,COVID-19 vaccines: a review of the safety and efficacy of current clinical trials
5914,Characterization of local SARS-CoV-2 isolates and pathogenicity in IFNAR -/-mice
5915,"Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the Syrian hamster model"
5916,"Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes"
5917,Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv 2021
5918,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous primeboost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
5919,Safety and efficacy of singledose Ad26.COV2.S vaccine against COVID-19
5920,Functional responsiveness of memory T cells from COVID-19 patients
5921,SARS-CoV-2 vaccination with CoronaVac: seroconversion rate in healthcare workers after 40 days
5922,Preliminary genomic characterization of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. Virological
5923,Negligible impact of SARS-CoV-2 variants on CD4 + and CD8 + T cell reactivity in COVID-19 exposed donors and vaccinees. bioRxiv
5924,Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid-Based Serological Assays
5925,"No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted"
5926,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant
5927,Coronavirus biology and 393 replication: implications for SARS-CoV-2
5928,Tracking changes in SARS-CoV-2 spike: evidence that 395 D614G increases infectivity of the COVID-19 virus
5929,mRNA vaccination boosts cross-variant 397 neutralizing antibodies elicited by SARS-CoV-2 infection
5930,Convergent antibody responses to SARS-400
5931,CoV-2 in convalescent individuals
5932,Mapping neutralizing and immunodominant sites on the 402 SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology
5933,Emerging SARS-CoV-2 variants reduce neutralization 405 sensitivity to convalescent sera and monoclonal antibodies
5934,D614G mutation of SARS-CoV-2 spike protein enhances 408 viral infectivity. bioRxiv
5935,"Public Health Scotland and the EAVE 410 II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital 411 admission, and vaccine effectiveness"
5936,Evidence for increased breakthrough rates of SARS-413
5937,CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals
5938,Vaccine breakthrough infections with SARS-CoV-2 variants. 416
5939,Changes in the humoral immunity response in SARS-CoV-2 418 convalescent patients over 8 months
5940,Vpr is required for efficient replication of human 422 immunodeficiency virus type-1 in mononuclear phagocytes
5941,A rapid and efficient screening system for neutralizing antibodies and 424 its application for SARS-CoV-2. Front Immunol
5942,Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and 426 its immune cross-reactivity with SARS-CoV
5943,Development of cell-based Pseudovirus entry 428 assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2
5944,Comparison of lentiviral 431 vector titration methods
5945,Cell entry mechanisms of SARS-CoV-2
5946,Key residues of the receptor binding motif in the spike protein of SARS-435
5947,CoV-2 that interact with ACE2 and neutralizing antibodies
5948,SARS-CoV-2 variant B.1.617 is resistant to 437 bamlanivimab and evades antibodies induced by infection and vaccination
5949,SARS-CoV-2 spike L452R variant evades 440 cellular immunity and increases infectivity
5950,SARS-CoV-2 spike P681R mutation enhances and 442 accelerates viral fusion
5951,1.617.2 and B.1.351 by BNT162b2 vaccination
5952,Rapid displacement of SARS-CoV-2 variant B.1.1.7 447 by B.1.617.2 and P.1 in the United States. medRxiv
5953,Reduced neutralization of SARS-CoV-2 B.1.617 449 by vaccine and convalescent serum
5954,BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 451 variants
5955,Infection and vaccine-induced neutralizing-antibody 453 responses to the SARS-CoV-2 B.1.617 variants
5956,Emerging SARS-CoV-2 variants of 455 concern evade humoral immune responses from infection and vaccination
5957,Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-458 elicited antibodies
5958,Serum neutralizing activity elicited by mRNA-1273 vaccine
5959,Complete mapping of mutations to the SARS-CoV-2 spike 462 receptor-binding domain that escape antibody recognition
5960,Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. 464
5961,SARS-CoV-2 variants B.1.351 and P.1 escape 466 from neutralizing antibodies
5962,SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune 468 escape
5963,Antibody neutralization to SARS-CoV-2 and variants after one year 470 in Wuhan
5964,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 472 variant of concern
5965,"Transmission, infectivity, and neutralization of a 474 spike L452R SARS-CoV-2 variant"
5966,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines
5967,WHO Coronavirus (COVID-19) Dashboard
5968,Messenger RNA encoding the full-length SARS-CoV-2 spike glycoprotein
5969,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted"
5970,Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil
5971,"Interim report: Safety and . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted"
5972,immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. medRxiv
5973,"Nussenzweig, mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants"
5974,The role of IgA in COVID-19
5975,"Comprehensive assessment of humoral response after Pfizer . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted"
5976,Elevated mucosal antibody responses against SARS-CoV-2 are correlated with lower viral load and faster decrease in systemic COVID-19 symptoms. medRxiv
5977,Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection
5978,Bronchus-associated lymphoid tissue (BALT) is not present in the normal adult lung but in different diseases
5979,Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva. bioRxiv
5980,SARS-CoV-2 detection by nasal strips: A superior tool for surveillance of paediatric population
5981,Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19
5982,"Lymphocyte homing to bronchus-associated lymphoid tissue (BALT) is mediated by Lselectin/PNAd, alpha4beta1 integrin/VCAM-1, and LFA-1 adhesion pathways"
5983,Regional induction of adhesion molecules and chemokine receptors explains disparate homing of human B cells to systemic and mucosal effector sites: dispersion from tonsils
5984,Preclinical and Clinical Demonstration of Immunogenicity by mRNA 25
5985,Mucosal immunity to severe acute respiratory syndrome coronavirus 2 infection
5986,Mucosal Immunology
5987,Sinovac says a booster shot for COVID-19 would increase antibody response tenfold within one week
5988,SARS-CoV-2 vaccination with CoronaVac: seroconversion rate in healthcare workers after 40 days. medRxiv
5989,Interferon-gamma release assay for accurate detection of SARS-CoV-2 T cell response
5990,SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction
5991,"RWYC Writing -original draft: SL, JYC, RWYC Writing -review & editing"
5992,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region"
5993,"Public Health Service (PHS), Centers for Disease Control (CDC) /Food and Drug Administration (FDA)"
5994,Coronavirus vaccine weekly summary of yellow card reporting
5995,Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series
5996,Varicellazoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: Report of 5 cases
5997,Herpes zoster reactivation after mRNA-1273 (Moderna) SARS-CoV-2 vaccination
5998,"Bern aldez A, Rodr ıguez-Jim enez P. Varicella zoster virus reactivation and mRNA vaccines as a trigger"
5999,Reactivation of herpesvirus infections after vaccinations?
6000,Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up
6001,Increased risk of stroke after a herpes zoster attack
6002,Analysis of vascular event risk after herpes zoster from 2007 to 2014 US insurance claims data
6003,Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19
6004,"Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine, historical cohort study"
6005,The cost-effectiveness of universal varicella vaccination in Italy: a model-based assessment of vaccination strategies
6006,The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013
6007,Risk of self-harm and suicide in people with specific psychiatric and physical disorders: comparisons between disorders using English national record linkage
6008,Thematic household survey report no. 58. Hong Kong
6009,Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents following comirnaty vaccination
6010,Multimorbidity and adverse events of special interest associated with CoronaVac (Sinovac) and Comirnaty
6011,Carditis following Covid-19 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac): a case-control study
6012,"Association between treatment with apixaban, dabigatran, rivaroxaban, or warfarin and risk for osteoporotic fractures among patients with atrial fibrillation: a population-based cohort study"
6013,Tutorial in biostatistics: the self-controlled case series method
6014,Self controlled case series methods: an alternative to standard epidemiological study designs
6015,The self-controlled case series method
6016,Do vaccines have a role as a cause of autoimmune neurological syndromes? Front Public Health
6017,Advances in mRNA vaccines for infectious diseases
6018,Toll-like receptor sensing of human herpesvirus infection
6019,Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan
6020,Thematic household survey report no
6021,Prevention of dabigatranrelated gastrointestinal bleeding with gastroprotective agents: a population-based study
6022,Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study
6023,COVID-19) Dashboard; 2021. World Health Organization
6024,"efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. The Lancet"
6025,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet"
6026,Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. The Lancet
6027,Clinical Spectrum of SARS-CoV-2 Infection. COVID-19 Treatment Guidelines; 2021. National Institute of Health
6028,"Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States"
6029,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area"
6030,Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease
6031,Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals
6032,First report of SARS-CoV-2 gamma variant in Turkey
6033,"Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. The Lancet Respiratory Medicine"
6034,Effect of vaccination and of prior infection on infectiousness of vaccine breakthrough infections and reinfections
6035,Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated 2 vaccine
6036,Neutralizing activities against the omicron variant after a heterologous booster in healthy 248 adults Receiving Two Doses of CoronaVac Vaccination
6037,Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and 251 necessary measures for global immunity
6038,Will the COVID-19 pandemic end with the delta and omicron variants? 254
6039,Breakthrough 256 infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose
6040,Severe breakthrough
6041,COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era
6042,Immunogenicity and safety of an intradermal BNT162b2 mRNA 263 vaccine booster after two doses of inactivated SARS-CoV-2 vaccine in healthy population
6043,The immunogenicity against variants of concern and reactogenicity of four COVID-19
6044,booster vaccinations following CoronaVac or ChAdOx1 nCoV-19 primary series
6045,Safety and efficacy 270 of the BNT162b2 mRNA Covid-19 vaccine
6046,An mRNA 273 vaccine against SARS-CoV-2 -Preliminary Report
6047,Safety and immunogenicity of the third booster dose with inactivated
6048,Omicron variant neutralization after mRNA-1273 booster vaccination
6049,SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
6050,COVID-19 vaccination followed by activation of 289 glomerular diseases: does association equal causation?
6051,CoV-2-specific T cells cross-recognize the Omicron variant
6052,Strength and durability of antibody responses to
6053,Challenges in ensuring global access to 222
6054,"COVID-19 vaccines: production, affordability, allocation, and deployment"
6055,Neutralizing antibody levels are highly 225 predictive of immune protection from symptomatic SARS-CoV-2 infection
6056,Correlates of protection against symptomatic and 228 asymptomatic SARS-CoV-2 infection
6057,Evidence for antibody as a protective 230 correlate for COVID-19 vaccines
6058,Comparative immunogenicity of 232 mRNA and inactivated vaccines against COVID-19
6059,BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong
6060,Spatiotemporal pattern of COVID-19 spread in Brazil
6061,Minist erio da Sa ude. COVID-19 painel coronavírus
6062,Fiocruz detecta mutação associada a variantes de preocupação no país
6063,Genomic epidemiology of hCoV-19. 2021). www.gisaid.org (accessed
6064,Opendatasus. campanha nacional de vacinação contra COVID-19
6065,Effectiveness data of the COVID-19 vaccine collected in Israel until 13.2.2021
6066,"Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England"
6067,Effectiveness of coronavac in the setting of high SARS-CoV-2 P1 variant transmission in brazil: a testnegative case-control study
6068,Performance of vaccination with coronavac in a cohort of healthcare workers (HCW) -preliminary report
6069,SARS-CoV-2 incidence and vaccine escape
6070,Minist erio da Sa ude. SIM. sistema de informações de mortalidade
6071,"Evolution of the deaths registry system in Brazil: associations with changes in the mortality profile, under-registration of death counts, and illdefined causes of death"
6072,a systematic subnational analysis for the global burden of disease study
6073,Emergency use ICD codes for COVID-19 disease outbreak
6074,Projeções da população
6075,Ethnic and regional variations in hospital mortality from COVID-19 in Brazil: a cross-sectional observational study
6076,"Description and comparison of demographic characteristics and comorbidities in SARI from COVID-19, SARI from influenza, and the Brazilian general population"
6077,"Characterisation of the first 250,000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data"
6078,SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys
6079,"Slow spread of SARS-CoV-2 in Southern Brazil over a six-month period: report on eight sequential statewide serological surveys including 35,611 participants"
6080,Desigualdades regionais na sa ude: mudanças observadas no Brasil de
6081,Minist erio da Sa ude. COVID-19 vacinação -distribuição de vacinas
6082,Projeto S: imunização em serrana faz casos de covid-19 despencarem 80% e mortes
6083,Effectiveness of the coronavac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: a test-negative case-control study
6084,Vaccine inequality: how rich countries cut Covid deaths as poorer fall behind
6085,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey
6086,Aversion to side effects in preventive medical treatment decisions
6087,COVID-19 vaccine hesitancy in a representative working-age population in France: A survey experiment based on vaccine characteristics
6088,Vaccine Hesitancy Survey Questions Related to SAGE Vaccine Hesitancy Matrix
6089,Strategies for addressing vaccine hesitancy-A systematic review
6090,Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)
6091,Republic of Turkey Ministry of Health. Frequently Asked Questions. COVID-19 Vaccination Information Platform
6092,Turkey Begins Administering Sinovac Shot to Health Workers
6093,Sex-based biology and the rational design of influenza vaccination strategies
6094,Harvard Humanitarian Initiative
6095,Oral Side Effects of COVID-19 Vaccine (OSECV). ClinicalTrials.gov. 2021
6096,The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies
6097,Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic
6098,Republic of Turkey Ministry of Health. T.C. Saglık Bakanlıgı Bilimsel Araştırma Platformu
6099,General Data Protection Regulation (GDPR) Compliance Guidelines
6100,Draft Landscape and Tracker of COVID-19 Candidate Vaccines
6101,"Report on Evaluation of Safety, Efficacy and Quality of CoronaVac COVID-19 Vaccine (Vero Cell) Inactivated. 2021"
6102,Reactions and Adverse Events of the Pfizer-BioNTech COVID-19 Vaccine
6103,"Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Moderna COVID-19 Vaccine"
6104,COVID-19 Vaccine AstraZeneca
6105,Global Health Observatory|By category|Sex distribution of health workers
6106,Republic of Turkey Ministry of Health
6107,Angular cheilitis of COVID-19 patients: A case-series and literature review
6108,The manifestation of oral mucositis in COVID-19 patients: A case-series
6109,Oral Complications of ICU Patients with COVID-19: Case-Series and Review of Two Hundred Ten Cases
6110,Oral candidiasis in non-severe COVID-19 patients: Call for antibiotic stewardship. Oral Surg. 2020
6111,Halitosis in COVID-19 patients. Spec. Care Dent
6112,Tongue ulcers associated with SARS-CoV-2 infection: A case series
6113,Oral Candidiasis of COVID-19 Patients: Case Report and Review of Evidence
6114,Low COVID-19 Vaccine Hesitancy in Brazil
6115,Vaccine confidence and hesitancy in Brazil. Cadernos de Saúde Pública
6116,Vaccine hesitancy: the next challenge in the fight against COVID-19
6117,How can a global pandemic affect vaccine hesitancy?
6118,Can a COVID-19 vaccine live up to Americans' expectations? A conjoint analysis of how vaccine characteristics influence vaccination intentions
6119,Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom
6120,Herd immunityestimating the level required to halt the COVID-19 epidemics in affected countries
6121,Five reasons why COVID herd immunity is probably impossible
6122,Covid-19 Casos e Óbitos
6123,"Group on Vaccine Hesitancy. Vaccine hesitancy: Definition, scope and determinants. Vaccine. 14 de agosto de"
6124,Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications. The Lancet Regional Health -Europe
6125,Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China
6126,"Hesitancy in the time of coronavirus: Temporal, spatial, and sociodemographic variations in COVID-19 vaccine hesitancy"
6127,High Rates of COVID-19 Vaccine Hesitancy and Its Association with Conspiracy Beliefs: A Study in Jordan and Kuwait among Other Arab Countries. Vaccines (Basel). 12 de janeiro de
6128,Assessing the Level and Determinants of COVID-19 Vaccine Confidence in Kenya. Vaccines (Basel). 23 de agosto de 2021
6129,Science Denial and COVID Conspiracy Theories: Potential Neurological Mechanisms and Possible Responses
6130,Male sex identified by global COVID-19 metaanalysis as a risk factor for death and ITU admission
6131,Men and COVID-19: A Biopsychosocial Approach to Understanding Sex Differences in Mortality and Recommendations for Practice and Policy Interventions
6132,Homens e masculinidades e o novo coronavírus: compartilhando questões de gênero na primeira fase da pandemia. Ciência & Saúde Coletiva
6133,Vaccine Hesitancy and Building Confidence in COVID-19 Vaccination | GOARN
6134,"Covid-19: Many poor countries will see almost no vaccine next year, aid groups warn"
6135,The people's vaccine: How a covid-19 vaccine will be a test of global accountability and equity
6136,"Covid-19: Social murder, they wrote-elected, unaccountable, and unrepentant"
6137,"9%) 127,713 (90.1%) Family income (monthly) None ≤ $197.17 $197"
6138,"8%) 2,828 (9.9%)"
6139,How important is the vaccine for someone who has already had COVID-19? Not important Not very important I don´t know Important Very important
6140,Has a family member died or been admitted to ICU for COVID-19? Yes No
6141,Importance of efficacy in decision to vaccinate No Yes I don´t understand efficacy data Indifferent
6142,Is the vaccine´s country of origin important in the decision to vaccinate? Yes No
6143,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration
6144,"Immunologic aspects of characteristics, diagnosis, and treatment of coronavirusdisease 2019 (COVID-19)"
6145,Structures and distributions of SARS-CoV-2spike proteins on intact virions
6146,Angiotensin-convertingenzyme2 is a functional receptor for the SARS coronavirus
6147,"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein"
6148,Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses
6149,A New SARS CoV-2 Dual Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection
6150,COVID-19: Significance of Antibodies
6151,Validation of a commercially available SARS-CoV-2 serological immunoassay
6152,Evaluation of nine commercial SARS-CoV-2 immunoassays
6153,An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment
6154,Antibody tests for identification ofcurrent and pastinfection with SARS-CoV-2. Cochrane Database Syst
6155,Diagnostic performance of COVID-19 serology assays
6156,Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25
6157,Development and performance evaluation of a rapid in-house ELISA for retrospective serosurveillance of SARS-CoV-2
6158,SARS-CoV-2 neutralizing antibodies: A network meta-analysis across vaccines
6159,Neutralizing Antibodies Against SARS-CoV-2 Variants Induced by Natural Infection or Vaccination: A Systematic Review and Individual Data Meta-Analysis
6160,Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines
6161,Neutralizing activity of BNT162b2-elicited serum-Preliminary report
6162,Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications
6163,COVID-19-neutralizing antibodies predict disease severity and survival
6164,Neutralizing antibody response and SARS severity
